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For Mum &Dad 
Genius is one percent inspiration, 
ninety-nine percent perspiration. 
(Thomas Alva Edison 1874 -1931) 
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Abstract 
Genetic susceptibility to type 1 diabetes is associated with the maJor 
histocompatibility complex (MHC) on human chromosome 6. To analyse the contribution 
of the class I region of the MHC to disease susceptibility, polymorphism of the class lb 
molecule HLA-E and several genetic markers within the region was investigated in 378 
British Caucasoid patients with type 1 diabetes as defined by the National Diabetes Group, 
100 multiplex families from the BDA Warren Repository and 216 unselected normal 
British Caucasoid controls. 
PCR-Sequence-Specific Oligonucleotide Probing (PCR-SSOP) was used to analyse 
polymorphism of the HLA-E gene, Restriction Fragment Length Polymorphism analysis 
was used to investigate the four genomic probes P3A, P3B, 28L and 66R and finally 
microsatellite analysis to examine the two markers P 1 and D6S306. 
The association of the class I region with type 1 diabetes was also investigated with 
respect to gender and age at onset of type 1 diabetes. Linkage with known MHC class II 
susceptibility alleles was also analysed and the transmission disequilibrium test was used 
to analyse the BDA multiplex families . 
Significant increases in the frequency of the 1.5; 1.5 kilo base (kb) (Pc = 0.0004) and 
1.8; 1.5 kb (Pc= 0.008) P3B genotypes were found in the patients compared to the controls. 
The P3B genotype 1.8; 1.8 was found to be decreased in the patients compared to the 
controls 26.6% vs 51.5% (Pc = 0.000002). This decrease in the 1.8; 1.8 P3B genotype was 
particularly apparent in those patients diagnosed before the age of 20 years. There were 
also differences in the frequency of the P3B genotype between males and female patients. 
The 1.5 P3B allele was increased and the 1.8 kb allele decreased in patients ( 46.1% and 
53.9%) respectively compared to normal controls (27.8% and 72. 1 %) respectively 
(Pc = <0.000001). The 1.8 P3B allele was increased in the <10 years compared to the 10-
20 years age group 60.2% vs 49.1% (Pc = 0.06). Further, the 1.8kb allele was increased in 
female patients with an age at onset of < 10 years compared to those in the 10-20 years 
group 63.5% vs 45.8% (Pc = 0.04). Analysis of the BDA multiplex families using the 
transmission disequilibirum test (TDT) showed that the 1.5kb allele was significantly 
transmitted from parents to affected offspring (Pc = 0.000002), suggesting that the 1.5 
allele is in linkage with a susceptibility locus for type 1 diabetes. There was a highly 
significant difference in the observed transmission of the 1.5kb allele in the > 10 years 
group compared to the observed transmission of the 1.8kb allele in the > I 0 years group 
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(Pc = 0.000002). 
Increased frequencies of the HLA-E genotypes 0101;0101 (Pc = 0.0007), 
0101;0103 (Pc = 0.025) were found in patients compared to controls. The HLA-E 
genotypes 0102;0104 (Pc= 0.001) and 0103;0104 (Pc= 0.004) were decreased in patients 
compared to controls. The 0101 ;0 101 genotype was increased in patients with an age at 
onset of 10-20 years compared to patients in the < 10 years group 4 7.0% vs 21 .1% 
(Pc = 0.001). The HLA-E 0101 allele was increased in patients compared to controls 
54.1% vs 28.7% (Pc = 0.000003). In contrast, the alleles 0102 and 0104 were decreased in 
patients compared to controls (Pc = 0.000003, p = 0.0000 1) respectively. The 0 I 03 allele 
was increased in patients with an age at onset of < 10 years compared to the 10-20 years 
group 34.1% vs 18.9% (Pc = 0.02) in contrast, the 0101 allele was increased in the 10-20 
years compared to the < 10 years 62.9% vs 47.6% (Pc = 0.07). The frequency of the 0103 
allele was increased in female patients in the < 10 years compared to the 10-20 years 
37.5% vs 16.2% (Pc = 0.04). Haplotype analysis showed the significant presence of the 
P3A-P3B-28L-HLA-E (4-1.5-3 .8-0101) haplotype in patients with type 1 diabetes, which 
suggested the possible association between the P3B 1.5kb allele and the HLA-E 0101 
allele. This was also supported by the presence of the 3 loci haplotype P3B-28L-HLA-E 
(1.5-3 .8-0101) that was found significantly present in patients. Combined genotype 
analysis ofthe P3B and HLA-E showed that the 0101-0103-1.5 genotype was significantly 
increased in patients compared to controls (Pc = 0.08). Analysis of the class li 'diabetes-
associated' alleles showed there was no significant linkage/association with either the P3B 
or HLA-E locus, suggesting that the class I association with type 1 diabetes may be 
independent of the class ll. 
In conclusion a strong association with type 1 diabetes has been identified within 
the class I region, localised to the central area of the region. The association is related to 
gender and age at onset of type 1 diabetes, particularly the 10-20 years age at onset group. 
Identified HLA-E as a novel susceptibility gene, which is the first report of an association 
between a class lb gene and an autoirnmune disease. 
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CHAPTER 1: GENERAL INTRODUCTION 
Diabetes Mellitus is one of the leading causes of morbidity and mortality in the 
Western world. The altered state of intennediary metabolism that it produces results in 
chronic sequelae which accounts for a large proportion of the cardiovascular and renal 
disease seen in the developed world, as well as being a major cause of blindness world-
wide. 
1.1 The History of Diabetes Mellitus 
The physician Arataeus of Cappadocia is credited with the first description of 
diabetes over 2000 years ago and was responsible for giving the disease its name. He 
noticed one of the essential clinical features of the disease was an excessive volume of 
urine, which had been described a few years earlier by Celsus. These early observations 
are all the more credible as the disease seems to have been uncommon in those days, or at 
least not commonly diagnosed. It was in the fourth century BC that the ancient Indians had 
first recorded the sweetness of diabetic 's urine. This observation was made after noticing 
ants congregating around the urine of diabetics. Various people have described similar 
observations throughout history, including Chen Chhuan in China in the seventh century 
AD, Avicenna an Arab physician of the eleventh century and finally in the seventeenth 
century by the Oxford physician, Thomas Willis. Willis made the clinical distinction 
between diabetes mellitus; the common type of diabetes called so due to the sweet tasting 
urine and diabetes insipidus the less common type with non-sweet urine. A century after 
the observations made by Willis, Matthew Dobson showed that the sweetness of diabetic 
urine was due to the presence of sugar, however the actual cause of the disease remained 
unknown. In 1788 Thomas Cawley discovered that the pancreas of a patient who bad died 
of diabetes showed substantial tissue damage, however the significance of this vital clue to 
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solving the cause of diabetes wasn't realised until over a hundred years later. In the first 
half of the nineteenth century Claude Bemard, a significant figure in the history of 
diabetes, proposed his theory on the cause of the disease. He suggested an excessive 
secretion of a sugary substance from the liver that we now know, as glucose was 
responsible. He also showed that the liver stored glycogen. This theory was generally 
recognised as the cause of diabetes, until the year 1879 when a chance discovery changed 
the universal belief. Von Mering and Oscar Minkowski while studying the process of 
digestion decided to look at the role of the pancreas and in so doing discovered that the 
removal of the pancreas led to the development of diabetes. Many years of research 
followed to isolate and characterise the anti diabetic substance within the pancreas and to 
increase our understanding of the disease. In 1921 Banting, Best, Collip and McCleod 
were responsible for one of the most dramatic events in the history of medicine, the 
discovery of insulin and its use in the treatment of diabetes. 
1.2 Anatomy and physiology of the pancreatic islets of Langerhans 
The pancreas consists of exocrine and endocrine tissue in a lobular structure, which has 
many acini and ducts. The exocrine tissue synthesises, stores and secretes digestive 
enzymes and is not affected by diabetes. The endocrine cells are specialised and organised 
into the islets of Langerhans, each of which contain from a few hundred to several 
thousand cells. The islets are encapsulated by collagen and are surrounded by a capillary 
network. The islet contain cells with different secretory functions : 
a) ~ cells which produce insulin are the target of attack in type 1 diabetes. These cells 
form the core of the islet and make up to 60% of the volume. 
b) a cells which secrete glucagon and are distributed around the periphery of the islet. 
These cells make up 10-20 % of the islet volume. 
c) 8 cells which have a scattered distribution, secrete somatostatin and comprise 5-10% of 
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the islet volume. 
d) Pancreatic polypeptide (PP) secreting cells comprises I 0-20 % of the islet and are 
located both in the periphery of the islet, as well as scattered through the exocrine 
tissue. 
The islets containing p cells are found within the head, body and tail of the pancreas, while 
the posterior duodenal portion ofthe gland contains islets with many a. and PP cells. 
Pancreatic p cells contain two types of granules -1) synaptic-like microvesicles 
(SLMV), which contain the enzyme glutamic acid decarboxylase (GAD). This synthesises 
y amino butyric acid (GABA) from glutamic acid, as well as synaptophysin secretory 
vesicles that contain insulin, carboxypeptidase H, betagranin, pancreastatin and cathepsin 
B. The cells are similar to neurons in releasing stored secretory products through 
exocytosis. Many thousands of secretory granules contain insulin in the form of insulin-
zinc hexamers, which is secreted in response to an increase in capillary blood glucose 
concentration. Glucose is taken up through a glucose transporter and metabolised within 
the p cells. The uptake of glucose gives rise to a signal in the insulin secretory granule, 
such that it fuses with the plasma membrane and the insulin is released into the 
bloodstream. In the process of exocytosis the enzymes lining the surface of the granule, 
such as carboxypeptidase H, become exposed to the environment external to the p cell. 
In contrast, the mechanism by which the synaptic-like vesicles are thought to fuse with and 
release their contents is different and enzymes like GAD are not thought to be exposed to 
the external environment under normal conditions. Within the islet, GABA may play a role 
in the regulation of proinsulin synthesis and insulin secretion and may inhibit glucagon 
secretion. This is similar to the action of GABA in the neurons where it acts as an 
inhibitory neurotransmitter. 
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1.3 Classifications and aetiology of Diabetes Mellitus 
Identifying and differentiating the various forms of a disease and placing them into 
a logical framework is essential to understanding the aetiology and natural history. 
Although various forms of nomenclature and diagnostic criteria had been proposed for 
diabetes mellitus, a systematic categorisation did not exist until nearly two decades ago. 
Diabetes mellitus is now recognised as a collection of disorders that are characterised by 
hyperglycaemia and glucose intolerance, due either to insulin deficiency or impaired 
effectiveness of insulin's action. The present classification of diabetes was developed in 
1979 based on research by an international workgroup sponsored by the National Diabetes 
Data Group (NDDG) of the National Institutes of Health, USA [National Diabetes Data 
Group. 1979, Harris et al. 1985]. The recommendations of the NDDG were later endorsed 
by the World Health Organisation (WHO) Expert Committee on Diabetes in 1980 and later 
in 1985 by the WHO Study Group on Diabetes Mellitus [World Health Organisation. 
1980, 1985]. These groups recognised two major forms of diabetes in the Western World, 
insulin dependent diabetes mellitus (IDDM) or type 1 diabetes and non-insulin dependent 
diabetes mellitus (NIDDM) or type 2 diabetes. Recently changes have been proposed to 
the original classification scheme of the NDDGIWHO committees for diabetes mellitus. 
Modifications to the classifications of all forms of diabetes have been suggested by the 
American Diabetes Association [The Expert Committee on the diagnosis and classification 
of diabetes mellitus. 1998]. 
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1.3.1 Type 1 diabetes mellitus QDDM) 
The diagnosis of type 1 diabetes is suggested by the symptoms of weight loss, 
polydipsia, polyuria, fatigue or recurrent infections accompanied by some of these 
symptoms. The symptoms are related to laboratory findings of ketoacidosis, 
hyperglycemia and glucosuria. The duration of the symptoms can vary from a few days to 
several weeks, although insulin secretory reserves may decline gradually before clinical 
presentation [Home et al. 1989]. Diagnosis can be confirmed by a random measurement of 
blood glucose greater than 1 Omrnol/1 on venous whole blood, if less than 4.4mmol/l then 
the symptoms are unlikely to be due to type 1 diabetes [Home et al. 1989]. If an 
intermediate value is measured a 75g-glucose tolerance test can be performed after an 
overnight fast. Type 1 diabetes is diagnosed by a fasting value of >6.7mmol/l and a 2 hour 
value of 11.1 mmol/1 on a capillary whole blood sample [World Health Organisation. 1985] 
Type I diabetes is generally characterised clinically by an abrupt onset of severe 
symptoms, an absolute dependence on exogenous insulin to sustain life and proneness to 
ketosis even in the basal state, all of which are caused by insulinopenia. Type 1 diabetes 
rarely occurs before 9 months of age, has a peak incidence between 5 and 15 years and 
declines thereafter [Lounamaa. 1996]. In developed countries type 1 diabetes is the most 
common form of diabetes among children and young adults and was therefore known as 
'juvenile-onset diabetes', however clinical onset can occur at any age. The onset of type 1 
diabetes in adults is not uncommon [Karges et al. 1995] in New Zealand 14.4% of type 1 
diabetic subjects were in the older onset group and required permanent insulin treatment 
[Scott and Brown. 1991]. 
Patients suffering from type 1 diabetes must adhere to a strict treatment regimen 
consisting of subcutaneous injections of insulin determined by an individual need, 
combined 
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with the dietary control of carbohydrate and fat intake. An important factor concerning the 
management of type I diabetes is in the early stages of onset when many patients go 
through what is tenned the ' honeymoon' phase of the disease; the patients are in partial 
remission. The reasons for this are still unclear, however it has been suggested that any 
remaining ~ cells be restored to normal function after appropriate treatment. During this 
time the need for insulin is dramatically reduced. This period is often short lived after 
which the patient becomes permanently insulin dependent. Long-tenn patients with type 1 
diabetes often develop microvascular complications due to hyperglycaemia and also 
macrovascular complications caused by hyperglycaemia and a combination of other 
factors. It has long been evident that complications associated with type 1 diabetes are 
dependent on the duration of the disease and also on how tightly the blood glucose is 
controlled. There is clinical evidence that the incidence of complications can be reduced 
by the tight control of the blood glucose concentration [Diabetes Control and 
Complications Trial Research Group, 1993]. Diabetic retinopathy, nephropathy and 
neuropathy are all microvascular complications that cause considerable morbidity. There is 
also growing evidence suggesting a role for genetic factors in the development of 
microvascular complications [Raskin. 1994, Chowdhury et al. 1995, Heesom et al. 1997, 
Heesom et al. 1998]. Retinopathy is one of the most common complications of type 1 
diabetes and is the major cause of all newly reported cases of blindness in the developed 
world. Microaneurysms of the retinal capillaries develop and lead to ischaemia and 
infarctions that appear as exudates. Patients can also develop nephropathy, the most 
common form of end stage renal disease (ESRD) in the United Kingdom [Andersen et al. 
1983, Laffel and Krolewski. 1989]. Nephropathy begins with overt proteinuria and 
37 
microalbuminuria caused by the effect on the glomerular vessels. The progression to ESRD 
can take more than 20 years and results in a reduction in the actual size of the kidney with 
the development of diffuse glomerulosclerosis [Nathan. 1993]. Finally, diabetic neuropathy 
is primarily a disease of the peripheral nerves [Tesfaye et al. 1996]. Other nerves can also be 
affected including the cranial and autonomic nerves. Symmetrical neuropathy is the most 
common form and causes a loss of sensation in the lower extremities, leaving patients prone 
to leg and foot lesions. Autonomic dysfunction can affect the heart, bladder and 
gastrointestinal tract [Greene et al. 1990]. Macrovascular complications in the form of 
cardiac and major vessel disease are the main causes of mortality in diabetes [Home et al. 
1989]. Type 1 diabetes effects lipoproteins and causes dyslipidemia characterised by an 
increase in very low-density lipoproteins (VLDL) and a decrease in high-density 
lipoproteins (IIDL). Due to this and several unknown factors a premature development of 
cardiovascular disease occurs in patients of both sexes. 
The characteristics of type 1 diabetes can be attributed to a reduction in the insulin-
secretory capacity due to the destruction of the pancreatic f3 cells of the islets of 
Langerhans. The aetiology of type 1 diabetes is still unclear, however the disease appears to 
be immune mediated and involves a combination of genetic and non-genetic factors. Genetic 
factors have been shown to be important risk factors for type 1 diabetes the most important 
of which are those within the Major Histocompatibility Complex (MHC) (IDDM 1) [Singal 
and Blajchman. 1973, Cudworth and Woodrow. 1975, Platz et al. 1981, Wolf et al. 1983, 
Davies et al. 1994, Hashimoto et al. 1994, Todd. 1995]. The insulin gene and surrounding 
region has also been identified as a susceptibility gene region (IDDM 2) [Bell et al. 1984, 
Hitman et al. 1985, 1986, Hitman. 1986, Lucassen et al. 1993, Bennett et al. 1995, Pugliese 
et al. 1997]. IDDMJ and IDDM 2 are estimated to contribute to about 400/o and 10% 
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respectively of the genetic susceptibility to type 1 diabetes. Recently several other non-
:MHC genes have been shown to be risk factors for susceptibility to type 1 diabetes [Davies 
et al. 1994, Hashimoto et al. 1994, Todd. 1995, Todd and Farrall. 1997]. 95% of patients 
with type 1 diabetes in North America and Europe possess one or both of lll,A DR3 or 
DR4 [Jenkins et al. 1990]. HLA DR3 and/or DR4 are associated with an increased risk of 
developing type 1 diabetes, while lll,A DR2 is considered to have a protective effect 
against the disease. DR3 or DR4 occur, however, in up to 60% of the normal population 
and are therefore unlikely to be the primary susceptibility determinants [Thomson et al. 
1988]. It was then suggested that these associations are due to the adjacent locus DQA1 
and DQB1 [Todd et al. 1987, Horn et al. 1988, Khalil et al. 1990]. Identical and non-
identical twin studies allow the genetic influence of a disease to be determined and the 
higher concordance rate in identical compared to non-identical twins is consistent with the 
involvement of genetic factors. The concordance rate of 3 6% in identical twins from the 
United Kingdom [Barnett et al. 1981 ], supports a role for both genetic and non-genetic 
factors in type 1 diabetes, due to the low concordance rate in identical twins. Evidence 
suggests that type 1 diabetes is a genetically heterogeneous disease such that different rates 
of disease progression exist determined by genes in the :MHC [Knip et al. 1986, Ludvigsson 
et al. 1986, Kaljalainen et al. 1989]. 
Auto immunity and abnormal immune responses of both the humoral and cellular arm 
of the immune system have been studied extensively in type 1 diabetes. Islet cell antibodies 
(I CA) are often present in as many as 70% of patients at the time of diagnosis compared to 
only 3% of age and sex-matched controls [Bingley et al. 1993a,b, 1996]. An increase 
frequency of insulin autoantibodies (IAA) has also been shown in newly diagnosed patients 
with type 1 diabetes [Atkinson et al. 1986, Eisenbarth and Jackson. 1992, Landin-Olsson et 
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al. 1992]. Antibodies to GAD have been found in up to 75% of newly diagnosed subjects 
[Vandewalle et al. 1995, Schmidli et al. 1994, Bonifacio et al. 1995] and these antibodies 
have also been detected up to 8 years before diagnosis [Palmer et al. 1991, Verge et al. 
1996]. Many studies have shown a seasonal incidence [Lounamaa. 1996, Green et al. 1992, 
Sekikawa and LaPorte. 1997, Levy-Marchal et al. 1995]. This has led to the suggestion that 
viral infections may be possible initiators of the immune-mediated destruction of the 
pancreatic J3-cells in a genetically predisposed person. However, the evidence for a role of 
viral infections is somewhat contradictory [Pietropaolo and Trucco. 1996]. It has also been 
suggested that there may be two different forms of the disease, Type la as described above 
and a less common Type lb which may be a more primary autoimmune form of the disease. 
From the above it is clear that type 1 diabetes results from multiple factors, even when the 
individual harbours genetic predisposition, which include viral infections, toxins and 
autoimmune responses. 
1.3.2 Type 2 diabetes mellitus (NIDDM) 
Type 2 diabetes is usually diagnosed later in life and can be further subdivided into 
patients who are obese (85%) and those who are not (15%). NIDDM greatly out-numbers 
all other forms of diabetes and constitutes approximately 80-90% of all cases of diabetes in 
the western world, compared to the 10-20% who suffer from type 1 diabetes. In North 
American Indians (Pima) and some populations in the South Pacific NIDDM is virtually the 
only form of diabetes [Zimmet et al. 1990]. The disease is characterised by a combination of 
insulin resistance and decreased insulin production due to impaired J3-cell function, although 
there may be normal levels of insulin in the basal state, mild insulinopenia, or above normal 
levels of insulin. Insulin resistance is the first detectable defect, this defect may occur 15-25 
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years before the clinical onset of the disease. The exact molecular site of the insulin 
resistance is unknown, even early on in the pathogenesis there are a number of alterations in 
the insulin action cascade. Initially, there is an attempt to compensate for this resistance 
with increased insulin secretion, but eventually, insulin secretion fails and the disease 
develops [Turner et al. 1995, Kalm. 1994, Clark et al. 1995, Mandrup-Poulsen. 1998). 
Patients with type 2 diabetes are not dependent on insulin, however insulin may be required 
for the correction of fasting hyperglycemia, if it can't be corrected by diet or oral 
hyperglycemic agents the normal method of control for type 2 diabetes. Ketosis is not a 
characteristic of patients with type 2 diabetes but may develop under special circumstances, 
such as severe stress caused by infections or trauma. The diagnosis of type 2 diabetes is 
generally made in adult years and was therefore formally known as 'adult-onset' or 
'maturity-onset' diabetes, or type 2 diabetes. The disease can also occur in young people 
and the age at onset tends to be much earlier in high-risk groups, such as Pacific Islanders 
and North American Indians [Zimmet et al. 1992). Complications can also be found in 
subjects with type 2 diabetes but after a much longer period of time, probably because the 
blood glucose levels do not reach the same heights in type 2 as in type 1 diabetes. The 
aetiology of type 2 diabetes has a major genetic component the evidence for which is the 
different prevalence between ethnic groups, the familial clustering and the high concordance 
in monozygotic twins [Barnett et al. 1981, Newman et al. 1987]. Identifying the nature of 
the genetic and inheritable components involved in type 2 diabetes has been difficult, 
hampered in part by the complex non-mendelian mode of inheritance [O'Rahilly et al. 1988, 
Turner et al. 1995, Khan. 1994, Ghosh and Schork. 1996]. However, recent linkage studies 
are starting to localise some of the genes that influence the development of the disorder 
[Hanson et al. 1998). There is no evidence that immunological factors play a role in the 
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pathogenesis of type 2 diabetes, except in certain very rare clinical syndromes 
characterised by severe insulin resistance due to the presence of anti-insulin receptor 
antibodies. Other defects that have been associated with type 2 diabetes are a mutation in 
the insulin gene in patients with high proinsulin levels [Steiner et al. 1990]. Also insulin 
receptor mutations in patients with marked insulin resistance [Taylor. 1993, Lauro et al. 
1998] and mutations of mitochondrial DNA associated with deafness and maternal 
inheritance [van den Ouweland et al. 1994, Cl ark et al. 1995, Saker et al. 1997]. 
Included in the sub-class of type 2 diabetes are people with maturity onset diabetes 
of the young (MODY). This occurs in families who inherit type 2 diabetes in an autosomal 
dominant way in children and young adults [Tattersall and Fajans. 1974, Froguel et al. 
1992]. MODY is a heterogeneous disorder and the study of the defined phenotype of 
MODY has allowed the identification of candidate genes and highly polymorphic markers. 
Mutations in four genes have been shown to cause MODY: glucokinase, hepatic nuclear 
factor 1 alpha (HNFl alpha), hepatic nuclear factor 4 alpha (HNF4 alpha), hepatic nuclear 
factor 1 beta (HNF1 beta) and insulin protein factor 1 (IPF1) [reviewed by Hattersley. 
1998]. However, most MODY families appear to have their own mutation and no 
common mutation has, as yet, been found. Apart from the genetic influence on the 
aetiology of type 2 diabetes a variety of lifestyle and environmental factors have been 
identified as important risk factors, including the degree of obesity, the amount of physical 
activity and the use of drugs such as steroids and anti-hypertensive drugs. Prominent 
among these factors is obesity, a major determinant in the development of insulin 
resistance. It is possible that the cause of type 2 diabetes is an underlying genetic factor, 
influenced also by environmental and lifestyle factors. 
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1.3.3 Further subtypes of diabetes mellitus 
Type I and type 2 diabetes are the major subtypes of diabetes mellitus. The other 
remaining categories of diabetes can be associated with a variety of other conditions and 
syndromes. Malnutrition-related diabetes mellitus (MRDM) is a variant of diabetes that 
has been characterised controversially as an independent entity [Abu-Barkare et al. 1986, 
Harris and Zimmet. 1997, Clark et al. 1995]. MRDM covers a variety of types known 
previously as tropical diabetes, pancreatic diabetes, endocrine pancreatic syndrome and 
ketosis resistant diabetes of the young There are two subclasses of MRDM; fibrocalculous 
pancreatic diabetes and protein deficient pancreatic diabetes [Clark et al. 1995]. Subjects 
of this disease are normally from poor tropical countries and appear underweight or 
emaciated. They also have clinical signs of past or present malnutrition and other dietary 
deficient states. The features of the fibrocalculous form are pancreatic fibrosis and 
calcification and clinical evidence of pancreatic endocrine and exocrine malfunction. The 
protein deficient form is characterised by ketosis resistance and extreme degrees of 
emaciation and wasting [Clark et al. 1995]. There is not much information on the 
epidemiology and aetiology of the disease, however a genetic basis has been suggested due 
to the occurrence of familial aggregation. 
Gestational Diabetes (GDM) is restricted to pregnant women when recognition or 
development of diabetes or impaired glucose tolerance (IGT) first occurs in pregnancy. 
Diabetic women who become pregnant are not included in this class. It is thought that 
GDM is caused by complex metabolic and hormonal changes that are not completely 
understood. After pregnancy women who had GDM have to be reclassified as either 
diabetes mellitus, impaired glucose tolerance (IGT) or previous abnormality of glucose 
tolerance (Prev AGT), in most cases Prev AGT occurs and glucose tolerance returns to 
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nonnal [Kjos et al. 1990, Harris and Zimmet. 1997]. However, there is an increased risk of 
IGT and type 2 diabetes developing 5-10 years after pregnancy [Coustan et al. 1993]. 
GDM occurs in about 3-5% of pregnancies in Western countries and it seems that age is 
the single most reliable correlate of abnonnal glucose tolerance in pregnancy. The clinical 
recognition of GDM is important because if it is untreated there is an increased risk of the 
off spring developing macrosomia and perinatal mortality [Scheuner et al. 1997]. There is 
a debate as to whether glucose intolerance is actually associated with pregnancy as a 
proportion of young (3-5%); non-pregnant women have clinical characteristics similar to 
those with GDM. This suggests that GDM may not be aetiologically related to pregnancy 
and is simply a pre-existing glucose intolerance detected during the metabolic testing 
carried out during prenatal care [Harris. 1988]. Secondary diabetes is one of the smaller 
subclasses of diabetes and is associated with a number of conditions and syndromes. 
Included in this are fonns of pancreatic disease, for example hemochromatosis associated 
with type 2 diabetes and hereditary relapsing pancreatitis associated with IGT-type 2 
diabetes. Also, endocrine disorders including Cushings syndrome, pheochromocytoma 
associated with IGT and glucagonoma. The administration of certain honnones, drugs and 
chemical agents can induce hyperglycemia and diabetes a few of which are, 
catecholamines, glucocorticoids, diruretics and antihypertensive agents, honnonally active 
agents, psychoactive agents, analgesic and finally anti-inflammatory agents [Harris and 
Zimmet. 1997]. Diabetes may also be associated with defects of insulin action caused by 
abnonnalities in the number or affinity of insulin receptors, or by antibodies to receptors 
and with rare amino acid substitutions in the insulin molecule [Harris and Zimmet. 1997]. 
Finally there are a large number of genetic disorders/syndromes that are frequently 
associated with diabetes (impaired glucose intolerance-lOT). Some of these syndromes are 
inborn errors of 
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metabolism i.e. glycogen storage disease type I associated with IGT, insulin-resistant 
syndromes i.e. ataxia telangiectasia, hereditary neuromuscular disorders i.e. Huntington's 
disease associated with IGT-type 2 diabetes and also Friedreich's ataxia associated with 
type l diabetes and type 2 diabetes. Progeroid syndromes i.e. Cockayne's syndrome 
associated with IGT, syndromes with glucose intolerance secondary to obesity i.e. Prader-
Willi syndrome associated with type 2 diabetes and also Cytogenetic disorders such as 
Down's syndrome associated with IGT and Turner's syndrome associated with IGT-type 2 
diabetes [Harris and Zimrnet. 1997]. 
The variety of conditions that have been covered in this section clearly illustrates the 
heterogeneity of the diabetic syndrome. 
This section has attempted to provide a brief description of the different forms of 
diabetes mellitus and their associated aetiologies. However, the rest of this thesis will 
focus on type I diabetes and the distinct characteristics associated with this form of the 
disease in more detail. 
1.4 Epidemiology of type 1 diabetes 
Epidemiology is the study of the distribution and determinants of health-related 
states or events in specific populations and the application of this study to the control of 
health problems [Last. 1988]. 
More is known about the epidemiology of type 1 diabetes than almost any other chronic 
disease. However, until the early eighties little was known about the worldwide 
epidemiology of type 1 diabetes. There was little information or no information for some 
countries, and what data was available was not standardised and therefore not directly 
comparable [Rewers et al. 1988, Karvonen et al. 1993, Tuomilehto et al. l992a, 
Lounamaa. 
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1996, Viiiiniinen et al. 1998, Green and gale. 1993]. In 1983 the Juvenile Diabetes 
Foundation sponsored a meeting where it was recognised how important registries would 
be for the investigation of the epidemiology of type I diabetes. A set of criteria was 
proposed for the registries; cases were to be under the age of 15 years at onset, diagnosed 
as having diabetes, on insulin at the time of diagnosis, and a resident of a defined 
community [LaPorte et al. 1985]. Also highlighted at the meeting was the enormous 
geographical variation in the incidence of type I diabetes, which had been shown by many 
studies [Bloom et al. 1975, Christau et al. 1977, Lounamaa. 1996]. The standardised 
collection and analysis of epidemiological data of type I diabetes was begun initially by 
The Diabetes Epidemiology Research International Group (DERI) [Rewers et al. 1988, 
Diabetes Epidemiology Research International Group, 1988]. DERI played a key role in 
collecting standardised incidence data between the late 1970's up to the mid 1980's, 
allowing the direct comparison of data between countries. The World Health Organisation 
Project, the Multinational Project for Childhood Diabetes (DIAMOND) was started in 
1990, followed by the collaborative research project EURODIAB-ACE that was set up to 
investigate the incidence of type I diabetes throughout the countries in Europe [Green et 
al. 1992]. Other collaborative groups have been established in many different countries and 
there are approximately !50 registries in over 70 countries. All of these studies provide a 
basis for the study of variations in the clinical characteristics and environmental 
determinants and their complex interactions in the cause and pathogenesis of type I 
diabetes [Green et al. 1992]. 
The large global variation m the incidence of type I diabetes is now well 
documented, and has shown that the difference between the highest and the lowest 
incidence is as much as 60-fold [Rewers et al. 1988, Green et al 1992, Diabetes 
Epidemiology Research International Group. 1990, Tuomilehto et al. 1992a, Bingley and 
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Gale. 1989, Karvonen et al. 1993, Viiiiniinen et al. 1998, Green and Gale. 1993]. This 
world-wide variation is also seen in small "pockets" of countries, particularly in the Baltic 
Sea region [Tuomi lehto et al. 1992b, Tuomilehto et al. 1996, Padaiga et al. 1997]. There is 
an apparent north-south gradient in the occurrence of type I diabetes and a verified 
positive correlation between the incidence and the distance to the equator. Countries below 
the equator have an incidence of 15.0-20.0 per 100,000, compared to countries above the 
equator were the disease is extremely common. The comparison of incidence between 
continents showed that the lowest incidence was found in Asia [Hua et al. 1994], followed 
by Oceania (Australia and New Zealand), and then South and North America and the 
highest rates were found in Europe [Karvonen et al. 1993, Sekikawa and La Porte. 1997]. 
The incidence is highest in Finland, 35.3 per 100,000 [Tuomilehto et al. 1992a, Karvonen 
et al. 1993] where there is a continual rise in the incidence [Karvonen et al. 1997, 
Tuomilehto et al. 1995, Viiiiniinen et al. 1998]. Followed by the other Nordic countries 
Sweden and Norway [Dahlquist et al. 1989, Joner and Sovik. 1989] compared to the lowest 
in Korea and Mexico, 0.6 per 100,000 [Rewers et al. 1988, Karvonen et al. 1993]. The 
largest intracontinental variation in incidence occurs in Europe, varying from the highest 
(35.3 per 100,000) in Finland [Tuomilehto et al. 1992a] to the lowest (4.6 per 100,000) in 
northern Greece [Green et al. 1992]. The incidence in Northern Europe is generally higher 
than the rates elsewhere in Europe excluding Sardinia where it is the second highest, 30.2 
per I 00,000 in the world after Finland [Green et al. 1992, Muntoni and Songini et al. 
1992]. The incidence in Denmark between 1970 and 1976 was approximately half of that 
in Sweden [Green et al. 1992, Nystr-,m et al. 1992], but by the end of the 1980's it was 
similar to Sweden and Norway. Denmark has now joined the high-risk Nordic countries 
and highlights the increasing incidence of type I diabetes in the First world. One striking 
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exception to the overall incidence levels in northern Europe is that of Iceland, where the 
incidence rate is only half that in Norway and Sweden and one third of that in Finland 
[Helgason et a!, 1992]. Intracountry variations in incidence rates have also been reported in 
a number of countries including the Nordic countries [Reunanen et al. 1982, Joner and 
Sovik. 1989, Hiigg!Of et al. 1982, Karvonen et al. 1997]. This has also been shown in the 
British Isles, [Bingley et a!, 1989, Metcalfe and Baum. 1991, Staines et al. 1993, 
Rangasami et al. 1997, Crow et al. 1991, Patterson et al. 1996, Zhao et al. 1998] and Italy 
has been shown to have the largest intracountry variation in Europe [Green et a!, 1992, 
Bruno et a!, 1993, Tenconi et al. 1995, Cherubini et al. 1997]. In North America the 
intracontinental variation in incidence is also large ranging from 0.6 per I 00,000 in 
Mexico to 23.9 per 100,000 on Prince Edward Island [Karvonen et al. 1993, Lounamaa. 
1996]. It has been suggested that the large variation in geographical incidence implies the 
involvement of environmental factors in the aetiology of Type I diabetes [Diabetes 
Epidemiology Research International Group. 1987]. It also reflects the distribution of 
ethnic populations, highlighting the importance of different genetic factors between 
populations [Karvonen et al. 1993]. 
A few studies have looked at the incidence of type I diabetes with respect to ethnic 
origin, either between different ethnic groups living in the same country or migrant studies 
between populations of the same ethnic origin but living in different countries [Bodansky 
et al. 1992]. The incidence among Caucasoid populations is higher than among other 
ethnic populations throughout the world [Rewers et al. 1988, MacDonald, 1980]. One of 
the first and most cited studies is one from Montreal, Canada which compares the 
incidence of type I diabetes among children of different ethnic backgrounds [Colle et al. 
1981 Siemiatycki et al. 1986]. From the study a noticeable difference in incidence was 
shown between the French in France and the French in Montreal. It was suggested that this 
maybe due to either 
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susceptibility genotypes for type 1 diabetes being introduced by immigrants from the 
British Isles or, differences in environmental factors between Montreal and France. Among 
Spanish and black populations the incidence of type 1 diabetes may vary geographically 
depending on the admixture of racial groups [Chakraborty et al. 1992, Carrasco et al. 1996, 
Lipton and Fivecoate. 1995, Tull et al. 1997]. Differences in incidence between Caucasoid 
populations are also seen, the incidence in Finland is over three times higher than in 
Estonia even though the two populations live in close proximity and are genetically similar 
[Karvonen et al. 1993]. The incidence of type I diabetes has been shown to vary in 
populations of the British Isles [Patterson et al. 1988, 1996, Rangasami et al. 1997, Zhao et 
al. 1998]. Although genetic susceptibility is involved in the development of type I 
diabetes, environmental factors must also be involved in the initiation or acceleration of 
the disease. 
Numerous studies over several decades have shown a seasonal variation in the 
diagnosis of type I diabetes. [Zhao et al. 1998, Lounamaa. 1996, Bingely and Gale. 1989, 
Metcalfe and Baum. 1991, Karvonen et al. 1993, Green and Gale. 1993, U:vy-Marchal et 
al. 1995, Karvonen et al. 1998]. It has been confirmed in both Northern and Southern 
hemispheres that more diabetics are diagnosed during the autumn and winter months. 
However, there are some exceptions in the seasonal pattern in France and Western Siberia 
no seasonal differences in type I incidence has been shown [Shubnikov et al. 1992]. Some 
studies have reported seasonal variation to be more marked in older children [Karvonen et 
al. 1993, Lounamaa. 1996] however, it has been shown that seasonal variation at 
presentation is apparent in all age groups even in the youngest ones [Levy-Marchal et al. 
1995]. A few studies have shown a pronounced seasonality of type I diabetes in children 
under the age of 6 years compared with older children [Gleason et al. 1982, Wadsworth et 
al. 1995]. Some studies have shown a more distinct seasonal variation in boys than in girls 
49 
[Lounamaa. 1996], but no significant gender difference was observed in the European 
study [Levy-Marchal et al. 1995]. It has been suggested that the seasonal variation of type 
1 diabetes may be due to the influence of infectious agents as the pattern mirrors periods of 
greater childhood viral infections. An infection may precipitate symptoms in a pre-diabetic 
child by causing an increase in the insulin requirement [Gamble. 1980, Dahlquist. 1993]. It 
has been shown that children born in the spring and summer are more likely to go on to 
develop type 1 diabetes, than those born in the winter months [Rothwell et al. 1996]. From 
this it has been suggested that environmental factors of a seasonal nature must be 
important and it is possible that the disease process may be initiated by a viral infection 
early in life [Leslie and Elliott. 1994]. HLA susceptibility markers may also influence the 
variation in seasonality, patients with DR4 have been reported to have a wider seasonal 
variation than those with DR3 [Eberhardt et al. 1985, Ludvigsson et al. 1986, Akerblom et 
al. 1997]. 
The pattern of age at onset for type I diabetes is generally the same throughout the 
countries, an increase in incidence up to the age of puberty followed by a decline. A peak 
in incidence at the age of 11-12 years in girls and a plateau of 12-14 years in boys has been 
shown in a number of studies [Lounamaa. 1996, Sekikawa and LaPorte. 1997, Green and 
Gale. 1993, Zhao et al. 1998, Dorman. 1997]. However, other studies have reported a 
bimodal distribution of the age of onset. A smaller increase in incidence occurring around 
the age of 5-7 years has been shown to be more marked in boys, with girls showing a more 
steady increase towards the peak in puberty [Staines et al. 1993]. An exception to the 
general pattern of age distribution is seen in Finland, where in the late 1960's and early 
1970's the pattern of age at onset was similar to that already described. However, due to 
the constantly increasing incidence of type 1 diabetes, in particular in the number of newly 
diagnosed diabetic children at a younger age, the pattern of age at onset of the disease has 
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changed to being remarkably high throughout childhood [Tuomilehto et al. 1992a, 
Tuomilehto et al. 1995]. It has been suggested that if the age distribution varies with the 
population risk of type I diabetes, there may be different risk factors or patterns of age-
specific susceptibility in different areas [Levy-Marchal et al. 1995]. A possible explanation 
for the different patterns of age distribution is related to the aetiology of type I diabetes. It 
has been suggested that the preclinical phase of type I diabetes extends over months or 
years with numerous environmental factors triggering a number of autoimmune attacks. 
Some of these factors may have a more severe or rapid effect during puberty than they do 
in younger children. Exposure to some of these environmental factors may also vary 
geographically [Levy-Marchal et al. 1995]. 
There is a small difference in the incidence of type I diabetes between males and 
females. In Caucasoid populations there is a slightly higher incidence of males than 
females [Tajima et al. 1993, Levy-Marchal et al. 1995, Bingley and Gale. 1989, Gardener 
et al. 1997, Patterson et al. 1996]. Other studies in Caucasoid populations have shown a 
slight increase in incidence in females compared to males [Zhao et al. 1998, Crow et al. 
1991]. In non-Caucasoid populations and countries with a low incidence of type I diabetes 
there is a slightly greater female incidence and many of these countries appear to have an 
excess of type I diabetes in females compared with males [Karvonen et al, 1993, Dorman. 
1997]. In the Finnish population, there are a greater number of males before the age of 
three and also after the age of eleven who develop type I diabetes compared to the female 
population [Tuomilehto et al. 1991]. Studies on the incidence of type 1 diabetes above the 
age of 15 years have in general shown a larger male excess after puberty, with an 
incidence almost twice as high than in females [Lounamaa. 1996]. The reasons for these 
differences in incidence between male and females differences are still unknown. 
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1.4.1 Infectious agents and type 1 diabetes 
The involvement of infectious agents in the aetiology of type 1 diabetes was 
hypothesised more than 15 years ago, however, the true existence and the real nature of 
this involvement still remains elusive [Yoon. 1991,1995, Ginsberg-Fellner et al. 1984, 
Hyoty et al. 1995a, Pietropaolo and Trucco. 1996, Haverkos. 1997, Schranz and Lernmark. 
1998]. Studies on congential rubella infection [Menser et al. 1978] provided evidence for 
an association between viral illness and an increased risk of autoimmune mediated type 1 
diabetes, but there is no evidence that the virus is an important contributor to the aetiology 
of type 1 diabetes in general [Lounamaa. 1996]. The risk of the rubella embryopathic 
syndrome is now reduced due to the introduction of vaccination programmes in rnost 
developing countries. However, the rubella syndrome has allowed an understanding of the 
mechanisms used by other perinatal viral infections that may affect the risk of type 1 
diabetes [Ginsberg-Fellner et al. 1984]. In 1968 it was reported that mice that were 
infected with the encephalomyocarditis virus (EMCV), a Picornavirus belonging to the 
cardiovirus group, developed hyperglycaemia and lesions of the pancreatic islets of 
Langerhans [Craighead and McLane. 1968]. High levels of antibodies to the Coxsackie B4 
virus (CBV), a Picornavirus belonging to the enterovirus group, have been shown within 3 
months of onset of type 1 diabetes [Gamble et al. 1973]. Inoculations of the virus into mice 
lead to the development of type 1 diabetes [Yoon et al 1979, Yoon. 1995]. Other studies 
have shown that maternal enteroviral infection during pregnancy, and CBV infection in 
particular, is a risk factor for type 1 diabetes [Dahlquist et al. 1995a,b, Hyoty et al 1995a]. 
The peak incidence of enteroviral infections occurs in late summer and early autumn, 
suggesting a link with type 1 diabetes, that is known to have a peak incidence in autumn 
and early winter. In a study on the siblings of diabetic children serological verification was 
found for an enterovirus infection almost twice as frequently in those who developed 
clinical type 1 diabetes as in siblings who remained non-diabetic [Hyoty et al. 1995a]. This 
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difference was seen close to the diagnosis of type 1 diabetes and several years before. It has 
been suggested there is a relationship between enterovirus infections and the pathogenesis 
of type I diabetes, due to the temporal association of the infections with increases in islet 
cell antibody levels, ICA and insulin autoantibodies, IAA, in the pre-diabetic siblings 
[Hyoty et al. 1995a]. In spite of the convincing experimental models, there is no 
conclusive evidence that type I diabetes can be caused by a Coxsackie virus infection 
[Tuvemo et al. 1989, Schranz and Lernmark. 1998, Pietropaolo and Trucco. 1996]. 
Viruses may act by two possible mechanisms, either via a direct cytolytic effect, or 
by triggering an autoimmune process leading to P-cell destruction [Pietropaolo and 
Trucco. 1996, Karges et al. 1995, Akerblom et al. 1997, Szopa et al. 1993]. Certain 
viruses, such as the rubella virus might induce a new antigen leading to P-cell specific 
autoimmune type I diabetes. Others like the CBV4 virus might be involved either by 
destroying p cells or by inducing autoimmunity through molecular mimicry in genetically 
susceptible hosts [Yoon and Park. 1993]. There has been much interest in the mechanism 
of molecular mimicry due to the discovery of homology between the islet autoantigen 
GAD65 PEVKEK sequence and the Coxsackie PC-2 antigen [Kaufman et al. 1992]. 
Current studies on T cells recognising this sequence have, however given conflicting 
results [Atkinson et al. 1994, Endl et al. 1997, Wicker et al. 1996, Vreugdenhil et al. 1998]. 
It has been shown in animal studies that the destruction of P cells is dependent on the 
genetic make-up of the virus and the genetic background of the host [Yoon et al. 1993, 
Yoon. 1995]. In humans the genetic susceptibility to virally induced type 1 diabetes 
appears to be HLA restricted. Evidence of viral infections in newly diagnosed type 1 
diabetic patients has been shown by the 
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associations between HLA risk antigens and IgM class antibodies to CBV [Eberhardt et al 
1985, D'Alessio. 1992]. A decrease in the frequency of T-lymphocyte proliferation in 
IDDM patients in response to CBV4 antigens when presented together by HLA-DR3 
positive cells has been shown, compared to an increased frequency of T-lymphocyte 
response to CBV 4 when associated with HLA-DR4 positive cells [Bruserud et al. 1985]. 
The HLA-mediated risk may be associated with the presentation of critical antigen 
epitopes by the risk-type HLA-molecules. This may play a role in the induction of cross-
reactive immune responses by homologous sequences in viral and ~-cell antigens, or it 
may determine whether the immune system recognises the autoantigens that become 
exposed in infected ~ cells. From this and the associations with the high-risk HLA-DQB 
alleles 0302 and 0201, it is suggested that the genetic susceptibility for enterovirus induced 
~-cell damage may be partly determined by the HLA genes [Hyoty et al. 1995b, 
Vreugdenhil et al. 1998]. Enterovirus infections in pregnant women increases the risk of 
type I diabetes in their offspring suggesting that viruses may initiate ~ -cell damaging 
process during foetal life [Hyoty et al. 1995b ]. 
Although rubella and CBV viral infections, in utero or later life have the strongest 
association with an increased risk to type I diabetes, other viral infections have also been 
suggested to be potential aetiological agents, these include Cytomegalovirus (CMV), 
encephalomyocarditis virus (EMCV) [Price. 1997, Pietropaolo and Trucco. 1996, Karges 
et al. 1995, Akerblom et al. 1997]. It has also been hypothesised that bacterial agents may 
have a role to play in the pathogenesis of type I diabetes in the form of superantigens 
[Conrad et al. 1994, Conrad et al. 1997, Akerblom et al. 1997]. 
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1.4.2 Nutritional factors and type 1 diabetes 
Nutritional factors have also been implicated, and may operate during the foetal and 
newborn period. At least two groups of dietary factors are high on the list of suspected 
diabetogenic agents, cow's milk protein (CMP) and nitrites, nitrates, and nitrosoamines, 
however the involvement of such factors is somewhat controversial [Lounarnaa. 1996, 
Leslie and Elliott. 1994, Akerblom and Vaarala. 1997, Akerblom et al. 1997, Gerstein. 
1994, Kostraba. 1994, Gerstein and VanderMeulen. 1996]. Many studies have shown that a 
short breast-feeding period or an early exposure to cow's milk is related to an increased risk 
for type 1 diabetes [Borch-Johnsen et al. 1984, Mayer et al 1988, Virtanen et al. 1991, 
1992, Verge et al. 1994, Gerstein. 1994, Saukkonen et al. 1998]. This effect may be due to 
maternal antibodies that prevent infections as well as the early intake of foreign proteins i.e. 
cow's milk protein. It has been shown in several studies that exclusive breast-feeding for at 
least 2 or 3 months [Virtanen et al. 1992, Verge et al. 1994] appears to reduce the risk of 
developing type 1 diabetes, with more patients with type 1 diabetes exposed to CMP before 
3-4 months of age compared to controls breast-fed for a duration of less than 3 months. It 
has therefore been suggested that the early introduction of CMP might be the actual risk 
factor and studies have shown it to be associated with an increased risk of type 1 diabetes 
[Kostraba et al, 1993, Virtanen et al, 1993, Verge et al, 1994, Cavallo et al. 1996, Vaarala 
et al. 1996, Akerblom and Vaarala. 1997]. Evidence that cow's milk exposure is linked to 
an increased risk of type 1 diabetes has been derived from a number of studies that include 
animal feeding studies, immunological studies in animals and humans and epidemiological 
studies. Studies in both the BB rat and the NOD mouse have implicated an immunological 
response to bovine serum albumin (BSA), which is an important constituent of CMP, in the 
development of type 1 diabetes. Elevated serum levels of lgG anti-bovine serum albumin 
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antibodies are present in both the BB rat and the NOD mouse, but not antibodies to any 
other milk proteins. These elevated levels of IgG were inversely related to the age of 
development of type 1 diabetes in the BB rat, the higher the level, the earlier the onset of 
diabetes [Beppu et al. 1987, Martin et al. 1991]. Similar results where found in patients with 
type 1 diabetes [Fiichtenbusch et al. 1997]. Most of the IgG antibodies are specific to a 17-
18 amino acid peptide within BSA (ABBOS). It has also been shown that a 69kDa ~-cell 
surface protein can immunologically cross-react with BSA, therefore an anti-BSA immune 
response may cross-react with and damage the pancreatic ~-cells, suggesting a link between 
CM exposure and ~-cell damage [Glerum et al. 1989]. The 69kDa protein is the autoantigen 
ICA 69, which has been identified on the surface of ~-cells in patients with type 1 diabetes 
and individuals at risk of developing type 1 diabetes. ICA 69 shares two short amino acid 
regions of similarity with BSA, but not with human albumin [Pietropaolo et al. 1993], some 
of the islet cell antibody activity may be specific for an antigen immunologically related to 
BSA It has been suggested that exposure to BSA or a BSA-derived peptide (ABBOS) may 
provoke an immunological response in genetically susceptible individuals, that cross-reacts 
with a ~-cell antigen such as ICA 69, the resulting ~-cell damage could then amplify the 
initial autoimmune process [Akerblom et al. 1993]. Cell-mediated immunity, which plays a 
key role in autoimmune ~-cell destruction [Atkinson and Maclaren. 1994], has been 
demonstrated in the presence of specific CMP's. Alternatively, early exposure of the 
immune system to epitopes within BSA may prevent the development of anergy to the 
structurally homologous ~-cell antigen ICA 69 and permit the development of ~-cell 
directed autoimmunity [Miyazaki et al. 1995]. Other mechanisms involving CM constituents 
such as ~-lactoglobulin and casein have also been proposed [Savilahti et al. 1993]. It was 
suggested that autoimmunity could be induced by molecular mimicry, when individuals with 
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disease associated HLA class IT molecules present the antigen, having been absorbed from 
an immature gut. ABBOS specific immune responses could then mediate destruction of 
pancreatic ~-cells through a shared epitope, in the event, for example, that an infection 
generated the systemic release of IFNy and induced the expression of ICA 69 on the surface 
of 13-cells. If, as suggested, ABBOS and ICA 69 share common epitopes, immune memory 
could be sustained and mediate ~-cell destruction [Ka.Ijalainen et al. 1992]. There is no 
consensus as to whether T cell reactivity is present, with a study showing a lack of immune 
response [Atkinson et al. 1993], whilst another study reported that T cell responsiveness 
could be demonstrated [Cheung et al. 1994]. Epidemiological studies have also found 
immunological evidence for an association between CMP and IDDM with increased levels 
of IgG and lgA to 13-lactoglobulin [Savilahti et al. 1988, 1993, Dahlquist et al. 1992], and 
also to BSA [Saukkonen et al, 1994]. These differences were found in newly diagnosed 
type 1 patients compared to normal healthily controls. In the latter study the difference 
between diabetics and controls was greatest in children below the age of three years. Also, 
siblings who contracted type l diabetes during the follow-up period were more likely to 
have a measurable level of IgA antibodies to BSA than those who remained non-diabetic 
[Saukkonen et al. 1994]. Similar results where also found in relation to HLA-DQ type and 
CMP antibodies [Saukkonen et al. I998]. When other dietary antigens were studied, there 
was no difference in IgG and IgA levels, suggesting that the immune response is not a non-
specific reaction to dietary components [Saukkonen et al. I994]. 
Many epidemiological studies including time-series and ecological studies have 
demonstrated an association with type I diabetes and the duration of breast-feeding. The 
only time-series study showed that the incidence of type I diabetes increased as the 
prevalence of breast feeding decreased [Borch-Johnsen et al. I984]. Correlation studies 
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have shown a strong positive linear correlation between the incidence of type I diabetes 
and cow's milk consumption in different countries [Dahi-Jorgensen et al. 1991, Fava et al. 
1994]. These studies provide evidence to support the hypothesis that cow's milk may 
contain a triggering factor for the development of type I diabetes. 
Although the data provided by these studies shows a convincing association, it 
may be over-represented as population studies can be confounded with other unmeasured 
environmental factors which may also be linked to higher rates of type 1 diabetes. Also 
time-series studies cannot take into account factors such as exposure to specific 
environmental agents and individual genetic susceptibility to type 1 diabetes. This led to 
the development of patient-specific case-control studies, comparing the feeding history in 
early infancy of type 1 diabetic patients and non-diabetic controls [Gerstein and 
VanderMeulen. 1996]. Evidence from case-control and epidemiological studies suggests 
that early exposure to CMP is a risk factor for type I diabetes in humans. Furthermore, 
patients with newly diagnosed type 1 diabetes have humoral and cellular immune 
responses to CM antigens, and the specific response to one of these antigens (BSA) is 
known to cross-react with at least one P-cell protein. However, this data cannot be used to 
directly distinguish between the possibility of a diabetogenic effect of early exposure to 
CM and a protective effect of breast-feeding [Gerstein & VanderMeulen, 1996] and also is 
insufficient to definitively establish a link between CM exposure and type I diabetes. No 
evidence has actually indicated that early CM exposure is necessary for the development 
of type I diabetes. There are at least two possible explanations for the observations of CM 
exposure and the development of type I diabetes. Firstly, CM exposure may accelerate the 
development of type I diabetes, but not initiate it. This is supported by case-control studies 
that showed type I diabetes developing at a younger age was more strongly associated 
with CM 
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exposure, than with type 1 diabetes developing in older children [Gerstein. 1994]. It is also 
supported by a study which demonstrated that type 1 diabetes develops at a later age in 
children who are breast-fed, compared to those who were bottle-fed [Bognetti et al. 1992]. 
Secondly, CM exposure may be confounded with some other factor that is casually related 
to type 1 diabetes, such as the processing or preparation of CM formulas, early 
gastrointestinal problems or viral infections [Szopa et al. 1993, Yoon. 1995, Gamble. 1980, 
Haverkos. 1997]. 
Some studies of infant nutrition have not supported the association between CM and the 
risk of type I diabetes, indeed preliminary findings of the DAISY study suggest a 
protective effect of early exposure to cow's milk [Norris et al. 1995]. Many other studies 
have also shown there to be no increase in risk of type 1 diabetes and the early 
consumption of cow's milk [Atkinson et al. 1993, Bodington et al. 1994, Li et al. 1995a]. 
Therefore the importance of cow's milk in type 1 diabetes remains unresolved at present, 
but the possible role of early infant and childhood diet requires further investigation 
[Kostraba. 1994]. 
The suggestion that 'enhanced' nutrition during childhood and adolescence 
predisposes to type 1 diabetes has been supported by evidence of a reduced incidence of 
diabetes during war time however, this may be due to lack of doctors. Also a high linear 
growth rate during puberty and an increased risk of type 1 diabetes. There is evidence of 
an increased growth rate for several years preceding type I diabetes [Blom et al. 1992]. 
Excessive weight gain in early infancy has also been associated with diabetes later in life 
[Baum et al. 1975, Johansson et al. 1994]. It appears that calorific intake during the early 
years of life and an accelerated growth rate may increase the risk of developing type 
!diabetes. It has been suggested that weight and growth parameters may have an effect on 
the ~-cell mass and thus influence the age at onset of type I diabetes [Khan and Couper. 
1994]. 
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1.4.3 Toxins and tvne 1 diabetes 
It has been suggested that toxins may also be important in the pathogenesis of type 1 
diabetes, in particular N-nitroso compounds [Lounamaa. 1996]. One of the first 
epidemiological studies to show a relationship between N-nitroso compounds and type 1 
diabetes was reported in Iceland. Males born in the month of October were more likely to 
develop type 1 diabetes than those born during the other months were. It was speculated 
that this was due to the tradition of parents consuming smoked and cured mutton that 
contains high amounts of N-nitroso compounds in the New year [Helgason and Jonasson. 
1981]. This was supported by a study in mice, fed with cured mutton, which had male 
offspring with hyperglycemia associated with ~-cell destruction [Helgason et al. 1982]. The 
Swedish Childhood Diabetes Study was established to evaluate risk factors for IDDM and 
included a study of different nutrients and food additives. Perinatal events, breast-feeding 
history, and aspects of social environments were also evaluated [Dahlquist et al. 1991, 
Dahlquist et al. 1990). A dose response relationship between the frequency of intake of 
foods rich in meat protein, complex carbohydrates, nitrosamines, nitrates/nitrites and type 1 
diabetes was shown. A Finnish study showed the daily intake of nitrite was greater for 
children with diabetes during the prediabetic period than for normal children. It was also 
higher in the mothers of children with diabetes than in the mothers of control children, 
[Virtanen et al. 1994]. The vitamin B derivative, nicotinamide has been reported to have a 
protective effect against the development of the disease [Lewis et al. 1992]. 
A number of chemical toxins can produce type 1 diabetes in humans. Some poison 
the ~-cells directly whilst others trigger an autoimmune process [Wilson and Ledoux. 1989, 
Leslie. 1993). The rat poison Vacor that contains the active ingredient, N-3-pyridymethyl-
N -p-nitrophenyl urea, can cause type 1 diabetes and neurotoxicity [Leslie. 1993]. A post 
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mortem study showed that extensive ~-cell damage occurred after fatal poisoning with 
Vacor [Karam et al. 1980]. Patients were found to have low insulin but normal glucagon 
levels, implying a specific cytotoxic effect to the ~-cells. Several other chemicals can 
sporadically cause mild hyperglycemia and glucose intolerance, including calcium channel 
blockers, corticosteroids, pentamidine and vincristine [Leslie. 1993]. 
Two drugs streptozotocin and alloxan have been used to generate animal models of 
toxin-induced type I diabetes. Alloxan causes acute ~-cell damage universally among 
vertebrates and streptozotocin selectively destroys pancreatic ~-cells in several mammals 
[Leslie. 1993]. Chronic exposure to lower doses of streptozotocin leads to an autoimmune 
like ~-cell destruction and gradual onset of type I diabetes. With a single high dose the ~­
cells of the pancreas are selectively degranulated after a few hours, then necrosed [Leslie. 
1993]. 
1.4.4 The aetiology of type 1 diabetes is multifactorial 
The genetic, immunological and environmental provoking factors that lead to type 
diabetes are complex. [Haverkos et al. 1997]. The interaction of immunological and 
environmental factors that predispose to type I diabetes may occur in the gut of a 
genetically susceptible host. Enteroviruses generally persist in the gut for several weeks 
after infection, an interaction with nutritional factors during this time may result in the 
production of a metabolite that is toxic to the ~-cells pancreas or perhaps initiates an 
immunological response. Further, viral-nutritional interactions could eventually reduce the 
insulin producing capacity to a level where insulin requirement exceeds the capability of 
the pancreas, resulting in clinical diabetes. Such a situation would be a stressful life event 
for example trauma, infection, pubescent growth spurt and pregnancy. It has also been 
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suggested that early exposure to foreign protein/nitrosamine during infancy might 'prime' 
the small intestine for subsequent viral-dietary interactions [Haverkos. 1997]. 
It can be hypothesised that a person may develop type 1 diabetes due to genetic 
susceptibility, exposure to some environmental factor(s) in utero or in postnatal life, which 
might have initiated the disease process, promoted its progress or precipitated the clinical 
manifestation of the disease. However, it still remains unclear why one child develops 
diabetes while some other child does not. 
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CHAPTER 2: THE STRUCTURE AND FUNCTION OF THE I-CELL 
RECEPTOR (TCR) AND THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) 
2.1 Introduction to the MHC and the TCR 
The following chapter is a description oftwo important components of the immune 
system, the major histocompatibility complex (MHC) and the T-cell receptor (TCR). The 
individual structure and function of the MHC and the TCR will be discussed and also how 
the two interact normally to produce an all important immune response and the 
development of tolerance. 
The immune system has two functional components that are involved in a normal 
reaction to foreign antigens within the body, the specific (acquired) immunity and non-
specific (innate) immunity. Non-specific immunity is the initial non-specific response to 
tissue injury produced by the body and specific immunity provides a mechanism for the 
body to selectively detect and eliminate foreign antigens. The two systems do not function 
independently and many of the cellular and soluble components have functions in both 
systems [Carroll and Prodeus. 1998]. Both systems have a humoral component consisting 
of the B cell system (B lymphocytes) involved in the production of antibodies and also a 
cellular component consisting of the T cell system (T lymphocytes). Both humoral and 
cellular immunity involve molecules of the MHC. 
2.1.1 The antigen-specific immune response 
The immune system is capable of dealing with a wide variety of foreign molecules 
and potentially harmful organisms with which it has had no previous contact, but avoids 
reactivity with self molecules which would be antigenic in other individuals and species 
[Benacerraf 1981, Karges et al. 1995]. The system can recognise pathogens that are 
external to the cells by general characteristics, which are different to those of the host. 
Immunoglobulin molecules on the surface of B cells provide a more specific form of 
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recognition. These molecules can interact with products secreted by microorganisms, a 
range of structures on the surface of an invading microorganism or substances related to an 
invader but expressed, intact on the surface of host cells. Pathogens that enter and exist 
within host cells cannot be dealt with by these mechanisms. However, the MHC has a 
specific function in allowing products of an invading intracellular microorganism to be 
recognised by the immune system. The specificity ofthe immune system is determined by 
the T cell, which orchestrates the immune response through a variety of effector 
mechanisms [Janeway and Travers. 1996]. Many of the immunoregulatory genes, which 
control T cell activation and various immune functions are located within the MHC 
[Altman and Trowsdale. 1989, Trowsdale and Campbell. 1992, Campbell and Trowsdale. 
1993, Trowsdale and Campbell, 1997, Powis and Geraghty. 1995]. For an intracellular 
pathogen to be identified by the immune system it must be expressed on the cell surface. 
Peptides derived from invading microorganisms are transported and displayed on the cell 
surface, by MHC class I and ll molecules. This allows the activation of the T cells, which 
are then able to recognise antigen specifically and initiate an appropriate mechanism for 
elimination ofthe foreign antigen. 
2.2 The structure of the TCR 
The TCR carries the specificity of aT-cell for an antigen and the repertoire ofTCR 
specificity's is the major determinant of an individual's immune responsiveness for 
antigens [Bently and Mariuzza. 1996, Bjorkman. 1997, Sloan-Lancaster and Alien. 1996, 
Karges et al. 1995, Janeway and Travers. 1996]. The structure of the TCR was first 
identified using anticlonotypic monoclonal antibodies, which were able to inhibit antigen 
specific activation of individual T -cell clones [Meuer et al. 1983]. The TCR is composed 
of a glycosylated polymorphic hetrodimer, ex.~, which is associated with a nonpolymorphic 
membrane-bound complex of proteins collectively known as CD3 [Clevers et al. 1988], 
see Figure 2.1. Over the years numerous studies have been carried out to determine the 
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complete TCR structure and binding to their MHC/peptide ligands [Yanagi et al. 1984, 
Janeway and Travers. 1996, Bentley and Mariuzza. 1996, Bjorkman. 1997]. It has been 
revealed that the a and 13 chains have a molecular weight of 40-45 kilodaltons and both 
have a similar amino acid sequence, with variable (V) and constant (C) domains. Sequence 
analysis has also shown a similarity between the al3 chains and the sequences of 
immunoglobulin molecules [Hoo et al. 1992, Bentley et al. 1995, Fields et al. 1995]. 
Studies have now confirmed a structural similarity between T -cell and B-cell receptors, the 
pairing of TCR V domains is similar to the pairing of antibody V domains, so that the TCR 
combining site for antigen resembles an antibody combining site [Garboczi et al. 1996, 
Garcia et al. 1996]. Both the a and 13 chains are composed of two domains, which in their 
three-dimensional structure closely resemble the variable and constant domains of 
immunoglobulins, 2 13-sheets that are joined by a disulfide bond. However, the C region of 
the a chain shows an unusual folding topology, instead of the well characterised 13-sheets 
connected by a disulfide bond the bond in the a chain connects a 13-strand within a 13-sheet 
to a helical region. The overall structure of the al3 heterodimer is essentially the same as 
the Fab portion of the antibody, but with a more rigid arrangement between the V and C 
domains of the two chains [Garcia et al. 1996], see Figure 2.2. The V region of the of the 
a and 13 chains that form the antigen-binding site of the TCR consist of regions analogous 
to the complementarity determining regions (CDRs) of immunoglobulins [Chothia et al. 
1988, Jorgensen et al. 1992, Bentley et al. 1995, Fields et al. 1995, Garboczi et al. 1996, 
Garcia et al. 1996]. There are six CDRs, three contributed from each V domain, CDR1, 
CDR2 and CDR3. The CDR3 loops are considered to be the most diverse of the three 
CDRs. It has been number suggested that the potential for TCR diversity is concentrated in 
the CDR3 regions, these loops were thought to contact the most variable part of the TCR's 
MHC/peptide ligand, the peptide. The less diverse CDR1 and 2 loops interact with the 
more constant MHC helices [Jorgensen et al. 1992, Chothia et al. 1988, Davis and 
Bjorkman. 1988], see Figure 2.3. However, recent studies have modified the predictions of 
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Fig 2.1. Structure of the T -cell receptor. The T -cell receptor heterodimer is composed of two 
transmembrane glycoprotein chains, a. and J3. The external portion of each chain consists of 
two domains, resembling immunoglobulin variable and constant domains, respectively. Both 
chains have carbohydrate side chains attached to each domain. A short segment analogous to 
an immunoglobulin hinge region connects the two constant regions to the membrane. The 
transmembrane helices of both chains contain positively charged (basic) residues within the 
hydrophobic transmembrane segment. The a. chains carry two such residues, while the J3 
chains have one (adapted from Janeway and Travers, 1996). 
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V a V~ 
Ca 
Fig 2.2. Three dimensional structure of a J~R ~~ is from the 2C cell line (Garcia et al. 1996). . 
Backbone ribbon of the 2C TCR shows that the a: chain is (residues 1-213) in pink and the ~ chain is 
(residues 3-247) in blue. Both a: and ~ chains are ~ strands indicated by arrows and fold into lg domains 
Jabeled according to the standard convention used for Ig folds. The disulfide bonds are shown in yellow 
balls, which are present within each domain and interchain disulfide. The CDRs are numbered from 1 to 4 
for each chain. 
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the earlier models that emphasised the importance of CDR3 regions in peptide contacts 
[Sant' Angelo et al. 1996]. It has been suggested that the CDR regions of both the a. and 13 
chains are involved in the interaction with the bound peptide, the CDR3 region of the 13 
chain having the greatest contact. A portion of the Vl3 CDR3 and all three CDRs of the Va. 
are in contact with the MHC helices [Garboczi et al. 1996]. A later study has shown that 
TCR V regions make contact with overlapping structures in the a. I and a.2 domain long a. 
helices [Smith and Lutz. 1997]. The a.l3 polypeptide chains form the TCR present on over 
90% of peripheral T -cells. However, there is another form of TCR present on 1-10% of 
peripheral T -cells that is formed by yo class of TCR polypeptides, these cells are usually 
CD4 and CD8 negative [Saito et al. 1984, Lanier et al. 1987, Brenner et al. 1986]. In 
general the structure yo TCR is similar to that of the a.l3 TCR, however, the CDR3 region 
of the y and 0 chains are more like those of the immunoglobulins than the a. and 13 TCR 
[Rock et al. 1994]. It has been suggested that the yo TCR recognise antigens differently to 
the a.l3 TCR, more like immunoglobulin recognition properties [Hass et al. 1993, Havran 
and Boismenu. 1994, Chien et al. 1996]. A large number of studies have investigated the 
recognition of antigen by the yo TCR, it has been suggested that TCR yo cells can respond 
to antigen without requiring MHC molecules [Schild et al. 1994]. Other studies have 
shown TCR yo cells recognise antigens in conjunction with MHC molecules [Ciccone et al. 
1989, Bosnes et al. 1990, Jitsukawa et al. 1988]. It has also been shown that yo T -cells can 
recognise antigen and initiate a cellular immune reaction without the usual antigen-
processing requirements, which suggests that yo T -cells may respond to antigens that 
would not be recognised by a.f3 T-cells [Kaufmann. 1994, Hirornatsu et al. 1992, 
Mombaerts et al. 1993]. The understanding of the role yo T-cells in the immune system is 
still limited, but they probably contribute to the immune defence, but in a way that is 
distinct from a.f3 T -cells. 
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Fig 2.3. The TCR and MHC-peptide complex interaction. The 2C-H-2Kb-peptide 
complex are shown in backbone tube. The MHC-peptide complex is below with the 
octamer peptide P1-P8 which locates between TCR and MHC and is shown as a large 
tube in yellow. The TCR is above within the CDR 1 and CDR 2 of a. chain in pink, hyper 
variable region 4 is in white. CDR 1 and CDR 2 of p chains in blue, hepervariable region 
4 in orange. The CDR3s are coloured in yellow (adapted from Garcia et al., 1996). 
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2.3 TCR gene organisation 
Four different loci encode the polypeptide chains for the TCR: TCRA, TCRB, 
TCRG and TCRD. The TCR is transcribed from continuous gene segments encoding the 
V, joining (J), C, hinge, transmembrane and cytoplasmic structural regions, with an 
additional diversity (D) region in TCR 13 and y chains [Yanagi et al. 1984, Hedrick et al. 
1984]. These gene segments in the TCRA, TCRB, TCRG and TCRD loci recombine in a 
developing thymocyte to produce a functional VDJ exon, encoding for TCBB and TCRD 
chains or VJ gene segments for TCRA and TCRG chains. This is then joined to a C-region 
gene segment by RNA splicing following transcription [Wilson et al. 1988, Davis and 
Bjorkman. 1988]. Rearrangements of two different sets ofreceptor genes distinguishes two 
cell lineages, one expressing a.l3 and another expressing yo. Diversity in the TCR is 
generated by the rearrangement of the large number of germline gene segments, somatic 
recombinations and combinatorial association of a. and 13 chains and the y and o chains. 
Most ofthe variability in the amino acid sequence is concentrated at the junction of the V 
and J regions in the a. and y chains and the D and J in the 13 and o, which encode the CDR3. 
This is further increased by the addition ofnon-germline encoded nucleotides at the V-D-J-
C 13 and V-J-C a. junctions (N region diversity) [Davis and Bjorkman. 1988]. A smaller 
though important additional diversity is generated by allelic polymorphism in the gene 
segments [Moody et al. 1998, Boysen et al. 1996]. It is the loss and addition of such 
nucleotides at the splicing sites that contribute the greatest degree of diversity to the 
generation of the immune repertoire. The genes involved in the recombination are 
recombinase genes (RAG) [Oettinger. 1996, Oettinger et al. 1990, Gellert. 1996, Lin and 
Desiderio. 1995, Thompson. 1995]. During development of the T-cell, the TCR a. and 13 
chain genes are rearranged by joining discrete segments and it has been shown that the 13 
chain genes are rearranged before the a. chain genes [Levelt et al. 1995], see Figure 2.4. 
The a. chain results from a V gene segment rearranging to a J gene segment to create a 
functional exon. The VJ exon is transcribed and spliced to C and generates the mRNA, 
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TCRA and TCRB genes rearrangement and expression 
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Flig 2.4. The rearrangement and expression of TCR a.- and P-chain genes. The TCRA 
and TCRB genes contain discrete segments V(D)JC, which are joined by somatic 
recombination during development of the T cells. A TCRA V gene segment rearranges to 
a TCRAJ gene segment to create a functional exon. The TCRA VJ exon is transcripted 
and spliced to TCRAC. The mature mRNA is then translated to generate the TCR a. -
chain protein. For the p chain, the procedure is the same as that in a. chain (adapted from 
Janeway and Travers, 1996). 
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which is then translated to give the TCR a chain protein. The 13 chain is like the 
immunoglobulin heavy chains, three gene segments, V, D and J encode the V domain, and 
the gene segments are rearranged to give a functional exon. The exon is transcribed and 
spliced to join VDJ to C and the resulting mRNA is translated to give the TCR 13 chain 
protein. The a and 13 chains combine to form the TCR al3 heterodimer soon after their 
synthesis. The TCRG and TCRD genes recombine in the same way and thereby generate a 
functional TCR yo heterodimer. The expression of TCR genes is controlled by T -cell 
specific transcriptional enhancers that bind partially overlapping sets of ubiquitous and 
lymphoid-specific transcription factors rather than by TCR gene rearrangements [Nikolic-
Zugic and Dyall. 1993, Wei et al. 1997]. These enhancers include the family of basic-
leucine zipper transcription proteins, the cyclic AMP response elements (CRE). Also 
members of the high mobility group (HMG) proteins, including the erythroid transcription 
sequence (Ets) proto-oncogene family [Leiden. 1993] and a core binding factor E3, 
although its role is unclear [Leiden. 1993]. The expression of the a and 13 chains appears to 
be regulated independently [Benoist and Mathis. 1992, W ei et al. 1997]. 
2.3.1 TCRA genes 
The human TCRA locus is located on the long arm of chromosome 14 at 14q 11-12 
[Caccia et al. 1985, Rabbitts et al. 1985]. The locus consists of 70-80 V segments; each 
containing an exon encoding a V region proceeded by an exon encoding the leader 
sequence that targets the protein to the endoplasmic reticulum for transport to the cell 
surface, see Figure 2.5. The J segments are located a considerable distance from the V 
segments and are in a cluster of approximately 60. The J segments are followed by a single 
C-domain segment, which contains four exons for the C and hinge domains and a single 
exon encoding transmembrane and cytoplasmic regions. The TCRA locus is interrupted 
between the J and V segments by another TCR locus the TCRD locus [Chein et al. 1987a]. 
There are currently 32 recognised TCRA V subfamilies 
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TCRAgenes 
LVx 70-80 Jx60 c 
Fig 2.5. The organisation of the human TCRA gene, there are about 70-80 variable, 60 
joining and a constant gene segments (adapted from Janeway and Travers, 1996). 
TCRB genes 
LVx52 Dl Jx6 Cl D2 Jx7 C2 
Fig 2.6 . . The organisation of the human TCRB gene, there are about 50 variable, a 
diversity, 6-7 joining and a constant gene segments (adapted from Janeway and Travers, 
1996). 
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[Wei and Concannon. 1996, Wei et al. 1997]. 
2.3.2 TCRB genes 
The human TCRB gene complex is located on chromosome 7 at 7q32-35 [Caccia 
et al. 1984, lsobe et al. 1985], see Figure 2.6. This region contains 57 VB gene segments 
that are subdivided into 26 families [Wilson et al. 1990, Robinson. 1991, Slightom et al. 
1994]. There are two TCRBC segments, separated by around 8kb, and each possesses a set 
ofTCRBJ ~segments and one TCRBD gene segment [Toyonaga et al. 1985, Clark et al. 
1984]. The two TCRBC segments are highly homologous, differing in only 4 amino acids. 
2.3.3 TCRG genes 
The human TCRG locus resides on the short arm of chromosome 7 at position 7p 15 
[Murre et al. 1985, Rabbitts et al. 1985], see Figure 2. 7. The genes are organised in a 
similar manner to those ofthe TCRB genes [Strauss et al. 1987]. The TCRGJ and TCRGC 
gene cluster are located next to each other and are flanked on their 5' sides by an array of 
TCRGV genes. There are approximately 14 V segments [Forster et al. 1987, Huck et al. 
1988). The five J segments identified in the TCRG locus can be divided into two groups 
comprising TCRGJl-3 located upstream of TCRGC1 and TCRGJ4-5 located upstream of 
TCRGC2 [Quertermous et al. 1986). The two TCRGC segments are structurally similar to 
the TCRAC and TCRBC genes, but have three exons. These encode the c domain, the 
connection peptide, transmembrane and intracytoplasmic portions, respectively. 
2.3.4 TCRD genes 
The TCRD locus in humans is located in the space between the TCRA V and 
TCRAJ gene segments [Chien et al. 1987b, Griesser et al. 1988], see Figure 2.8. There are 
three TCRDD segments [Loh et al. 1989] and three TCRDJ segments and a single constant 
segment. There are at least six TCRDV segments interspersed among the TCRA V gene 
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TCRG genes 
(\P)Vxl2 Jx3 Cl Jx2 C2 
Fig 2.7 .. The organisation of the TCRG genes in human. More than 14Vsegments and 5 J 
sections and 2 C segments are constituted the TCRG genes (adapted from Janeway and 
Travers, 1996). 
TCRD genes 
V>6 Dl D2 03 Jx3 c 
lFig 2.8 . The organisation of the TCRD genes in human. There are TCRDD segments 
and three TCRDJ segments, a single constant segments. There are at least six 
TCRDV(adapted from Janeway and Travers, 1996). 
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segments [Takihara et al. 1989]. 
2.4 The role of the T -cell antigen receptor 
The interaction between T cells and antigen presenting cells (APCs) depends on a 
complex series of cell surface molecules [reviewed by Sloan-Lancaster and Alien. 1996, 
Janeway and Travers. 1996, Madden. 1995]. This interaction necessitates the physical 
close contact of the two cells in which, the TCR acts as a multicomponent signalling 
device between the cells. The TCR is a membrane bound heterodimer protein as described 
in section 2.2. The TCR is found on the surface of immature T -cells were it has an 
important role in thymic ontogeny and the development of tolerance (this will be addressed 
in section 2.1 0) and is also present on the surface of all mature T -cells. The TCR is 
associated with a number of protein molecules on the surface of the cell, which include the 
CD3 complex and the co-receptors CD4 or CD8 and also CD45 [Wilson and Garcia. 
1997]. It has been shown that the simultaneous binding of these molecules and the TCR to 
the MHC molecule/peptide complex is necessary to activate T -cells [Salter et al 1990]. The 
CD3 complex plays an essential role in signal transduction and is often considered to be 
part of the TCR, acting as the messenger from extracellular to intracellular events 
[Jorgensen et al. 1992, Klausner and Samelson. 1991, Weiss and Littman. 1994]. CD3 is 
also involved in T cell activation and is required for the cell surface expression of the TCR 
[Gallagher et al. 1998, Janeway and Travers. 1996]. The CD3 complex consists of at least 
five polypeptide chains/proteins, y, o, &, ~ and TJ, see Figure 2.9. The y, o and & are 
structurally related single domain polypeptides belonging to the immunoglobulin 
supergene family and exist as noncovalently associated y/e and o/& dimers [Koning et al. 
1990, De La Herra et al. 1991, Exley et al. 1995, Wilson and Garcia. 1997]. They consist 
of extracellular domains, a transmembrane region and a long cytoplasmic domain, that 
contains sequences called immuno-receptor tyrosine-based activation motifs (ITAMS). 
These allow the polypeptide chains to associate with cytosolic protein tyrosine kinases 
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TCR 
recognition 
CD3 CD3 
signaling 
Fig 2.9. The outline structure of the TCR:CD3 complex. The TCR:CD3 complex 
contains eight polypeptide chains. Two are the disulfide-bonded a and p chains of the 
TCR. The other six chains, one y and 8, two of E and~ chains, collectively called CD3, 
which will signal to the interior of the cell when antigen binding has occurred. The TCR 
and CD3 are co-ordinately expressed at the T cell surface (adapted from Janeway and 
Travers, 1996). 
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(PTK) involved in transmembrane signalling. The PTKs are Src kinases p561ck and p5cfr', 
these activated kinases appear to be responsible for the subsequent phosphorylation of the 
CD3 IT AMS on their tyrosine residues, which then serve as binding templates for proteins 
containing the SH2-domain that are involved in downstream signalling events [Dianzani et 
al. 1992, Gauen et al. 1992, Sousa et al. 1996]. The~ and TJ polypeptides are structurally 
distinct [Ohno and Saito. 1990, Wilson and Garcia. 1997], and can exist as either a ~ or 
1;/TJ dimer in the CD3 complex. The ~ chain contains three sets of IT AM sequences, which 
suggests a role in signal transduction [Irving and Weiss. 1991, Exley et al. 1994, Irving et 
al. 1993]. The cytoplasmic domains of the CD3 e and CD3 ~ chains have been shown to 
independently generate signals for T -cell development and function [Shinkai et al. 1995]. 
Upon interaction with the MHC-antigen complex, it has been shown that most of the PTK 
activity occurred as result of the y and o chains. But the reaction of another kinase 
associated with the ~ chain called ZAP-70 has been shown to be important, resulting in 
phophorylation [Straus and Weiss. 1993, Bu et al. 1995, Isakov et al. 1995]. 
Previous models supported a single ligand specificity for any particular T -cell, 
however, a number of studies have demonstrated a flexibility in this recognition. It has 
been shown that naturally occurring altered peptide ligands for any TCR exist in the 
repertoire of self-peptides, or, in nature derived from pathogens. This can affect the 
phenotypes ofT -cells and implies that several signalling mechanisms exist that are linked 
to the TCR/CD3 complex, which can be dissociated from each other as a direct result of 
the nature ofthe ligand bound [reviewed by Sloan-Lancaster and Alien. 1996]. 
CD4 and CD8 molecules are well-characterised markers ofT-cells, because they 
distinguish between helper and cytotoxic T -cells. They also act as co-receptors that 
potentiate the activation signals delivered through the TCR [reviewed by Janeway and 
Travers. 1996]. It has been suggested that the two molecules are not functional analogues 
[Julius et al. 1993, Wiest et al. 1993], and have probably evolved differently to reflect the 
functions of mature T -cells. Both molecules interact with invariant regions of the MHC 
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class I and class II molecules respectively, stabilising the immune recognition complex. 
CD4 is a single transmembrane polypeptide composed of four immunoglobulin-like 
domains [Dianazani et al. 1992, Janeway and Travers. 1996], see figure 2.1 0. The 
cytoplasmic domain interacts strongly with the protein tyrosine kinase called p56Ld, which 
enables the CD4 molecule to be actively involved in signal transduction [Eck et al. 1994, 
Sousa et al. 1996]. CD4 binds only to class II molecules, through a region that lies mainly 
on a lateral surface of the first domain. There are two binding sites that have been 
identified on the class II molecule, which are a loop in the J32 domain and a site in the a.2 
domain, both of which are away from the binding site of the TCR [Konig et al. 1992, 
Konig et al. 1995, Cammarota et al. 1992, Brown et al. 1993]. CD8 is a disulfide-linked 
heterodimer comprising of an et and J3 chain, each chain contains a single immunoglobulin-
like domain linked to the membrane by a segment of polypeptide [Leahy et al. 1992, 
Janeway and Travers. 1996], see Figure 2.1 0. CD8 binds only to class I molecules, CD8 
binds to the ct3 domain loop of the MHC class I molecule [Lim et al. 1998, Garcia et al. 
1996, Salter et al. 1989, 1990, Conolly et al. 1990, Gao et al. 1997]. It has also been 
recently shown that the CD8 J3 chain may interact with the TCR in the absence of a 
MHC/peptide complex to promote energetically favourable conformations, which increase 
TCR ligand binding [Lim et al. 1998]. The interaction of the TCR with a MHC/peptide 
complex provides the signal, which leads to both CD4 and CD8 involvement. Once 
activated these co-receptors associate with p56Lcl<, leading to the phosphorylation of the 
CD3 complex and initiation of signal transduction [Weiss et al. 1991, Sousa et al. 1996, 
Lim et al. 1998, Sloan-Lancaster and Alien, 1996], see Figure 2.11. 
T -cell activation through the tyrosine kinases associated with the TCR complex is 
regulated by another T -cell surface molecule called CD45 [Trowbridge and Thomas. 
1994]. This molecule is a transmembrane glycoprotein that can be expressed as multiple 
isoforms [Janeway. 1992, Janeway and Travers. 1996]. The cytoplasmic tail of CD45 
contains phophotyrosine phosphatase activity, which can dephosphorylate tyrosine kinases 
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CD4 
cos 
a. 
Fig 2.1 0. The outline structures of the C04 and COS co-receptor molecules. The C04 
molecule exists as a monomer and contains four immunoglobulin -like domains. The amino-
terminal, 0 1 is similar in structure to an immunoglobulin variable domain. The 0 2 is different 
from the V and C domains and has been termed a C2 domain. The ftrst two domains of C04 
form a rigid rod-like structure that is linked to the two carboxy-terminal domains by a flexible 
link. The binding site for MHC class II molecules is thought to involve both the 0 1 and 0 2 
domains of C04. The COS molecule is a heterodimer of an a and a 13 chain that are 
covalently associated by a disulfide bond. The two chains of the dimer have very similar 
structures, each having a single domain resembling an immunoglobulin variable domain and a 
stretch of peptide believed to be in a extended conformation that links the V domain to the 
cell membrane (adapted from Janeway and Travers, 1996) 
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(A) 
(B) 
Infected cell 
Antigen presenting cells 
CD4 (Thl) 
Secretion of IL2, IFN-y 
and other cytokines 
IL4, IL5 Secretion 
of antibody 
CD4 (Th2) B-cell 
CD8 T -cell releases granzymes enter target cell 
Target cell lysed 
Fig 2.11 . TCR ex~ bearing T-cells express surface markers either CD4 or CD8. The CD4 and CD8 
molecules are important in antigen recognition by T cells and also this two lymphocyte subsets have 
different functions in immune system. CD8 molecules bind to a site on the cx3 domain of class I MHC 
molecules, whereas CD4 binds to a site between the cxl and a2 domains of a class II molecules. And CD8 
lymphocytes recognise the peptide antigens presented by MHC class I bearing cells and kill the infected 
cells, whist CD4 lymphocytes recognise the peptides presented by MHC class II bearing cells, which 
normally are professional antigen presenting cells and activate macrophages to kill the pathogens or 
activate B cells to produce antibodies 
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associated with the receptor and co-receptor molecules, resulting in increased kinase 
activity [Mustelin et al. 1989]. T cells that lack CD45 are defective in signalling through 
the TCR [Koretzky et al. 1990], suggesting that CD45 has a critical role in maintaining the 
TCR signal transduction apparatus and influencing T-cell responses [Janeway and Travers. 
1996]. 
The interaction between lymphocyte function antigen 1 (LF A-1) a heterodimeric 
polypeptide on the T-cell and intercellular adhesion molecule 1 (ICAM-1 or CD54), a five 
domain protein on the APC which belongs to the immunoglobulin supergene family, is 
necessary for the binding ofthe T-cell and APC. LFA-3 is a two domain immunoglobulin-
like molecule on the APC which interacts with CD2 (LF A-2), a single transmembrane 
polypeptide on the T -cell surface. These interactions lead to the amplification of the T -cell 
activation signal initiated by the TCR-CD3 complex [Siege! et al. 1991, Janeway and 
Travers. 1996]. 
2.5 History of the MHC 
Discrimination of self from non-self was first demonstrated in mammals by the 
rejection of grafts of foreign tissues, such as tumours in mice. The genes that control 
rejection of non-self tissues were subsequently mapped to a region termed H-2 on 
chromosome 17 in mice, which became known as the major histocompatibility complex 
(W:IC). Gorer in 1936 [Gorer. 1936] made the original identification of the MHC and 
showed that blood type segregated with susceptibility and resistance to a transplantable 
tumour in mice. The human leucocyte antigen (IU,A) system was discovered by Dausset in 
1958 and is located on the short arm of chromosome 6 in the distal portion of the 6p21.3 
band [Dausset and Hors. 1984]. Dausset realised that the human leucocyte antigens 
encoded in this region were similar to other MHC systems and that the histocompatibility 
effect may be common to all mammals [Klein. 1986]. Doherty and Zinkernagel in 1974 
conclusively showed that the function of MHC molecules is the discrimination of self from 
82 
non-self in the immune system. The first mammalian :MHC gene to be isolated was in man 
by Ploegh et al. 1980, followed a few years later by the first non-mammalian MHC gene 
which was identified in the chicken [Bourlet et al. 1988]. 
2.6 Structure of the MHC 
The MHC region in man spans approximately 4000 kilobases (kb) of DNA and has 
been divided into three regions on the basis of the structure, function and alloreactivity of 
the gene products [Steinmetz and Hood. 1983, Trowsdale and Campbell. 1992, 1997]. A 
molecular map of the :MHC in man is shown in figure 2.12. 
:MHC class I and class II molecules are polymorphic cell surface glycoproteins that 
are known as Jll,A-A, -B, -C and -DR, -DQ, -DP in man and H-2, 1-A and I-E in the 
mouse. The main function of these molecules is the recognition, processing and 
presentation of self and foreign peptides to T -cells, which results in the activation of the T-
cell and the initiation of an immune response. T -cells only recognise antigen by the 
interaction of the TCR (section 2.4) with processed antigen presented by :MHC molecules. 
This is known as MHC restriction, and was first demonstrated for murine class I antigens 
by Doherty and Zinkemagel in 1974. It was shown that T-cells recognise lymphocytic 
choriomeningitis virus antigen in association with H-2Kk could not recognise the same 
antigen associated with H-2Kd or H-2Db alleles. 
:MHC class I molecules are expressed on virtually all nucleated cells but their levels 
vary from tissue to tissue and are subject to regulation [Singer and Maguire. 1990, 
Geraghty. 1993, Ting and Baldwin. 1993, Le Bouteiller. 1994]. The highest levels of 
expression are found on immunocompetent cells and the lowest levels are found on muscle 
cells, nerve cells, hepatocytes, corneal endothelial, endocrine cells (with the exception of 
the adrenal gland), mature trophoblasts and pancreatic epithelial cells [Daar et al. 1984a, 
Natali et al. 1984]. :MHC class I molecules present antigenic peptides that have been 
processed in the cytosolic compartment of the presenting cell. They also present viral 
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(adapted from Charron, 1997) 
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proteins, which become incorporated in the host cells, machinery during infection. Peptides 
presented by class I molecules are recognised by CD8+ T-cells [Townsend and Bodmer. 
1989, Janeway and Travers. 1996] that are primarily involved in cell-mediated cytotoxicity 
ofvirus-infected cells [Lew et al. 1986, Parham. 1988, Janeway and Travers. 1996]. 
MHC class II molecules generally present antigens that are associated with 
membrane bound organelles and are derived from endocytosed extracellular proteins. Class 
II molecules present peptides to CD4+ helper T cells, which is an essential prerequisite for 
a humoral immune response [Benacerraf. 1981, Gregersen. 1989, Janeway and Travers. 
1996]. The expression of class II molecules is restricted to specialised antigen presenting 
cells (APC) of several types that occur at different locations throughout the body. These 
include B cells that are specialised APCs that can specifically recognise free antigens by 
their surface immunoglobulin molecules, and present them to T -cells. Macrophages and 
other phagocytic cells including Kupffer cells of the liver and marginal zone macrophages 
of the spleen. Also, the epithelial cells in a number of different organs including the 
gastrointestinal tract, thymus, proximal renal tubules and mesangial cells of the kidney and 
vascular tissue. However, the capillaries in the human brain and placenta do not appear to 
express class II antigens: this may relate to the fact that both of these tissues are relatively 
immunologically privileged. Class I and class II molecules are also expressed on the 
surface of dendritic cells including Langerhan's cells of the skin, dendritic leucocytes, 
which reside in most body tissues and also follicular dendritic cells [Natali et al. 1981, 
Daar et al. 1984a,b]. 
A number of tissues have been shown to express class I and class II molecules 
under pathological conditions. Hypoexpression of class I molecules has been detected on 
the surface of lymphoid cells in patients with type 1 diabetes whilst hyperexpression of 
class I molecules occurs on the surface of pancreatic islet cells [Bottazzo et al. 1985, Foulis 
et al. 1987, Faustman et al. 1991, Fu et al. 1993, Fu et al. 1996]. Hypoexpression of class I 
molecules has also been detected on the lymphoid cells of multiple sclerosis patients [Li et 
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al. 1995b]. Class II molecules have been shown to be aberrantly expressed on lymphoid 
cells in type 1 diabetic patients [Foulis et al. 1987, Foulis and Farquharson. 1986] and have 
also been found on thyroid epithelial cells of some patients with Grave's disease and 
Hashimoto's thyroiditis [Todd et al. 1990]. 
The MHC class I region contains genes that code for the classical HLA antigens 
(class la), A, B and C and the non-classical HLA-E, F, G and X (class lb) [Koller et al. 
1988, Geraghty et al. 1987, Geraghty et al. 1990]. Also a number of new putative genes 
and polymorphic microsatellite markers have been located in this region [Weissenbach et 
al. 1992, Crouau-Roy et al. 1994, Bouissou et al. 1995, Malfroy et al. 1997, Wei et al. 
1993, Mizuki et al. 1997, Shiina et al. 1997, Janer and Geraghty. 1998, Gruen et al. 1996]. 
12 pseudogenes, truncated genes and gene fragments have been identified in the class I 
region [Geraghty et al. 1992a,b]. The class I region of the mouse contains the genes 
encoding the classical serologically defined H-2 loci, H-21<, H-20 and H2-L [Hood et al. 
1983, Steinmetz and Hood, 1983]. In addition to the genes encoding these antigens the 
region also includes 18-26 genes that map to the Qa-2, 3, Tla and M regions. The Qa- and 
Tla-encoded molecules are expressed on subpopulations of lymphoid cells and some 
leukemias. The differences in tissue distribution and the absence of extensive 
polymorphism suggest that the function of Qa and Tla molecules may differ from that of 
H-2, K, D and L proteins [Geraghty et al. 1990]. The class II region encodes the HLA-D 
antigens, consisting of three groups, DP, DQ and DR, the ABC transporter genes, the large 
multifunctional protease (LMP) genes, plus a number of others, making a total of over 30 
genes. In the class II region of the mouse there are at least two distinct molecules, 1-A and 
1-E. The genes that code for the HLA antigens are the most polymorphic family of 
expressed genes in both humans and the mouse. In man, the serological, functional, 
biochemical and genetic properties can define HLA alleles. A different system of 
nomenclature applies depending on the method of detection. When the antigens are 
serologically defined they are named HLA-A, B, C, DR and DQ followed by a numerical 
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code that corresponds to the chronological order of their definition e.g. AI, B8, DR3. The 
use of a "w" between the locus and allele indicates that these alleles are not fully 
characterised and have a "workshop" status for e.g. Aw33, Cw7. However, in the eleventh 
International Histocompatibility Workshop (IHW), the use of all "w"s was discarded 
except for lfl-A-Bw4, Bw6 and lil-A-C alleles. lfl-A types defined by the T-cell are 
named Dw followed by a numerical code e.g. Dwl2. Finally, lfl-A alleles defined by 
nucleotide sequence analysis are named using the gene designation, followed by an 
asterisk and a four of five digit number. The numbers represent the nucleotide sequence 
subtype and also indicate whether there are two or more different nucleotide sequence 
variants of an allele. Alleles of murine H-2 antigens are denoted by superscript letters, for 
example H-2Kd and l-Ad. The MHC class m region encodes some of the proteins involved 
in the classical and alternative complement pathways including, C2, C4 and Bf and also the 
tumour necrosis factor (TNF) and heat shock proteins (HSP70). The murine MHC also has 
a fourth class of genes called Qa and Tla, which code for at least 29 class IV antigens 
whose products are involved in differentiation of haemopoietic cells [Steinmetz and Hood. 
1983]. 
More than 200 genes have been located in the MHC to date [Trowsdale and 
Campbell. 1997]; these include expressed genes, many of which have immunological 
functions in antigen processing and presentation [Campbell and Trowsdale. 1993) 
pseudo genes and genes of unknown status. The density of genes found so far in the class II 
and m regions is about one every 20 kilobases (kb). A large number of polymorphic 
multicopy genes have been identified, which are thought to have arisen from repeated gene 
duplication during evolution (Leelayuwat et al. 1995, Kasahara et al. 1996]. Some of the 
genes and transcribed sequences identified in the MHC are not structurally or functionally 
related to the MHC complex [Campbell and Trowsdale. 1993, Trowsdale and Campbell. 
1997]. A general insight into the molecular structure and gene organisation within the 
MHC was initially provided by pulsed-field gel electrophoresis (PFGE}, but the picture 
87 
remained incomplete [Dunham et al. 1987]. Due to advances in the techniques of 
molecular cloning and DNA sequencing over the past decade, it has now been possible to 
complete this picture. The use of overlapping cosmids and yeast artificial chromosomes 
(YACs) in the cloning of the MHC lead to the isolation of20 new coding sequences within 
the class IT and class m regions [Sargent et al. 1989, Spies et al. 1989]. Such techniques 
were limited to these two regions and the cloning of the class I region remained partial, 
restricted only to the HLA-A, HLA-B and HLA-C genes [Bronson et al. 1991]. The use of 
these techniques led to the entire MHC being cloned in a series of Y ACs and also resulted 
in a complete physical map ofthe HLA class I region [Abderrahim et al. 1994]. Continued 
studies into the class I region have brought the knowledge up to the level of the other two 
regions and provided a greater understanding into the genomic organisation of the region 
and set the stage for the determination of the complete nucleotide sequence of HLA class I 
[Bouissou et al. 1995, Venditti et al. 1994, Krishnan et al. 1995, Amadou et al. 1995, 
Shiina et al. 1998, Mizuki et al. 1997, Malfroy et al. 1997, Janer and Geraghty. 1998). 
During such studies the large-scale variability of the class I region among different HLA 
haplotypes has also been observed [Geraghty et al. 1992c, Watanabe et al. 1997]. 
The genes within the MHC represent an evolutionary dynamic situation where 
duplications and loss of expression of genes have occurred leaving functional genes 
alongside genes in various states of disuse. The duplicative nature of the MHC genes 
allows the MHC to keep up with the constantly changing immunological forms of attack 
undertaken by various pathogens. It is also possible that products of newly activated or 
duplicated genes could replace molecules that have lost their function as a result of 
deleterious mutations in their genes [Cadavid and Watkins. 1997]. 
2.6.1 MHC class I genes 
The human MHC class I region spans at least 2000 kilobases (kb) of DNA and is 
larger than both the class IT and class Ill regions. The class I region is located at the 
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telomeric end of the MHC (Figure 2.13) and is telomeric of the class m region [Dunham et 
al. I987]. The HLA-I7locus marks the centromeric arbitrary limit ofthe region and HLA-
F the most distal class I locus to be identified so far, located about 250 kb from HLA-A, 
was arbitrarily considered as the telomeric boundary of the class I region. However, the 
recent identification of an HLA class I-like gene about 4Mb telomeric of HLA-A suggests 
that this boundary may be even more distal than HLA-F [Feder et al. I996]. The first 
sequencing of this region was carried out by Ploegh et al. [ I980] in his search for the genes 
encoding the classical HLA antigens. He reported the isolation and partial sequencing of a 
cDNA clone corresponding to the C-terminal portion of a human class I antigen. In hybrid 
selection experiments, this clone detected a I650 base mRNA, which is larger than the 
mRNA coding region expected from the size of the class I protein. This suggested that the 
class I genes consist of both coding regions (exons) and non-coding regions (introns). It 
was subsequently shown that each region of a class I protein is encoded by separate exons 
within a class I gene [Malissen et al. I982]. Exon I encodes the signal (leader) peptide, 
which is removed co-translationally by a proteolytic enzyme in the endoplasmic reticulum. 
The three extracellular regions of the class I a. chain are encoded by exons 2 - 4 and ex on 
5 encodes the transmembrane region. Finally, the cytoplasmic region is encoded by the 
remaining I to 3 exons depending on the particular class I gene. The total number of exons 
within a class I gene therefore varies between 6 and 8. 
The class I region appears to have a reduced density of genes compared to either 
the class II or class ill regions (Figure 2.13), especially in the region of approximately 700 
kb between the INT3 and BATI genes, where more than 40 expressed genes have been 
identified [Campbell & Trowsdale, I993]. This is probably because the class I region has 
not been studied so extensively as the others, however, due to a number of studies like 
those already described new genes are continually being identified in the class I region. 
The importance of cloning and characterising the class I portion of the MHC has been 
shown firstly, by the association of specific HLA class I alleles with the susceptibility to 
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several diseases. Although the direct involvement of known Ill-A class I products has been 
shown, in other cases the genetic predisposition maps to a non-class I gene within the 
:MHC. Secondly, results of unrelated Ill-A identical bone marrow transplants suggest that 
polymorphic genes present within the :MHC other than the classical class I and 11 genes 
may affect the incidence and severity of graft versus host disease [Geraghty. 1993). 
Thirdly, a detailed map of the human MHC would allow an in depth understanding of the 
evolutionary history of a highly diverse part ofthe mammalian genome [Geraghty. 1993). 
The most extensively studied molecules of the class I region are the classical 
transplant antigens Ill-A-A, -B and -C. The classical class I genes (class la) share a number 
of features, they encode glycoprotein heavy chains that are expressed on the cell surface of 
essentially all nucleated cells, in association with a2m. The genes have been shown to be 
unevenly scattered within the class I region. The Ill-A-B and C loci are located in a 
centromeric position and are the most closely associated, separated by 85-130 kb and each 
associated with CpG island [Dunham et al. 1987, Lawrance et al. 1987, Chimini et al. 
1988]. These loci are separated from the telomeric ID..A-A and the main clusters of class I 
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Fig 2.13: Map of the class I region of the human Major Histocompatibility Complex (MHC) 
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genes by approximately 1200 kb. They are among the most polymorphic genes that have 
been described [Klein et al. 1990] and their protein products have a dual physiological 
property: they bind and present intracellularly processed foreign peptides to the TCR of the 
CD8+ cytotoxic T-cells. The critical role oflll..A-A, -Band -C in the immune response 
may explain their association with the susceptibility to a number of diseases. 
A susceptibility locus for Psoriasis vulgaris has been mapped near to the lll..A-C 
locus and it has been suggested that lll..A-C may be the susceptibility gene [Wuepper et al. 
1990, Asahina et al. 1992]. This susceptibility correlates with the presence of alanine at 
position 73 in the a.1 domain helix of the lll..A-C molecule [Asahina et al. 1992]. The 
presence of alanine in this position was significantly increased in patients with psoriasis, 
when compared with healthy controls, suggesting that this part of the lll..A-C molecule 
may be important in the disease susceptibility. lll..A-C alleles have also be associated with 
type II diabetes [Groop et al. 1983] and acute lymphoblastic leukemia [D'Amaro et al. 
1984]. There is substantial evidence that lll..A-C molecules can modulate the activity of 
certain natural killer cell populations [reviewed by Moretta et al. 1997, Lanier. 1998]. 
Natural killer cells (NK cells) have an important role in immune surveillance for altered 
cells not expressing class I MHC or expressing altered class I molecules [Garrido et al. 
1995, Ikeda et al. 1997, Moretta et al. 1992, 1994]. The first inhibitory receptors identified 
on the surface of certain NK cell subsets were found to be specific for lll..A-C [Moretta et 
al. 1993]. The receptor was known as p58 and the interaction between lll..A-C and this 
receptor resulted in the inhibition of NK-cell-mediated cytotoxicity and therefore 
protection of the lll..A-C expressing cell [Moretta et al. 1996, Vitale et al. 1995]. This 
receptor belongs to a family of receptors called killer cell inhibitory receptors (KIRs) and 
other receptors in this family have been shown to recognise polymorphsisms of the lll..A-C 
molecule these are known as KIR2DLI and KDR2DL2 [Lanier. 1998]. Activating 
receptors have also been identified that are specific to lll..A-C alleles and are present on a 
different set of NK cells. The interaction of this receptor known as p50 with the specific 
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HLA-C allele results in the, activation of the NK cell [Moretta et al. 1995]. The activity of 
p50 is regulated by inhibitory receptors that are eo-expressed at the surface of the NK cell 
[Moretta et al. 1995]. The physiological role of this activating receptor is still undefined, 
but it is possible that different peptides bound by the HLA-C molecule may influence the 
affinity of the receptor-HLA-C interactions [Garrido et al. 1997, Moretta et al 1997]. It is 
possible there is a link with the role of HLA-C alleles in the regulation of NK cell activity 
and the association of HLA-C with disease susceptibility. Inhibitory NK cell receptors 
have also been identified for HLA-B and HLA-A alleles, known as p70 and p70/140 
respectively [Ciccone et al. 1994, Gumperz et al. 1995, Vitale et al. 1996]. 
There is a strong association between the recessive iron storage disorder, hereditary 
haemochromatosis (HFE) [Simon et al. 1987) and the class I region. Linkage 
disequilibrium studies showed that the HFE gene was located within an HLA-A sub-region 
[Boretto et al. 1992, Yaouanq et al. 1994], further studies extended this region to D6S105, 
a genetic marker telomeric oflil.,A-A [Jazwinska et al. 1993]. Both have been shown to 
have strong allelic associations with the disease. Seven new non-Iil.,A class I genes have 
been localised around the HLA-A locus that may be associated with haemochromatosis 
and have therefore been named HCG I-VII (Haemochromatosis Candidate Gene) [El 
Kahloun et al. 1992]. Also a number of novel non-Iil.,A gene fragments have been 
identified in the Iil.,A-A sub-region, the role of these as potential haemochromatosis 
candidates has been investigated [El Kahloun et al. 1992, Goei et al. 1994]. Recently a 
novel MHC class I like gene has been found to be mutated in patients with hereditary 
haemochromatosis, this is considered to be a potential candidate gene for hereditary 
haemochromatosis [Feder et al. 1996]. The gene has provisionally been designated Iil.,A-H 
and may be located outside the MHC complex, although the localisation of this gene 
extends the telomeric boundary of the class I region. Certain HLA-A alleles may be linked 
to the susceptibility to type 1 diabetes [Jenkins and Mijovic. 1995, Bonifacio. 1995). HLA-
A alleles have also been implicated in the rapid and complete autoimmune destruction of 
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pancreatic ~ cells in co-operation with other type 1 diabetic susceptibility antigens 
[Nakanishi et al. 1993]. Serological and molecular typing studies have showed that the 
ffi..,A-A alleles may be 'anchors' for type 1 diabetic susceptibility haplotypes [Tienari et al. 
1992, Fennessy et al. 1994], whilst ffi..,A-A alleles may have an age dependent association 
with type 1 diabetes [Mizota et al. 1995, Fujisawa et al. 1995]. 
HLA-B8, -B15 and -B18 were the first serological markers associated with type l 
diabetes [Cudworth and Woodrow. 1976, Singal and Blajchman. 1973, Nerup et al. 1974]. 
Later studies have identified an association with HLA-B alleles [Nejentsev et al. 1997, 
Pittman et al. 1982, Reijonen et al. 1997]. ffi..,A-B has been associated with the myasthenia 
gravis disease locus [Degli-Esposti et al. 1992, Janer et al. 1998 in press] and also with the 
Behcet's disease locus, showing a strong association with fll..,A-B51 [Mizuki et al. 1992]. 
This is just a small example of the many diseases that have been shown to be strongly 
associated or linked with particular fll..,A-A., -B and -C alleles. Hypoexpression or 
hyperexpression of class I molecules has also been found on the surface of certain tissues 
in type 1 diabetes and other diseases. This may be due to altered class I gene expression or 
disruption of the mechanisms involved in the assembly of the class I molecules [Bottazzo 
et al. 1985, Foulis et al. 1987, Faustman et al. 1991, Fu et al. 1993, 1996, Li et al. 1995b]. 
Initial studies of the class I region revealed that there were more genes than could 
be accounted for by the classical ffi..,A-A., -B and -C loci [Orr et al. 1982, Orr and Demars. 
1983]. Southern blotting of genomic DNA with a class I gene probe detected 18 cross-
hybridising restriction fragments [Koller et al. 1988]. These were shown to include non-
classical (class lb) class I loci ffi..,A-E [Koller et al. 1988], ffi..,A-F [Geraghty et al. 1990] 
and ffi..,A-G [Geraghty et al. 1987], due to their restricted tissue distribution, limited 
polymorphism and function. Further analysis of the class I multigene family has shown 
that there are 12 ffi..,A-A related class I sequences in addition to the six fll..,A genes. The 12 
sequences consist of 4 gene fragments, 4 truncated genes and 4 full length pseudogenes all 
of which are closely related to the ffi..,A genes and are of unknown biological significance 
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[Geraghty et al. 1992a, Geraghty et al. 1992b]. The 4 gene fragments display homology 
over short regions and are known as J-aA-17, J-aA-21, 1-aA-30 and J-aA-81. J-aA-17 is 
most closely related to 1-aA-B and C, J-aA-21 to HLA-A, J-aA-30 to the pseudogene 
J-aA-92 and 1-aA-E [Geraghty et al. 1992a]. The 4 truncated genes show homology over 
longer portions and include 1-aA-75, 1-aA-80, J-aA-90 and J-aA-16. 1-aA-75 is most 
closely related to J-aA-A2 and 1-aA-G and has some polymorphism. J-aA-80 is located 
20 kb centromeric to 1-aA-A and two allele variants have been identified that are related to 
1-aA-A. 1-aA-90 is located in the telomeric vicinity of 1-aA-G and shares a very similar 
overall structure with J-aA-80 [Geraghty et al. 1992a]. The 4 full-length pseudogenes are 
known as J-aA-54/HLA-H, J-aA-59/fll..A-J, J-aA-70 and J-aA-92 [Geraghty et al. 
1992b]. Each of them has an exon-intron structure similar to a classical l-a A class I gene 
as well as homologies in their 5' and 3' flanking regions. 1-aA-H is located approximately 
1 OOkb centromeric to 1-aA-G and six alleles have been characterised with a general 
structure similar to J-aA-A2. It has therefore been suggested that 1-aA-H represent a 
functional peptide-presenting gene. 1-aA-J is located 50 kb centromeric to 1-aA-A [Messer 
et al. 1992] and there are 3 alleles of the pseudogene. 1-aA-J is closely related to 1-aA-A 
and also 1-aA-G and it shares some features with 1-aA-B, -C and -H. The third 
pseudogene 1-aA-70 has the most extensively disrupted coding sequence and also appears 
to be polymorphic [Geraghty et al. 1992b]. Finally, the a.3 domain of 1-aA-92 has a high 
homology with other class I genes, especially 1-aA-E. The pseudogenes are characterised 
by one or more substitutions that inactivate the coding sequence. The sequence 
comparisons with other class I genes show regions that are conserved and others that have 
diverged and show similarity with the non-classical genes. The existence of these gene 
fragments, truncated genes and pseudogenes in the class I region can be explained by the 
occurrence of a large series of duplications and deletions during the evolution of the class I 
region [Leelayuwat et al. 1995, Kasahara et al. 1996]. 
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As previously discussed the information on the genomic organisation of the class I 
region was somewhat limited. However, due to a number of studies over the past decade 
we now have a better understanding of the organisation of the class I region [Chimini et al. 
1988, Koller et al. 1989, Chimini et al. 1990, Bronson et al. 1991, Geraghty et al. 1992c, 
Venditte et al. 1994, Amadou et al. 1995, Malfroy et al. 1997, Mizuki et al. 1997, Shiina et 
al. 1998, Janer and Geraghty.1998]. The studies have led to the identification of a number 
of new genes and have also confirmed the positions and transcriptional orientations of the 
members of the ffi.A class I multigene family. Included in this are the non-classical class I 
genes (class lb genes), HLA-E the most divergent member of the non-classical gene family 
and has been mapped to around 700 kb telomeric to HLA-C and 550 kb centromeric to 
HLA-A. HLA-F and G have been mapped telomeric to HLA-A [Campbell and Trowsdale. 
1993, Trowsdale and Campbell. 1997]. Most of the physical maps have placed the HLA-F 
locus telomeric to HLA-G [Chimini and Pontarotti. 1991]. However, one study has 
suggested that the HLA-F locus is located centromeric to HLA-G [Abderrahim et al. 
1994]. This discrepancy was explained as an inversion polymorphism involving the HLA-
A, G and F loci. It has been shown that this region contains insertion/deletion 
polymorphisms ofup to 50 kb [El Kahloun et al. 1992, Geraghty et al. 1992c]. These class 
lb genes encode molecules that are structurally very similar to the classical products. They 
are defined as a separate entity due to their restricted tissue distribution, very low 
polymorphism and the absence of defined function [Shawar et al. 1994]. However, recent 
studies investigating their tissue distribution, expression of products, extent of 
polymorphism and functional importance suggest that their distinction from the classical 
class I genes may not be appropriate. 
HLA-G is considered unique amongst the members of the class I multigene family 
due to the restricted pattern of expression on the extravillious cytotrophoblast cells of the 
placenta, especially during the first trimester of pregnancy [Geraghty et al. 1987, Kovats et 
al. 1990, Houlihan et al. 1995, Guillaudeux et al. 1995]. By contrast, only intracellular 
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HLA-G proteins are expressed in the villous cytotrophoblast [Le Bouteiller and Lenfant. 
1996]. Studies have shown that HLA-G may not be as restricted in its expression, as HLA-
G transcripts have been demonstrated in a wide variety of cells in foetal and adult tissues. 
However, the low m.RNA levels detected may reflect a basal transcription that has no 
physiological significance [Onno et al. 1994]. This suggests that extravillous 
cytotrophoblast cells express HLA-G molecules. It has been shown recently that HLA-G is 
transcribed in lymphocytes, however, the role and the function of HLA-G products in 
lymphocytes is as yet unknown [Amoit et al. 1996, Amiot et al. 1997]. 
The HLA-G gene produces at least 4 distinct kinds of membrane-bound HLA-G 
proteins (4 isoforms) using complex alternative splicing mechanisms of m.RNA splicing. 
G1 is a full-length transcript/polypeptide, G2 is missing the a.2 domain, G3 is devoid of the 
a.2 and a3 domains and G4 lacks the a3 domain [Ishitani and Geraghty. 1992, 
Kirszenbaum et al. 1994]. This alternative splicing mechanism has been shown in placental 
tissues [reviewed in Le Bouteiller and Lenfant. 1996]. A homodimer of the G2 protein may 
function as a classical class II molecules [Ishitani and Geraghty. 1992]. The HLA-G gene 
can also encode two soluble forms of the protein [Fujii et al. 1994]. 
It was originally thought that HLA-G was non-polymorphic, however studies have 
now shown that six HLA-G alleles exist, due to polymorphisms in both the non-coding and 
coding regions [Castro et al. 1996, Pook et al. 1991, Morales et al. 1993, Alvarez et al. 
1997, Yamashita et al. 1997, Alizadeh et al. 1993, Ven and Ober. 1994, Amaiz-Villena et 
al. 1997]. 
Although no specific function has yet been clearly assigned to HLA-G several lines 
of evidence, in particular the restricted expression to the placental tissue, strongly suggest 
that HLA-G may play an important role in the maintenance of maternal tolerance to the 
foetus during pregnancy. It is well known that classical class I and class II molecules are 
not detected in the placenta, although HLA-C may be expressed. This observation may 
explain how the semiallogeneic foetus is tolerated by the maternal immunological system. 
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However, the absence of classical HLA molecules cannot explain how the foetus can be 
protected from maternal NK killing or infections. To determine the actual function of 
HLA-G the antigen presenting properties of the molecule have been investigated [reviewed 
by Le Bouteiller and Lenfant. 1996]. The similarity of the three dimensional structure of 
HLA-G to HLA-A2, makes it likely that it can bind and present peptide as classical class I 
molecules [Bjorkman et al. 1987a, Madden. 1995]. It has been shown that both cell surface 
and soluble HLA-G are capable of presenting self peptides [Lee et al. 1995, Diehl et al. 
1996), suggesting that HLA-G is capable of inducing a cytolytic T -cell (CTL) response. It 
is also likely that HLA-G can bind peptides of viral origin as it has been suggested that 
placental tissue be exposed to only a limited diversity of viral infections [Lee et al. 1995]. 
It is possible that HLA-G is involved in a mechanism by which an antigen is presented to 
the maternal immune system inducing lysis by maternal CTL and preventing the spread of 
infection in the placenta. 
It has been proposed that HLA-G molecules mediate the protection from decidual 
NK cells (a predominant CD56+ leukocyte found in the uterus), thereby playing an 
important role in maintaining maternal immune tolerance to the foetus [King et al. 1997]. 
Several studies have shown the ability ofHLA-G to partially protect target cells from NK-
mediated cell lysis [Chumbley et al. 1994, Rouas-Freiss et al. 1997, Pazmany et al. 1996, 
Munz et al. 1997, Mitsuishi et al. 1997]. The data from these studies suggests the presence 
of an HLA-G receptor on the surface of NK decidual cells, however, there is some 
conflicting evidence as to which KIR is involved in the recognition of HLA-G molecules. 
It has been suggested the p58.1 and p58.2 as well as the p70 receptor are involved 
[Pazmany et al. 1996, Moretta et al. 1997, Munz et al. 1997]. At variance with the results 
already outlined, subsequent studies have suggested that neither p58 or p70 recognises 
HLA-G, the recognition ofHLA-G is mediated by the CD94/NKG2A receptor and finally 
there is an unidentified receptor that can be detected at a functional level [Pende et al. 
1997, Perez-Villar et al. 1997, Soderstrom et al. 1997]. It has been suggested the 
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membrane-bound HLA-G1 and HLA-G2 isoforms are the public ligand for NK-cell 
inhibitory receptors, therefore having a protective role against NK cell cytotoxicity and 
conferring immunological tolerance to foetal tissues protecting the foetus [Rouas-Freiss et 
al. 1997, Moretta et al. 1997]. Soluble HLA-G has also been implicated in the interaction 
with NK specific inhibitory receptors and also inhibiting the function of alloreactive T-
cells, therefore playing a role in immunological tolerance [Amaiz-Villena et al. 1997, 
Mitsuishi et al. 1997]. 
Like class la loci, HLA-E is transcribed in a variety of tissues, including adult and 
foetal thymus and liver; lymph nodes; spleen; unactivated T and B cells; activated T -cells; 
skin; mucosa colon; eosinophils, as well as first, second trimester and term placentas, 
extravillous membranes and amnion epithelium cells [reviewed in Le Bouteiller. 1994, 
Houlihan et al. 1995, Wei and Orr et al. 1990]. Its transcriptional expression has also been 
detected in all human cell lines whatever the tissue origin, including those that do not 
express any other class I genes such as the choriocarcinoma cell line JAR and the level of 
expression varied depending on the tissue. Although the transcriptional expression of 
HLA-E is widespread the actual cell surface expression is low. It has been suggested that 
this is due to retention and accumulation ofHLA-E protein in the endoplasmic reticulum, 
together with a low stability of the HLA-E molecule during transport to the cell surface. It 
is possible that this could be because of defective binding of available endogenous peptides 
[Uibrecht et al. 1992]. 
There has been conflicting data on the polymorphism of HLA-E, initial studies 
suggested that were only two alleles of HLA-E [Geraghty et al. 1992d] and these two 
alleles have been detected in later population studies [Grimsley and Ober. 1997]. However, 
four HLA-E alleles have been detected in other studies [Amaiz-Villena. 1997, Boyson et 
al. 1995] and four HLA-E alleles were detected in this present study. It has also been 
shown that there is no significant linkage disequilibrium between HLA-E and HLA-A or 
HLA-E and HLA-G [Amaiz-Villena et al. 1997]. It has been suggested that this may be 
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due to the low polymorphism at the HLA-E locus, however, other low polymorphic and 
neighbouring HLA-G locus shows linkage disequilibrium with HLA-A [Amaiz-Villena et 
al. 1997, Morales et al. 1993]. It has been hypothesised that this reflects an altogether 
different function ofHLA-E proteins regarding antigen presenting or to antigen presenting 
repertoire shaping. 
Recent studies have shown that the expression of HLA-E on the cell surface is 
regulated by the binding of peptides derived from the signal sequences of certain HLA 
class I molecules and the primary peptide anchor residues are at positions 2 and 9 [Braud et 
al. 1997,1998]. This observation was confirmed by the resolution ofthe crystal structure of 
HLA-E [O'Callaghan et al. 1998]. The overall conformation ofHLA-E is quite similar to 
other class la proteins [Madden et al. 1995], however, the peptide-binding groove is more 
restrained, tailored to fit the hydrophobic peptides derived from the leader segments of 
other class I polypeptides. This allows HLA-E to bind leader peptides with high specificity 
and affinity. A number of recent investigations have identified a number ofHLA-A, -B, -C 
and -G alleles that are recognised by inhibitory NK cell receptors [Phillips et al. 1996, 
reviewed in Moretta et al. 1997]. The expression of class I molecules on target cells 
renders them resistant to lysis by most NK cells [Ljunggren and Karre. 1990]. Inhibitory 
receptors expressed by human NK cells belong to either the KIR or the C-type lectin 
superfamily. The best characterised members of the KIR family contain two (p58 
molecules: CD158) or three (p70 molecules: NKB1) immunoglobulin-like domains and 
different receptors of this family bind defined groups of classical HLA class I molecules 
[Long et al. 1997, Moretta et al. 1997, Lanier and Phillips. 1996]. The second family of 
receptors is composed of two subunits: CD94 paired with one member of the NKG2 family 
of proteins [Lanier et al. 1997]. The CD94-NKG2-A heterodimer transmits signals that 
lead to the inhibition of the lytic process. Numerous studies suggest that this heterodimer 
recognises a broad panel of classical HLA class I molecules [Phillips et al. 1996]. This 
study also showed that only the HLA alleles that possess a leader peptide capable of 
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upregulating HLA-E surface expression confer resistance to NK-cell mediated lysis, which 
implies that their action is mediated by HLA-E. Further studies verified that the CD94-
NKG2-A, -B and -C are specific receptors for HLA-E alleles with bound leader peptides 
derived from permissive HLA-A, -B, -C and -G polypeptides [Braud et al. 1998, Borrego 
et al. 1998, Lee et al. 1998] (Figure 2.14). These studies showed that HLA-E is involved in 
regulating NK-cell mediated cytotoxicity both positively and negatively. The capacity of 
HLA-E to preferentially bind leader segments of class I molecules demonstrates a novel 
mechanism whereby NK cells expressing essentially non-polymorphic receptors can 
monitor the expression of self class I molecules that are constantly undergoing genetic 
diversification. HLA-E acts as a sentinel that reflects the status of class I on the cell, 
detecting events that disrupt the synthesis or transport of conventional class I molecules. It 
may also be important in NK cell tolerance to self by preventing autoreactivity of NK 
cells; in particular by NK cells that lack KIR specific for self class I molecules [Lanier. 
1998, Long. 1998, Braud et al. 1998, Borrego et al. 1998]. The specific binding ofHLA-E 
to the receptor CD94-NKG2-C leads to the activation of NK cell cytolytic activity 
[Houchins et al. 1997]. The mechanism by which activation rather than inhibition is 
induced by certain class I NK-cell-receptor homologues was unknown. However, a recent 
study has discovered a signal-transduction molecule called DAP12, which couples an class 
I molecule on the surface of the NK cell to an activating signal-transduction pathway 
within the cell [Lanier et al. 1998, Colonna. 1998]. The question has been asked how can 
inhibitory and activating MHC class I receptors; 
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KIR3D KIR2D CD94/NKG2 
Natural Killer Cell 
Target cell 
HLA-B HLA-C HLA-E 
Endoplasmic reticulum 
HLA-A, -B, -C, -G HLA-E 
Translation 
Fig 2.14: The HLA-A, -B, -C, -E of natural killer (NK) cell tolerance to self 
(adapted from Long. 1998) 
The first part of the diagram shows the two types of receptors specific for self-HLA class 
molecules to inhibit NK cells, the lectin-like heterodimer CD94/NKG2 binds to HLA-E, 
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Continued legend for figure 2.14: 
whose transport to the cell surface is limited by the availability and binding of signal 
sequence derived peptides (indicated in lime green). The KIR receptors with three 
(KIR3D) or two (KIR2D) immunoglobulin domains recognise HLA-B and -C 
respectively, HLA-B and -C bind many different peptides (pink). The lower part of the 
diagram illustrates the first steps in synthesis of HLA class I molecules. The class I 
polypeptide associates with ~2-microglobulin (black) and a peptide delivered from the 
endoplasmic reticulum (pink) by TAP. HLA-E binds signal-sequence-derived peptide from 
other HLA class I molecules, and this binding is also TAP dependent. 
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interact to regulate the activity of NK cells? Several hypothesises have been suggested, 
including inhibitory receptors recognise self MHC class I molecules (preventing 
atuoreactivity), whereas activating receptors detect non-self MHC class I molecules that 
may be encoded by invading viruses. Also inhibitory receptors may regulate effector and 
cytotoxic responses and activating receptors could mainly control NK-cell proliferation, 
promoting NK-cell expansion during development. The discovery of the mechanism by 
which the activating receptors signal may make it easier to define the biological function of 
activating receptors. As a result of a number of investigations it appears that a function for 
HLA-E has been demonstrated, as an important regulator ofNK cell activity. Also having 
a role in the development ofNK cell tolerance to self, by providing a mechanism by which 
NK cells can monitor selfMHC class I expression and therefore prevent autoreactivity. 
The investigation of the class Ib molecule HLA-F is limited. In the adult, HLA-F 
mRNA is present in skin, resting and activated T cells and B cells, and is also detectable at 
relatively high levels in second trimester human foetal liver [reviewed in Le Bouteiller and 
Lenfant. 1996, Geraghty et al. 1990]. Transcription of HLA-F was also detected in human 
placenta however it was not localised in a particular trophoblast cell subpopulation [Wei 
and Ort. 1990]. Two alleles of HLA-F have been identified that have three amino acid 
differences [Geraghty et al. 1990] therefore the level of polymorphism appears extremely 
low. 
The HLA-F gene is conserved in several species suggesting that it may still have a 
possible function. Only five out of ten highly conserved residues present in the antigen-
binding site remain unaltered in the HLA-F, therefore if the protein is able to bind peptides 
they may be restricted by a unique subset of TCR [Geraghty et al. 1990]. Developing 
hepatic epithelium in man expresses both HLA-E and F in the presence of y/8 T -cells 
suggesting that y/8 TCR may be the ligand of some class Ib molecules [Geraghty et al. 
1990]. However, specific recognition of HLA-F by human y/8 T cells has not been 
reported. Due to the pattern of expression HLA-F may play an important role in 
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haematopoiesis and/or foetal development, but no specific function ofHLA-F has yet been 
determined. 
2.6.2 Non-m...A genes in the MHC class I region 
Based on the overall length ofthe class I region and the estimated 100,000 genes in 
the human genome it was predicted that additional genes to the class I multigene family 
might exist [Fan et al. 1993, 1995, 1996, Wei et al. 1993, Gruen et al. 1996, Janer and 
Geraghty. 1998]. Advancements in various techniques have led to novel genes and 
transcribed sequences being found in the class I region, approximately 80 non-HLA genes 
have been identified. Many, but not all, are structurally and functionally distinct from the 
class I multigene family [Trowsdale and Campbell. 1997], see figure 2.13. A few of the 
identified non-HLA class I genes are described in the following section: 
OTF3 ( octamer-binding transcription factor 3) belongs to a multigenic family that 
encodes a group of related transcription factors called the POU family. The transcription 
factors contain a particular type of DNA binding domain the POD-specific and a homeo 
domain. OTF3 has been shown to bind to a regulatory element required for both ubiquitous 
and tissue-specific gene expression [Le Bouteiller. 1994]. OTF3 has been mapped a 100 to 
110 kb telomeric of HLA-C [Crouau-Roy et al. 1994], a later study has precisely 
positioned OTF3 (POUSF1) between HLA-C and the S gene, to approximately 30 kb 
centromeric of the S gene [Krishnan et al. 1995]. Two isoforms of OTF3 (Oct3A and 
Oct3B generated by alternative splicing) have also been detected at low but detectable 
levels in adult human tissue [Takeda et al. 1992]. It has been suggested that OTF3 may 
have a role in early development. 
The S gene (for skin) was identified near to an evolutionary conserved sequence, 
160 kb telomeric ofHLA-C [Zhou and Chaplin. 1993]. The S gene is expressed at high 
levels in human skin and its expression is restricted to differentiating keratinocytes in the 
granular layer of the epidermis. Although the function of the S protein is unknown, its 
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restricted pattern of expression suggests that it may participate to the structure and 
differentiation of the skin. 
PS is a multiple copy gene family unrelated to ID-A genes but maps within the 
class I region. The PS-1 coding sequence is centromeric to ffi-A-E and IS kb telomeric to 
ID-A-X. The PS-2, PS-3 and PS-4 copies are located around ID-A-A, the PS-S copy is next 
to ffi.A-G and the PS-6 copy could be telomeric to ID-A-A or centromeric to ID-A-X 
[Vemet et al.l993 ], but it has also been mapped to the region near to ffi..A-17 [Trowsdale 
and Campbell. 1997]. A new member ofthe family has been identified that is found 1.3 kb 
upstream offfi..A-17 and has been named PS-8 [Miziki et al. 1997b]. It is not clear whether 
the PS-8 gene expresses some tissue-specific transcript and encodes a functional protein 
[Mizuki et al. 1997b]. The transcription of PS-1 is restricted to lymphoid tissues, which 
suggests an immunological function of its product. 
The HSR1 gene codes for a putative GTP-binding protein that is located less than 2 
kb centromeric to the ffi.A-E gene [Vemet et al. 1994] and which has been shown to be 
part of a new subfamily of GTP-binding proteins. It is transcribed in a large number of 
tissues and it has been suggested that HSRI protein could be secreted on the cell surface. 
The gene for the 13-chain of tubulin (TUBB) was mapped to a segment 1 S0-350 kb 
telomeric offfi.A-C at the First International Workshop on human chromosome 6 in 1992 
[Volz et al. 1993]. 
A distinct family of five related sequences in the class I region have been identified 
and shown to be distantly homologous to class I chains. The genes are known as MIC 
genes (MHC class I chain-related genes), MICA and MICB are located near to ID-A-B and 
the other members MICC, MICD and MICE have been localised near the ID .. A-E, A and F 
genes [Bahram et al. 1994, Shiina et al. 1998]. MICA has been shown to be highly 
polymorphic and closely related to MICB, these two are the only functional members of 
the family, the others are truncated gene fragments [Bahram et al. 1996a,b, c, Mizuki et al. 
I997b]. MICA and MICB have a unique pattern of tissue expression and it has been 
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suggested that each has a potential to direct the synthesis of a functional class I molecule 
[Groh et al. 1996]. It has been shown that :MICA is in linkage with HLA-C and HLA-B, 
suggesting the presence of a recombinational hot spot in this area between :MICA and 
MJCB [Ota et al. 1997]. A polymorphism in the :MICA gene has been shown to be 
associated with Behyet disease [Mizuki et al. 1997a]. Both genes are regulated by promoter 
heat-shock response elements related to those of HSP70 genes, which indicates the 
possible cell surface expression of the :MICA and B proteins. However, a probable 
immunological function of :MICA and B remains to be investigated [Groh et al. 1996]. 
The identification and characterisation of new genes and markers in the class I 
region is a continuous process. A number of studies have extended the area of investigation 
[Amadou et al. 1995, Bouissou et al. 1995, Malfroy et al. 1997, Mizuki et al. 1997b, Shiina 
et al. 1998, Janer and Geraghty. 1998], which has led to the discovery of new genes and 
genetic markers. New multigene families have been identified whose members are 
dispersed throughout the class I region [Shiina et al. 1998]. Some of the novel genes 
discovered in the MHC class I region may have an immune function, whereas others, 
having no obvious relationship with the MHC and could have a role in the developmental 
process. The discovery of new genes and genetic markers in the class I region is important 
as a number ofHLA class I genes have been strongly associated with number of diseases. 
2.6.3 MHC class II genes 
The human MHC Class II region spans approximately I 000 kb and is at the 
centromeric end of the MHC [Dunham et al. 1987]. Over 30 genes have been mapped in 
the class II region of the MHC using various molecular techniques [Trowsdale & 
Camp bell, 1997], see figure 2.15. The class II genes are subdivided into genes that code for 
the a-chain and genes that code the 13-chain of the class II molecules. The a-chain genes 
being, DRA [Lee et al. 1982), DQA [Auffray et al. 1984) and DPA [Trowsdale et al. 1984) 
all of which have been isolated and sequenced. In addition there is DNA [Trowsdale & 
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Kelly, 1985] and DMA [Kelly et al. 1991], DMA appears to be a distant relative of class II 
a. genes and is required for the normal assembly of peptides with MHC class IIII molecules 
[Kelly et al. 1991, Monaco. 1992, Roche. 1996, Teisserenc et al. 1997]. At least seven 
class II A genes, which are not alleles of each other, have been identified [Trowsdale et al. 
1983, 1985, Spielman et al. 1984, Trowsdale and Campbell, 1992]. These genes exhibit 
homology with immunoglobulin and class I genes and consist of four or five exons 
encoding the leader sequence, first and second domain, connecting peptide, transmembrane 
and cytoplasmic regions of the a. chains. 
The class II B-chain genes are, DRB [Long et al. 1982, 1983], DQB [Larhammer et 
al. 1982, 1983] and DPB [Roux-Dosseto et al. 1983] all of which have been sequenced and 
mapped in the class II region. Also present are DOB [Tonnelle et al. 1985, Servenius et al. 
1987] and DMB [Kelly et al. 1991,Teisserenc et al. 1997], that together with DMA appears 
to be important in the normal assembly of peptides with MHC class 11 and class I 
molecules [Monaco. 1992, Roche. 1996]. Sequence analysis has shown that at least 16 
expressed class 11 B genes, which have similar intron-exon organisation and polymorphic 
regions to the A genes, are present [Bodmer et al. 1992, 1997]. 
There are four different DRB genes that are expressed and encode ~-chains, which 
can associate with the a.-chain encoded, by the DRA gene. The DQ sub-region contains 
DQAI and DQB 1 genes that are expressed and also an additional set of pseudogenes, 
DQA2, DQB2 and DQB3, which are not expressed due to the presence of altered upstream 
promoter sequences [Shewey et al. 1992]. The DP region consists of two functional genes, 
DPA1 and DPB1 and two pseudogenes, DPA2 and DPB2. Located between the DP and the 
DQ sub-regions are DNA and DOB, these do not appear to be expressed as a functional 
108 
CENTROMERIC TEOLMERIC 
DRBl DRB2 
DPBI OPAl DQB2 DQB3 
DPB2 DPA2 ~ I LMP2 RJNG9 DOB l l l 
r-
l l 
----
..... 
r r \ o! r i \ r 1 \ r r r 
RJNGJ RING2 COLIJA2 RJNG3 DMA DMB TAPt LMP7 TAP2 
DQA2 DQBl DQAl 
r r r 
DRB3 DRB9 DRA 
I expressed gene with unknown function I pseudogene expressed gene 100 kb 
Fig 2.15: Map of the class 11 region of the human Major Histocompatibility Complex (MHC) 
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heterodimeric ap chain pair [Gregersen. 1989]. Class 11 A or B genes within a sub-region 
share about 90% homology in their nucleotide sequences and have about 70% homology 
with the A orB genes of other sub-regions [Gregersen, 1989]. 
2.6.4 Non-HLA genes in the MHC class 11 region 
A gene has been identified that is located between the DNA and DOB loci in the 
class li region [Trowsdale et al.l990, Spies et al. 1990, Shepherd et al. 1993], which was 
shown to code for a protein belonging to the ABC (ATP-binding cassette) transporter 
family. This protein, designated TAPI (transporter associated with antigen processing), 
consists of an ATP-binding domain and an amino (N) terminal hydrophobic region, which 
spans the membrane. A second transporter gene was also identified, T AP2, that is located 
between TAP I and DOB in the human MHC class II region [Powis et al. 1992]. The 
protein products of both genes form heterodimers whose function is to transport ions, small 
molecules and peptides from the cytoplasm into the lumen of the endoplasmic reticulum 
and are therefore essential for the normal functioning of the class I antigen processing 
pathway [Monaco. 1992, Carrington et al. 1993, Accolla et al. 1995, Sub et al. 1996]. Both 
genes have been shown to be polymorphic [Teisserenc et al. 1997] and the expression of 
TAP I is enhanced in the presence of IFNy [Trowsdale et al. 1990, Rodriguez et al. 1997]. 
Because of their role in antigen processing and their location within the class II region of 
the MHC, these genes have attracted attention as possible disease susceptibility loci. There 
has been conflicting reports that TAP genes are associated with susceptibility to type I 
diabetes [Colonna et al. 1992, Ronningen et al. 1993, Faustman et al. 1991, Wang et al. 
1995, Fu et al. 1996]. 
Also within the class 11 region are two genes, LMP7 (large multifunctional protease) which 
maps between TAP! and TAP2 and LMP2 that maps immediately centromeric to TAP! 
[Brown et al. 1991, Glynne et al. 1991 Kelly et al. 1991]. Both genes share homology with 
proteosome, which is a multicatalytic proteinase complex that is abundant in the cytosol of 
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all eukaryotic tissues that have been examined [Goldberg and Rock, 1992]. It has been 
suggested that LMP2 and LMP7 are two components of the proteasome which is 
responsible for degrading cytoplasmic proteins into short peptides which can be 
translocated into the endoplasmic reticulum by the TAP transporter [Teisserenc et al. 
1997]. Two alleles of LMP2 have been identified [Kelly et al. 1991] however, 
polymorphism within LMP7 has not yet been investigated [Teisserenc et al. 1997]. 
Several genes, including the collagen gene, COLIIA2 [Hanson et al. 1989] and 
many other genes of unknown function have been mapped to the class 11 region [Campbell 
and Trowsdale. 1997]. Three new genes identified in the class II region have been named 
RING genes (really interesting new gene), RING!, RING2 and RING3. RING2 is a 
steroid and prostaglandin dehydrogenase-related protein [Hanson et al. 1991 ]. Also 
identified in this region are RING9 and Y5, which have no known function [Glynne et al. 
1991, Spies et al. 1990]. 
2.6.5 MHC class Ill genes 
In the intervening class Ill region the genes for the components of the complement 
system are located [Woods et al. 1982, 1984, Carroll & Porter, 1983, Whitehead et al. 
1983), see figure 2.16. The positions ofC2, Bfand C4 have been determined, C2 and Bf 
genes are less than 2 kb apart and lie about 30 kb telomeric of the C4A and C4B genes, 
which are separated from each other by about 10 kb [Carroll et al. 1984]. It has been 
shown that there are only 14 nucleotide differences between C4A and C4B, 12 of which 
occur on the a-chain [Belt et al. 1984]. There are two forms ofC4B (16kb short gene and 
22kb long gene) that differ by the presence or absence of a large intron [Yu et al. 1986], 
the C4A gene is 22 kb long. Both the C4A and C4B loci are polymorphic, 13 alleles are 
recognised at the C4A locus and 19 at the C4B locus [Caroll et al. 1984]. Two genes 
coding for cytochrome P450 steroid 21-hydroxylase, CYP21A and CYP2l B are positioned 
immediately centromeric to 
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the C4A and C4B genes respectively [Carroll et al. 1985]. CYP21A is a pseudogene, but 
shares 99% nucleotide sequence similarity with CYP21B in their exons [White et al. 
1986]. CYP21B codes for an enzyme that is expressed in adrenal tissue and is essential for 
the synthesis of cortisol [Kominarni et al. 1980]. 
The genes for tumor necrosis factor (TNF)-a. and TNF-P are tandemly arranged 
within a 7kb region in the class m region. The TNF locus maps 250kb centromeric to 
HLA-B and 350kb telomeric to the C2/Bf complex [Spies et al. 1986]. Both cytokines 
encoded by the TNF genes are potent immunomodulators and essential mediators of the 
inflammatory response [Pociot et al. 1993]. It has been suggested that an abnormal or dis-
regulated expression of TNF could be a factor predisposing an individual to autoimmune 
disease [Jacob et al. 1990]. A number of studies have suggested a link between 
polymorphisms in both the TNF-a. and TNF-P genes and type 1 diabetes [Newton et al. 
1998, Day et al. 1998]. Also located in this region are three genes that code for the heat 
shock protein, HSP70-1, HSP70-2 and HSP70-HOM [Sargent et al. 1989] and several 
genes that code for proteins of unknown function. Nine different expressed genes denoted 
BA Tl-9 (HLA-B associated transcripts) have been identified [Spies et al. 1989a, 1989b, 
Shiina et al. 1998] and 12 genes that are known as B 144 and G 1-11, which include BAT2, 
3, 4, 6, 7, 8 and 9 [Sargent et al. 1989, Nalabolu et al. 1996].1t has been suggested that 
Gll possibly codes for a protein kinase, G9 codes for sialidase enzyme and G2 (BAT2) 
encodes a proline-rich protein that is 228 kda in size [Trowsdale & Campbell, 1997]. Other 
novel class m region genes include G12-18 [Spies et al. 1990; Kendall et al. 1990], OSG 
(opposite strand gene) [Morel et al. 1989] and RAGE, a member of immunoglobulin 
supergene family and a receptor for advanced glycosylation end products of proteins 
(AGEs). Also PBX2 (HOX12), a homeobox gene related to PBX1 and NOTCH3 which 
may be involved in cellular interactions [Sugaya et al. 1994]. 
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2.6.6 The complement system 
Complement was discovered many years ago as a heat-labile component of normal 
plasma that augments opsonisation of bacteria by antibodies and allows some antibodies to 
kill bacteria. The complement system is a series of distinct plasma proteins, many of which 
are proteases. They are involved in complementing the effector functions of antibodies by 
lysing target cells, opsonisation for phagocytosis and activation of cells of the immune 
system [reviewed by Carroll and Prodeus. 1998]. There are three pathways by which the 
effector functions of complement can be activated, the classical pathway activated by 
antibody binding to antigen. The lectin pathway initiated by binding of a serum lectin to 
carbohydrates on bacteria or viruses and finally the alternative pathway initiated when a 
spontaneously activated complement component binds to the surface of a pathogen 
[Muller-Eberhard. 1988, Fearon and Locksley. 1996]. All three pathways lead to the 
formation of C3 convertase that cleaves C3 molecules to produce C3b, which binds 
covalently to the surface of foreign antigens. The C3 convertase occupies a central position 
in the cascade of the complement system. The pathways consist of a number of precursor 
proteins that are proteolytically cleaved to reveal membrane-binding sites. The attachment 
of a particular protein to a membrane renders the protein active so that it can catalyse the 
proteolytic activation of the next complement component. Each component can activate 
many precursor proteins of the next step in the pathway, which results in a cascade reaction 
with amplification at each stage. 
C3b is the activated form of C3 and has an intramolecular thioester bond that can 
covalently link with the hydroxyl or amino groups on a wide variety of microorganisms 
and other antigens. This allows C3 receptor bearing phagocytic cells to bind to C3b and 
facilitate the engulfment of the pathogen. C3b is also involved in the production of the 
membrane attack complex (MAC), which breaks down lipid bilayers allowing the free 
exchange of electrolytes and water across the cell membrane. This results in osmotic lysis 
and can cause disassembly of viral envelope membranes. Finally, the binding of C3b 
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initiates the alternative pathway, resulting in the amplification of complement activation. 
CSa and C3a mediate local inflammatory responses and also have anaphylotoxic effects 
including smooth muscle contraction in a wide variety of tissues, mast cell degranulation 
and neutrophil activation. 
C2, Bf and C4 three components of the complement system are encoded in the 
MHC. C4 consists of three disulphide-linked chains, CL, l3 and y, it is synthesised as a single 
polypeptide precursor [Schreiber and Muller-Eberhard, 1974, Muller-Eberhard. 1988] and 
exists as two isotypes, known as C4A and C4B. C2 and Bf are serine proteases consisting 
of single glycopolypeptide chains. The C2, Bf, C4A and C4B proteins are highly 
polymorphic [White. 1989, Muller-Eberhard. 1988]. 
2.6. 7 MHC Polymorphism 
The many genes of the class I, II and m regions are considered to be highly 
polymorphic and the list of "new" alleles discovered for a particular gene is constantly 
expanding [Bodmer et al. 1997]. Examination of nucleotide sequences has revealed that 
class I polymorphism is clustered in three main hypervariable regions (HVRs) of the CL! 
and CL2 domains [Parharn et al. 1988]. Class II diversity is due to three HVRs in the CLl and 
131 domains, which are encoded by the second exons of the genes [Marsh and Bodmer. 
1991]. Polymorphism in the class m C4 genes is clustered in the C4d region of the CL-
chains [Carnpbell et al. 1990]. 
Within the different classes of MHC genes a nucleotide sequence homology has 
been shown suggesting that the various gene loci are derived from multiple duplication 
events of ancestral genes, which occurred before the evolution of homo sapiens [Trowsdale 
et al. 1985, Gregersen. 1989, White. 1989, Hughes and Nei, 1993, K.litz et al. 1992, 
reviewed by Cadavid and Watkins. 1997]. The class I and class II molecules belong to the 
immunoglobulin supergene family and probably evolved from a primordial cell surface 
receptor gene [Hunkapiller and Hood. 1989]. The mechanisms that are involved in 
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generating allelic variation are controversial and include point mutations, gene conversion 
and recombination events [Ra.sk et al. 1985, Gorski and March. 1986, Erlich and 
Gyllensten. 1991, Cadavid and Watkins. 1997]. However, several lines of evidence suggest 
that gene conversions are the most important mechanism of MHC class I and class II 
allelic diversification [Gregersen. 1989, Ohta. 1995, Parham et al. 1995]. 
MHC allelic variation is probably the result of natural selection of polymorphic 
variants which confer resistance to infection [Doherty and Zinkernagel, 1975, Bodmer et 
al. 1989, Riley and Olerup. 1992, Cadavid and Watkins. 1997]. The selection for 
polymorphic variants occurs in distinct HVRs and at different levels in the different MHC 
loci, DRA and DRB4 are not polymorphic but DRB 1 is the most polymorphic. Therefore 
closely linked DNA sequences can become eo-inherited with the new allele and preserved 
in the population even if these sequences have no functional significance. This is known as 
linkage disequilibrium, a state where closely linked genes on a chromosome remain 
associated such that the frequency of the pair of alleles occurring together is greater than 
the product of the individual gene frequencies [Bodmer et al. 1987]. (The tendency for 
alleles at different loci to occur on the same chromosome more often than expected by 
chance). Linkage disequilibrium is a characteristic feature of the MHC and involves 
different haplotypes in different populations [Baur et al. 1984, Bodmer et al. 1987]. 
2.6.8 MHC gene expression 
The expression of MHC class I and class II molecules on the surface of cells plays 
a crucial role in the immune response and is subject to physiological, pathological and 
pharmacological regulation. One of the main regulating influences is interferon-y (IFNy), 
which has been shown to induce the expression of both class I and II molecules [Shaw et 
al. 1985, Halloran et al. 1986, Rodriguez et al. 1997, Le Bouteiller. 1994]. Other enhancers 
of MHC expression include IL-4, TNFcx and granulocyte-monocyte colony stimulating 
factor, whereas glucocorticoids, prostaglandins, insulin, insulin like growth factor, 
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hydrocortisone and a-fetoprotein have all been shown to down-regulate Iv1HC expression 
in various cell types [Halloran et al. 1986, Benoist and Mathis. 1990, Le Bouteiller. 1994]. 
The expression of Iv1HC class I and 11 molecules can also be altered by the 
immunosuppressive drugs such as cyclosporine A [Groenewegen et al. 1985]. 
Regulation of Iv1HC expression occurs at the level of transcription involving 
complex interactions between cis-acting regulatory sequences and trans-acting protein 
factors. Many studies that have used transfected cell lines and transgenic mice have 
indicated that the majority of the cis-acting elements are located 150-200 bp upstream from 
the 5' ends of the genes. Critical sequence motifs include theW, X, Y, CCAAT and TATA 
boxes in the class 11 promoters and enhancer A, the IFN response element (IRE), enhancer 
B and the CL sequence upstream from the class I genes [Pan-Yun Ting and Baldwin, 1993]. 
Additional enhancer sequences have been located 1-2 kb upstream from the genes and 
possibly within coding regions [Le Bouteiller. 1994]. These regulatory sequences interact 
with a number of sequence specific DNA binding proteins; these include members of the 
interferon regulatory factor (IRF) family, NF-xB proteins, RF-X, NF-X, OTF-2 and OTF-1 
[Janeway and Travers. 1996]. 
2.7 Structure ofMBC class I molecules 
Iv1HC class I molecules are composed of two polypeptide chains: an Iv1HC-encoded 
CL glycopolypeptide of 40kd and a non-glycosylated ~2-microglobulin (~2m) chain of 12kd 
which is encoded on chromosome 15, see figure 2.17. The a-chain is a glycoprotein, 
consisting of a polypeptide and short carbohydrate chains. It is divided into three 
functional regions, extracellular, a hydrophobic transmembrane and a hydrophilic 
cytoplasmic region. The extracellular region is more than 280 amino acids long and 
represents the bulk of the a-chain. The transmembrane region is 23 residues long and the 
cytoplasmic region 25-32 amino acids long. The extracellular region of the a-chain is 
divided into three domains, al, CL2 and CL3. The al domain consists of90 amino acids, the 
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Fig 2.17. The structure of a MHC class I molecule. (a) A computer graphics representation of a human 
MHC class I molecule, HLA-A2 has been cleaved from the cell surface by the enzyme papain (One can not 
see the transmembrane region and the short stretch of peptide). (b) A ribbon diagram of the structure. The 
a. chain folds into three domains, a.l, a.2, and a.3. The a3 domain and ~z-m show similarities to Ig C 
domains and have a similar folded structure. (c and d) The a.l and a.2 domains fold together into a single 
structure consisting of two segmented a. belies lying on a sheet of eight antiparalle P-strands. The folding 
of the a.l and a.2 domains creates a long cleft or groove, which is the site at which peptide antigens bind to 
the MHC molecules. The a3 domain and P2-m connect with non-covalent bond. Only a. chain span the cell 
membrane (adapted from Janeway and Travers, 1996). 
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a.2 of92 and the a3 of91 amino acid residues; the three domains are encoded on separate 
exons 2, 3 and 4 respectively [reviewed in Klein. 1986, Germain. 1994, Stem and Wiley. 
1994, Madden. 1995]. This structure is stabilised by the non-covalent association with the 
single-domain f32m chain [Benacerraf 1981, Mali ss en et al. 1982, Lew et al. 1986] and 
results in the formation of af3 dimers. The a3 and f32m domains are relatively conserved 
and show amino-acid sequence homology to immunoglobulin constant domains and 
therefore adopt a standard immunoglobulin fold [Bjorkman et al. 1987a, Orr et al. 1979, 
Madden. 1995]. However, it has been stated that the a3 domain is itself somewhat 
variable, among class I molecules, relative to the rest of the structure. It is likely that this 
variation is due to different crystal packing forces and the weak coupling of the a3 domain 
to the remainder ofthe protein [Saper et al. 1991, Madden et al. 1992, 1995, Fremont et al. 
1992]. The a1 and a.2 domains are considered the most polymorphic and do not show any 
significant sequence homology to immunoglobulin C or V domains, but have been 
reported to show weak sequence homology to each other [Orr et al. 1979, Bjorkman et al. 
1987a, Lawlor et al. 1990, Madden. 1995]. The a3 domain contains a site, which interacts 
with the CD8 molecule [Salter et al. 1990, Connolly et al. 1990, Garcia et al. 1996]. The 
membrane-distal a1 and a.2 domains form the top of the molecule with their helical sides 
facing away from the cell [Bjorkman et al. 1987a, Saper et al. 1991, Madden et 8.1. 1991, 
1995] and both exhibit a high degree of polymorphism giving rise to the allelic variants of 
class I antigens which have homologies as low as 70% [Lew et al. 1986]. The crystal 
structure of a number of class I molecules has been determined including HLA-A2, HLA-
A68, HLA-B27, H-2Kb and H-2Db, which allowed the nature of the interaction between 
class I molecules and antigen to be understood [Bjorkman et al. 1987a,b, 1985, Madden et 
al. 1991, 1993, Saper et al. 1991, Garboczi et al. 1994, Fremont et al. 1992, Silver et al. 
1992, Stura et al. 1992, Tan et al. 1997]. These studies have shown that the class I 
molecules have a similar overall structure. The a1 and a.2 domains have a similar tertiary 
structure and the tertiary structure of the a3 domain is similar to the f3zm domain, see 
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figure 2.17. The a3 and lhm domains lie proximal to the cell membrane and each consists 
of two antiparallel 13-pleated sheets, one sheet consisting of four 13-strands and the other of 
three 13-strands. The space between the two sheets is filled with hydrophobic side chains, 
so that the interior of the domain is inaccessible to water. The two sheets are connected by 
a single disulphide bond perpendicular to them, with the two sulphur atoms located near 
the centre of the domain. The a1 and a2 domains lie distal to the membrane and each 
consists of four 13-strands forming a single, anti parallel 13-pleated sheet of eight 13-strands. 
This is topped by a a-helical region, which is stabilised by a disulphide bond on the a2 
domain and hydrogen bonding between the a1 and a2 domains. The interface between a1 
and a2 includes hydrogen bonding between the N-terminall3-strands of each domain at the 
centre of the eight-stranded sheet and contacts between the C-terminal ends of the helical 
regions and 13-sheet residues in the other domain. TheN-terminal part of the sheet consists 
of 3 antiparallel strands; the middle part is folded into one or two helices. Carbohydrate 
residues are attached to the region of contact between a1 and a2. Two long a-helices, one 
from each of the a domains are packed against the 13-pleated sheet, but instead of packing 
against each other, the two helices are separated by an extended groove approximately 25-
30 A long and 10-12 A wide and 11 A deep (see figure 2.17), which runs through the 
middle. Side chains from the helices form the sides of the groove and the bottom is formed 
by side chains from the central 13-strands of the a 1-a2 13- pleated sheet [Bjorkman et al. 
1987b, Madden et al. 1991,1992, 1993, Saper et al. 1991,Fremont et al. 1992, Matsumura 
et al. 1992]. Bjorkman et al. ( 1987a) described a region of electron density within the 
groove of an ffl..A-A2 molecule, which was not accounted for by the ffl..A molecule and 
predicted it to be a peptide that eo-crystallised with the A2 molecule. This has also been 
shown in other studies and other class I molecules [Saper et al. 1991, Garboczi et al. 1994, 
Madden et al. 1991 1993, Collins et al. 1994]. 
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The groove is located on the top surface of the molecule and the size, shape and 
localisation of a peptide like molecule eo-crystallised within this groove suggests that it is 
the foreign antigen binding site. Bjorkman et al. ( 1987b) identified the accessible residues 
on the two helical regions of a 1 and a2 and on the P-strands located between them that are 
in the vicinity of the binding site and are therefore likely to be important for the T -cell 
recognition of class I molecules. Residues of the central P-strands of the a 1-a2 ~-pleated 
sheet and residues on the a-helices are potential ligands for antigenic peptides. Of the 17 
polymorphic amino acid residues that contribute most to class I allelic variability, 15 are 
located in or around the groove. The amino acids predicted to be serological epitopes are 
all located on the a-helices in the a1 and a2 domains on top of the groove and appear to 
be directly accessible to antibodies. The amino acids involved in T -cell recognition are 
mostly located within the groove suggesting that antigen binding is the prerequisite for T-
cell reactivity, although some are located outside the groove and are involved in direct 
recognition and binding of the T -cell receptor, see figure 2.19 [Garcia et al. 1996]. In 
addition, there are ten residues pointing into the antigenic recognition site that are 
conserved. Further studies ofthe crystal structure of the HLA-A2 molecule led to 2.6 A 
resolution of the structure [Saper et al. 1991] and the discovery of six pockets of diverse 
shape and composition within the groove which appear suited for the binding of side-
chains from antigenic peptides. Peptide-like structures are bound in an extended ~-strand 
conformation with the amino and carboxy termini precisely positioned at the ends of the 
groove by numerous hydrogen bonds and side-chains bound in deep pockets within class I 
molecules [Madden. 1995]. 
2.8 Structure of MHC class 11 molecules 
Like class I molecules, class II molecules are heterodimers consisting of two 
different polypeptide chains a and ~ of 33kd and 29kd respectively. Both the a and P 
chains consist of an extracellular region, a connecting peptide, a hydrophobic 
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Fig 2 .18. The MHC class II molecules structure. (a) A computer graphics representation of a human MHC 
class II molecule, HLA-DRl . (b, c and d) The MHC class II molecule is composed of two transmembrane 
glycoprotein chains ex and~. Each chain contains two domains, cxl and cx2 or ~1 and ~2. The ribbon diagram 
shows that the cx2 and ~2 domains have structure similarities to Ig constant domains. The cxl and ~ 1 folds to 
form the peptide-binding cleft. Both chains span the membrane (adapted from Janeway and Travers,l996). 
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83 residues in length, the 131 domain 89 residues and the second domain is the same in both 
a and 13 chains, 94 residues in length [reviewed in Klein. 1986, Madden. 1995]. The 
membrane proximal or second domains, a2 and 132, are homologous to the a3 and l32m 
domains of the class I molecule and the immunoglobulin C region and exhibit little 
variability between alleles. The membrane distal a1 and 131 domains exhibit homology 
with the class I a1 and a2 domains. Only the 131 domain has an internal disulphide bond 
and the a1, 131 and a2 domains are glycosylated [Travers et al. 1984, Korman et al. 1985, 
Gregersen, 1989, Brown et al. 1993, Stem et al. 1994, Jardetzky et al. 1994]. The 132 
domain contains a CD4 binding site [Konig et al. 1992, Cammarota et al. 1992] and it has 
also been shown that the a2 domain also interacts with the CD4 molecules [Konig et al. 
1995]. The a1 and 131 domains contain the polymorphic amino acid residues that 
contribute most to allelic variability. 
The three-dimensional structures of the class I and class II molecules are very 
similar, due to the sequence homology between the two molecules. One of the main 
differences in structure being the membrane distal domains that are present on one protein, 
the a-chain, in the class I molecules, but on separate a and 13 polypeptides in class II 
molecules, see figures 2.17, 2.18. In the class I molecule the a1 and a.2 domains are paired 
by an approximate dyad axis of symmetry forming an "intramolecular dimer" [Bjorkman et 
al. 1987a]. The sequence homology between a1 and a2 of class I and a1 and 131 of class II 
[Travers et al. 1984] suggest a similar structure for the class II a1/131 intermolecular dimer 
[Brown et al. 1993, Madden. 1995]. A hypothetical model for peptide binding to a class II 
molecule was proposed based on comparisons of conserved and polymorphic residues in 
the class I and II sequences [Brown et al. 1988]. The alignment of the amino acid 
sequences of the class II a1 and 131 domains with the class I a1 and a.2 sequences 
respectively to conserved glycosylation sites, disulphide bonds and salt bridges, predicted a 
similar antigen binding cleft for both class I and II molecules. As for class I, the peptide-
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binding groove consists of a floor formed by an antiparallel 13-pleated sheet structure of 
eight 13-strands, which is framed on two sides by ex-helices from the ex 1 and 131 domains, 
see figure 2.18. In the antigen binding groove of the class II molecule the conserved and 
polymorphic amino acids in both the ex-helical and 13-strands reside in homlogous positions 
to those in the HLA-A2 molecule. In the class II structure amino acid insertions and 
deletions relative to the class I are located in the loops connecting the aligned regions of 
the polypeptides. The distribution of ploymorphic residues is consistent with the theory 
that some of these control interactions with antigen, being located in the floor, or pointing 
into the groove from the ex-helices and others interact with the TCR, pointing upwards 
from the tops of the ex-helices, see figure 2.19. Several clusters of polymorphic residues, 
spaced across the binding site, appear to provide the mechanism by which different types 
of class II molecules selectively bind peptides of different sequences [Sette et al. 1989, 
Stem et al. 1994, Jardetzky et al. 1994, Brown et al. 1993]. It has been shown that class II 
molecules can form parallel exl3 heterodimers and it has been suggested that this has 
important implications for the interaction of MHC class II molecules and the TCR. The 
class II exl3 heterodimer may lead to an increased affinity for the CD4 co-receptor and 
facilitate TCR dimerisation resulting in signal transduction [reviewed by Bentley and 
Mariuzza. 1996, Madden. 1995]. However, it has also been stated that the dimer may be a 
crystallisation artefact [Brown et al. 1993]. 
2.9 Antigen presentation 
Both class I and class II MHC molecules present processed antigen in a way that 
enables it to be recognised by the TCR. The presentation of antigen is due to the 
intracellular generation of protein fragments by degradation and the binding and transport 
to the cell surface of these peptides in stable association with MHC molecules [Brodsky 
and Guagliardi. 1991,Germain and Margulies. 1993 Germain 1994, Accolla et al. 1995, 
Chicz and Urban. 1994, Adam and Humphreys. 1995, Sanderson et al. 1995, Malarkannan 
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Fig 2.19 .. MHC molecules bind peptides tightly within the cleft in crystal structures. (a) 
The peptide is bound in an elongated conformation with both ends tightly bound at either 
end of the cleft in the case of MHC class I molecules. For MHC class II molecules (b), 
the peptide is also bound in an elongated conformation but the ends of the peptide 
extends beyond the cleft. ( c and d) TCR recognises the upper surface of MHC class I or 
class II molecules. The residues of the MHC molecule are shown in white and the peptide 
is in red (adapted from Janeway and Travers, 1996). 
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et al. 1995, Shastri et al. 1998]. Class I and II molecules appear to be specialised for the 
capture of peptides present in specific cellular compartments. Peptides derived from 
proteins synthesised by the presenting cell, including also fragments of viral proteins 
produced during infection (intracellular antigens), are generally presented to CD8+ T-cells 
by class I molecules. Class II molecules present peptides derived from exogenous, 
internalised proteins (extracellular antigen derived peptides), to CD4+ T-cells. However, 
once an antigen is in the cytosol it is possible to go through either route, as long as the cell 
undergoes class II expression [Chicz et al. 1993, Accolla et al. 1995]. Both class I and class 
II molecules are recognised by TCRs using the same pool of variable genes however, there 
are differences between the two classes of MHC molecule in the way that they associate 
with antigen. 
2.9.1 Antigen presentation by class I molecules 
The antigen-binding groove, which is lined with polymorphic amino acid residues, 
was identified from the three-dimensional crystallographic structures of the human and 
murine class I molecules, see figure 2.19. The presence of an electron density within this 
groove, which is consistent with a peptide structure, suggests that class I molecules present 
short peptides derived from intracellular processing of antigenic proteins. This suggestion 
is supported by the observations that synthetic peptides derived from influenza virus 
nucleocapsid [Townsend et al. 1986) and matrix [Gotch et al. 1987] proteins could 
sensitise target cells for HLA-B37 and A2 restricted T-cell cytotoxicity respectively. It has 
also been demonstrated with the use of peptides derived from influenza virus and the 
sensitisation of target cells for murine H-2Db and H-2Kb and T-cell stimulation [Shastri et 
al. 1995a,b, Goth et al. 1996]. The direct binding of peptides to various affinity-purified 
class I molecules [Chen & Parham, 1989, Chen et al. 1990) and viable target cells 
[Luescher et al. 1991] has been demonstrated. It has been reported that peptides composed 
of nine amino acids bound most efficiently to class I [Schumacher et al. 1991]. However, 
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the length of peptides does vary from 8-11 residues long, peptides of 13 residues long have 
also been isolated from HLA-A2 molecules [Chen et al. 1994, Urban et al. 1994, 
Henderson et al. 1992, Guo et al. 1993, Madden. 1995]. Naturally fanned peptides present 
in murine cells have been purified and analysed and it has been found that the MHC type 
detennined the cellular peptide composition [Falk et al. 1990, Young et al. 1994]. Pep tides 
are held in a largely extended confonnation and run the length of the cleft, with the N-
tennini and C-tennini parallel to the orientation of the a 1 a helix [Madden et al. 1991 ], 
see figure 2.19. The bound peptide generally has a prominent kink approximately one third 
of the way from the N-tenninus, which lifts the peptide main chain up away from the floor 
of the cleft [Madden et al. 1991]. One of the most impressive features of peptide binding is 
the ability of class I molecules to fonn extremely stable complexes with peptides while 
simultaneously accommodating considerable sequence variability. A given peptide binding 
groove can bind hundreds or thousands of different peptides, identical or homologous at 
only a few side chain positions [reviewed by Madden. 1995]. Comparison of the structures 
of numerous class I peptide-MHC complexes reveals that this flexibility is achieved by the 
structurally equivalent binding of a small subset of each peptide's residues [Madden et al. 
1991, 1992, 1993, Guo et al. 1993, Zhang et al. 1992, Young et al. 1994]. Among these, 
the binding of charged and polar atoms of the peptide main chain, which provides essential 
side-chain sequence-independent peptide-MHC interactions. This collection of hydrogen 
bonds and van der Waals contacts help stabilise the binding of the peptide. In addition 
there are interactions with a few peptide side chains that supplement the main-chain 
binding energy and impose some sequence selectivity on the peptides bound by a particular 
MHC molecule, see figure 2.20. 
The amino acid sequences of naturally processed peptides have been investigated 
by acid extraction from purified class I molecules, H-2Kd, H-2Kb, H-2Db and HLA-A2 
[Falk et al. 1991, Rammensee et al. 1995]. It was reported that all the peptides were 
octamers or nonamers with distinct positions showing a strong bias for particular amino 
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Fig. 2.20. 17 A and B. The conserved residues that interact with the main chain atoms of the N-
and C- tennini. of peptide are shown in red (highly conserved) and green (less conserved). At 
the N- and C-terrnini of the peptide backbone hydrogen bonds (dotted lines) are formed 
(adapted from Matsumura et al. , 1992). 
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acids (motif residues) for each MHC allele. Peptides acid-eluted from purified HLA-B27 
molecules were analysed and it was shown that all peptides were nonamers and most were 
derived from intracellular proteins including histones, ribosomal proteins and heat shock 
proteins [Jardetzky et al. 1991, Madden et al. 1991, 1992, 1995]. Examination ofthe amino 
acid sequence of the bound peptides indicated that the sequence would be restricted at a 
number of positions to a B27-specific sequence motif, because these peptide side chains 
are bound in 'pockets' in the bottom and sides of the binding groove. A motif is the 
characteristics shared by most of the peptides presented by a particular HLA molecule 
[Rammensee. 1997]. Of the nine amino acid positions in the peptide, position 2 was 
invariably arginine, positions I and 9 were positively charged residues, position 3 was 
hydrophobic, position 6 was non-polar and positions 4, 5, 7 and 8 were fairly unrestricted 
with respect to the amino acid. Nonameric peptides have also been eluted from HLA-A2 
molecules, but analysis of the amino acid sequence of the peptide has shown a difference 
in the amino acids at particular positions compared to B27. The amino acid at position 2 
was invariably leucine and position 9 was a non-polar valine, leucine or isoleucine residue 
[Wei and Cresswell, 1992, Henderson et al. 1992, Hunt et al. 1992a]. Further, studies of 
HLA class I alleles and bound peptides have shown that some HLA molecules are almost 
identical in their peptide specificity. However, even very closely related HLA molecules 
sharing the same basic peptide motifs differ in their fine specificity, especially at the non-
anchor positions [Rammensee. 1997, Lamas et al. 1997, Barouch et al. 1995, Rammensee 
et al. 1995, Rudwaleit et al. 1996, Villadangos et al. 1995, Fiorillo et al. 1995]. The basic 
motifs are almost identical H-2Kb molecules preferentially bind octapeptides with tyrosine 
or phenylalanine at position 5 and leucine at position 8 [Matsumura et al. 1992, Zhang et 
al. 1992]. The crystal structures of the A2 [Saper et al. 1991 ], B27 [Madden et al.1992] and 
H-2Kb [Zhang et al. 1992] have revealed pockets that are situated along the binding 
groove, formed by MHC side chains that protrude into the peptide-binding cleft from the 
a-helices and !3-pleated sheet and form an irregular surface known as a pocket. The side 
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chains are of polymorphic residues in the class I molecule and are suited for the binding of 
the side chains of the motif residues of the peptide, see figure 2.20. This suggests that 
different class I molecules bind peptides of varying specificity's. The residues that fit into 
these pockets have been termed "anchor" residues and two or three in a peptide are 
required for optimal binding by a class I molecule [reviewed by Madden. 1995]. The 
specificity of peptide binding is therefore restricted by these "anchor" residues and each 
class I molecule can bind many different peptides, although cytotoxicity assays have 
demonstrated that different peptides vary in their immunogenicity [ Adorini et al. 1988, 
Engelhard. 1994]. This type of binding is termed primary anchor binding and as already 
mentioned above the side-chain binding pockets vary widely in the restrictiveness of their 
binding preferences. In addition to the strict side chain-binding pockets there are further 
interactions with peptide side chains at positions that do not have as strict a preference for 
individual side chains, known as secondary anchor binding. Different kinds of structural 
interactions underlie these interactions including, "loose" pockets, part-time pockets and 
non-pockets [reviewed by Madden. 1995]. Also important in the binding of peptide are a 
number of conserved residues that are clustered at the very ends of the binding groove. 
These residues interact with the NH2 and COOH groups of the peptide via hydrogen bonds 
that link together the a-helices and the 13-pleated sheet at both ends of the binding groove 
therefore restricting the size and conformation of the bound peptide [Matsumura et al. 
1992, Madden et al. 1992, Elliott et al. 1994], see figure 2.20. The peptide structurally 
knits together and presumably stabilises the three-dimensional structure of the entire 
peptide binding domain ofthe class I molecule [Madden. 1995]. 
The eo-crystallisation of bound peptide with class I molecule indicates that strong 
binding must take place. It has been demonstrated in several studies that stable post-
synthetic assembly and expression of class I chains depends on the intracellular binding of 
peptides and empty class I molecules are rarely expressed on the cell surface [Townsend et 
al. 1989, Fahnestock et a! 1992, Buchholz et al. 1995, Goth et al. 1996, Rock et al. 1991, 
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Benjamin et al. 1991]. It has been shown that the a2 helix ofthe a2 domain that forms one 
side of the binding groove is particularly flexible. Its relative position varies depending on 
the class I allele and the bound peptide, which in turn may have an affect on the assembly 
of the :MHC-peptide complex and therefore the eventual expression of the class I 
molecules [Smith et al. 1996]. This prevents aberrant binding of extracellular peptides, 
which might lead to cytotoxic destruction of cells. 
The process of antigen presentation begins with both the heavy chain and l32m 
mRNA being targeted to the endoplasmic reticulum (ER) by amino-terminal signal 
sequences that are cleaved off once the molecules have been cotranslationally translocated 
into the ER, see figure 2.21. The remainder of the antigen-processing pathway is thought to 
involve the protease genes, LMP2 and LMP7 and the ABC transporter genes, TAP! and 
TAP2 [reviewed by York and Rock. 1996]. LMP has been suggested as the protease 
responsible for the digestion of intracellular proteins to peptides in the cytoplasm. The 
genes encoding at least two of its subunits (LMP2 and LMP7) map to the :MHC class II 
region [Glynne et al. 1991, Kelly et al. 1991b], are polymorphic and IFNy-inducible [Yang 
et al. 1992, Akiyama et al. 1994, Belich et al. 1994, Teisserenc et al. 1997] and are 
expressed in all eucaryotic tissues examined. However, these gene products have been 
shown not to be essential for antigen processing [Amold et al. 1992, Yewdell et al. 1994], 
but a role for LMP in determining the specificity of proteolysis was suggested [Driscoll 
and Finley. 1992]. However, there is evidence that LMP2 and LMP7 have a more 
important role, which was provided using mutant mice, lacking either LMP2 [Van Kaer et 
al. 1994] or LMP7 [Fehling et al. 1994]. The level of cell-surface class I expression was 
reduced compared to normal expression in the mice without the LMP genes. LMP has 
distinct endopeptidase activities which cleave after basic, acidic or hydrophobic residues, 
suggesting that it might preferentially generate peptides with the carboxy terminal motif 
residues required for class I binding. This would account for the polymorphism in the LMP 
genes and their genetic linkage with class I, whose allotypes bind peptides with distinct 
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carboxy terminal motifresidues [Jardetzky et al. 1991, Matsumura et al. 1992, Shastri et al. 
1995b, Madden. 1995]. It has therefore been suggested that the role of LMP is to 
controVregulate the production of peptides, by altering the pattern of cleavage, favouring 
the generation of immunogenetic peptides [reviewed by York and Rock. 1996]. 
The degradation of the intracellular proteins occurs in the cytoplasm but the 
resulting peptides bind to newly synthesised class I molecules in the endoplasmic 
reticulum (ER) [Townsend et al. 1989, Bennink et al 1982, Buchholz et al. 1995, Accolla 
et al. 1995]. The cytosol is not the only site generating peptides; ER proteases are also able 
to produce naturally processed antigens, provided they are equipped with ER retention or 
translocation signals [Accolla et al. 1995). The remarkable precise excision of antigenic 
peptides from their precursor polypeptides suggests there are specific flanking residues that 
influence presentation efficiency. Various studies have been carried out to investigate this 
by altering the sequences flanking a particular epitope, in some cases these alterations had 
no effect [Hahn et al. 1992], while in others the pattern of presentation was decreased 
[Eisenlohr et al. 1992]. This is presumably owing to altered cleavage patterns by proteases 
[Niedermann et al. 1995]. Differences in the susceptibility to proteolytic cleavage has also 
been linked to C-terminal flanking residues [Shastri et al. 1995b]. The major pathway for 
degrading proteins in the cytosol is ATP-dependent and highly conserved from yeast to 
mammals [York and Rock. 1996]. In this process proteins are hydrolysed to oligopeptides 
by a large multicatalytic proteolltic particle, the proteasome [Rechsteiner et al. 1993, 
Peters. 1994, York and Rock. 1996]. There are two forms of the proteasome, a 20S 
cylindrical particle composed of four rings [Lowe et al. 1995]. In mammalian cells, the 
outer rings are made up of seven distinct a. subunits, thought to be primarily structural and 
regulatory, while the inner rings are composed of seven distinct 13 subunits that from the 
catalytic sites [LOwe et al. 1995]. The other form is a 26S particle, which contains as its 
proteolytic core the 20S structure associated with many additional subunits that regulate its 
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Fig.2.21: Antigen processing pathway for presentation by major histocompatibility 
complex (MHC) class I molecules 
Intracellular proteins are proteolytically digested into short peptides, possibly by the large 
multifunctional protease (LMP). The peptides are actively transported into the endoplasmic 
reticulum (ER) via the transporter associated with antigen processing (TAP) gene products, 
where they drive the synthesis of MHC class I molecules. The peptide-class I complexes 
are then exported via the trans-Golgi to the cell surface. 
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activity [Rechsteiner et al. 1993, Peters. 1994]. The degradation of many cellular proteins 
is initiated by their modification with the small polypeptide ubiquitin [Ciechanover. 1994]. 
Ubiquitin is attached via an isopeptide bond to lysines on the substrate and on other 
ubiquitins. This process requires ATP and several enzymes (El, E2 and E3) that activate 
the ubiquitin and transfer it to the protein substrate. The polyubiquitin chain serves as a 
molecular tag that marks a protein for rapid degradation by the 26S proteasome. The 
specificity of this process is determined by E2 and/or E3 enzymes, which bind to specific 
substrates and then conjugate ubiquitin. A number of studies that have investigated the role 
of the ubiquitin-proteasome pathway in antigen presentation, have provided conflicting 
results on the importance of ubiquitination, but it appears that for some selected model 
antigens, ubiquitin conjugation plays a role in MHC class I presentation [reviewed by York 
and Rock. 1996]. The role of ubiquitin in antigen presentation indirectly implicates the 
proteasome as the protease responsible for generating presented peptides. Limited data 
suggests that the products from the proteasome are typically between five and eleven 
amino acids long [Tokunga et al. 1994]. This is the size range for peptides, which is 
optimal for binding to different MHC class I molecules. There is direct evidence that the 
proteasome has a role to play in antigen presentation [Rock et al. 1994b, Grant et al. 1995] 
and it has been suggested that the proteasome is the major pathway for generating class I 
presented peptides [Rock et al. 1994b]. Peptides cleaved by proteases other than the 
proteasome, including peptides derived from signal sequences cleaved by the signal 
peptidase can also be presented via MHC class I molecules, so long as they contain the 
appropriate binding motifs [Henderson et al. 1992, Eisenlohr et al. 1992, Rock and York. 
1996]. It is still unclear whether the peptides produced by the proteasome are identical to 
those bound by the class I molecules, or whether they undergo further processing in the 
cytosol or in the ER. If further processing dose take place is the proteasome responsible for 
N- or C- terminal cleavage [York and Rock. 1996]. Generally the peptides that are 
produced lack a recognisable N-terminal signal sequence; therefore the peptides are 
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actively transported across the ER membrane [York and Rock. 1996]. This function is 
almost certainly performed by the products ofthe TAP1 and TAP2 genes. There is some 
doubt as to whether A TP transporters are required for peptides to reach nascent class I 
molecules [Amaiz-Villena. 1993, Levy et al. 1991, Koppelman et al. 1992] however, other 
studies using mutant cell lines have suggested that T AP1 and T AP2 are required for the 
transport ofpeptides [Spies et al. 1992, Neefjes et al. 1993, Sheperd et al. 1993, York and 
Rock. 1996]. TAP1 and TAP2 form a single complex that consists of 6 transmembrane 
domains, which is located in the ER membrane [Kelly et al. 1992, York and Rock. 1996] 
and that regulates the transport of peptides into the lumen of the ER [Sheperd et al. 1993]. 
The sequence ofboth the TAP1 and TAP2 subunits shows consensus ATP-binding sites in 
the cytoplasmic domain, near the C-terminus [Muller et al. 1994]. The peptide-binding site 
is also in the cytoplasmic region and is probably formed by both subunits [van Endert et al. 
1994]. Peptide binds to the TAP complex independently of ATP, while peptide 
translocation is A TP-dependent. The defect in antigen presentation in cells that lack TAP 
function suggests that this transporter is responsible for supplying most peptides for class I 
presentation and therefore must have a broad specificity. However, studies have shown that 
the transporter may have some selectivity, as a genetic polymorphism in the TAP genes of 
rats affected the repertoire of presented peptide [Livingstone et al. 1991]. More recent 
studies have suggested that the transporters have a definite preference for peptides of a 
certain length, but less dramatic sequence preferences [Howard. 1995]. It is has also been 
suggested that TAP might play an active role in the assembly of class I molecules, 
associating with 'empty' peptide receptive molecules in the ER, resulting in a TAP-class I 
complex [Suh et al. 1994, Ortmann et al. 1994, York and Rock. 1996, Elliott. 1997]. TAP 
does not bind to stable, peptide-loaded molecules, in fact, the ATP-dependent delivery of 
peptides to TAP-class I complexes results in the release ofthe class I molecules from TAP 
[Suh et al. 1994, Ortmann et al. 1994]. This release is peptide specific and is dependent on 
the MHC class I allele involved. It has also been shown that polymorphism of T AP2 
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affects the spectrum of peptides which can be bound by the class I molecule [Acolla et al. 
1995, Powis et al. 1992b]. It has also been shown that TAP-class I molecules are found 
associated with two additional molecules: the ER-resident calcium-binding chaperone 
calreticulin and a novel 48kDa glycoprotein called tapasin [Sadasivan et al. 1996, Ortmann 
et al. 1994]. A similar multi-component complex has been demonstrated in the mouse, the 
ER-resident calcium-binding chaperone is calnexin [Suh et al. 1996]. It has been suggested 
that the binding of the chaperone molecules are required for the formation of the ternary 
complex with TAP. TAP does not bind to calreticulin in the absence of class I and it is the 
class I molecules that binds directly to TAP and not the chaperone molecule [EIIiott. 1997]. 
The biogenesis of this chaperone-class I complex is therefore of crucial importance for 
initiating and maintaining an interaction with TAP. It has been shown that tapasin is also 
essential for the interaction between class I and TAP protein [Grandea et al. 1995, 
Greenwood et al. 1994]. Therefore in the ER newly synthesised class I molecules form part 
of a macromolecular complex and the interaction between all the components are essential 
for maintaining the overall stability ofthe loading complex [EIIiott. 1997, Bresnahan et al. 
1997]. Residues in both the a.3 and a.2 domains of the class I molecule have been shown to 
be important in the peptide regulated interaction with TAP [Suh et al. 1996, Carreno et al. 
1995]. The binding of peptide by the class I molecule and the completion of class I 
assembly results in a stepwise dissociation ofT AP and the chaperone molecules from the 
class I molecule [Sadasivan et al. 1996, Suh et al. 1996]. The trigger of this disassembly is 
unknown but one possibility is that a peptide-induced conformational change in the class I 
molecule triggers the dissociation from the complex. Such a conformational change is seen 
in the absence of Jhm and has been implicated when peptides bind to empty class I 
heterodimers [Elliott et al. 1991, Catipovic et al. 1994]. It has been hypothesised that the 
exposed side of the a.2 helix forms part of the binding site for one or more of the 
components of the loading complex. When the binding groove of the class I molecule is in 
a 'relaxed' conformation (without bound peptide) the a.2 helix is displaced from the 
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binding groove and is in a position to create a high affinity binding site for factors in the 
loading complex. However, when the C-terminal end of an appropriate peptide is 
introduced into the binding groove, it may only be able to make full complement of 
hydrogen bonds if the a2 helix is displaced inwards, towards the groove. This would lead 
to the disruption of the binding site for the cofactors of the loading complex and cause the 
dissociation of the fully assembled class I molecule from the loading complex [EIIiott. 
1997]. The conformational change in the class I molecules enables the class I complex to 
move from the ER through the Golgi where N-linked carbohydrates are modified and then 
the plasma membrane where the bound peptide is presented in a recognisable form to 
CD8+ T -cells. 
2.9.2 Antigen presentation by class ll molecules 
MHC class II molecules are known to be very similar to class I molecules in overall 
structure [Brown et al. 1993, Madden. 1995], but the differences are significant in the 
context of antigen presentation. The specificity of peptide binding to class II molecules is 
more degenerate than for class L but locus-specific and allele-specific motifs have been 
identified [Jardetzky et al. 1990, O'Sullivan et al. 1991, Stem et al. 1994, Hammer et al. 
1992, Rotzschke and Falk. 1994, Ranunensee. 1997, Ranunensee et al. 1995, Vartdal et al. 
1997, Johansen et al. 1994, 1996]. A number of studies have now identified class II 
binding motifs the characteristics of which are common to the nine amino acid stretches 
accommodated in the HLA groove of most of the peptide ligands associated with a 
particular class II molecule. However, unlike the peptides bound to class I molecules there 
are a number of exceptions, which makes determining the motif sequence more difficult 
[Falk et al. 1994, Vartdal et al. 1997, Rammensee. 1997]. The binding motif of the HLA-
DQ2 allele has been identified by sequencing a number of peptides that were eluted from 
affinity-purified DQ2 molecules. The binding motif has anchors at positions PI, P4, P6 P7 
and P9, P4 is aliphatic or negatively charged residues, P7 is negatively charged residues 
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and P9 is bulky hydrophobic residues [V artdal et al. 1997, Johansen et al. 1994, 1996]. 
Potential binding motifs have been identified in a number of other class II molecules and 
some have been shown to bind allo-specific peptides [Harris et al. 1993, Kwok et al. 1996, 
Feugeas et al. 1997]. It has been reported that some residues appear to interact with both 
class II and the TCR, suggesting that the peptide is bound as an extended two-dimensional 
13-strand structure [Sette et al. 1987, Rotzschke and Falk. 1994]. Several amino sequences 
in various class II molecules have been identified that are required for T -cell recognition 
[Brown et al. 1986, Madden. 1995]. 
The analysis of amino acid sequences of peptides bound to class II molecules 
showed that there were several peptides of differing lengths (thirteen or more amino acids) 
that were found to correspond to the same core determinant [Rudensky et al. 1991, 
Rotzschke and Falk. 1994]. Evidence has also shown that different peptides, which bind to 
the same class II molecules can shift their amino termini by one or two positions so that the 
same or structurally related amino acids occur at particular positions [Rudensky et al. 
1992, Rotzschke and Falk. 1994, Madden. 1995]. Various studies have revealed common 
core determinant regions of six to fourteen residues in length with flanking regions of 
varying lengths at both ends [Hunt et al.1992b, Chicz et al. 1992, 1993]. Peptides that are 
associated with class II molecules are termed as 'nested sets' a family ofpeptides sharing a 
common core sequence with extensions at either the N- or C- terminal ends. The fact that 
MHC class II molecules can bind peptides of varying lengths suggests that the binding 
groove is open at both ends (see figure 2.22), allowing peptides to protrude in either 
direction from a central motif [Brown et al. 1993]. Compared to MHC class I molecules 
were the peptide binding groove is of fixed dimensions which accommodates peptides of a 
restricted length of eight or nine residues. In the class II molecule there are conserved 
residues that interact with the main chain of a bound peptide within the binding groove, 
however the residues are not clustered at the ends of the groove as in class I molecules, but 
are distributed along the length of the open ended groove (see figure 2.22), therefore 
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Fig 2.22 . The distribution of conserved residues in the class II peptide-binding site. 
Three conserved asparagine residues , 62 and 69 in the a 1 helical region and 82 in the ~ 1 
helical region. Conserved tryptophan ~ 61 and arginine a 76 locate in the side chain. A 
special arrangement of hydrogen bonds from conserved class II HLA residues to the 
peptide main chain (yellow) (adapted from Stern et al., 1994). 
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allowing the peptide to protrude from each end [Madden. 1995]. Most peptides bound to 
:MHC class ll have either an aliphatic or aromatic residue near the N-terminus, which binds 
in a hydrophobic pocket formed by a cluster of polymorphic residues [Brown et al. 1993] 
and which is located on the left-hand side of the binding groove [Chicz & Urban, 1994]. 
TheN-terminal residue is therefore considered as the dominant 'anchoring' residue and is 
responsible for the orientation of the peptide in the groove. The anchor residues in contrast 
to other residues are very specific, P4 of DRB 1 *030 1 is strictly aspartate and an important 
feature of class ll motifs are residues not allowed at otherwise degenerate anchors 
[Rammensee. 1997]. The positively charged amino acids arginine and lysine, for example, 
are not allowed at P4 of DRB1 *0401 and 0404, whereas the acidic amino acids aspartate 
and glutamate are not liked by P4 ofDRB1 *0402. This anchor specificity is reflected by 
the structure of the pocket formed by the class n molecule [Rammensee. 1997]. 
Additional peptide side chain-binding pockets are found along the length of the binding 
groove and can be correlated with the observed peptide-binding motif [Brown et al. 1993, 
Stem et al. 1994, Madden. 1995]. It has been shown that interactions of peptide side chains 
with structurally complementary pockets in DQ molecules is critical for allele specific 
peptide binding and T -cell reactivity [K wok et al. 1997]. Studies have demonstrated that 
the codon 57 region ofthe DQB1 chain is an important immunodominant region forT-cell 
recognition through a peptide dependent mechanism. A negatively charged residue at 
codon 57 is favoured to interact with an small non-charged residue on position 9 of the 
peptide and a non-charged residue at codon 57 is favoured to interact with a negatively 
charged residue on position 9 of the peptide. In both cases, the reulting :MHC-peptide 
complex is sufficient for comparable T-cell recognition [Kwok et al. 1997]. The amino 
acid at position 57 in DQB 1 alleles has been shown to have important implications in type 
1 diabetic susceptibility, this will be discussed in more detail in chapter 3. A 
predominance of peptides of certain lengths suggests that these protruding ends are 
enzymatically trimmed after peptide binding to class ll. Since a number of autoimmune 
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diseases are associated with a particular Ill..A class IT molecule, including type 1 diabetes, 
comparison of the peptide motifs of the disease associated allele with that of closely related 
alleles not associated with the disease, could be informative with respect to the disease 
inducing self or foreign peptides [Friede et al. 1996]. 
In contrast with class I that binds endogenously synthesised peptides in the ER, 
class IT molecules generally acquire peptides from exogenous proteins in endocytic 
compartments, see figure 2.23. A study was carried out that followed the fate of class I and 
class IT molecules from their biosynthetic sites in the ER, using immunogold staining of 
human B cell cryosections [Peters et al. 1991]. Synthesis of class I molecules is associated 
with the acquisition of peptides in the ER, whereas class IT molecules synthesised in the 
ER bind a non-polymorphic, non-:MHC encoded polypeptide, the invariant chain (Ii) (CLIP 
class IT-associated Ii peptide) [Roche & Cresswell, 1990, Sanderson et al. 1995, Accolla et 
al. 1995]. It has been suggested that Ii promotes the proper folding of the class IT molecule 
resulting in the export of only functional molecules from the ER and also prevents the 
binding of antigenic peptides by associating with the binding site, or it may bind to another 
site on the class IT molecules in such a way that the conformation is altered [Accolla et al. 
1995, Adams and Humphreys. 1995]. Budding of the ER leads the class I and class IT 
molecules to the trans-Golgi reticulum where they are sorted for transport to the plasma 
membrane and the endocytic pathways respectively. The class IT containing vesicles, 
together with endosomes containing internalised antigenic proteins, fuse to form a 
compartment with lysosomal characteristics that is enriched in class IT molecules but 
devoid of class I, the compartment is referred to as the MHC class IT compartment (MIIC) 
[Germain. 1994, Roche et al. 1993, Romagnoli et al. 1993]. Within the MIIC the protein, 
which arrives into the cell by phagocytosis, causing a coated pit which fuses with an 
endosome, is proteolytically degraded to peptides which binds to the class IT molecules, 
replacing Ii by a protease dependant process that results in the degradation ofli. This leads 
to a conformational change in the class IT molecule and the peptide-class IT complex is then 
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Fig 2.23: Antigen processing pathway for presentation by major 
histocompatibility complex (MHC) class 11 molecules. 
Extracellular proteins are internalised via the endocytic pathway. Class II molecules are 
biosynthesised in the endoplasmic reticulum (ER) where they are noncovalently associate 
with the invariant chain (li). They are transported via the Golgi, which fuse with an 
antigen-containing endosome to form the acidic MHC class II compartment (MIIC). Here, 
the antigen is proteolytically cleaved into peptides, which bind to the class II molecules, 
replacing li. This confers a stable compact conformation on the class II molecules, which 
are then transported to the cell surface. 
142 
exported to the cell surface for presentation to T -cells. Ii chain is important in the early 
stages of intracellular transport as it targets the class II molecule to the MIIC via its 
cytosolic tail [Anderson and Miller. 1992]. It has also been suggested that signals within 
the Ii protein can allow endogenously synthesised proteins to efficiently enter the :MHC 
class II presentation pathway and the luminal residues of Ii bind to the class II molecule 
[Sanderson et al. 1995]. Further evidence has been provided that class II molecules acquire 
peptides in the MIIC using mutant cell lines transfected with DR3 genes [Riberdy et al. 
1992, Germain. 1994]. 
Class II molecules can be expressed 'empty' on the cell surface, which is consistent 
with the biological roles of class I and class II molecules. The assembly and expression of 
class I is dependent on stable binding by peptides based on motif sequences fitting the 
polymorphic pockets on the molecule. This prevents 'empty' class I molecules being 
expressed on the cell surface and the subsequent binding of extracellular peptides, which 
might lead to inappropriate cytolysis by CD8+ T -cells. The requirement for stable binding 
also imposes a limit on the number of suitable peptides generated from a protein that can 
bind to a class I molecule however, only one from a whole set of viral proteins is required 
to effect T-cell cytotoxicity. In contrast, class II molecules are less selective and readily 
accept peptides with a much wider range of variability than class 1 Class II molecules 
might find numerous peptide determinants within a single protein. Therefore, although 
there are a limited number of different class II molecules present in a certain individual, it 
is possible to initiate humoral immune responses against a whole spectrum of unknown 
antigens. 
Peptide binding by MHC molecules as discussed in this chapter is not an 
immunological end in itself; it is a prerequisite for the antigen-specific T -cell recognition 
that regulates cellular interactions in the immune system. The structure of the TCR-
peptide-MHC complex and the contacts made between the domains of the TCR and MHC 
molecules has been discussed in section 2.2 [reviewed by Bjorkman. 1997]. Antigen 
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specificity is also important in the interaction between MHC molecules and TCR Since a 
given MHC molecule forms complexes with many peptides, antigen specificity requires 
each complex to have a unique conformation at the TCR binding site [Madden.l995]. A 
number of studies involving side-chain substitutions have identified a number of peptide 
side chains that appear not to affect peptide-MHC binding but dramatically alter TCR 
recognition. These have been termed "flag" side-chains and most are prominently exposed 
at the surface of the MHC-peptide complex and provide the TCR with direct access to the 
antigenic identity of the bound peptide [Madden et al. 1992, Fremont et al. 1992, Stern et 
al. 1994, Garboczi et al. 1996]. Several peptide side chains appear to be sandwiched 
between the MHC and TCR molecules, some are involved in MHC binding others are 
involved in TCR contact [Madden. 1995]. Also some of the variable peptide side chains 
that contribute to the TCR binding surface of structurally characterised peptide-MHC 
complexes also make substantial MHC contacts, either in secondary anchor pockets or 
along the upper edge of the binding groove [Madden et al. 1993, Silver et al. 1992, Young 
et al. 1994, Stem et al. 1994]. Furthermore, since part of the TCR recognition surface is 
contributed directly by the peptide main chain and also side chains of the bound peptide 
the conformation of the peptide provides additional antigenic specificity to the TCR-
peptide-MHC interactions. Another important factor in the interaction of TCR and MHC 
molecules is the possible formation of MHC homodimers that have been identified in 
crystal form [Borwn et al. 1993]. It has been considered that dimers may be artefacts of 
crystallisation, but it is possible that they may reflect an interaction that is only stable in 
vivo as part of a larger complex involving TCR and the eo receptor CD4. It has been 
suggested that the presence of such dimers of class IT-peptide complexes would induce 
TCR dimerisation resulting in signal transduction [Brown et al. 1993, Bentley and 
Mariuzza. 1996, Madden. 1995]. It is clear that MHC-peptide-TCR recognition is the 
fundamental trigger of the cellular immune response. But such recognition ofMHC 
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molecule and TCR is also important in the development of tolerance, which will be 
discussed in the following section. 
2.10 Tolerance 
The immune system functions as a network of different cells and molecules that 
normally act together to protect the body from infectious agents, but remain unresponsive 
to its own self-antigens. The prevention from attacking self is known as tolerance. The 
processes of clonal deletion/negative selection of developing B and T lymphocytes in bone 
marrow and the thymus respectively achieve tolerance to self. Their natural diversity to 
antigen recognition includes ability to recognise self-antigens, whether they are bound to 
MHC molecules as for T -cells, or not as for B-cell recognition. Lymphocytes are selected 
(positive selection) that are non-reactive to self-antigens. Lymphocytes that recognise and 
react to self-antigen are destroyed. The MHC molecules themselves act as antigens and 
clonal deletion ofT lymphocytes reactive to self-MHC molecules without bound antigen 
occurs. The immune system is normally tightly regulated, but a breakdown in the 
regulation of the system, which can lead to a loss of self-tolerance may result in the 
development of autoimmune disease as type 1 diabetes (this will be discussed in more 
detail in later sections). The following sections describe the development ofT -cells and the 
mechanisms involved in the maintenance of tolerance. 
2.10.1 T-cell subsets 
T -cells do not belong to a functionally homogenous population; instead they 
represent a number of different functional subsets. Each subset has its own characteristic 
function, lifespan and repertoire of antigenic surface markers by which its member can be 
identified. Functional competence with respect to a T -cell function is acquired during the 
differentiation of T -cells in the thymus (thymic ontogeny). In the cortex of the thymus 
there is a mixture of early, intermediate and mature T-cells at their various stages of 
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differentiation and maturation. Thymic progenitor cells express no TCR (thymocytes), this 
is acquired when the immature cells migrate from the cortex to the medulla of the thymus 
were the cells also express both cell surface markers CD4 and CD8 and are therefore 
referred to as "double positive" thymocytes. Rearrangement of the V, D and J gene 
segments at the TCRB locus allows for the cytoplasmic expression of the 13 chain. This is 
followed by V -J rearrangement at the TCRA loci, culminating in a.l3 TCR expression on 
the cell surface of immature thymocytes (as described in sections 2.3 and 2.4). The a.l3 
TCR expression is preceded by expression of the other TCR, the y8 heterodimer. It is 
partially due to the random rearrangement of germline V, D and J gene segments that 
creates the enormous repertoire of TCR specificities for antigenic peptides and MHC 
molecules. It has been shown that during the thymic education process there is selection 
for or against, particular V segments depending upon the Ill.A type of the individual, 
therefore Ill.A antigens have an influence on the TCR repertoire [Gulwani-Akolkar et al. 
1997). Additional diversity is generated by the random insertion and deletion of 
nucleotides at the TCRVJ and TCRVDJ junctional regions. Subsequent maturation of the 
T -cells leads to the mature "single-positive" stage of development, when the T -cell 
expresses only one of the accessory molecules, either CD4 or CD8, and has increased the 
density of TCR expression to that of circulating T -cells. This final maturation stage takes 
place in the cortex of the thymus, which is were the mature T -cells leave the thymus to 
circulate in the peripheral blood. The expression of CD4 and CD8 allows differentiation of 
T -cells into their two major functional subsets. CD4+ cells function as T helper (T H) cells 
and CD8+ cells function as cytotoxic T cells (Tc). Cells expressing CD4 recognise antigen 
presented by class II molecules, whilst those with CD8 recognise antigen associated with 
class I molecules. There is another subtype ofT -cell known as the T suppressor cell (T s) 
that belongs to the regulatory category ofT -cells, T H cells also belong to this group. 
Following recognition of an antigen associated with a class II MHC molecules TH 
cells exhibit clonal proliferation, specific to the same antigen-MHC class II complex. The 
146 
T H clones function as facilitators of the immune response by activating B-cells, T c cells, 
and other effector cells of the immune response by the secretion of a variety of cytokines 
(see section 2.12.5). The cytokine profile that is secreted by the T H cells divides them into 
two populations T H 1 and T H2, which produce different effects upon the immune system 
[Alien and Maizels. 1997]. The T H 1 response consists of a cytokine profile including IL-2 
and IFN-y, which results in the activation of a cell-mediated immune response involving 
T c cells and macrophages. In contrast, the T H2 response activates a B-cell response, as the 
cytokine profile includes IL-4 and IL-5. The phenomenon that is now known as TH1/TH2 
was once described as "immune deviation" due to the capacity of an immune response to 
be expressed primarily either by antibody production or by "cell-mediated" immunity 
[Parish. 1996]. Early evidence suggested that different populations ofT -cells provided help 
for antibody production and mediated cellular reactions [Segal et al. 1972]. The discovery 
of cytokines and their classification into T H 1 and T H2 groupings renewed the interest in the 
T-cell classes [Mosmann et al. 1989b]. The TH11TH2 phenomenon has been linked to the 
pathogenesis of type 1 diabetes [Cohen. 1997, Rabinovich. 1994, Bach. 1997], this will be 
discussed in more detail in later sections. The functional division ofT H 1 and T H2 cannot be 
absolute, as cytokines such as TNFa, GM-CSF and IL-3 are produced by both populations 
and both TH1 and TH2 responses are required to deal with many antigens [Alien and 
Maizels.1997,Kelso.1995]. 
T s cells can suppress both the humoral antibody response and the cell-mediated immune 
response. Ts cells can inhibit B-cell function directly and also by inhibiting T H activation. 
Some Ts cells are antigen-specific whereas others seem to lack antigen specificity. 
Tc cells interact with an antigen-:MHC class I complex and produce IL-2 by stimulation of 
CD28, a molecule expressed on T-cells [Fraser et al. 1991]. IL-2 promotes activation by 
into its effector form, the cytotoxic T lymphocyte (CTL). The CTL, eliminates altered 
'self cells, by the activation of soluble (e.g perforins) and cell membrane effectors (Fas 
ligand) to induce lysis or apoptosis. CTLs are CD8+ and therefore class I :MHC dependent 
147 
(which is expressed on all nucleated cells); it can recognise and mediate the destruction of 
any altered body cell. 
Other T -cell subsets include T -memory cells (T M), which are long-lived progeny cells of 
T-cells corresponding to B-memory cells. The long-life is possibly due to the fact that 
exposure to antigen has somehow programmed them for a long-life, so they are able to 
persist in lymphoid tissues. Because they are already clonally expanded the cells are able 
to mount an effective and rapid secondary response to foreign antigen. T-amplifier cells 
(TA), these are less mature, short-lived T -cells that remain in the spleen and thymus 
without recirculating. TA cells have been found to enhance the functional activities of B-
and T-cell populations. Finally, there are delayed hypersensitivity T-cells (T oH or T 0). 
These cells play an important role in delayed hypersensitivity reactions, which also depend 
on the persistence ofT M cells and protect the body against certain major infectious diseases 
[Janeway and Travers. 1996]. 
Upon completion of TCR gene rearrangements in the thymus, immature T -cells 
undergo a complex series of elimination and selection events based on TCR engagement 
with MHC-peptide complexes on thymic epithelium and dendritic cells. T-cells that are 
capable of binding to self-antigen plus self-MHC molecules are deleted from the pool ofT-
cells, this is known as negative selection. T -cells whose receptors are capable of interacting 
with self-MHC molecules expressed in the thymus undergo positive selection for further 
differentiation. By subjecting T-cells to such education, the system selects for cells that are 
"obsessed" with self-MHC and yet are unable to react with self-MHC combined with any 
self-antigen that the T -cell encountered during the later stages of ontogeny. 
2.10.2 Central tolerance 
Thymic differentiation provides a critical first screen for the selection of cells with 
wanted antigen receptors and the elimination, by active censure or neglect of unwanted 
cells. 'Unwanted' here means cells that cannot recognise autologous MHC (no activation 
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signals, clonal neglect) or cells that recognise MHC combined with self-peptides, negative 
selection, TCR binding triggers apoptosis in immature T -cells. This selection process that 
takes place in the thymus is termed 'central tolerance' [Schwartz. 1990]. The aim of central 
tolerance is mainly the clonal deletion (death) of unwanted cells and the shaping of a 
repertoire with all cells able to recognise self-MHC. There is also a process called clonal 
deactivation, which allows T -cells to survive and emigrate from the thymus although they 
appear non-functional, maybe anergic (see section 2.12.3). Whether this reflects a degree 
of leakiness in the clonal deletion mechanism or serves a specific purpose is unknown. T-
cells are positively selected on the basis of recognition of antigen in the context of self-
MHC [Zinkernagel et al. 1978]. Much of what is known about tolerance has come from 
studies using mouse models. Most of the cell death that occurs in the thymus is due to cells 
failing positive selection, however, cell death can occur at another stage. The positively 
selected cells are exposed further to self-peptides bound to self-MHC, those that bind 
strongly to this complex also die, negative selection or clonal deletion [Kappler et al. 
1987). Positive selection occurs on the basis of the ability ofT -cells to respond to foreign 
antigens when presented in the context of self-MHC. It is not possible for all 'foreign' 
antigens to be present in the thymus during development; therefore some of the positive 
selection must also involve the recognition of 'self -peptides, but obviously in a different 
manner to that of negative selection. If this is the case then both positive and negative 
selection may involve the interaction of TCR self-peptide and self-MHC; however, it may 
be that there is a role for recognition of the MHC alone. It has been shown that the MHC-
peptide binding, TCR binding and aggregation as well as densities of the interacting 
members of the trimolecular complex play differential roles forT-cell selection/elimination 
that appears more and more as affinity/avidity-driven [Ashton-Rickardt et al. 1994, Karges 
et al. 1995, McDevitt. 1997]. It has also been questioned as to how a repertoire of TCRs is 
selected for exogenous peptides for which the receptors are specific, as well as negative 
selection, for self antigens, of peptides which are not expressed in the thymus. It has been 
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suggested that peptides are important in positive selection [Ashton-Rickardt et al. 1993, 
1994]. However, if as suggested by this model that a single peptide can perform this 
function, then it would appear that either many different TCRs are capable of recognising 
the same peptide or that the MHC can be recognised alone. It has also been shown that the 
nature and dose of peptides is important in positive selection [De Magistris et al. 1992, 
Hogquist et al. 1994, Ashton-Rickardt et al. 1994). It has been suggested that there may be 
a unique set of peptides found in the thymus, but no were else, that could drive positive 
selection, but further studies have not provided evidence for this. 
It is likely that there are a number of mechanisms involved in T -cell developmental 
selection. It is possible that a breakdown in this selection system could result in the release 
ofT -cells that are capable of reacting against 'self, which may be involved in an immune 
reaction leading to autoimmunity. 
2.10.3 Peripheral tolerance 
Central tolerance can only involve antigens that were encountered in the thymus 
and therefore cannot include all possible peptides expressed by the host at some point in 
time. The process of positive and negative selection in the thymus is complemented by 
another process known as peripheral tolerance [Lo et al. 1988]. Although there are a 
number of controlling factors that regulate central tolerance, potentially autoreactive cells 
do leave the thymus into the periphery, such cells are also dealt with by the process of 
peripheral tolerance. 
Clonal Anergy 
A non-deletional mechanism exists in the periphery that results in the clonal inactivation of 
cells, which is known as clonal anergy. Anergy can be transient or a prelude to 
programmed cell death. One form of anergy induction results in T -cell activation in the 
absence of eo-activation signals. One important signal is generated by conjugation of T-
cell CD28 with the B7 family of proteins on the antigen presenting cell, but other co-
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stimulatory pathways exist [Linsley and Ledbetter. 1993, Karges et al. 1995]. In the 
absence of the second signal the T -cell becomes unresponsive to subsequent exposures to 
antigen. Studies have shown that the activation ofT -cells via TCR and CD28 engagement 
protects against the development of anergy and potential apoptosis [Mcleod et al. 1997]. 
Another mechanism that can result in anergy is the engagement of TCR with very high 
affinity [Sloan-Lancaster et al. 1993], and it has been suggested that this mechanism has a 
role in type I diabetic autoimmunity [Karges et al. 1995]. As already explained in the early 
section 2.4, the nature of peptide engagement with the multi-chain TCR-CD3 complex is 
translated into post-receptor binding activation events through differential phosphorylation. 
Anergic peptides, homologous, but not identical to a stimulatory sequence, fail to trigger 
phosphorylation of the TCR ~-chain, which ultimately results in incomplete activation and 
produces T-cell anergy [Sloan-Lancaster et al. 1994, Karges et al. 1995]. T-cell anergy is 
characterised by an inability to produce 11...-2; the presence of 11...-2 can often bypass the 
anergic responses [Karges et al. 1995], as may other cytokines in some circumstances. This 
reflects the use of a common receptor chain, 11...-2 receptor ye, by 11...-2, 11...-4, 11...-7 and 11...-9; 
the signal transduction pathway involving this receptor chain and the janus kinases Jakl, in 
particular Jak3 are critical for the expression (or bypass) of anergy [Karges et al. 1995]. 
The maintenance of the non-responsive state ofT -cells requires continual exposure to the 
antigen and there is evidence that clonal anergy can be induced in the thymus [Ramsdell 
and Fowlkes. 1992, Karges et al. 1995]. A recent study using differential display reverse 
transcription-PeR (DDRT-PCR) has implicated a number of known genes in the process of 
anergy including, genes encoding signalling intermediaries, cytokines and their receptors, 
but also a number novel genes were identified. These are still to be characterised, but may 
have an important role in the development of anergy [Ali et al. 1997]. It has also been 
suggested that there are additional ways to that of induction of anergy, which are involved 
in the regulation of responsiveness of T -cells and these may differ in their functional 
consequences and biochemical mechanisms. Some of these are, supraoptimal 
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concentrations of antigen can cause unresponsiveness as measured by proliferation but an 
augmented response as measured by cytokine production. Pre-treatment of T HI cells with 
ll...-2 can render them unable to produce a broad array of cytokines upon stimulation 
through the TCR [Fitch et al. 1997]. However, the biochemical mechanisms involved in 
mediating these unresponsive states remain to be fully investigated, but it is suggested that 
they are due to distinct molecular defects. 
Ignorance 
It has also been suggested that there may be mechanisms that result in atuoreactive T -cells 
being unable to respond to self-antigen until activated by an external event, this is known 
as ignorance. The idea was first suggested due to studies using transgenic mouse models in 
which a viral protein was expressed on the surface of the pancreatic 13-cells [Ohasi et al. 
1991, Old stone et al. 1991]. This process would result in the maintenance of tolerance, as 
components of self may exist, to which cells can react, but under normal circumstances do 
not. However, it is possible that the immune system could become autoantigenic by 
molecular mimicry, where by an external infectious agent with a sequence homologous to 
the self-antigen would initiate an immune response, which could also attack the self protein 
in the same way [Janeway and Travers. 1996]. 
Antigen sequestration 
Some self-proteins are present in cells that would normally elicit an immune response but 
are hidden from the immune system, in what are known as immunologically privileged 
sites [Janeway and Travers. 1994, 1996]. These self-antigens may not induce tolerance 
because they are not expressed early enough in life before tolerance is normally induced, 
due to their presence in these immunological privileged sites, which include the anterior 
chamber of the eye. Similarly, there may be a repertoire of antigens that are never normally 
seen by the immune system because they are sequestered within cells and do not 
participate in the pathways that lead to presentation of antigen on the surface of cells. 
These may only be seen as antigens if infection or inflammation somehow damages 
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normally intact cells and they would be seen as foreign. 
Regulatory ceUs 
It has been suggested that self-reactive cells survive and retain the ability to respond to 
antigen, but are held in check by a group of T -cells known as suppressor cells (T s), 
described in section 2.10.1. Ts may act directly on TH cells and antigen presenting cells, or 
by secreting suppressive factors. The first to describe this phenomenon was Gershon 
( 1971) but since then, many other studies have also shown that transfer of T -cells can exert 
a suppressive effect on otherwise reactive cells. The existence ofTs cells has been disputed 
but a number of studies have provided evidence that a subset ofTs cells exist [reviewed by 
Janeway and Travers. 1996, Salgame et al. 1991, Fowell and Mason. 1991]. 
2.10.4 Breakdown of tolerance 
In most individuals tolerance to self is maintained throughout life, but in others 
there is a breakdown of the mechanisms that eliminate self-reactive cells, inactivate them, 
or regulate their activity. This results in the presence of autoreactive cells being present in 
the system that have the potential to mount an immune response against self. It has been 
shown that self-reactive T -cells are not rare in normal hosts [Karges et al. 1995], but it is 
still unclear which cells are targeted for elimination by central and peripheral tolerance 
mechanisms and which cells are allowed to escape and why. While it is still unclear as to 
why these escaped cells do not normally cause tissue destruction (autoimmune disease), it 
is important to note that autoimmunity (self-reactivity) does by no means imply 
autoimmune disease. There is a trigger that initiates the destruction of tissue by self-
reactive cells, which if sustained can lead to the development of autoimmune disease. 
Autoimmunity is considered to arise due to loss of self-tolerance, but there are many 
questions as to the exact processes involved and whether autoimmune disease is an 
abnormal repsonse to a 'normal' self, or a normal respone to an abnormal (altered) self? 
Autoimmunity and autoimmune disease will be discussed in more detail in a later chapter. 
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2.11 T CeU activation 
As already described in previous sections T cells co-ordinate the immune response 
through their programme of differentiation that is induced following antigenic stimulation. 
This small section describes the events following the recognition of a :MHC-peptide 
complex and resulting proliferation and production of cytokines. This process occurs both 
in the thymus during the selection of the T -cell repertoire in the development of tolerance 
and also in the periphery after exposure to foreign antigens. The critical requirement for 
antigen-specific T cell activation is the interaction of the TCR with the :MHC-antigen 
complex on an APC. This interaction results in a eo-stimulatory signal produced by the 
APC in the form of interleukin-1 {ll.--1). IL-l is required for the antigen-dependent 
activation of helper T cells and induces T cell expression of IL-2R and the production of 
cytokines. IL-2 stimulates the clonal expansion of CD4+ and CD8+ T cells and other 
immunocompetent cells expressing IL-2R. CD8+ cytotoxic T cells are dependent on 
helper cells because they produce little IL-2 of their own. Colony stimulating factors 
promote haematopoiesis of bone marrow stem cells. lnterferon-y (IFN-y) and TNF-a have 
cytotoxic effects and are produced by cytotoxic T cells. IFN-y is involved in the activation 
of macrophages and TNF-a enhances the phagocytosis ability of macrophages. TNF-a. 
shares many of the inflammatory properties of IL-l and is produced by macrophages. IL-5 
and IL-6 stimulate activated B cells to differentiate into antibody-producing plasma cells; 
IL-4 promotes activation of B cells, proliferation and differentiation into plasma cells; and 
IL-7 is involved in the promotion of B cell activation. All this results in an inflammatory 
response which is characterised by the recruitment of several immunocompetent cell types, 
the production of soluble serum proteins and the generation of antibodies which can 
neutralise viruses and antigens. Antibodies also target cells for complement-mediated 
cytolysis or cytotoxicity by natural killer cells. The clonal expansion of T and B cells 
leaves the immune system primed to respond to the same antigen on future exposure 
[Janeway and Travers. 1996]. 
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CHAPTER3: GENETIC SUSCEPTffiiLITY TO TYPE 1 DIABETES 
3.1 Introduction 
Various studies have provided evidence for the involvement of genetic factors in the 
aetiology oftype 1 diabetes [reviewed by Cucca and Todd. 1996, Field and Tobias. 1997]. 
The genetic background of type 1 diabetes is however, complex. First, the genes involved 
in the disease are not 'disease genes' but 'susceptibility genes', the disease being expressed 
in only a minor proportion of susceptible individuals. Second, the susceptibility is 
polygenic, the main area being mapped to the MHC. In addition several others, among 
them the insulin gene have been linked to the genetic predisposition of the disease. Third, 
type 1 diabetes is genetically heterogeneous, different combinations of susceptibility and 
protective genes leading to a dose effect which influences the penetrance of the disease 
[Deschamps and Khalil. 1993]. Also new approaches to the study of the genetics of type 1 
diabetes by mapping the whole genome have led to the conclusion that several 
predisposing genes are involved and that the predisposition to type 1 diabetes is inherited 
as a combination of several unfavourable gene alleles [Davies et al. 1994, Todd. 1995, 
Wicker et al. 1995, Owerbach and Gabbay. 1996, Todd and Farrall. 1997]. 
3.2 Approaches to the study of the genetic susceptibility to type 1 Diabetes 
A number of approaches are available to study the factors involved m the 
susceptibility to type 1 diabetes as outlined below. 
3.2.1 Population studies 
Much of the data that is available on the susceptibility to diabetes is provided by 
population studies. The comparison of populations of subjects that are affected by the 
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disease with those that are not, have formed the basis of association analysis of many 
disease susceptibility markers. Some of the first studies were performed by serological 
analysis in Caucasoid subjects [Singal and Blajchman, 1973, Nerup et al. 1974, Wolf et al. 
1983]. Later, restriction fragment length polymorphism (RFLP) linkage analysis, where the 
marker allele may represent the susceptibility gene itself, or a gene closely associated with 
it, featured in early population studies of HLA linkage analysis. Identification of a 
significant difference between those affected by the disease and normal controls suggests 
that a genetic locus at or near the marker locus influences disease predisposition. The 
association is a result of linkage, with linkage disequilibrium between the marker and 
disease loci. This technique was also used in the initial attempt to identify non-HLA 
susceptibility markers [Hitman. 1986]. RFLP analysis allowed the identification of markers 
that may play a role in the generation of diabetes i.e. genes related to immune function, or 
specific to islet ~ cells. These could then be examined to see if there is a genetic basis for 
functional changes, which may account for the difference between susceptible and non-
susceptible individuals. The population method can produce spurious associations if the 
patients and controls are not accurately matched for ethnic background, inaccurate 
matching can occur if there is unrecognised stratification in the population being sampled. 
3.2.2 Family studies 
Family studies have also been important in highlighting the influence of both 
environmental and genetic factors in determining the onset of diabetes. Many such studies 
have been initiated worldwide; some of which contain large numbers of families. These 
include the Barts-Oxford study (initiated as the Barts-Windsor prospective family study) 
[Walker and Cudworth, 1980, Wolf et al. 1983] in the UK, the DiMe study in Finland 
[Tuomilehto-Wolf et al. 1989] and the Pittsburgh study group in USA [Cavender et al. 
1984] amongst many others. Diabetes has been reported in up to 25% of families 
[Lorenzen et al. 1994] however, in populations where a diabetes registry allows complete 
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ascertainment, it is estimated that the disease occurs within families in approximately I 0% 
of subjects [Dahlquist et al. 1985, Tuomilehto et al. 1992a]. This suggests that most 
diabetes is sporadic. Despite this a positive family history is still considered as a risk 
determinant and an indication of type 1 diabetes as a hereditary disorder, but 90% of all 
newly diagnosed diabetic children have no family history. In high-risk populations such as 
those of Sweden and Finland it has been shown that approximately twice as many fathers 
had type 1 diabetes at the time when diabetes was diagnosed in a child under the age of 15 
[Tuomilehto et al. 1992a]. It has also been shown that the offspring of fathers with type 1 
diabetes have a much higher risk than do offspring of diabetic mothers [El-Hashimy et al. 
1995, Tuomilehto et al. 1995, The EURODIAB ACE study group. 1998]. A birth-cohort 
effect was seen, with a higher cumulative incidence at 14 years of age in offspring born 
after 1975 compared with those born in 1975 or before, which was also more marked for 
offspring of male rather than female parents [Tuomilehto et al. 1995]. Various studies have 
shown that familial cases of type 1 diabetes develop at an earlier age, in some cases 
between the ages of 1 and 2 years, compared to sporadic cases [Dahlquist et al. 1989, 
Shield et al. 1995]. It has been suggested that this early age at onset may be due to a 
greater genetic and smaller environmental contribution to the initiation of the autoimmune 
process or, the inheritance of HLA alleles that are associated with a more fulminant 
autoimmune-mediated J3 cell destruction once the process is initiated [Shield et al.1995]. 
The risk of developing type I diabetes in siblings of diabetic children has been shown to be 
increased in a number of studies [Dahlquist et al.1989, Tuomilehto et al. 1992, The 
EURODIAB ACE study group. 1998]. 
Although it has been shown that most of the diabetes occurs sporadically, multiplex 
family studies have provided a powerful means of looking for linkage of genetic markers 
with diabetes. In 1988 three collections of large numbers of families with more than one 
case of type 1 diabetes were initiated. The Human Biological Data interchange (HBDI) 
collected families from the USA [Lernmark et al. 1990], the British Diabetic Association 
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Warren repository encompassed the collections of UK families [Bain et al. 1992] and a 
collection of families from France from Philippe Froguel and Mark Lathrop [Hashimoto et 
al. 1994]. Linkage analysis enables estimates to be made of the distance between a 
susceptibility locus and a particular marker. It also allows genotypes to be defined and 
disease associated haplotypes to be identified [Bennett et al. 1995]. In addition, prospective 
family studies may allow the assessment and development of markers that can be used for 
the prediction of disease and would allow therapeutic interventions to be tested. The 
relative contribution of both genetic and environmental factors to explain familial 
clustering can be studied by these studies looking at frequency of the disease in families 
with adopted and natural children. Genome wide studies in human and NOD mice have 
found that familial clustering can be explained by the sharing of alleles at more than ten 
different loci, with the MHC making the major contribution [reviewed by Todd. 1997, 
Todd et al. 1991, Wicker et al. 1995, Vyse and Todd. 1995, Davies et al. 1994, Hashimoto 
et al. 1994, Todd and Farrall. 1997]. It has been suggested that the relative contribution of 
the MHC to familial clustering may differ between different countries. The differences 
seen between different countries suggests the existence of genetic or locus heterogeneity 
(contributions of different genes resulting in an identical phenotype) which is probably due 
to the population-specific frequencies of predisposing and protective alleles at various loci. 
3.2.3 Twin studies 
Identical twin studies are a unique type of family study that can provide information 
on the relative importance of genetic i.e. heritability and environmental factors in the 
disease aetiology. A number of identical twin studies have been carried out over the years 
that have compared the frequency of concordance of monozygotic twins and dizygotic 
twins [reviewed by Lounamaa. 1996, Gottlieb and Root. 1968, Bamett et al. 1981, Srikanta 
et al. 1983, Kumar et al. 1992, Kaprio et al. 1992, Kyvik et al. 1995]. Identical and non-
identical twins generally share environmental factors to the same degree, including factors 
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preceding birth, but differ for genetically determined features. As with other studies of the 
genetic susceptibility to type 1 diabetes, different populations have yielded varying 
estimates. The largest twin data set has been studied in the UK, but initial studies were 
considered to be biased towards concordant pairs with a concordance for type 1 diabetes in 
monozygotic twins of 50% [Bamett et al. 1981]. A later prospective study by the group 
yielded a concordance estimate of about 36% [Millward et al 1986, Olmos et al. 1988]. It 
was also suggested that eo-twins could be diabetes 'protected' if they did not develop 
diabetes within 8 years of onset of the disease in the index twin [Olmos et al. 1988]. 
However, in Finland which has a population based twin registry (and therefore an unbiased 
complete ascertainment for concordance) it was found that there was a pairwise 
(proportion of affected pairs that are concordant) concordance rate amongst monozygotic 
twins of 13% and probandwise (proportion of all probands that belong to concordant pairs) 
concordance rate of 23% [Kaprio et al. 1992]. This rate was higher than in dizygotic twins 
where the concordance rates were 3% pairwise and 5% probandwise respectively. A 
similar pattern in monozygotic and dizygotic twins was observed in a Danish study [K yvik 
et al. 1995]. 
The results from twin studies provide significant evidence for a genetic contribution 
to the aetiology of IDDM however, the concordance frequencies seen also suggest non-
genetic factors have a role to play [reviewed by Cucca and Todd. 1996]. 
3.2.4 Trans racial studies 
From population studies it is clear that there are different susceptibility haplotypes 
involved in different racial populations. This may be because there is a different genetic 
basis for the disease, which interacts with a diverse set of environmental factors. However, 
if the disease has the same genetic basis in different racial groups, then transracial studies 
can provide an approach to studying markers associated with a disease. Whilst population 
studies identify areas of susceptibility, it is often difficult to map individual genes 
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particularly in the :MHC where there is strong linkage disequilibrium (see section 3.2.1). 
Linkage disequilibrium is a major characteristic of the MHC and certain combinations of 
alleles at different loci (e.g. DRB1, DQA1 and DQB1) are often inherited together as a 
haplotype. Thus a significant disease association with a particular allele may either reflect 
a true association with that allele or may be secondary to linkage disequilibrium with the 
true susceptibility allele elsewhere on the haplotype. These secondary associations can 
hinder the accurate mapping of disease susceptibility in the MHC. The use of transracial 
studies partly overcomes this problem of distinguishing primary from secondary HLA 
associations, by exploiting the interracial differences in patterns of linkage disequilibrium 
which result from rare recombination events during evolution. Assuming genetic 
susceptibility to the disease to be identical in all races, any allele consistently associated 
with disease in each race, despite differences in linkage disequilibrium, is likely to be a 
primary disease determinant [Cucca and Todd. 1996]. 
3.2.5 Animal models 
Animal models are important as they form the basis for the study of disease 
processes in humans. Genes have been studied in humans on the basis of analogy to those 
found to be important in animal models - a candidate gene approach. In diabetes the NOD 
mouse and BB rat have provided a great deal of information about the genetic influence on 
the pathogenesis of type 1 diabetes [reviewed by Karges. 1995, Cucca and Todd. 1996, 
Vyse and Todd. 1996, Todd et al. 1991, Wicker et al. 1995]. 
3.3 Genetic predisposition 
When studying the possible association of a gene with a particular disease, 
consideration should be given to the fact that the genes involved code for molecules that 
have a functional bearing on the disease concerned. Genes are most commonly selected 
because of the function of the proteins they code for, which might be directly involved in 
160 
the aetiology of the disease. However, it is also the case that the gene may be mutated and 
not expressed therefore the disease may be caused by a lack of a particular protein. 
The MHC is a prime candidate for investigating the genetic predisposition to an 
autoimmune disease because it has a pivotal role in the regulation of the immune system. 
One of the important features in determining genetic susceptibility is the identification of 
disease-associated alleles. Within the MHC allelic polymorphism has been studied in a 
number of ways which include serological analysis, mixed lymphocyte reaction and 
primed lymphocyte testing, RFLP, polymerase chain reaction (PCR) amplification, 
microsatellite analysis, sequence-specific oligonucleotide probing and direct sequencing. 
With the use of these techniques in the previously described studies alleles can be 
identified as positively associated or predisposing when they occur at a significantly higher 
frequency among patients compared to controls. Alleles are considered to be negatively 
associated or protective if the opposite is found. 
3.4 Susceptibility to type I diabetes and the MHC 
Many of the early studies concentrated on single markers of disease and among 
these were serological studies that first showed a positive association between HLA-B 15, 
B8 and to a lesser extent Bl8 and B40 with type I diabetes [Cudworth and Woodrow. 
1975, 1976, Nerup et al. 1974, Singal and Blajchman. 1973]. However, studies in different 
races showed little consistency in HLA-B associations (see Table 3.1). Further analysis 
revealed a stronger disease association with the class II antigens HLA-DR3 and DR4 and 
alleles of the HLA-DRB I locus, which was found to be consistent across races [Cud worth 
and Woodrow, 1975, Nerup et al. 1974, Singal and Blajchman, 1973, Wolf et al. 1983]. 
The alleles encoding these antigens have been shown to be in linkage disequilibrium with 
those encoding B8 and B 15 respectively in Caucasoid populations [Wolf et al. 1983, 
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BLA-B 
B8 
BlS 
Table 3.1 
Caucasoid 
+ 
+ 
Asian 
N+ 
N 
Japanese 
R 
N 
Chinese 
R 
N 
Negroid 
+ 
N 
BLA-B associations with type 1 diabetes in different racial groups 
KEY: + = positive association, - = negative association and N = neutral association. N+ 
and N- denote inconsistent positive and negative associations. R = race in which the 
antigen is rare or absent. 
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Karges et al. 1995, Klitz et al. 1995, Cucca and Todd. 1996, Cavan et al. 1997, Nejentsev 
et al. 1997]. In addition to a predisposing HLA-DR effect, there is evidence that HLA-DR 
alleles may be important in conferring protection from or resistance to type I diabetes, or 
that such alleles are associated with the disease loci that encodes protection [reviewed by 
Cavan et al. 1997, Cucca and Todd. 1996, Thomson et al. 1988, Wolf et al. 1983]. The 
HLA-DQ region has been shown to be strongly associated with both susceptibility and 
resistance to type I diabetes [Festenstein et al. 1986, Michelsen and Lemmark. 1987, 
Khalil et al. 1990, Todd et al. 1989]. The association of the class 11 region, HLA-DR and 
DQ, is considered to be stronger than the class I. However, a number of recent studies have 
provided increasing evidence that genes within the class I region play an important role in 
the susceptibility to type I diabetes [Tienari et al. 1992, Demaine et al. 1995, Fennessy et 
al. 1994, Nakanishi et al. 1993, Fujisawa et al. 1995, Mizota et al. 1995]. It has also been 
proposed that both class I and class 11 genes have interdependent susceptibility effects 
when inherited together as an extended haplotype [Rich et al. 1984, Fujisawa et al. 1995, 
Tienari et al. 1992, Fennessy et al. 1994]. The importance of haplotypes (an association of 
several genes together) in defining susceptibility or resistance to type I diabetes has been 
shown in a number of studies, including population, family and twin studies [Sheehy et al. 
1989, Ikegami et al. 1995, Caillat-Zucman et al. 1997]. It is also clear from these studies 
that more than one susceptibility region, even within the MHC, is important and that 
susceptibility is not solely encoded within an individual region or by an individual locus. 
As no single gene has been identified it has been suggested that the genetic susceptibility 
to type I diabetes is heterogeneous i.e. contributions of different genes resulting in an 
identical phenotype. 
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3.4.1 HLA-DR-associated susceptibility to type l diabetes 
Very high proportions of patients with type I diabetes possess either HLA DR3 
and/or DR4 [Platz et al. 1981, Wolf et al. 1983]. A number of population and family 
studies have demonstrated this association which is shown in the table below: 
HLA-DR3 and DR4 strongly positively Platz et al. 1981; Barbosa et al. 1982; 
associated with diabetes in population Deschamps et al. 1980; Ratter et al. 1983 
studies 
HLA-DR3 and DR4 strongly positively Ginsberg Fellner et al.l982; Anderson et 
associated with diabetes in family studies al. 1983b; Wolf et al. 1983 
Higher prevalence offfi..A-DR3 and DR4 Johnston et al. 1983 
in identical twins concordant for diabetes, 
compared with those discordant for the 
disease 
Table 3.2 HLA-DR3 and DR4 associations with type 1 diabetes 
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The association of DR3 and DR4 is consistent across many different racial groups 
confirms the importance of these lll..A-DR types in the susceptibility to type 1 diabetes. 
Other DR subtypes have also been positively or negatively associated in different racial 
groups, the details of which are summarised in the table 3.3: 
The most consistent negative association with type 1 diabetes is with DR2. The 
frequency of the DR2 is low across a number of patient populations compared to normal 
controls. It has been suggested this may be a specific protective effect or that DR2 is in 
linkage disequilibrium with a disease gene or genes that encode protection from or 
resistance to type 1 diabetes [Wolf et al. 1983]. DR15, a subset of DR2 has also been 
shown to have a protective effect in a number of races [Cavan et al. 1993, Mijovic et al. 
1991]. Other DR types associated with protection include DR13 (a subset ofDR6), which 
has been shown to be strongly protective in a large Caucasoid population [Cavan et al. 
1993], but has also been linked with susceptibility. lll..A-DR5 and lll..A-DR7 may also 
have a protective role to play [Karges et al. 1995]. 
Ninety five percent of Caucasoid type I diabetic subjects possess one or both of 
DR3 or DR4, which are positively associated with disease in all races in which they are 
common [Jenkins et al. 1990, She. 1996, Cavan et al. 1997, Field and Tobias. 1997]. The 
strong association with both DR3 and DR4 suggests that there may be two separate 
susceptibility genes, each in linkage disequilibrium with DR3 and DR4 operating at the 
same or different loci [Owerbach et al. 1983, Raum et al. 1984]. This is further supported 
by the enhanced disease susceptibility conferred by DR3/4 heterozygosity relative to either 
homozygote (30-40% of diabetic patients [Gottlieb and Eisenbarth. 1996]), which indicates 
that DR3 and DR4, or genes closely associated, may act synergistically in predisposing to 
the disease [Rotter et al. 1983, Lesile et al. 1989, Knip et al. 1986, Karges et al. 1995, Field 
and Tobias. 1997, Cavan et al. 1997, Caillat-Zucman. 1997]. 
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HLA-DR Caucasoid Asian Japanese Chinese Negroid 
1 + 
2 N N 
3 + + R + + 
4 + + + N+ + 
5 N 
6 N- N- N N-
7 N- N N N + 
8 N 
9 N N + N + 
13 N- N- N N-
15 N N 
Table 3.3 HLA-DR associations with type 1 diabetes in different racial groups 
KEY: +=positive association, -=negative association and N =neutral association. 
N+ and N- denote inconsistent positive and negative associations. R = race in which the 
antigen is rare or absent. 
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The increased risk inferred by the DR3/DR4 heterozygote was amongst the first evidence 
that more than one gene may predispose to type 1 diabetes i.e. the genetic heterogeneity of 
the disease and that at least two modes of susceptibility to type 1 diabetes. It has been 
suggested that DR3 or a closely linked gene acts recessively in the absence of DR4, with 
most patients with DR3 also having a second high-risk HLA haplotype. DR4 or a linked 
gene acts with dominant susceptibility in the absence ofDR3; most DR4 carrying patients 
do not carry a second high-risk haplotype [Louis & Thomson. 1986, Jenkins et al. 1991, 
She. 1996]. 
HLA-DR3 and DR4 are also associated with a phenotypic heterogeneity seen within 
type 1 diabetes. DR3 is associated with a primary autoimmune form of the disease that has 
an onset throughout life and probably accounts for a significant fraction of older-onset type 
1 diabetes [reviewed by Scheuner et al. 1997]. In childhood it's associated with a milder 
more slowly progressing form [Ludvigsson et al. 1986]. DR4 is not as strongly associated 
with autoimmune disease and appears to have an earlier age at onset, which is more acute, 
severe and aggressive [Ebberhardt et al. 1985]. This form also exhibits seasonality and 
may be related to viral infections [reviewed by Scheuner et al. 1997]. The frequency of the 
DR3/DR4 heterozygotes significantly decreases as the age at onset of type 1 diabetes 
increases, conversely the frequency of other DR3 and DR4 genotypes is significantly 
increased as the age at onset increases [Caillat-Zucman et al. 1992, Dubois-Laforgue et al. 
1997]. 
Several studies have mapped the susceptibility to HLA-DQ rather than to the DR 
locus [reviewed by She. 1996, Yasunaga et al. 1996, Festenstein et al. 1986, Michelsen et 
al. 1987, Owerbach et al. 1989, Todd et al. 1987,1989, Khalil et al. 1990]. However, HLA-
DQ has been shown not to have an exclusive effect on the susceptibility of type 1 diabetes, 
indicating the importance of the DRB 1 locus in determining susceptibility and protection 
[Sheehy et al. 1989, Huang et al. 1995 She. 1996, Yasunaga et al. 1996, Harfouch-
Hammoud et al. 1996]. Particular DRB 1 *04 subtypes have been shown to have a distinct 
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effect on the predisposition and also the protection to type 1 diabetes, which is independent 
of that of the DQB locus [Sheehy. 1992, Van der Auwera et al. 1995, Cucca et al. 1995, 
Harfouch-Hammoud et al. 1996, Reijonen et al. 1997, Caillat-Zucman et al. 1997]. By 
combining various sets of data from a number of studies it is possible to suggest a 
hierarchy of DR4 subtypes from most to least associated with type 1 diabetes summarised 
in Table 3.4. It has also been suggested that the ORB 1 locus contributes a separate 
determinate and is not simply part of a haplotype determined by HLA-DQ [Sheehy et al. 
1992, Caillat-Zucman et al. 1997]. The DR4 subtypes that have a protective effect (see 
Table 3.4) are protective even when associated with the susceptible HLA-DQB1 *0302 
allele [Caillat-Zucman et al. 1997]. There are 6 amino acid positions in the HVR3 region 
that differ in the different DR4 subtypes [Gregerson. 1989] and these correlate with the 
degree of type 1 susceptibility, which is also seen in rheumatoid arthritis. 
Although the synergistic effect of DR3/DR4 heterozygosity has been shown to be 
important, DR3 homozygosity sometimes confers an equal or even higher risk perhaps 
reflecting the presence of other genes on the DR3 haplotype [Caillat-Zucman et al. 1997]. 
From the above it is clear that the class II HLA-DR region has an important role in 
both the susceptibility and protection to type 1 diabetes. But it is also clear that other genes 
within the region or beyond are also important in influencing both susceptibility and 
protection to the disease. 
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DR4 subtypes Hierarchy~t 
DRB1*0405 1 
DRB1 *0401 2 
DRB1*0402 3 
DRB1*0404 4 
DRB1*0403 5 
DRB1*0406 6 
DRB1*0407 7 
Table 3.4 Hierarchy ofHLA-DR4 subtypes associated with type 1 diabetes 
* Average strength of association, based on data from many different populations 
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3.4.2 HLA-DOAl and DOBl-associated susceptibility to type 1 diabetes 
The ability to analyse alleles, as well as haplotypes, indicated that DR was not the 
only locus encoding susceptibility to diabetes. Initial studies using restriction fragment 
length polymorphism (RFLP) analysis revealed that the lll..A-DQB 1 locus was even more 
strongly associated with type 1 diabetes than DRB I [Owerbach et al. I983, Michelsen et 
al. I987]. Sequence analyses showed that alleles encoding aspartic acid (charged residue) 
at position 57 of the DQ~ chain were associated with resistance/protection. Alleles 
encoding a neutral or hydrophobic residue at this position such as alanine, valine or serine 
conferred susceptibility [Todd et al. I987, Horn et al. I988]. There have been many 
studies, which have found that the DQB I region encodes susceptibility or protective alleles 
[Bohme et al. 1986, Michelsen and Lernmark et al. 1987, Nepom et al. I987, More! et al. 
I988, Owerbach et al. I989, Ronningen et al. I989, Baisch et al. I990, Dorman et al. I990, 
Thorsby and Ronningen, I993, Sanjeevi et al. I995, She. I996, Thorsby. I997] and some 
of these studies suggest that this is the main determinant. 
There is however, evidence to suggest that susceptibility is not encoded simply by 
the presence or absence of a single residue: Firstly, a study examining the segregation of 
Asp 57 positive alleles within families showed that diabetes correlated with the presence of 
DQB I *0302 (non-asp). The unaffected siblings did not inherit the 'protective' 
DQB I *030 I (asp) allele any more frequently than affected siblings [Nepom and Robinson. 
1990]. Secondly, DQB I asp or non-asp residues are not sufficient to account for 
susceptibility in all races. Studies have reported that in Japanese and Mexican American 
patients there are high frequencies of alleles, which encode asp at position 57 [Y amagata et 
al. I989, Awata et al. I990, Sanjeevi et al. 1993, I995]. 
It is clear that other determinants must play a role and it has been suggested that 
lll..A-DQAI may represent a susceptibility locus, the DQ ~chain interacting with the DQ 
a chain, which is also polymorphic to form a heterodimer [Jacobs et al. I992, Tisch and 
McDevitt. I996, She. 1996, Cucca et al. I995]. This has been supported, in part, by 
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transracial analysis, which examine features common to susceptibility determinants across 
different racial groups [Todd et al. 1989]. These have suggested a primary role for alleles 
at the DQA1 locus in determining differences across racial groups and therefore in 
determining susceptibility and resistance to the disease. For example, the DRB 1 *07-
DQB1 *0201 haplotype is positively associated with type 1 diabetes in Negroids, but is 
considered to be neutral in Caucasoid patient populations. The Negroids and the Caucasoid 
DRB1 *07-DQB1 *0201 haplotypes only differ at the DQA1 locus: the Negroid haplotype 
possesses the predisposing DQA1 *0301 allele whereas the Caucasoid haplotype possesses 
the DQA1 *0201 allele that is thought to be protective [Todd et al. 1990b). It is therefore 
possible that the DQA1 locus determines the disease association ofDR7 haplotypes from 
these races as the only differing allele is at the DQA1 locus. 
Many other studies have suggested that a single residue does not encode 
susceptibility and it is a combination of DQA 1 and DQB 1 determinants that is important 
[Nepom et al. 1987, Owerbach et al. 1988, Todd, 1990b, Khalil et al. 1990, 1992, Baisch et 
al. 1992, Tienari et al. 1992, Petronzelli et al. 1993, Tosi et al. 1994, She. 1996, Caillat-
Zucman. 1997,Thorsby. 1997]. The demonstration that in Caucasoid populations, disease 
associated DQA1 alleles encode arginine at position 52 has led to the theory that disease 
susceptibility correlates with the expression of a DQ molecule bearing Arg52 on the a 
chain and lacking Asp57 on the 13 chain, the so-called 'diabetogenic heterodimer' [Khalil et 
al. 1990). 
It has been suggested that HLA-DQ has an exclusive effect on the susceptibility and 
protection to type 1 diabetes, in-part due to the role of the DQf357 residue and also the 
presence of some cis or trans-encoded DQ a.f3 dimers on a particular haplotype [Todd et al. 
1987, Nepom et al. 1987, She. 1996]. It has also been suggested that the association of 
DR3 and DR4 be merely due to the presence of particular DQB and DQA alleles [Nepom 
et al. 1986, reviewed by Cavan et al. 1997). However, it now seems clear that neither 
single nor multiple residues in DQ proteins, or the total DQ proteins can account fully for 
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the HLA association with type 1 diabetes. It involves combinations of alleles at different 
class II loci, resulting in haplotypes that are associated with susceptibility or resistance to 
type 1 diabetes [She. 1996]. Taken together, HLA associated predisposition to develop 
type 1 diabetes appears to be the net effect mainly of the combination of DQ of DR 
molecules carried by an individual. Where some DQ and DR4 molecules appear to be the 
most important, maximum susceptibility is associated with DQA1 *0301, DQB 1 *0202, 
when present together with DRB*0405. In contrast, maximum protection is associated with 
DQA1 *0102, DQB1 *0602 and DRB*0403 or 0406 and is dominant over susceptibility 
[Thorsby. 1997, Undlien et al. 1997]. It has been suggested that the most important alleles 
are those of the DR loci, the presence of the DR alleles DRB 1 *0403 and 0406 is dominant 
over the DQ8 associated susceptibility [Sheehy et al. 1989, Erlich et al. 1990, Khalil et al. 
1992, Undlien et al. 1997]. A recent study has suggested that particular HLA-DR, -DQ 
genotypes are associated with different 13-cell functions in type 1 diabetes, certain 
genotypes may induce a stronger autoimmune destructive response against target 13-cell 
cells than other DR-DQ genotypes [Sugihara et al. 1997]. Haplotype and genotype 
analyses from different populations suggest that HLA-DRB1 and -DQB1 loci encode 
primary etiological components and influence type 1 diabetes in the same way [Cucca et 
al. 1995, Todd, 1994], namely by peptide-binding and T cell recognition [Sanjeevi et al. 
1995, Sheehy. 1992, Kwok et al. 1995, Ellerman and Like. 1995, Nepom, 1990, Roustasias 
and Papadopoulos. et al. 1995, Wucherpfenning and Strominger. 1995a]. The following 
table is a summary of some of the class II HLA associations found in type 1 diabetes in 
different racial groups: 
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DRBI DQAI DQBI DQBiaa57 Caucasoid Negroid Japanese 
1 0101 0501 Valine + + 
2(15) 0102 0602 Aspartate 
2(16) 0102 0502 Serine + 
3 0501 0201 Alanine + + R 
3 0501 0401 Aspartate N R 
4 0301 0301 Aspartate N N 
4 0301 0302 Alanine + + 
4 0301 0401 Aspartate + 
5 0301 0501 Aspartate N N N 
6(13) 0103 0603 Aspartate 
6(13) 0102 0604 Valine + 
6(14) 0101 0503 Aspartate N 
7 0201 0301 Alanine N N 
7 0201/0301 0301/0201 Alanine + 
8 0501 0401/2 Aspartate N 
9 0301 0201 Alanine + 
9 0301 0303 Aspartate N + 
Table 3.5 MHC class II haplotypes that have been positively or negatively 
associated with type I diabetes in different racial groups. 
KEY: + = positive association, - = negative association and N = neutral association. R= 
race in which antigen is rare or absent. Many of these associations were demonstrated with 
methods that did not allow allele specific assignment and alleles have been inferred from 
known linkage disequilibrium. 
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3.4.3 HLA-DOA2 IDXal and DP-associated susceptibility to type 1 diabetes 
The DQA2 genes are found centromeric to the DQAI and BI genes. Although the 
DNA sequences suggest that they are not pseudogenes [Auffray et al. I984, Okada et al. 
I985], no protein product has, as yet been detected. DQA2 has been shown to be 
polymorphic and the two alleles are DQA2 U and DQA2 L Studies have shown that there 
is an association of the DQA2 U allele with type I diabetes and that this association occurs 
particularly in DR3 positive patients [Hitman et al. I986b]. Subsequently it has also been 
shown that the allele was associated with increased frequency with DR4 in contrast to 
controls [Hitman et al. I987]. DQA2 is in strong linkage disequilibrium with the DRA and 
DRB3 loci and the two alleles of DQA2 have been shown to be associated with particular 
DRA and DRB3 alleles [Gorski et al. I987, Carrier et al. I989]. Further studies have 
shown the alleles not to play a role in conferring different risks for diabetes, even though 
they are in strong linkage disequilibrium with risk conferring haplotypes [Carrier et al. 
I989]. Other studies have confirmed an association of the DQA2 U allele with type I 
diabetes, but it has been concluded that this did not represent a primary genetic locus 
conferring susceptibility [Hitman et al. I986b]. 
It is possible that DP loci (or a nearby locus) may also contribute to susceptibility in 
both Caucasoid populations [Caffrey et al. I990, Baisch & Capra, I992, Jackson and 
Capra. I993, Tait et al. I995, Noble et al. I997] and other ethnic groups [Easteal et al. 
I990a, Yamagata et al. I99I, Magzoub et al. I992, Erlich et al. I996]. However, the 
results so far are conflicting and not completely definitive. A group studying an Australian 
population has found that there was an increase in DPw3 and that the age at onset of the 
population was higher than that of many other genetic susceptibility studies in type I 
diabetes [Easteal et al. I990b]. It was suggested that this might reflect genetic 
heterogeneity at different ages of onset of the disease. An association with the rare 
DPBI*020I allele and type I diabetes has been shown in a Belgian population, but 
analysis of extended haplotypes indicated that the association was most likely due to 
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linkage disequilibrium of this allele with DR3 [Buyse et al. 1994]. Studies of DP 
associations both in a Mexican-American population and also in a number of Caucasoid 
multiplex families has suggested that the DPB 1*0301 allele contributes to type 1 
susceptibility independently of linkage disequilibrium [Erlich et al. 1996, Noble et al. 
1997]. It has been suggested that in some cases the effect of a DPB 1 allele on disease 
susceptibility may be dependent on its DR context and for other alleles there is an 
independent effect on susceptibility [Noble et al. 1997]. 
3.5 Possible mechanisms of MHC class 11-associated susceptibility to type 1 diabetes 
When studying the genetic association/linkage of any disease it is important to 
relate it to function. A large number of genetic associations have been found with type 1 
diabetes, but these associations differ in Caucasoid populations and also more markedly in 
different racial groups, for example Oriental and African populations have very different 
haplotypes as shown in Table 3.5. There have been many attempts to investigate whether 
there is a unifying hypothesis to explain the differences seen in genetic susceptibility 
across and within different populations. It is also possible that the heterogeneity found with 
respect to the genetic background may be simply due to different environmental factors 
that may operate in different populations giving rise to diverse manifestations of the 
disease. 
3.5.1 Correlation between disease and MHC allele specific residues 
It has been suggested that a possible unifying theory is the correlation between 
disease and specific residues in the alleles that have been found to be associated with type 
1 diabetes [reviewed by Cucca and Todd. 1996]. Biochemical and structural studies have 
suggested a key functional role of DQI3 chain residue 57. Five peptide-binding pockets 
have been proposed for the DQ molecules [Roustsias and Papadopoulos. 1995]. B57 is part 
of the fifth pocket and it has been shown that the replacement of an aspartate (Asp) residue 
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in DR molecules resulted in a decrease in peptide affinity [Marshal! and Liu. 1994]. In DQ 
molecules the replacement of another residue by an Asp residue prevented the binding of 
certain peptides [Kwok et al. 1995]. B57Asp forms a salt bridge with DQA79Arg (Arg-
arginine) and these residues form hydrogen bonds with the proximal amide nitrogen and 
carbonyl oxygen of the bound antigenic peptide [Reich et al. 1994, Wucherpfennig and 
Strominger. 1995b]. B57 also plays an important role in the electrostatic properties of the 
DQ molecule [Sanjeevi et al. 1995]. Studies analysing the peptides bound by certain HLA 
DQ alleles that have an identical sequence except at position 57 in the B have shown 
striking differences in the binding of selected peptides, providing further evidence for the 
importance ofthe residue at position 57 [Kwok et al. 1996, McDevitt. 1997]. Although the 
single aspartate residue at position 57 of the DQB 1 chain is an attractive hypothesis of 
dominant protection, it does not answer all the questions and does not take into account 
heterozygous effects. It is possible that other residues in the antigen binding pocket that 
contact the peptide antigen may be important in identifying alleles that play a role in 
binding autoantigenic peptides. A number of studies have shown other residues in the DQB 
chain to be important in peptide binding and susceptibility to type 1 diabetes including 
those that make up the first and second peptide binding pockets [Sanjeevi et al. 1993, 1995, 
Kwok et al. 1993, 1996]. Residues at positions B45 and B49 both of which occur at the 
dimerisation patch, in predisposing and resistant alleles, are important in facilitating or 
reducing the formation of homodimers and therefore T -cell activation [Roustsias and 
Papadopoulos. 1995]. As already mentioned, it has been suggested that position 52 of the 
DQA1 chain plays an important role. An arginine residue at this position, in combination 
with a non-aspartate residue at position 57 on the DQB 1 chain encodes high susceptibility 
[Khalil et al. 1990, 1992, Heimberg et al. 1992, Buyse et al. 1994]. Although residue 52 of 
the DQA chain is useful for risk assessment it has been suggested that association with 
disease is simply through linkage disequilibrium with certain DQB1 alleles [Sheehy et al. 
1992, Todd. 1995, Cucca and Todd. 1996]. Polymorphisms in the B chain ofHLA-DR also 
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plays a role in type 1 diabetes [reviewed by Cucca and Todd. 1996), residue 74 may help 
explain the protective associations of DRB 1 * 0403 and 0406. However, no single residue 
explains the associations of the DRB l alleles, it has been suggested that the combined 
presence of serinine, alanine and glycine at positions 57, 74 and 86 respectively, 
differentiate the highest risk allele DRB 1 * 0405 from the protective allele DRB 1 * 0403 
[Cucca et al. 1995, Huang and She. 1995). There are restrictions within the grooves of the 
MHC peptide binding sites for particular residues, this suggests that some MHC molecules 
will bind particular peptides much better than others and the peptide binding grooves 
consist of regions that are detennined by both the a. and 13 chains. However, no unique 
sequences within the class II alleles of patients with diabetes have been identified and 
therefore this cannot be the whole explanation [Todd et al. 1987, Horn et al. 1988, Cucca 
and Todd. 1996). 
As DQ encoded molecules have been shown to be important in detennining 
susceptibility and the fact there is a high frequency of heterozygosity, it has been suggested 
that there is synergy of haplotypes, which include DR3 and DR4. It is possible that the 
product of the DQA 1 locus of one chromosome pairs with the product of the DQB 1 locus 
of the other chromosome creating a hybrid molecule and these are recognised by T cells 
[Nepom et al. 1987, Kwok et al. 1990, Cucca and Todd. 1996). This is known as 
transcomplementation and results in the broadening of diversity of MHC class II antigens 
available to participate in the immune response, especially relating to the DQ region. The 
presence of these hybrid molecules may allow presentation of novel eptitopes and these 
may have an effect on the immune response. This could be either by altering a nonnal 
response to an environmental agent or by allowing an abnonnal response to a 'self 
antigen'. Although this is a possible theory for disease expression, these hybrid molecules 
also exist in non-affected siblings of patients with diabetes [Nepom et al. 1987] and some 
affected patients have genotypes, which would be unable to fonn hybrids [Tuornilehto-
Wolfet al. 1992]. 
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The crystallisation of the MHC class II molecule DRI showed the dimerization of 
the molecule [Brown et al. 1993]. Further studies have shown that within the dimer, the 
peptide pocket may be created by the a chain of one molecule pairing with the 13 chain of 
another molecule [Stem and Wiley. 1994, Roustias and Papadopoulos. 1995] and this may 
give a similar effect to that oftranscomplementation. 
3.5.2 Peptide affinity hypothesis 
The susceptibility of type 1 diabetes appears to be encoded by more than one HLA 
type. On the basis of this it has been suggested that the different HLA associations with 
type I diabetes may be explained on the basis of a hierarchy of affinities of the MHC 
molecules for diabetogenic peptides [Nepom. 1990, Gammon et al. 1991, Thorsby. 1997]. 
(Different disease associations of class II alleles suggest that particular HLA molecules 
may be more effective either in binding antigen, or in interacting with the T -cell receptor, 
thereby influencing disease susceptibility). It is possible that an individual is susceptible if 
they encode a MHC gene that has the highest affinity for a diabetogenic peptide, which can 
then activate autoreactive T -cells. It is suggested that diabetogenic peptides exist which 
bind to different MHC class II molecules with a hierarchy of affinities. An individual is 
susceptible when the product of the gene is the most efficient peptide binder among the 
different MHC class II molecules. Individuals are protected when products of MHC class 
II genes that are more efficient and bind the same peptide with higher affinity fail to 
activate autoreactive T -cells [Nepom et al. 1990]. However, studies in type 1 diabetic 
families suggest that this may not be the case. It has been shown that siblings of diabetics, 
which are positive for a strongly resistant allele DQB I* 0602 rarely develop diabetes 
although they can produce high titres of autoantibodies to several islet cell antigens 
[McDevitt. 1997]. This finding indicates that resistant alleles binding islet cell peptides are 
capable of inducing an immune response, which does not result in destruction of islet 13-
cells, a result that is more compatible with differential induction of an inflammatory versus 
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a protective T -cell response [McDevitt. 1997]. The synergism that it is found in patients 
that are HLA-DR3/DR4 heterozygotes may be accounted for by the Nepom hypothesis, in 
that trans encoded HLA-DQ molecules may bind diabetogenic peptides with greater 
affinity. This may also explain why some patients encoding haplotypes with the same 
individual DQ association with a different DR may not have synergistic susceptibility. For 
example DR3/4 heterozygotes are susceptible to diabetes but DRS/4 are not. 
This model could explain why certain combinations of alleles encode MHC class II 
molecules, which make an individual susceptible, neutral or protected (relatively) from 
type 1 diabetes. Peptide competition probably occurs at an early stage in peptide 
processing, which suggests that other molecules may be involved in determining 
susceptibility. The stability of different MHC class II molecules as well as differential rates 
of transcription and expression might have a role to play, as may the control of quantitative 
levels of a susceptibility allele relative to other MHC class II genes. It has also been 
suggested that this model could perhaps account for peptides encoded by non-MHC genes 
competing for binding diabetogenic peptides to class II susceptibility genes and that 
individuals with the same HLA genes may have different degrees of susceptibility 
dependent on the relative binding affinities of these peptides. 
The exact nature of the proposed diabetogenic peptides is still under discussion, 
however a number of antigens have been strongly implicated in the development oftype 1 
diabetes [reviewed by Cucca and Todd. 1996, Schranz and Lemmark. 1998, Tisch and 
McDevitt. 1996], these will be discussed in more detail in chapter 4. It is possible that 
some are derived from self-proteins and compete with exogenous peptides, or they could 
be fragments of antigenic proteins that are involved, in immune activation. It has been 
suggested that the diabetogenic peptide might have a positively charged residue at the 
anchor position P9 so that it would bind with high affinity to BAsp57-positive DQ 
molecules. If an individual possessed these molecules it would lead to general tolerance 
(peripheral and/or thymic) induction/peptide competition. Such peptides would bind with 
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lower affinity to predisposing molecules thereby escaping tolerance [Cucca and Todd. 
1996]. Others have suggested the P9 position of a diabetogenic peptide might be Asp or 
Glu since DQB57 is Ala or Val in susceptibility molecules [Wucherpfennig and 
Strominger. 1995b]. Eluting peptides from antigen presenting cells would allow the nature 
of the peptides to be examined, and would lead to the identification of the autoantigens. It 
would also provide a possible means of testing certain models proposed and may provide a 
method for generating synthetic peptides, which could be used therapeutically. Although a 
number of techniques have been developed to examine peptides from class I and II 
molecules in the case of pancreatic islets there are technical problems and peptides cannot 
be obtained for examination so easily. 
3.5.3 Tolerance induction 
It has been suggested that disease-associated phenotypes could result in the positive 
selection of pathogenic clones, which escape negative selection [Moller et al. 1990, 
Thorsby. 1997]. It is therefore thought that autoimmunity is not caused by reactivity 
against peptides that contribute to positive or negative selection, but occurs because of 
immune reactivity against determinants that do not contribute to selective processes in the 
thymus. In this case, reactivity against 'self depends on pathogenic T -cell clones being 
present in the periphery in sufficient numbers, it then only requires that these 
autoaggressive T -cells become activated, probably when they are stimulated by cross-
reactive antigens. 
Another model based on the induction and maintenance of tolerance has been 
proposed [Sheehy et al. 1992] in which there is active suppression by regulatory T-cells 
and non-susceptible genotypes play a dominant role. It is suggested that a class II molecule 
that binds a peptide and presents it effectively in the proper orientation can stimulate the 
regulatory T -cell, which results in a strong protective effect. Lesser degrees of protection 
would result from weaker bound peptides and therefore a hierarchy among class II 
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molecules may exist: Protective > neutral > non-protective and it is suggested that this 
protective effect may be cumulative. This may occur in the thymus or the periphery were 
protective DQ and DR molecules would bind diabetogenic peptides with high affinity 
thereby facilitating tolerance or non-responsiveness. Susceptible molecules would bind 
diabetogenic peptide with lower affinity than protective molecules, thereby allowing T-
cells with anti-13-cell reactivity to escape tolerance and to be present in the individual. 
Susceptible molecules carry out the antigen-presentation during 13-cell destruction 
[Ellerman and Like. 1995). This model is consistent with Wraith's model of low affinity 
autoantigenic peptides and the presence in healthy individuals of self-reactive T -cells 
[Fairchild and Wraith. 1992]. 
Other studies have led to the suggestion of the differential avidity model of MHC 
and autoimmune type I diabetes [Ridgway and Fathman. 1998). A number of studies have 
shown that the NOD mouse has a wide variety of autoreactive (in vivo) and 
autoproliferating (in vitro) T-cells, that are, recognising such a wide variety of self 
antigens, because such cells are not deleted in the thymus [Slaterry et al. 1990, 1993, 
Carrasco-Marin et al. 1996]. The differential avidity model of thymic selection may 
explain how negative selection might be affected by the MHC class 11 molecular structure. 
According to differential affinity it is not the intrinsic TCR affinity for its ligand alone, 
which determines whether aT-cell will be deleted, but the "avidity" of the interaction. The 
avidity of the T -cell/MHC interaction is a combination of the intrinsic TCR affinity, the 
density of the TCR on a thymic T-cell and the density of the peptide/MHC complex on the 
thymic antigen presenting cell [Ashton-Rickardt et al. 1994). It has been shown that both 
positive and negative selections occur at fixed thresholds of MHC/T -cell avidity [Jameson 
et al. 1995, Nossal. 1994, Janeway. 1994]. It has been suggested that a decreased self 
peptide binding by class 11 molecules would lower the effective ligand dose of the 
MHC/peptide complex, necessitating a compensatory increase in TCR affinity to achieve 
an equivalent avidity threshold for positive (as well as negative) selection. Such a shift 
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would result in the selection of a population of peripheral T -cells with a high-affinity 
receptor repertoire for self; such T -cells could potentially mediate autoimmunity [Ashton-
Rickardt et al. 1993, 1994, Kim et al. 1996, Ridgway and Fathman. 1998]. It has been 
suggested that the model of differential avidity in thymic selection of the peripheral T -cell 
repertoire explains the phenomena of "autoproliferation". It also suggests that the thymic 
selection of high-affinity self-reactive T -cells, in the setting of poor peptide binding MHC 
molecules, is necessary prerequisite for the development of type 1 diabetes [Ridgway and 
Fathman. 1998]. 
3.5.4 Superantigens 
Superantigens are produced by bacteria, mycoplasma and viruses and bind directly 
to the lateral surface ofMHC molecules and the V region of the~ chain ofT-cell receptors 
and have been associated with type 1 diabetes [reviewed by Karges et al. 1995, Conrad et 
al. 1994, Marrack and Kappler. 1990]. Superantigens do not bind in the peptide groove, are 
not processed in the same manner as normal antigens and can bind one or a few of the 
different V~ regions resulting in the stimulation of 2-30% of all T -cells [Janeway and 
Travers. 1994, 1996, Bentley and Mariuzza. 1996). Superantigen binding was initially 
considered insensitive to the choice MHC, however there is now strong evidence that 
TCRIMHC contacts probably modulate the fine specificity of superantigen as a function of 
MHC isotype and allele [Bentley and Mariuzza. 1996]. It has been suggested that T -cells, 
which are specific for self-antigens expressed by pancreatic ~ cells and are usually 
inactivated by the immune system, may become activated by exposure to a superanitgen. 
This means that the T -cells activated by a superantigen could mediate specific tissue 
damage, which is then MHC restricted [MacDonald and Acha-Orbea. 1994, Karges et al. 
1995]. Another possible effect of superantigens is that non-specific mediators of tissue 
damage such as cytokines would be produced on superantigen stimulation. This could then 
damage islet ~ cells and lead to the release of antigens, which would be recognised after 
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processing by specific T -cells activated by the superantigen [MacDonald and Acha-Orbea. 
1994]. Studies ofTCR repertoire in islet cell infiltrating T-cells from newly diagnosed type 
1 diabetic patients, showed that there was a selective expansion of islet T -cells carrying 
TCR with one specific variable segment (VI37) of the TCR 13-chain [Conrad et al. 1994, 
Karges et al. 1995]. This led to the suggestion of a superantigen-driven, islet-specific T-
cell selection in diabetic patients. It has been suggested that a pancreatic islet cell 
membrane bound superantigen is involved as a factor in the pathogenesis of diabetes 
[Conrad et al 1994, 1997] however, the exact nature and origin of the superantigen(s) and 
their functional role in 13-cell destruction is to be determined. The possible involvement of 
exogenous or endogenous superantigen is another compelling element in the pathogenesis 
oftype 1 diabetes. 
3.5.5 HLA-DO vs DR associations 
In functional terms, all the MHC class II products already mentioned can present 
antigen to human CD4+ cells however, when T -cell clones are tested they are more often 
restricted to lll.A-DR as found in type 1 diabetes [van Vliet et al. 1989, Roep et al. 1992, 
Karges et al. 1995, Cavan et al. 1997] and other diseases. It is possible that this is merely 
due to in vitro techniques favouring DR restricted clones as other experiments have shown 
HLA-DQ restricted responses [Mellins et al. 1987]. It is possible that although HLA-DQ 
restricted cells are not abundant in the periphery, they have an important role in positive 
and negative thymic selection, rather than a major role in antigen presentation to mature T-
cells [Altmann et al. 1991, Sheehy et al. 1992, She. 1996]. It is therefore possible that 
certain DQ alleles are associated with susceptibility to type 1 diabetes because they fail to 
delete receptors involved in auto-reactivity. HLA-DQ expression is relatively high in the 
thymic cortex and it may be that particular DQ alleles positively or negatively select 
particular Vl3 families among OR-restricted T -cells. If the predisposition to type 1 diabetes 
involves both repertoire selection through HLA-DQ and peripheral presentation through 
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Jfl...A-DR, this may be an explanation for the fact that diabetes susceptibility is best 
accounted for by a contribution from both Jfl...A-DR and DQ. The presence of the strong 
negative association of the DQB 1 *0602 allele, in the presence of DR4 or DQB I *0302 has 
raised the suggestion that HLA-DQ primarily confers protection. This is perhaps by 
induction of tolerance and it has been suggested that DQ-restricted T -cells are involved in 
immunological suppression, with DQ molecules presenting antigen to 'suppressor-inducer' 
T -cells which, in turn, induce CD8+ suppressor T -cells to bring about immunosuppression 
[Sasazuki et al. 1989, Cavan et al. 1997]. In contrast, Jfl...A-DR confers susceptibility, 
perhaps by induction ofautoreactive T-cells [Kockum et al. 1993, Cucca and Todd. 1996]. 
3.6 Other MBC genes associated with type 1 diabetes 
The genetic risk for type 1 diabetes cannot be entirely explained by the association 
with the Jfl...A-DQ and DR molecules. It has therefore been suggested by the presence of 
extended haplotypes associated with the disease and data from the NOD mouse model of 
type I diabetes that other genes in the human MHC further influence the disease risk 
[Ikegami et al. 1995, Yamoto et al. 1995]. 
Extended haplotype studies indicate that it is crucial, not only to look at individual 
loci, but that there is a better correlation with susceptibility to diabetes when a larger 
region of the MHC is examined, including the loci of the class I, ll and m regions [Raum 
et al. 1984, Tuornilehto-Wolf et al. 1989, Martell et al. 1990, Martinez-Laso et al. 1991, 
Degli-Esposti et al. 1992b, Fennessy et al. 1994, Thomas et al. 1995, Langholz et al. 1995]. 
It may not be possible to assign a greater importance of one locus over another when 
several are involved and indeed there may be additive effects. There is evidence from 
animal models that both CD4 and CD8 cells are important in disease induction [Bendelac 
et al. 1987, Miller et al. 1988, Reich et al. 1989, Todd et al. 1991, Wicker et al. 1994, 1995, 
Serreze et al. 1994, Vyse and Todd. 1996] and this is also likely in the human disease. 
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3.6.1 Class I association 
Extended susceptibility haplotypes in human type I diabetes indicate that different 
haplotypes with apparently identical class IT loci but different class I alleles predispose to 
disease to significantly different degrees. Studies using a congenic NOD mouse strain have 
also provided evidence that there is an important determinant outside of the class IT region, 
which may be within the class I region [Ikegami et al. 1995]. Studies have shown that there 
is a reduced expression of class I antigens on the surface of lymphoid cells in-patients with 
type I diabetes [Faustman et al. 1991]. A defective expression of class I molecules on the 
surface of lymphoid cells and also defective transcription of HLA class !-processing genes 
has been associated with type 1 diabetes [Fu et al. 1993, 1996]. However, it has been 
suggested that the association with certain class I alleles is not due to a defect in the 
peptide transporter encoded by the TAP gene as suggested by the above studies [Serreze et 
al. 1996]. In contrast, hyperexpression of class I molecules on the surface of pancreatic 
islet cells in diabetic insulitis has been shown [Bottazzo et al. 1985, Foulis et al. 1987, ltoh 
et al. 1993, Somoza et al. 1994]. A Japanese study has shown HLA-A24 to be associated 
with the rapid onset of the disease and complete autoimmune destruction of islet ~-cells. It 
has been suggested that this HLA-A24 promoted pancreatic ~-cell destruction but in eo-
operation with other type 1 diabetes susceptibility antigens [Nakanishi et al. 1993, 1995]. 
The progression of this ~-cell destruction and the resulting symptoms has been shown to 
vary depending on the age at onset of type 1 diabetes [Kobayashi et al. 1993, Karjalainen 
et al. 1989]. Extensive serological and molecular studies in Finland have suggested that 
certain HLA-A alleles may be linked to the susceptibility to type 1 diabetes [Tienari et al. 
1992, Fennessy et al. 1994]. The association of HLA-A alleles was examined by 
characterising the HLA A2, Cw1, B56, DR4, DQ8 haplotype, which confers the highest 
absolute risk in this population and is present in 5.5% of diabetic individuals compared 
with 1.1% of non-diabetic individuals. The B56, DR4 haplotype is conserved and is only 
associated with 4 HLA alleles, of which only HLA-A2 is significantly increased in 
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diabetes. Patients who were non-DR3 and non-DR4 possessed 2 HLA-A alleles associated 
with diabetes from HLA-A28, A24, A3 or A2 [Fennessey et al. 1994). It was proposed 
from these studies that HLA-A alleles may be 'anchors' for disease susceptibility 
haplotypes. However, it was also suggested that a gene or genes in the class I region may 
modulate the risk of type 1 diabetes, but in association with the class II 'diabetes 
susceptibility' DQ heterodimers. Even in the light of such studies there is still much 
debate concerning the contribution of class I genes to the genetic risk of IDDM [Jenkins 
and Mijovic, 1995, Bonifacio. 1995). It has been suggested that the MHC class I region 
may contain susceptibility genes which are independent of the class II loci [Demaine et al. 
1995). 
Whilst it has been shown that the class II region is involved in determining 
susceptibility to type 1 diabetes, further studies have shown that this association is 
dependent upon the age at onset of the disease [Karjalainen et al. 1989, Knip et al. 1986, 
Ludvigsson et al. I986, Caillat-Zucman et al. I992, Awata et al. I995]. However, a recent 
study from Japan suggested that HLA class I is associated with age at onset of type 1 
diabetes, while class II alleles confer susceptibility to the disease [Fujisawa et al. I995). 
The study reported that HLA-DR9, DQAI*030I, DQBI*0303 and DQBI*040I were all 
strongly associated with susceptibility in patients with type I diabetes, whilst HLA-B7 was 
shown to be a marker of early onset of the disease. The association is not necessarily with 
the HLA-B7 locus, it may be a gene in close proximity or one in linkage disequilibrium 
with the locus, but the data suggests the gene responsible maps to the class I region and not 
the class II region. Other recent studies have also suggested a role for HLA-B alleles or a 
gene in linkage as an additional risk factor in the development of type I diabetes 
[Nejentsev et al. 1997, Reijonen et al. I997]. Another study of the class I region has 
identified a new gene marker, P3B that is strongly associated with type 1 diabetes and 
further analysis revealed that the association was particularly strong in those patients with 
an age at onset between IO and 20 years [Demaine et al. I995). The results were similar to 
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those reported in the Finnish population in the same age range of I 0-20 years, where 
patients who are unable to form a 'diabetes susceptibility' DQ heterodimer tend to have 2 
copies of a HLA-A allele associated with type 1 diabetes [Fennessey et al. 1994]. It has 
been suggested that the influence of the class I or II susceptibility loci varies according to 
age at onset of the disease - the class II region being important in early childhood and the 
class I region in older groups [Fennessy et al. 1994, Demaine et al. 1995]. The association 
of the P3B region was also shown to have no significant linkage with class II DQA1 or 
DQB 1 alleles, suggesting that it is an independent marker [Demaine et al. 1995]. 
These studies show that it is possible there are other genes within the MHC, which 
encode molecules that are involved in immune functions and which may also have a 
modulating effect on the HLA molecules [Demaine et al. 1995, Degli-Esposti et al. 1992]. 
Other regions of the MHC complex that are not involved in antigen presentation have also 
been studied in relation to susceptibility to type 1 diabetes. Due to the strong linkage 
disequilibrium that exists across the MHC it is difficult to ascribe an independent 
association of a loci that may be identified. Some of the areas investigated include the 
complement C4 region and HSP, TNF a., within the class m region and TAP in the class II 
region and these are discussed below. 
3.6.2 Non-BLA factors associated with type 1 diabetes 
3.6.2.1 Complement C4 and Heat shock proteins 
BfFI was one of the first class m alleles to be associated with early onset of type 1 
diabetes [Bertrams et al. 1981]. Associations have also been found with the alleles of C4 as 
increased frequencies of the C4AQO allele and the C4B3 allotype have been shown 
[Marcelli-Barge et al. 1984, Rich et al. 1985]. It has been suggested that there is a 
susceptibility gene mapping near the C4 locus, which acts independently of the HLA-DR, 
DQ association in DR3/4 heterozygotes [Thomsen et al. 1988]. It has been suggested that 
the genetic basis for the low levels of C4 seen in 25% of type 1 diabetic patients [V ergani 
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et al. 1983] and the low C1q, C3 and C4 levels in different groups of patients 
[Charlesworth et al. 1987] may be due to the differences in complement alleles between 
patients and controls. It has also been suggested that single gene copies of the C4 genes are 
a common feature of diabetes-associated haplotypes [Serguado et al. 1992]. 
In addition to an association with complement genotypes, it has also been shown 
that there is an association with the HSP70 locus in type 1 diabetes. Although restriction 
fragment length polymorphism analysis (RFLP) has demonstrated an increase in an 8.5kb 
RFLP fragment of the HSP70-2 gene among patients [Caplen et al. 1990]. This allele 
occurred on DR3 haplotypes and it was suggested that the increase in the 8.5kb RFLP 
merely reflected the disease association of the DR3 haplotype [Pugliese et al. 1992, Pociot 
et al. 1993b]. However, it has been shown in Japanese patients with type 1 diabetes that 
there is no association with HSP70-2 [Kawaguchi et al. 1993]. 
Heat shock proteins (HSP) have a role to play in the immune response, so the 
association with type 1 diabetes is an important one even if it is not independent of other 
HLA genes. Members of the HSP family are involved in modifying protein structure and 
function as well as having a role in lymphocyte homing, protection against the effects of 
tumour necrosis factor, processing of foreign antigens, recognition and rejection of virus-
transformed tumour cells [Kaufman. 1990]. Antibodies to HSPs have been shown in a 
number of autoimmune diseases, antibodies to HSP-65 have been observed in type 
diabetes [Takei et al. 1993]. HSP-65 has been suggested as an autoantigen in type 1 
diabetes [Jones et al. 1990] and there is evidence it may play a role in the aetiology of type 
1 diabetes in the NOD mouse model [Eiias et al. 1990]. A spontaneous development of 
autoantibodies and autoreactive T -cells reactive to the HSP-60 has been shown in the NOD 
mouse early in the process of 13-cell destruction [Birk et al. 1996, Cohen. 1997, Elias et al. 
1990, 1991]. A 24-amino-acid segment of the HSP-60 was later identified and designated 
peptide p277 and was shown to be associated with the development of type 1 diabetes, 
with the appearance of antibodies to HSP-60 and T -cells reactive to HSP-60 and the p277 
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peptide [Birk et al. 1996, Elias et al. 1991, 1995 Cohen. 1997]. The p277 peptide features a 
motif that allows the binding to the MHC class Il molecule 1Ag7 of the NOD mouse 
[Reizis et al. 1997] and also to the susceptible HLA-DQ 0302 molecules [Kwok et al. 
1996]. Newly diagnosed type I diabetic patients have also shown T -cell responsiveness to 
p277 [Cohen. 1997]. 
3.6.2.2 TNFa. and B 
Other genes within the class m region have been investigated for a possible 
association with type I diabetes and these include the TNFa. and ~ genes [Badenhoop et al. 
1989, Pociot et al. 1991, llonen et al. 1992, Newton et al. 1998]. In type I diabetes, TNFa 
is actively expressed by islet-infiltrating mononuclear cells during the development of 
autoimmune diabetes and enhances both IL-l mediated cell cytotoxicity and interferon-
induced HLA class Il expression in vivo [Pociot et al. 1991, Ohashi et al. 1993]. It is itself 
upregulated by IL-l [Yamada et al. 1993]. It has been suggested that an abnormal or 
disregulated expression of TNF could be a factor predisposing an individual to 
autoimmune disease [Newton et al. 1998]. Various polymorphic regions within the TNFa 
and TNF~ gene loci have been described and characterised in relation to type I diabetes 
[Messer et al. 1991, Donen et al. 1992, Udalova et al. 1993, D'Alfonso and Richiardi. 
1994, Newton et al. 1998]. RFLP analysis using the enzyme Nco I has demonstrated two 
polymorphisms ofthe TNF~ gene, which were detected by a TNFa cDNA probe [Webb 
and Chaplin. 1990]. The alleles have been reported to correlate with differential expression 
of TNFa and ~ [Pociot et al. 1993, Whichelow et al. 1996]. The S.Skb allele was tightly 
associated with the haplotype HLA AI, B8, DR3 and the IO.Skb allele with Bw62-DR4 
haplotype, therefore both were found in diabetic patients [Badenhoop et al. 1989, Pociot et 
al. 1991]. Subsequently the S.Skb allele was also shown to be associated with the DR4 
haplotypes [Donen et al. 1992]. Heterozygosity for the TNF alleles were significantly more 
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frequent in patients than normal controls. A polymorphism in the TNFI3 gene has been 
shown to be associated with type I diabetes but only in the presence of either a DR3 or 
DR4 allele [Newton et al. 1998]. It is suggested that the risk incurred by this 
polymorphism is associated with the larger haplotype involved and therefore does not 
contribute an independent risk [Newton et al. 1998]. 
TNFa polymorphisms have been examined and a number of microsatellite 
polymorphic regions of the human TNFa locus have been identified. The alleles have been 
shown to be associated with type I diabetes however, it is likely that these alleles are just 
haplotype markers as no separate effect from the Ill..A-DR association could be found 
[Jongeneel et al. 1991, Pociot et al. 1993c, Cox et al. 1994]. 
A microsatellite polymorphism identified in TNFa has been shown to modulate the 
risk of type I diabetes in patients with the high risk genotype HLA DQAI *0501 -
DQBl *0201 I DQAI *0301- DQBI*0302 and it has been recently suggested that TNFa is 
part of a 'diabetogenic haplotypes' [Hanifi Moghaddam et al. 1997, 1998]. 
A functional correlation with different allele types and the production ofTNFa and 
ILl has been shown [Fugger et al. 1989, Molvig et al. 1990, Pociot et al. 1991]. Functional 
differences in TNFa production has been linked to TNF microsatellites on extended 
haplotypes [Pociot et al. 1993d]. It has been suggested that TNFa or 13 in conjunction with 
IFNy are produced in response to viral infection, this may lead to the aberrant expression 
of Ill..A class II expression on the pancreatic 13 cells [Bottazzo et al. 1985, Foulis and 
Farquharson, 1986, Foulis et al. 1987]. It is still unclear whether TNF polymorphisms and 
associated functional differences have any bearing on the pathogenesis of diabetes due to 
the data it is possible that a combination of factors is likely to account for susceptibility of 
different haplotypes. 
190 
3.6.2.3 T APl and T AP2 
Following the recent identification ofthe TAPl and TAP2 genes within the class IT 
region [Beck et al. 1992] and their role in antigen processing [Townsend and Trowsdale. 
1993] they have been considered possible candidate genes. Allelic polymorphism at the 
TAP 1 and T AP2 loci in relation to susceptibility to type 1 diabetes has been investigated in 
a number of studies [Jackson and Capra. 1993]. Using single stranded conformational 
polymorphism (SSCP) analysis, four alleles ofT APl have been identified [Colonna et al. 
1992, Jackson and Capra. 1993, Teisserenc et al. 1997]. The TAPl *0301 was shown to be 
associated with type 1 diabetes showing a high relative risk but the association was linked 
to that of DQAl or DQBl type [Jackson and Capra. 1993]. Studies investigating the 
genetic susceptibility linked to TAP in the two clinical forms of type 1 diabetes (type la 
and type lb) indicated that DRBl *03 and DRBI *04 differed in the two forms as discussed 
in section 3.4 .1 and the TAP 1-C allele occurred more often among DRB I *04 patients, 
suggesting that the TAP genes are linkage with HLA DQ-DR [Maugendre et al. 1996]. 
Other studies have shown no significant associations [Colonna et al. 1992, Nakanishi et al. 
1994, Kawaguchi et al. 1994]. 
Two early studies showed an increase in frequency ofT AP2-A among patients, 
with a decrease seen in the T AP2-B allele, controversy has arisen as to whether these 
results represent primary associations or are the effect of linkage disequilibrium. Some 
studies have suggested there is no separate effect, only that associated with linkage 
disequilibrium [Ronningen et al. 1993, van Endert et al. 1994b, Cucca et al. 1994, 
Maugendre et al. 1996] and others have reported that there is protection from type 1 
diabetes linked to the T AP2-A allele, which is independent of the class II associations 
[Caillat-Zucman et al. 1993]. More recently, after increasing and reanalysing the data the 
lack of an independent effect of the T AP2 genes was confirmed by Caillat-Zucman et al. 
( 1995), this was also found in other studies [Esposito et al. 1995]. It has been suggested 
that the hypoexpression of MHC class I molecules found on the surface of lymphoid cells 
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in patients with type I diabetes is due to reduced transcription and function of TAP genes 
[Faustman et al. 199I, Fu et al. 1993, I996, Wang et al. I995]. However, overall it appears 
that this region does not contribute a major susceptibility locus but may subdivide other 
linked susceptibility loci. 
A recent study has also suggested that the genes encoding LMP2 and LMP7 may 
have an additive role in the determination of the HLA-encoded susceptibility to type I 
diabetes [Deng et al. I995]. The independent effect of these genes was supported by the 
significant differences in LMP frequencies in HLA class Il haplotype-matched patients and 
controls however; this is only a preliminary study. 
3.7 Non-MHC genes associated with susceptibility to type 1 diabetes 
A significant component of inherited susceptibility to type I diabetes has been 
shown to be encoded by genes outside the MHC, although the MHC is still considered to 
be the main region associated with the disease and is termed IDDM I. The search for non-
MHC/non-HLA genes was initially limited to candidate gene studies in human 
populations; the subsequent use of animal models of type I diabetes identified a number 
regions associated with disease susceptibility, which could be used in human studies. This 
use of comparative mapping has now been largely superseded by exclusion mapping of the 
human genome using highly polymorphic microsatellite markers. 
3.7.1 Candidate gene studies 
3.7.1.11nsuiin gene region <INS) 
The autoimmune process leading to type I diabetes is highly specific to pancreatic 
~ cells the only cells that produce insulin. It is therefore logical that the insulin gene found 
on chromosome II p I5 would be a candidate for a susceptibility locus and there is strong 
evidence for this [Bell et al. I984, Hitman et al. I985, 1986, Awata et al. 1985, Julier et al. 
1991, Bain et al. 1992b, V an der Auwera et al. 1993]. Initial studies of possible diabetes 
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susceptibility and the insulin gene were inconclusive. Later studies using RFLP linkage 
analysis showed a polymorphic region situated 5' to the insulin gene to be associated with 
type 1 diabetes [Bell et al. 1984, Hitman et al. 1985, Elbein et al. 1985]. These results were 
substantiated by a number of association studies [Julier et al. 1991, Bain et al. 1992, 
Owerbach and Gabbay et al. 1993] and also evidence from genome-wide mapping/linkage 
analysis using microsatellite markers [Davies et al. 1994, 1996, Hashimoto et al. 1994, 
Todd et al.1995, Owerbach and Gabbay. 1996, Bennett and Todd. 1996, Todd and Farrall. 
1997] and this polymorphic region became known as IDDM2. The 5' polymorphic region 
of the INS arises from a variable number of tandem repeats (VNTR) and the polymorphism 
of this VNTR is divided into three classes, class I, II and m according to the number of 
repeats. Class I alleles have been positively associated with type 1 diabetes [Bell et al. 
1984, Hitman et al. 1985, Hitman et al. 1986, Bennett et al. 1995, 1996, Vafiadis et al. 
1996] and class m alleles have been found to be protective [Owerbach and Gabbay. 1993, 
1996, Undlien et al. 1995, Bennett et al. 1995]. More detailed analysis of the INS region 
identified a number of polymorphisms outside of the VNTR that were shown to be in 
strong linkage disequilibrium and therefore suggested to be associated with type 1 
diabetes. This indicated that the susceptibility to type 1 diabetes was within a 4.1kb region 
that included the INS and VNTR [Julier et al. 1991, Bain et al. 1992, Lucassen et al. 1993, 
Owerbach and Gabbay. 1993, Bennett et al. 1995, 1996, Undlien et al. 1995, Vafiadis et al. 
1996]. Subsequently, analysis of the transmission of different haplotypes in families and 
population based studies in other ethnic groups provided strong evidence that the IDDM2 
mutation was actually within the minisatellite repeat sequence 596 base pairs upstream of 
the insulin gene ATG codon (VNTR) and the association of the other identified 
polymorphisms was secondary to this primary association [Bennett et al. 1995, Julier et al. 
1994, Undlien et al. 1995, Vafiadis et al. 1996]. It is not known at this time whether the 
repeat number, element sequence, element number or location within each VNTR allele 
relates to disease susceptibility. For instance, recent studies have suggested that not all 
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class m and class I alleles are equally associated with disease susceptibility [Owerbach 
and Gabbay. 1993, Undlien et al. 1995, Bennett et al. 1995]. Some class m alleles appear 
to be strongly protective, while others are weakly protective or neutral [Owerbach and 
Gabbay. 1993, Undlien et al. 1995]. In addition there are subtypes of class I alleles 
including the 698-VNTR that have been found to be negatively associated with disease 
susceptibility [Bennett et al. 1995]. It has also been suggested that the VNTR region may 
have a biological role in modulating gene expression [Owerbach et al. 1982, Weaver et al. 
1992, Bennett et al. 1995, Lucassen et al 1995, Kennedy et al. 1995], other VNTR 
sequences have been shown to be involved in the regulation of transcription, such as the 
HR.AS1 3'VNTR [Green and Krontiris. 1993]. The 5'VNTR could alter the chromatin 
structure 5' of the INS gene, affecting its accessibility to regulatory molecules and 
therefore possibly its rate of transcription [Hammond-Kosack et al. 1993]. However, the 
exact role is presently unknown because of conflicting reports as to whether the class I 
alleles cause lesser [Kennedy et al. 1995] or greater gene expression [Bennett et al. 1995, 
Lucassen et al.1995]. It has been suggested that the difference seen in the different studies 
may be due to the use of haplotypes carrying different class I alleles [Bennett et al. 1995]. 
There was evidence for heterogeneity of the association between type 1 diabetes and 
different alleles the class I. However, other groups have found no evidence of 
heterogeneity of risk between subgroups of class I alleles [Owerbach and Gabbay. 1993, 
McGinnis and Spielman. 1995a] and this is still a point of debate [McGinnis and Spiel man. 
1995b]. Among diabetic offspring of class Illli heterozygous parents, class m VNTR 
alleles occur less frequently [Bennett et al. 1996]. It has been shown that in pancreatic islet 
cells, class m VNTR correlated with approximately 30% lower levels of insulin mRNA 
expression [V afidias et al. 1997]. It has also been suggested that the lower expression of 
this gene can reduce type 1 diabetes risk by reducing the levels of circulating autoantigen 
(i.e. insulin), also as a response to insulin deficiency there would be an increase in 
expression of IGF2 resulting in a neutralising of the destruction of pancreatic 13 cells 
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[Vafidias et al. 1997]. Another hypothesis to explain the dominant protective effect of 
VNTR class m is the link of class m alleles to the expression of insulin and proinsulin in 
the thymus [V afiadis et al. 1997, Pugliese et al. 1997, Schranz and Lernmark. 1998]. It was 
shown that the level of INS mRNA expressed in the thymus compared to the pancreas was 
very low, but the expression level of INS mRNA in VNTR 1/Ill heterozygotes was higher 
than in VNTR class I homozygotes. It has been speculated that this increase in expression 
may be sufficient to induce negative selection in the thymus, resulting in the deletion of 
autoreactive T -cells and a reduced predisposition to type 1 diabetes. As proinsulin in the 
thymus was expressed in levels higher than insulin, it is likely that epitopes shared by 
proinsulin and insulin are important in the induction of tolerance [Pugliese et al. 1997]. 
This region outside of the MHC is where there has been the most consensus that a 
further susceptibility gene is present. Although the nature of any interaction between INS 
and lll..A remains controversial, some studies have suggested that there is linkage to lll..A-
DR4 [Julier et al. 1991, Lucassen et al. 1993]. Others have shown that the INS has 
maximum effect on disease predisposition in subjects with low lll..A determined risk 
[Metcalfe et al. 1994] and others have shown no HLA linkage [Raffel et al. 1991, Bain et 
al. 1992, Van der Auwea et al. 1993, 1995b]. There is also some controversy over the 
parent of origin effects on INS susceptibility; some studies have suggested a role for 
maternal genomic imprinting [Julier et al. 1991, Bennett et al. 1995, Pugliese et al. 1994, 
Polychronakos et al. 1995], others have found no evidence [Bain et al. 1992, Bennett et al. 
1995]. There appears to be uncertainty around some aspects of the INS, but it is clear that 
it still has an important role to play as an additional marker for type 1 diabetes. 
3.7.1.2 T-ceU receptor genes 
T -cells recognise antigen when it is in combination with lll..A molecules on the 
surface of antigen presenting cells. This recognition is facilitated by the TCR, a 
heterodimeric cell surface molecule comprising an a and ~ chain, both with constant and 
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variable regions. The details of the TCR function, structure and genes are discussed in 
chapter 2. 
A number of studies have examined association between restriction fragment length 
polymorphisms of the TCRA and TCRB constant regions and type I diabetes. Associations 
with the TCRAC region have been negative [Hoover et al. 1989, Sheehy et al. 1989b, 
Concannon et al. 1990). A number of studies have found associations with the TCRBC 
region [Hoover et al. 1986, Millward et al. 1987, Ito et al. 1988, McMillan et al. 1990, 
Hibberd et al. 1992] however, there are some that have not [Niven et al. 1990, Concannon 
et al. 1990]. The differences found in these studies may be due to heterogeneity in the 
patient populations, this was suggested by the extension of the Hoover study ( 1986) to a 
larger patient group that no longer showed an association. However, an association existed 
in the sub-population of patients who were HLA-DR3/X where X was not DR4 [Hoover et 
al. 1989). These studies are concerned only with susceptibility owing to variation in 
germline TCR genes. Somatic diversification mechanisms allow the random addition or 
deletion of nucleotides at junctions between TCR gene segments. Therefore the TCR 
products expressed on the surface of the T -cell are not entirely encoded in the germline. A 
study using type 1 diabetic multiplex families has shown that the expression of the TCR ~­
chain variable regions 2S1 and 3S1 may be associated with type 1 diabetes [Craddock et al. 
1998). The level of expression of TCRBV2S 1 in the multiplex families was significantly 
higher than in normal controls for both CD4+ and CD8+ T -cell subsets. The increased 
expression was shown not to be associated with age, sex, HLA type or the diabetic 
phenotype. It has also been shown that the association between the TCRB locus and type 1 
diabetes depended on the absence of complications after 20 years of type 1 diabetes in the 
patient group, which suggests that there are genetic determinants to diabetic complications 
[Hibberd et al. 1992]. However, it is suggested that these associations are due to the close 
proximity of the TCRBC locus to the aldose reductase gene [Pate! et al. 1993, 1996, 
Heesom et al. 1997, 1998). 
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3.7.1.3 Immunoglobulin heavv chain (Gm) regions/genes 
Antibody production against islet cell antigens, insulin and glutamic acid 
decarboxylase (GAD) has been show to be a secondary phenomenon in susceptibility to 
type I diabetes [reviewed by Schranz and Lernmark. I998]. The immunoglobulin heavy 
chain region is located on chromosome I4q32 and Gm allotypes have been associated with 
a number of autoimmune diseases, suggesting it as a candidate for genetic susceptibility to 
type I diabetes. Although, this has not been confrrmed as an additional susceptibility 
region in diabetes [Klitz et al. I989, Fimmers et al. I989]. However, it has been proposed 
that that genes encoding Gm allotypes, or in linkage disequilibrium with them may 
contribute to susceptibility through interactions with the HLA region [Field et al. I989]. 
The allotype Glm(2) has been associated with increased type I diabetes risk in HLA-DR3 
individuals and G3m(5) resulted in increased risk in HLA-DR4 individuals [Field et al. 
I984]. Gm allotypes have also been reported to interact with TCRB region genes in type I 
diabetes [Field et al. 1991]. It has also been shown that there is a lack of association with 
Ig switch regions [Hitman et al. 1986c, Millward et al. I988]. 
3.7.1.4 2'-5' oligoadenylate synthetase gene 
2'-5' oligoadenylate synthetase is an enzyme that catalyses the polymerisation of 
adenine nucleotides into a long chain of adenine units - 2'-5' oligoadenylate which activates 
ribonuceases that are normally present in the cell in an inactive form and these can then 
degrade messenger RNA. This enzyme is induced by interferon a and y as well as TNFa 
and ~ and is important in antiviral activity. The 2'-5' oligoadenylate synthetase gene has 
been shown to be polymorphic, but there was no association shown between the 3 
genotypes detected and type 1 diabetes [Hitman et al. I989], it is therefore considered that 
this gene is not a primary susceptibility locus for type 1 diabetes. 
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3. 7.2 Comparative mapping and genome linkage analysis 
The best evidence for the existence of susceptibility genes outside IDDM1 and 
IDDM2 came initially from a number of genetic analysis studies using the NOD mouse 
[Reviewed by Todd. 1997, Merriman and Todd. 1996, Todd et al. I991, Love et al. I990, 
Todd and Bain, 1992, Risch et al. I993, Wicker et al. I995]. It was suggested that there 
were at least I 0 loci outside of the MHC and INS region that contributed to disease 
development [reviewed by Vyse and Todd. I996, Risch et al. I993, Todd et al. 199I, 
Wicker et al. 1995]. The data collected from these studies was used to identify human 
homologues of the disease susceptibility loci identified in the mouse in comparative 
mapping studies. However, with the exception of the MHC in the mouse and HLA in 
humans such studies have been unsuccessful. The following table summarises the loci 
associated with type I diabetes identified in the NOD mouse: 
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IDDM locus Chromosome number Reference 
ldd-2 9 Prochazka et al. 1987 
ldd-3 3, proximal Todd et al. 1991, Lord et al. 1995 
ldd-4 11 Todd et al. 1991 
ldd-5 1, proximal Comall et al. 1991 
ldd-6 6 Wicker et al. 1995 
ldd-7 7 Ghosh et al. 1993 
ldd-8 14 Ghosh et al. 1993 
Idd-9 4 Rodrigues et al. 1994 
ldd-10 3, distal Ghosh et al. 1993 
Idd-11 4 Wicker et al. 1995 
ldd-12 14 Serreze et al. 1994b 
Idd-13 2 Wicker et al. 1995 
ldd-14 13 Wicker et al. 1995 
ldd-15 5 Wicker et al. 1995 
Table: 3.6 Candidate IDDM loci in the NOD mouse 
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Recent studies using affected sib-pairs, linkage maps of a large number of highly 
polymorphic microsatellite marker loci and fine mapping techniques have confirmed the 
importance of IDDMI and IDDM2, but have also shown that there is possibly over II 
other chromosome regions involved [Davies et al. I994; Hashimoto et al. I994, Todd et al. 
I995, Todd. I997, Merriman and Todd. I996, Todd and Farrall. I997]. Table 3.7 is a 
summary of the genome search data showing the IDDM loci in humans. 
New candidate IDDM loci are continually being discovered, some recent and yet to be 
confirmed discoveries are not included in Table 3.7, among them are IDDMII, I2 and 13. 
IDDMII which has been located on chromosome I4q24.3-q3I by linkage to the 
microsatellite marker DI4S67 in sib-pair analysis [Field et al. I996]. IDDM I2 and I3 
have been located on chromosome 2q33 [Nistico et al. I996, Morahan et al. I996]. 
IDDMI2 has been reported to be linked to and associated with the CTLA-4 locus [Nistico 
et al. I996], which is a strong candidate gene for type I diabetes [Waterhouse et al. I995, 
Tivol et al. I995]. CTLA-4 is a negative regulator ofT -cell proliferation and is linked to 
the gene for CD28, the product of which stimulates T -cells to divide on engagement of the 
antigen TCR with MHC/peptide complex. Other studies have shown polymorphisms of the 
CTLA-4 gene to be linked to the susceptibility of type I diabetes and also to Graves' 
disease [Donner et al. I997, Owerbach et al. I997, Van der Auwera et al. I997, Yanagawa 
et al. I995]. It is possible that there is a susceptibility gene in the region that predisposes to 
both diseases via an autoimmune mechanism, with CTLA-4 and CD28 being prime 
candidates [Todd and Farrall. I997]. 
The various studies shown in Table 3.7 provide strong evidence to suggest linkage 
of a number of new markers with type 1 susceptibility. However, additional analysis is 
required to prove linkage and decipher specific interactions between the loci. It is clear the 
type 1 susceptibility has the potential for gene complexity and that not only can several 
loci provide susceptibility/protection, but there maybe epistatic interactions among the 
various loci [Risch et al. I993, Cordell et al. 1995]. From data collected so far it has been 
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suggested that some loci will act independently (heterogeneity) [Cordell et al. 1995], while 
others will interact (epistasis) [Rjsch et al. 1993]. 
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Chromosome Locus Reference 
6p21 IDDMI Davies et al. 1994 
llpl5 IDDM2 Davies et al. 1994 
Bennett et al. 1995 
I5q26 IDDM3 Field et al. 1994 
llql3 IDDM4 Davies et al. 1994, 
Hashimoto et al. 1994, Luo et al. 1996, Owerbach & 
Gabbay, 1995. 
6q25 (ESR) IDDM5 Davies et al. 1994, Luo et al. 1995, Owerbach & 
Gabbay, 1995, Delepine et al. 1997 
18q IDDM6 Davies et al. 1994, Merriman et al. 1997, 1998 
2q31 IDDM7 Davies et al. 1994, Copeman et al. 1995, Owerbach 
& Gabbay, 1995 
6q27 (D6S264) IDDM8 Davies et al. 1994, Luo et al. 1995, Owerbach & 
Gabbay, 1995, Delepine et al. 1997 
3q21-q25 IDDM9 Gough & J.A.T (unpublished) 
Xq DXSI068 Cordell et al. 1995 
I Op 11.2-q 11.2 IDDMIO Davies et al. 1994, Hashimoto et al. 1994, 
Reed et al. 1997 
7p GCK Rowe et al. 1995 
Table: 3. 7 Candidate IDDM loci in humans 
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CHAPTER4: 
4.1 Introduction 
AUTOIMMUNITY AND THE PATHOGENESIS OF TYPE 1 
DIABETES 
Autoimmunity can be considered as a dysfunction of the immune system. It has been 
regarded as break down of tolerance to self i.e. an abnormal response to a 'normal' self- but it 
may be due to the alteration of self by pathogenic organisms or agents, resulting in body cells 
recognised as foreign, i.e. a normal response to an 'abnormal' (altered) self. Autoimmunity 
(i.e. self-reactivity) does by no means imply autoimmune disease. Autoimmune disease arises 
from a sustained adaptive immune response specifically mounted against self, which results in 
lasting tissue destruction destruction/damage. The mechanisms of tissue damage in 
autoimmune disease are essentially the same as those that operate in protective immunity and 
in allergy. It is believed that autoimmunity is initiated by a response involving T -cells; 
cytotoxic T -cell responses and inappropriate activation of macrophages can cause extensive 
tissue damage, while inappropriate T -cell help can initiate a harmful antibody response to self-
antigens [Janeway and Travers 1996). Three conditions were postulated which any disease 
defined as autoimmune should fulfil [Humphrey and white. 1963]; 
i) there should be evidence for immune involvement of some stage of the disease 
ii) the lesions characteristic of the disease should be inducible in experimental animals by the 
suspected antigen 
iii) the lesions should then be reproduced in syngeneic recipients by transferring the 
pathogenic cells or antibodies. 
Many factors are thought to contribute in triggering and precipitating autoimmunity, including 
genetic and/or environmental factors, as well as defects in the immune system itself. 
Autoimmune diseases can be broadly classified into organ-specific autoimmune 
disease or systemic autoimmune disease (Table 4.1). Organ-specific autoimmune disease 
results from an 
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Hashimoto' s thyroiditis 
Primary myxoedema 
Thyrotoxicosis 
Autoimmune atrophic gastritis 
Addison's disease 
Type 1 diabetes mellitus 
Goodpasture's syndrome 
Myasthenia Gravis 
Pemphigus vulgaris 
Pemphigoid 
Sympathetic opthalmia 
Phacogenic uveitis 
Multiple sclerosis 
Autoimmune Haemolytic anaemia 
Idiopathic leucopenia 
Primary biliary cirrhosis 
Active chronic hepatitis 
Ulcerative colitis 
Sjogren's syndrome 
Rheumatoid arthritis 
Dermatomyositis 
Scleroderma 
Mixed connective tissue disease 
Systemic lupus erythematosus 
Table 4.1 The spectrum of auto immune diseases. 
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ORGAN SPECIFIC 
NON-ORGAN SPECIFIC 
response that is directed against a specific cellular component of an organ (i.e. thyroid gland in 
Hashimoto's disease and Graves disease, islet ~ cells of pancreas in type 1 diabetes). 
Systemic, where autoantibodies are produced against a wide range of antigenic determinants 
in multiple organs or tissues and /or immune complexes (i.e. Systemic lupus erythematosus -
SLE). 
Most of the processes by which autoimmunity could arise have been suggested from 
work in animal models or in vitro studies, as the events preceding the onset of clinical 
appearance of autoimmune disease cannot be studied. There are a number of possibilities as to 
how autoimmunity can arise: 
a) MHC molecules may have a preferential capacity to bind different potentially 
autoantigenic peptides and present them to T-cells. For example one single variation 
(polymorphism) in an amino acid residue of the HLA-DQ molecule ~ chain confers 
susceptibility to type 1 diabetes [Todd et al. 1987]. Alternatively, in the context of type 1 
diabetes, it may be that there is an absence of particular protective MHC molecules. This 
could be seen as protection arising from a single or multiple MHC molecules binding and 
presenting effectively, potential autoantigenic peptides in order to induce tolerance. If this 
is not present in an individual, this process of induction of tolerance does not occur 
[Sheehy. 1992]. Loss of tolerance may arise if autoreactive T -cells are not removed in the 
thymus. 
b) Antigenic similarities may occur between antigenic components of pathogens and self-
antigens- molecular mimicry. An example of this is in rheumatic fever, where antibodies 
to group A streptococci react with cardiac myosin [Dale and Beachey. 1985]. Viral T-cell 
epitopes also have similarities to self-peptides [Wucherpfenning and Strominger. 1995a] 
and could lead to an autoantigen directed T -cell response. 
c) Self-antigens not previously encountered by the immune system could be released 
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following damage to cells by toxic influences. This cannot be regarded as a break down of 
tolerance; rather immune response to an antigen recognised as foreign. 
d) MHC molecules may be aberrantly expressed on non-APC tissue cells, allowing antigen 
from internal cellular components to be combined with and presented by the MHC 
molecule. There is evidence for aberrant MHC expression in both thyroid autoimmune 
disease and type 1 diabetes [Lankisch and Banks. 1998]. IFN-y is known to induce 
expression of class II MHC molecules on a number of non immune cells [Janeway and 
Travers. 1996], including pancreatic 13 cells, thyroid acinar cells and intestinal epithelial 
cells. It has been hypothesised that infection and trauma, both resulting in local IFN-y 
production, cause MHC expression on non APC cells, resulting in inappropriate T -ce11 
activation. IFN-y would also induce the production of other pro-inflammatory cytok:ines 
that would help activate effector cells. 
e) Expression of eo-stimulatory molecules to allow tissue cells to activate T -ce11s effectively 
[Nickoloff et al. 1993]. 
t) Alteration in cytok:ine environment. 
In spite ofthe presentation of these possible mechanisms as separate entities it is unlikely that 
any occur in isolation, more that autoimmune diseases such as type 1 diabetes result from a 
combination of a number of these events, a multifactorial process. 
4.2 Type 1 diabetes - a chronic autoimmune disease 
Over the past two decades enough information has accumulated to classify type 1 
diabetes as a chronic autoimmune disease [Eisenbarth. 1986, Castano and Eisenbarth. 1990, 
Bach. 1995, 1997]. Evidence in favour of this include, the occurrence of autoantibodies to islet 
ce1ls, cell-mediated immune reactivity to islet cell antigens detected in the peripheral blood, 
lymphocytic infiltration in 'diabetic' islets and immunogenetic susceptibility as in other 
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autoimmune endocrine diseases [Bottazzo et al. 1990, Akerblom et al. 1997]. In the following 
sections humoral autoimmunity (autoantibodies) and cell-mediated autoimmunity (T-cells) to 
pancreatic 13 cells in the development of type 1 diabetes will be discussed: 
4.3 Autoantigens in type 1 diabetes 
In type 1 diabetes an autoantigen is commonly defined by two characteristics 1) it is 
the target antigen of a cellular or humoral immune reactivity specifically associated with type 
1 diabetes and 2) it is a self-molecule present in, on or near pancreatic 13 cells [Karges et al. 
1995]. Although there have been many putative autoantigens, no single antigen has yet been 
accepted and it may well be that different molecules are recognised in different subjects as 
part of the heterogeneity of the disease. Most autoantigens have been identified by reactivity 
with diabetes-associated autoantibodies from patients and, in some cases, such as for insulin 
and glutamic acid decarboxylase (GAD), proliferative responses of peripheral blood 
mononuclear cells from newly diagnosed or pre-diabetic patients [ Atkinson et al. 1992, 
Honeyman et al. 1993, Harrison et al. 1993, Schranz and Lernmark. 1998], have been 
observed for these putative autoantigens. Autoantigens can be considered as either 
"recombinant" were the autoantigen has been identified and prepared in large quantities, or 
not were it is considered as "candidate" autoantigen [Schranz and Lernmark. 1998]. A 
different type of autoantigen is those detected by T -cells (T -cell autoantigens ). These 
autoantigens or T -cell epitopes differ whether the peptides are presented by HLA class I or 
class II molecules. Table 4.2 lists the autoantigens and associated autoantibodies that have 
been implicated [reviewed by Karges et al. 1995, Falorni et al. 1995, Gottlieb and Eisenbarth. 
1996, Schranz and Lernmark. 1998]: 
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Autoantigen Antibodii Autoantibodl: References 
GAD '64K antigen'- 65K, 64K antibody or anti GAD Baekkeskov et al. 1982, 
67K antibody-GAD65Ab 1990, Grubin et al. 1994, 
GAD67Ab Kaufman et al. 1992, 
+ Hagopian et al. 1993, Velloso 
et al. 1993, Vandewalle et al. 
1995, Schimidi et al. 1994. 
Insulin and Proinsulin Insulin autoantibodies (IAA), Palmer. 1993, Srikanta et al. 
Proinsulin antibody 1986, Hartling et al. 1989, 
+ Bohmer et al. 1991, Kuglin et 
al. 1988, Landin-Olsson et al. 
1992, Brusic et al. 1997, 
Gorus et al. 1994, 
Vandewalle et al. 1993, 
Bingley et al. 1996, Thivolet 
et al. 1988. 
ICA512/IA-2 Islet cytoplasmic antigen Rabin et al. 1992, 1994, 
(ICA512Ab or IA-2Ab) Payton et al. 1995, Lan et al 
+ .1994, Bonifacio et al. 1995b 
IA-2J3Phogrin IA-2J3Ab Cui et al. 1996, Wasmeier et 
al. 1996, LaGasse et al. 1997, 
Payton et al. 1995. 
37K, 40K, SOK (50 derived Anti SOK, 40K and 37K Christies et al. 1990, 1992a, 
from GAD65/67; 37K antibodies b, 1993, Payton et al. 1995. 
derived from IA-213; 40K + 
derived from IA-2) - tryptic 
fragments of islet 
homogenates 
ICA69 Anti-bovine serum albumin Pietropaolo et al. 1993, 
antibody (ICA 69Ab) (+) Martin et al. 1991. 
38K-jun-B jun-BAb (+) Honeyman et al. 1993. 
Carboypeptidase H CPHAb (+) Castano et al. 1991. 
Heat shock protein (Hsp) hsp60 anttibodies Jones et al. 1990, Ozawa et 
al. 1996 
DNA Topoisomerase II Antibodies and autoantibodies Huang et al. 1981, Chang et 
DNA Topoisomerase II (+) al. 1996. 
Glima 38 Glima 38 autoantibodies (+) Aanstot et al. 1996. 
lmogen 38 (T-cell reactive To be determined Arden et al. 1996. 
autoantigen) 
Monosialoganglioside ICA (+) Dotta et al. 1989, 1995, 
GM2-islet cytoplasmic Nayak et al. 1985. 
antigen 
SulEhatides To be determined Buschard et al. 1993. 
Table 4.2 Autoantigens and Antibodies associated with type 1 diabetes 
KEY:+ established,(+) partially established 
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The oldest and least defined marker for type 1 diabetes is at the same time still the single most 
sensitive tool to monitor diabetic autoimmunity. ICA in diabetic sera were discovered by their 
specific binding and visualisation on cryosections of human pancreas [Bottazzo et al. 1974]. 
Autoantigens associated with the pathogenesis of type I diabetes have been identified using 
methods involving serum or plasma by immunoprecipitation [Baekkeskov et al. 1982, Schranz 
and Lernmark. 1998]. The highest diagnostic sensitivity and specificity have been achieved 
when the autoantibody analyses are carried out as radioimmunoassay with recombinant 
autoantigens [Greenbaum et al. 1992, Verge et al. 1995]. Except for insulin itself none of the 
characterised putative autoantigens are islet or P cell specific. 
Some of the putative autoantigens are membrane components, some are the contents of 
the two types of granules found in the islet and many are intracellular proteins or their 
components. These may be released in the natural course of events. For example, contents of 
secretory granules such as insulin and related proteins and carboxypeptidase H, are released in 
the process of normal exocytosis. Some of these intracellular proteins may be expressed on the 
surface, such as insulin and carboxypeptidase H [Larsson et al. 1989, Aguilar-Diosdado et al. 
1994]. There is no evidence that others, such as GAD, are on the cell surface [Colman et al. 
1987, Vives-Pe et al. 1993, Schranz and Lernmark. 1998]. It might be expected that molecules 
in various compartments that have different functions in the cells, might be differentially 
recognised in the context of being a potential autoantogen and at varying times. 
The presence of an islet cell autoantibody signifies that an autoimmune reaction has 
taken place. Islet cell autoantibodies are viewed as markers of this anti-islet autoimmune 
reaction and therefore as markers of disease. Autoantibodies are not considered instrumental 
in type 1 diabetes pathogenesis and autoantigens are considered as targets of autoimmunity 
rather than a trigger for autoimmune T -cell responses [Pietropaolo et al. 1993, Tisch et al. 
1993, K.arges et al. 1995, Schranz and Lernrnark. 1998]. It would be expected that if an 
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autoimmune response is specifically directed against a target organ, then the initiating antigen 
recognised would be a protein or a peptide bound to MHC molecules that is specifically 
related to the organ in question - in this case the pancreas. Many of these autoantigens are not 
specific. As the initial pathogenic event is not known, it remains to be seen which of these 
molecules plays a primary role (if indeed there is a single initiating autoantigen) and why 
many of these molecules, which should not incite an immune reaction, become 
immunoreactive [Schranz and Lemmark. 1998]. The extensive heterogeneity of the islet-
specific autoantibodies may be explained by the number of different autoantigens that are able 
at drive an autoimmune response. The aggregation of single autoantigens, forming subcellular 
particles, may be recognised as antigenic complexes that initiate and maintain even more 
heterogeneous, islet-specific, autoimmune responses [Atkinson and MacLaren. 1993, 
Pietropaolo and Eisenbarth. 1994]. As most of the autoantigens are physiologically located in 
the cytoplasm of the islet cells and are not 13 cell specific, the initiall3 cell specific insult must, 
therefore, be due to a different causative agent [Pietropaolo ans Trucco. 1996]. It has been 
postulated that they are recognised by T -cells after damage has been done to the islet cells, 
perhaps as a result of viral infection or inflammation [Karges et al. 1995, Schranz and 
Lernmark. 1998]. Alternatively, they could be recognised in a cross-reaction with genuine 
foreign antigenic molecules - molecular mimicry. Antigenic mimicry describes the fact that 
small, naturally non-self peptide epitopes share sequence homology with protein regions on 
self-protein in an immuncomptent host [Oldstone. 1987]. This is particularly so for molecules 
which have similarities to viruses, such as GAD with Coxsackie B4 virus, P2-C protein 
[Kaufinan et al. 1992, 1993, Ellis and Atkinson. 1996, Hou et al. 1994, Atkinson et al. 1994, 
Schloot et al. 1997, Tian et al. 1994, Vreugdenhil et al. 1997]. The 52K protein with Rubella 
virus and also the cross reactivity of ICA69 with antibodies to BSA in cows milk protein, it 
has been hypothesised that dietary exposure to BSA in early life would result in cross-reactive 
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immune memory to the peptide and a pool of BSA/ ABBOS reactive cells. Future diabetic 
patients on encountering dietary BSA/ ABBOS would stimulate these cells and replenish 
reactive T -cell pools. This mechanism could provide for one important aspect of diabetic 
autoimmunity [reviewed by Karges et al. 1995]. 
The nature of the autoantigens remains one of the central questions in attempts to 
understand the pathogenesis of type 1 diabetes. The one (if any) of these antigens has a 
dominant primary role and which is then followed by secondary immunisations to a variety of 
antigens that do not normally elicit autoimmune responses is still to be determined. 
4.3.1 Autoantibodies 
The presence of autoantibodies directed against islet antigens represents the hallmark 
of the humoral immune abnormalities associated with type 1 diabetes. Antibodies against a 
variety of islet-related antigens can be observed in the circulation well before the clinical onset 
of the disease [Gorsuch et al. 1981]. However, it is well known that some individuals may 
have these antibodies for extended periods of time, without ever developing diabetes [Bosi et 
al. 1991]. They may also be present for years after diagnosis [Kaufman et al. 1992, Dotta and 
Esienbarth. 1997]. It is not thought that antibodies have a pathogenic role in disease. In all 
animal models used, disease has not been transferred by this route. Table 4.2 in section 4.3 
lists some ofthe autoantibodies that have been linked to type 1 diabetes. Many of the putative 
autoantigens listed in the table have been identified because of the presence of autoantibodies 
in diabetic patients. 
Although functional autoantibodies have been described in other autoimmune diseases 
such as Graves' disease, where stimulating antibodies to the TSH receptor play a role in the 
pathogenesis of disease [Hall. 1989], in diabetes, most of the autoantibodies found are not 
thought to play a functional role [Schranz and lernmark. 1998, Dotta and Esienbarth. 1997]. 
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However, antibodies have been described that inhibit the insulin response to glucose in rats 
[Kanatsuns et al. 1983, Webster et al, 1989] and also inhibit the glucose transport into rat islet 
cells [Johnson et al. 1990]. 
Most of the studies of autoantibodies in type 1 diabetes have concentrated on their use 
in prediction of the disease and there have been many studies looking at their prevalence and 
predictive value [reviewed by Schranz and Lernmark. 1998, Dotta and Esienbarth. 1997, 
Palmer. 1993, Thivolet et al. 1992, Hagoplain et al. 1995, Landin-Olsson et al. 1992, Aanstoot 
et al. 1994, Gorus et al. 1997, Bingely et al. 1993a,b, 1996]. Islet cell antibodies (ICA) have 
been the most investigated and many models of prediction of diabetes are based on the 
presence or absence of these antibodies. ICA are present in 60-80% of new onset type 1 
diabetics, in 3% of first degree relatives and in 0.2% of the general population, therefore the 
measurement ofthese provide a sensitive assay. ICA can be present in circulation years before 
the clinical onset of the disease [Palmer et al. 1991, Verge et al. 1996]. Several workshops 
have been held in order to standardise ICA and insulin autoantibodies assays by comparing 
reproducibility, sensitivity and specificity of the assays performed in different laboratories -
the current standard unit of measurement are JDF units (Juvenile Diabetes Foundation). These 
measurements are important to try to allow for international comparison in the effort to 
develop markers of prediction of the disease [Dotta and Esienbarth. 1997]. 
Islet cell antibodies can be subdivided and there is data to suggest that different subsets 
of ICA are associated with different risks for diabetes [ Gianani et al. 1992, Genovese et al. 
1992]. Antibodies that are 'restricted', which is responding to human and rat islets but not to 
mouse and stain only p cells rather than whole islets, are found in relatives who are ICA 
positive but who do not progress to diabetes [Gianani et al. 1992]. A similar result was found 
in the study where antibodies were termed 'selective' and they gave a granular appearance 
with staining restricted predominately to p cells and were found in the majority of endocrine 
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autoimmune patients who did not develop diabetes and not in newly diagnosed diabetic 
patients [Genovese et al. 1992]. It was also shown in these studies that the cytoplasmic ICA 
was usually high titer anti-GAD autoantibodies [Gianani et al. 1992, Genovese et al. 1992]. 
Like ICA, competitive anti-insulin autoantibodies (IAA) can be detected in the 
circulation well before the clinical onset of type 1 diabetes, representing another 
immunological marker for the detection of individuals at risk of developing the disease. IAA 
are present in about 60% of new onset type 1 diabetics prior to insulin therapy and show a 
marked inverse age correlation [V ardi et al. 1988a, Srikanta et al. 1986]. The overall 
prevalence is more common among young children than among adolescents or adults [Landin-
Olsson et al. 1992, V ardi et al. 1988b]. The diagnostic sensitivity and specificity of IAA for 
type 1 diabetes have been assessed in numerous studies of selected patients [Srikanta et al. 
1986, Arslanian et al. 1985]. Population and Diabetes Registry-based studies of patients and 
matched controls [Hagopian et al. 1995, Landin-Olsson et al. 1992, Gorus et al. 1994, 
Vandewalle et al. 1993], as well as among first-degree relatives progressing [Bingley et al. 
1996, Thivolet et al. 1988] or not to type 1 diabetes [McCulloch et al. 1990, Barmeier et al. 
1991]. 
GAD65 has been demonstrated as the major autoantigen in type 1 diabetes [Karlsen et 
al. 1991, Petersen et al. 1994, Kaufman et al. 1992, Hagopian et al. 1993] and special interest 
has been focused on this autoantigen. It has been shown that 70-80% of type 1 diabetes sera 
recognised GAD65 whereas only 10-20% recognise GAD67 [Falorni et al. 1995, Vandewalle 
et al. 1995]. The highest diagnostic sensitivity ofGAD65Ab has been found at onset of type 1 
diabetes [Falomi et al. 1995, Vandewalle et al. 1995, Schrnidli et al. 1994, Bonifacio et al. 
1995] and typically 80% of the patients have GAD65Ab. The sensitivity does not seem to 
decrease with increasing age as is the case for IAA and ICA512Ab [Vandewalle et al. 1995, 
Hagopian et al. 1995]. The frequency of GAD65Ab is increase among first degree relatives 
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and predict type l diabetes [Verge et al. I996, Kaufman et al. I992, Bonifacio et al. I995]. 
The evidence, thus far, is that the various autoantibodies provide useful markers for 
disease and in the prediction of type I diabetes. It has been suggested that the combination of 
autoantibodies provide the most sensitive screening for the general population in the 
prediction of the disease [Bingley et al. I993c]. 
4.4 T-ceUs in type 1 diabetes 
In a diabetic pancreas there is an insulitis which refers to a chronic inflammatory 
infiltrate of mononuclear cells that may be confined to some of the pancreatic islets, shown in 
post-mortem studies [Gepts. I965]. In the pancreas of such patients, there are also islets which 
have no residual islet ~ cells, but do contain normal glucagon-secreting A-cells, sornatostatin-
secreting D-cells and pancreatic polypeptide-secreting PP-cells [Gepts and De Mey. I978, 
Atkinson and Maclaren.I994]. Bottazzo et al. (I985), examined the pancreas of a I2-years 
old girl who died with newly-diagnosed type I diabetes, using monoclonal antibodies and 
found that the majority of lymphocytes infiltrating the islets were T -cells, predominately 
CD8+ cells, with vari~~:ble numbers (generally smaller then CD8+) of CD4+ T-cells and 
natural killer cells. The majority of the cells expressed lll.A-DR and a proportion expressed 
the ll..,-2 receptor - markers of lymphocyte activation. Monocytes and macrophages that are 
also known to be present [Bach. I994, I997, Atkinson and Maclaren. I994] were not 
identified, as monoclonal antibodies recognising dendritic or antigen-presenting cells were not 
available at the time. 
Other studies of post-mortem pancreata have confirmed the presence of the majority of 
CD8+ T -cells within the islets, although CD4+ T -cells were also present and many cells over 
expressed class II molecules, suggesting activation. It has been shown in studies of the NOD 
mouse that the infiltrate appears several weeks before diabetes onset and CD4+ T -cells appear 
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frrst and their presence is necessary for CD8+ T -cell migration [Thivolet et al. 1991]. The 
TCR usage was also studied and it was shown that the TCRBV usage within the insulitis was 
heterogeneous at this time. Cells with yo TCRs were not found [Hanninen et al. 1992). It has 
also been shown that the pancreas of two patients who had died at the onset of diabetes, 
contained some islets with a few insulin-producing cells [Conrad et al. 1994). It has been 
suggested that there is a selective expansion of TCRBV7 but unselected TCRA V in the islet 
infiltrating T -cells [Conrad et al. 1994]. 
In studies using pancreatic biopsy specimens from 18 alive, newly diagnosed patients 
with type 1 diabetes, it was shown that the infiltrating mononuclear cell population consisted 
of cells that were CD4+, CD8+, B cells and macrophages, with CD8+ cells being predominant 
[Itoh et al. 1993]. Further studies have also shown that the TCRBV gene usage of the 
infiltrating cells appears to be heterogeneous although the TCRA V populations may be more 
restricted [Y amagata et al. 1993]. 
The actual nature of the effector T -cell have been investigated, in the NOD mouse 
diabetes can be transferred by the infusion of spleen cells from diabetic mice (CD4 and CD8 
cells are 13( cell specific CD8 T -cells, which has led to the suggestion that CD4 cells could 
play the predominant role. CD4 clones alone have been shown to transfer the disease [Haskins 
and McDuffie. 1990], however, CD8 clones can also transfer the disease [Wong et al. 1996). 
Therefore the discussion on the nature of the cell directly at the origin of the 13 cell lesion 
remains open [Bach. 1997]. 
In addition to examining the presence of T -cells within the pancreas, it is also 
important to take account of other changes that may take place in the pancreas, so that the 
presence of insulitis may be placed in the context of an immune response as a whole. It has 
been shown that the pancreatic islets showed hyperexpression of class I molecules in the 
affected cells and some 13 cells, which were still producing insulin had aberrant expression of 
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MHC class II molecules [Bottazzo et al. 1985]. This was supported by a larger post-mortem 
study, were it was found that endocrine cells expressing HLA-DR were insulin containing and 
that most islets, in which these cells were present, had no evidence of insulitis [Foulis et al. 
1986, 1987]. It was suggested that within an individual islet, this aberrant DR expression on ~ 
cells might precede the inflammatory infiltrate. Once the cells became insulin deficient, no DR 
expression could be detected. Studies have also confirmed the hyperexpression ofMHC class 
I by endocrine cells and this also appears to precede insulitis [Foulis. 1990). 
Other changes, such as alterations in adhesion molecules and homing receptors, occur 
in the pancreas. It has been reported that ICAM-1 is increased in the endothelial cells of some 
patients [Hanninen et al. 1992, Itoh et al. 1993]. There is increasing evidence that adhesion 
molecules may play an important role in the entry of cells into tissue and in animal models, 
the role of integrin VLA-4 has been shown to be important [Yang et al. 1994, Baron et al. 
1994, Burldy et al. 1994]. However, this has not yet been demonstrated in the human disease. 
There is plenty of evidence for the presence of T -cells at the site of pancreatic 
destruction in diabetic patients, but there have been many studies that have investigated 
changes in peripheral T -cells in diabetes, both at the time of diagnosis as well as later in the 
disease. However, some of the earlier studies have been somewhat variable. Some studies 
have shown an increase in the total peripheral T -cells [Ilonen et al. 1991 ], others have reported 
no change and others have shown a decrease [Al-Kassab and Raziuddin. 1990, Johnston et al. 
1988]. There has also been a discrepancy in the changes of circulating CD4+ and CD8+ T-
cells and also the ratio of these two T -cell types in newly diagnosed and longstanding diabetic 
patients [Pozzilli et al. 1983, Faustman et al. 1989, llonen et al. 1991]. Due to the variability of 
these earlier studies the observations give little information about what is happening 
functionally in the target organ. 
Many studies have been performed to examine antigen specificities of T -cells in pre-
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diabetic subjects as well as newly diagnosed patients both in total peripheral blood 
populations, as well as in cloned populations of T -cells. It has been shown, in vitro, that 
peripheral blood lymphocytes have reactivities to a variety of putative autoantigens. Islet-
reactive cells are present within total peripheral blood [Harrison et al. 1992, Schranz and 
Lernmark. 1998, Karges et al. 1995, Dotta and Esienbarth. 1997]. Reactivity to glutamic acid 
decarboxylase (GAD) has been demonstrated, both in newly diagnosed diabetic patients and 
relatives who have high titres of islet cell antibodies [Atkinson et al. 1992] as well as to 
GAD65 peptides [Hao et al. 1993, Panina-Bordignon et al. 1995, Schranz and Lernmark. 
1998]. There appears to be a dichotomy in the immune response to GAD, high concentrations 
of circulating autoantibodies to GAD being associated with low proliferation of peripheral T-
cells to GAD and vice versa [Harrison et al. 1993]. It was suggested that if GAD is a 
pathogenic autoantigen, then sensitisation to 13 cell GAD is more likely to lead to diabetes 
when the immune response deviates toward the expansion of autoreactive T -cells, rather than 
towards the generation of autoantibodies [ Schranz and Lemmark. 1998]. T -cell reactivities to 
bovine serum albumin have also been found, although the responses were also seen to other 
albumin species and this seems to correspond to the ABBOS sequence, which resembles 
ICA69 [Cheung et al. 1994, Karges et al. 1995]. 
It has also been shown from studies using T -cell clones that have been generated from 
peripheral blood that there are cells present in the peripheral blood that are islet reactive and 
can respond to components of the rat insulinoma [Kontianen et al. 1991]. Also cells that are 
reactive to components derived from the insulin secretory granule [Roep et al. 1991] and the 
cell surface membrane of human islets [Peakman et al. 1994]. In addition, some cells are 
autoreactive and recognise autologous B lymphocytes in the absence of other exogenous 
antigens [Miller et al. 1993, Karges et al. 1995] and appear to recognise peptides, derived from 
one class ll 13 chain and presented by another [Karges et al. 1995]. This supports the 
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hypothesis that autoreactive T -cells r~cognise autologous peptides, in association with MHC 
and some of these peptides are derived from self-MHC molecules. T-cell clones ate useful for 
studying the behaviour of cells that may have pathogenic qualities and are a tool for 
identifying the nature of the autoantigen(s). The fact that most T-cell clones isolated appear to 
be lfl..,A-DR restricted, whereas :m...A-DQ seems to be more associated with disease, may 
reflect the low level of:m...A-DQ expression on antigen presenting cells [Aitmann et a! 1991, 
Karges et al. 1995] or may represent the fact that in vitro culture methods select for DR 
restricted cells. 
4.4.1 TH1ffH2 dicbtomy in type 1 diabetes 
In the immune system subsets of cells do not operate in isolation. Any immune 
response occurs as a result of immunoregulatory changes in terms of both helper and effector 
functions. Macrophages and dendritic cells that play a role as antigen presenting cells are also 
important. Different subsets of cells within the immune system interact with each other, not 
only by direct contact, but also by the production of cytokines. All of the cells involved in the 
immune system produce a number of cytokines and a number of these are summarised in 
Table 4.3. 
It is known that different subsets of cells produce different cytokines and 
helper/inducer function is believed to be mediated by these [Swain et al. 1988, Rousset et al. 
1992]. CD4+ helper T -cells are subdivided into two distinct types due to the production of 
certain cytokines as discussed in section 2.12.1, TH1 and TH2. TH1 cells produce ll...2 and 
IFNy and are important mediators of cell-mediated immunity. In contrast, TH2 cells, which 
produce llA and ll..,10, are important in 'helping' antibody responses and therefore humoral 
immunity. The cytokines produced by THl cells inhibit TH2 cells and vice versa. 
It has been shown that autoreactive T -cells are present in the normal immune system 
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but there exist immunoregulatory cells that suppress the autoreactive potential [Reich et al. 
1993, Karges et al. 1995]. One ofthe mechanisms by which this could occur is the production 
of opposing cytokine products. It has been suggested, due to investigations in some mouse 
models, that the immune response leading to type 1 diabetes involves an imbalance in 
immunoregulatory circuits that leads to changes in the balance of TH1 and TH2 subsets 
[Rabinovitch. 1994]. It has been hypothesised that type 1 diabetes is associated with a TH I 
response, due to the fact that cytokines produced by these cells have linked to the development 
of the disease. Transgenic expression of IFNy leads to an autoimmune insulitis followed by 
diabetes [Sarvetnick et al. 1990] and monoclonal antibodies against IFNy inhibit the 
development of diabetes in NOD mice [Campbell et al. 1991]. Polymorphisms in the IFNy 
have also been linked to type 1 diabetes [Pociot et al. 1997, Awata et al. 1994]. It has been 
postulated that ITA producing cells (TH2) can inhibit cell-mediated immune responses, partly 
by the down-regulation ofiFNy production by TH1 cells [Fowell et al. 1993, Price. 1997]. In 
contrast, there have been reports that suggest that type I diabetes in NOD mice is TH2 
mediated, which suggests that diabetes could occur as a result of disturbed immunoregulation 
[Anderson et al. 1993]. ILl, TNFa and IFNy have been directly implicated in 13 cell 
destruction and/or inhibition of insulin release, possibly via nitric oxide produced by non-13 
cells [Corbett et al. 1995, Rabinovitch et al. 1995, Price. 1997]. 
What alters the balance or regulatory subsets of cells and what determines whether 
THI or TH2 predominate? Microorganisms can stimulate certain subsets of T -cells and the 
cytokine environment produced can further direct the T -cells, which proliferate and those that 
are inhibited. This suggests again a role for the environment in triggering the disease. 
There are however, other fundamental ways in which T -cells are thought to be differential into 
TH1 or TH2 subsets. This may be a function of the amount of antigen present, as it has been 
shown that low doses of antigen tend to generate TH2 cells from naive CD4+ cells and high 
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doses tend to generate TH1 cells [Constant et al. 1994]. If type 1 diabetes is a TH1 mediated 
disease, it is possible that an environmental agent such as an infection could lead to an 
increase in the level of antigen expressed, skewing responses towards a TH1 type of response. 
This could give rise to a decrease in immunoregulatory TH2 subsets and therefore allow an 
activation of CDS and other effector cells. Alternatively, an increase in TH2 subsets could 
increase the production of some subtypes of antibody and this could provide protection. The 
observation that higher levels of GAD antibodies, for instance, seem to be protective may 
support this hypothesis [Esienbarth. 1993, Dotta and Esienbarth. 1997, Schranz and Lernmark. 
1998]. As well as the studies where there are different responses by T -cells to an antigen when 
compared with antibody response [Harrison et al. 1992, Karges et al. 1995]. Evidence from 
animal models has suggested that responses to different antigens are genetically determined, 
the genetic predisposition of the animal influences whether a TH2 or TH1 phenotype develops 
[Sher and Coffman. 1992, Scott et al. 1994, Alien and Maizels. 1997]. It has been shown that 
the peptide p277 derived from HSP60 is capable of inducing a THI - TH2 shift [Birk et al. 
1996, Elias et al. 1991, Elias and Cohen. 1994, Elias and Cohen. 1995, Cohen. 1997]. It has 
been shown early in the process of P cell destruction in NOD mice that autoantibodies and 
autoreactive T -cells to this peptide p277 are developed and it has been shown that p277 is 
associated with autoimmune diabetes in mice and men [Birk et al. 1996, Elias et al. 1991, 
Cohen. 1997]. However, it has also been shown that P cell destruction can be arrested by the 
subcutaneous administration of peptide p277, which was compatible with a shift in anti-p277 
T-cell reactivity from a THI-like phenotype to a TH2-like phenotype [Elias et al. 1997, 
Cohen. 1997], resulting in the secretion of II..A and IL 10 and antibodies to p277. It was 
suggested that the presence of this peptide triggered a resetting of the cytokine profile of the 
autoimmune reaction following a transient wave of TH2 reactivity that "suppressed" the 
pathogenic THI reactivity [Elias et al. 1997, Cohen. 1997]. 
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Cell type 
CD4+TH1 
CD4+TH2 
CD8+ 
Macrophage 
Dendtritic cell 
Cytokine produced 
IL2, IL3, IFNy, TNFa, TNFP, GM-CSF 
IL2,IL3,IL4,ILS,IL10 
IFNy, TNFP 
ILl, TNFa, GM-CSF 
ILl, TNFa, GM-CSF 
Table 4.3 Cytokines produced by cells of the immune system 
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In addition to the important role of cytok.ines, there are other molecules expressed both 
on T-cells and antigen presenting cells that play a role in the development of immune 
responses. Among these are molecules that belong to the B7 family, which are found on 
antigen presenting cells and interact with CD28 and CTLA4 on activated T -cells. In the NOD 
mouse model it has been shown that antibodies to the co-stimulator B7-2 inhibit the onset of 
disease whereas antibodies to B 7-1 and the expression of this molecule accelerate the disease 
process [Lenschow et al. 1995, Wong et al. 1995]. 
Other molecules important in immune responses are the adhesion molecules, including 
intercellular adhesion molecule-1 (ICAM-1 ); it has been suggested that high expression of 
these may increase endothelial adhesion of mononuclear cells and enhance their accumulation 
in the pancreas during diabetic insulitis [Hanninen et al. 1992]. 
Overall, it is likely that there is an interaction with a number of different molecules 
when immune responses occur and there may be changes within the systems that regulate the 
expression and function of these that contribute to pathogenesis of disease. 
4.5 Animal models of diabetes 
A number of animal models have been used to try to understand further the pathogenic 
mechanisms that give rise to type 1 diabetes in humans. The models cannot be take to 
represent exactly the events that occur in disease in man as the disease has been manipulated, 
many animals are from highly inbred strains and many of the animals used do not have 
analogous biology to that of man. Animal models have provided much useful information in 
the study of disease processes and as the target organ in man is inaccessible, they have 
allowed much insight to be gained into possible pathogenic mechanisms in relation to immune 
function. Particular care needs to be taken in consideration of the transgenic animals, as they 
can represent unphysiological conditions and the effects may not be related to naturally 
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occurring autoimmune diabetes. Table 4.4 shows some of the animal models of type 1 
diabetes. Although study of each of these animal models has given insight to some aspects of 
the development of diabetes, the NOD mouse is a much studied model for human type 1 
diabetes, as there are many components that appear to be analogous to the human disease. The 
BB rat is in some ways superior to the NOD mouse, due to the faster disease development in 
both male and female animals, development of ketoacidosis, ease of islet cell preparation, 
however the genetics of BB rats is less well characterised and other factors make the NOD 
mouse the preferred model of study [reviewed by Karges et al. 1995]. 
4.5.1 NOD mouse model of type 1 diabetes 
The NOD mouse spontaneously develops type 1 diabetes with remarkable similarities 
to the human disorder [Tochino. 1987, Kikutano and Makino. 1992]. Autoimmune islet-cell 
destruction is a similar characteristic [Wang et al. 1991, Castano and Esienbarth. 1990], as are 
the appearance of autoantibodies to 13 cell components [Castano and Esienbarth. 1990, Karges 
et al. 1995] defects in T -cell activity [Faustman et al. 1989, Serreze et al. 1994, 1996], 
sensitivity of the disease to immunosuppression [Castano and Esienbarth. 1990] and the 
presence of susceptibility genes in the :MHC [Todd et al. 1991, Wicker et al. 1995]. One of the 
differences is that NOD females have approximately twice the frequency of disease compared 
to males (80-90% vs 40-50%) [Pozzilli et al. 1993], whereas in humans males and females are 
equally effected. However, in this present study and another recent study it has been suggested 
that the frequency among male and females is different [Cucca et al. 1998]. Large variation in 
the global NOD mouse diabetes incidence has been reported, which suggests a role of 
environmental factors in determining whether these genetically susceptible animals develop 
the disease [Pozzilli et al. 1993]. lnsulitis is first noted at 3 to 4 weeks of age and virtually all 
female and male NOD mice have insulitis by 3 months of age [Fujita et al. 1982]. Although 
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Animal Model 
Non-obese diabetic mouse (NOD) 
Bio-breeding rat (BB) 
Streptozotocin induced diabetes 
Alloxan induced diabetes 
Transgenic mice with transgenes for 
1) cytokines such as IL12, INFy, IL10, 
TNFa. combined with B7; 
2) TCRs; 
3) viral proteins 
Diabetes induced by irradiation and 
thymectomy 
References 
Makino et al. 1980 
Chappel and Chappel. 1983 
Like and Rossini. 1976 
Dunn and McLetchie. 1943 
Heath et al. 1992, Sarvetnick et al. 1990, 
Wogenson et al. 1994, Guerder et al. 1994 
Katz et al. 1993 
Adarns et al. 1987, Roman et al. 1990, 
Oldstone et al. 1991, Ohashi et al. 1991 
Fowell and Mason. 1991. 
Table 4.4 Animal models of type 1 diabetes 
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CD4+ and CD8+ T -cells are the most prominent cells in insulitic lesions of NOD mice, B 
cells, dendritic cells and macrophages are also present [Miller et al. 1988, Lo et al. 1993, 
Wicker et al. 1995, Karges et al. 1995]. 
Genetic susceptibility is complex in this animal model and currently at least 1 5 genes 
have been identified, by backcross experiments, microsatellite mapping and genome-wide 
scanning (see Table 3.6., chapter 3). The genes are thought to play a role in both the 
development of insulitis and subsequent destruction of the islet P cells giving rise to diabetes 
[Ghosh et al. 1993, Serreze and Leiter. 1994, Wicker et al. 1995, Vyse and Todd. 1996]. In the 
NOD mouse the genetic makeup is sufficient to cause P cell destruction because under germ-
free conditions the disease is almost 100% penetrant [Todd. 1991]. In the NOD mouse the 
major determinant of the MHC-encoded component has been mapped to the class ll region 
(Idd 1 ). The I-Ag7 molecule, which is the homologue of the human DQB 1 *0302 it is unique in 
that it dose not have aspartate residue at position 57 [Wicker et al. 1995]. This indicates that 
the (Asp/non-AspS? correlation is conserved across species, which would be expected since 
the basic biochemical properties of class 11 molecules are unlikely to vary significantly 
between species [Cucca and Todd. 1996]. Mice are protected if a different I-A molecule such 
as 1-AK is substituted, or if the I-AG7 has an amino acid substitution at position 56 from 
histidine to proline [Lund et al. 1990, Wicker et al. 1995]. It has been suggested that Idd 1 
controls the efficiency of tissue-specific autoantigens [Wicker et al. 1995, Cucca and Todd. 
1996]. Use of the NOR mouse (a control strain for NOD which also has this MHC) does not 
get the disease demonstrates that other loci are required [Serreze and Leiter. 1994]. This has 
also been shown by genome-wide screening by linkage analysis using inbred mice and large 
pedigrees [Risch et al. 1993, Todd et al. 1991, Wicker et al. 1995]. NOD mice do not express 
lE, the homologue ofDR in humans, transgenic and breeding experiments have shown that lE 
expression is protective for insulitis and type 1 diabetes, although it is not sufficient [Podolin 
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et al. 1993, Cucca and Todd. 1996]. MHC class I is considered to be important as it has been 
observed that NOD mice crossed with 132-microglobulin null mice do not develop either 
insulitis or diabetes [Katz et al. 1993, Wicker et al. 1994b, Serreze et al. 1994, 1996]. This 
indicates that diabetogenesis in NOD mice requires normal expression levels of the relatively 
common class I gene products, presumably to select and target 13 cell autoreactive CDS+ T-
cells [Serreze et al. 1996]. It has previously been reported that NOD mice express lower levels 
ofMHC class I and that this alone may cause diabetes [Faustman et al. 1991] and later studies 
have suggested similar [Fu et al. 1993, 1996]. However, this has not been confirmed by other 
studies [Gaskins et al. 1992, Wicker et al. 1992, Serreze et al. 1996]. Although many of the 
other genes encoding susceptibility have not definitely has a function assigned, a number of 
other genes identified are interesting in that they encode molecules that may have a bearing on 
immune function. For example; Idd 10 has been suggested to code for the high affinity Fe 
receptor for IgG FcyRI [Prins et al. 1993, Wicker et al. 1995] and Idd 5 has been linked to 
genes on chromosome I that affect the function ofmacrophages [Comall et al. 1991, Wicker 
et al. 1995]. Whether any of these susceptibility genes have human analogues remains to be 
determined. 
The disease in NOD mice is mediated by T -cells and both CD4 and CDS cells are 
required. If the NOD mouse is crossed with 132-microglobulin null mice, as mentioned 
previously, which lack class I and are deficient in CDS T -cells that neither insulitis nor 
diabetes develops and this is probably related to the deficiency of CDS T -cells rather than the 
lack of antigen presentation by class I [Wicker et al. 1994b, Serreze et al. 1996]. Similarly, a 
cross with MHC class II negative mice has shown that insulitis does not develop in the 
absence of CD4 cells [Katz et al. 1993]. Neonatal thymectomy prevents the development of 
diabetes, as it is thought to prevent the development of autoreactive T -cells [Karges et al. 
1995]. Adoptive transfer experiments have shown that to effectively transfer diabetes, both 
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CD4 and CD8 cells are required [Miller et al. 1988, 0 'Reilly et al. 1991]. Although it has been 
suggested that CD4 cell clones can perform this function [Haskins and McDuffie. 1990] and it 
has also been shown that CD8 clones can transfer disease [W ong et al. 1996], therefore the 
nature of the cell directly at the origin of~ cell destruction remains open. 
The autoantigen against which disease is initiated has not been characterised. GAD is a 
candidate for the early autoantigen and T -cell reactivity to this antigen has been demonstrated 
early in insulitis. T -cells from older animals develop reactivity to other epitopes of GAD65, as 
well as to HSP60, peripherin and carboxypeptidase H [Kaufman et al. 1993, Tisch et al. 1993, 
Schranz and Lernmark. 1998]. 
As in human type 1 diabetes, many questions about the pathogenesis of diabetes in this 
model remain to be answered, but as new findings occur, this allows a means to understand 
fundamental immune processes in a disease model which has some close parallels to the 
human disease. It may also allow new lines of enquiry to be developed in type 1 diabetes in 
humans, complementing the studies that are already and continually in progress. 
Figure 4.1 represents the factors/schemes that have been discussed throughout the 
previous chapters, which are considered to be involved in the pathogenesis of type 1 diabetes. 
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Figure 4.1 Representation of pathogenesis of type 1 diabetes 
228 
4.6 Aims of this thesis 
As discussed in the earlier chapters of this thesis there has long been a debate about the 
genetic susceptibility to type I diabetes and the question whether l.\1HC class I or class 11 
involvement is more important. The class 11 region has been the most studied area in relation 
to genetic susceptibility however, there is increasing evidence that genes within the class I 
region play an important role in susceptibility to type I diabetes and this may be independent 
of the class 11 region. Therefore, the main aim of this project was to be the first comprehensive 
study of the class I region in association with type I diabetes. 
The initial investigation was to extend the previous findings of an independent marker within 
the class I region associated with type I diabetes [Demaine et al. 1995]. This was achieved by 
using a panel of highly polymorphic microsatellite markers and conventional genomic probes, 
which mapped a substantial area of the class I region to locate potential diabetic susceptibility 
gene(s). The investigations were carried out in both a large sporadic population of type I 
diabetics and also a selection ofBDA Warren repository multiplex families. Due to the strong 
associations found with class 11 HLA-DQ and -DR 'susceptibility genes' detected in the class 
I region were investigated for linkage to class 11 susceptibility loci/alleles. Previous studies 
have suggested that there is a difference in genetic susceptibility at different ages at onset of 
type 1 diabetes, associations in the class I region was also investigated for a relationship with 
the age at onset of the disease. A number of autoimmune diseases have been shown to have a 
link with gender and associations mapped to the class I region were studied in relation to the 
gender of the patient. 
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CHAPTERS: 
5.0 Materials 
5.0.1 Water 
MATERIALS AND :METHODS 
Double distilled tap water was used to make up all stock, general purpose and specialist 
solutions. Sterile water (Baxter Healthcare UK) was used to make oligonucleotide probe 
and primer solutions and used for PCR. 
5.0.2 Reagents 
All reagents used were analytical grade or equivalent. 
Acetic acid, Disodium ethylene diamine tetra-acetic acid, Glycerol, Hydrochloric acid, 
Magnesium chloride, Maleic acid, Orthoboric acid, Sodium chloride, Sodium citrate, 
Sodium dodecyl sulphate, Sodium hydroxide, Sucrose, Tris (hydroxymethyl) aminomethane 
and Tween 20 were purchased from BDH Laboratory Supplies-Merck Limited UK. 
Chloroform, Ethanol and Methanol were purchased from Rathburns Limited UK. 
Ammonium persulphate, Ethidium Bromide, N-Lauroylsarcosine, Tetra-methyl-ammonium-
chloride, Tetra-methyl-ethylene-diamine (TMED), Dextran sulphate, Sephadex G-50, 
Triton -X-100 and Xylene cyanol were purchased from Sigma Chemicals UK. 
5.0.3 Specialised reagents, enzymes and materials 
Agarose, the DIG luminescent detection system, Random pnmer labelling kit and the 
restriction enzymes were purchased from Boehringer Mannheim GmBH Germany. JM109 
cell line and 5' end labelling ClAP kit was purchased from Promega USA. DH5cx. competent 
cells and ampicillin were purchased from Gibco BRL-Life technologies UK. Taq 
polymerase and PCR buffer were purchased from HT Biotechnology UK. Deoxynucleoside 
5'-triphosphates (dNTP's) and T4 Polynucleotide kinase (T4 PNK) were purchased from 
Pharmacia Biotech Sweden. cx.3"2P dCTP and -("2P dATP redivue radioactive isotopes and 
Rapid Hybridisation buffer were purchased from Amersham International UK. Plasmid 
230 
miniprep Kit was purchased from Qiagen Ltd Germany. 3.MM Whatman paper (Whatman 
International UK.) was used in the southern blotting station and 50 x 30 cm filter paper from 
Heto Laboratory Equipment UK. was used for polyacrylamide gel support and drying. 
5.0.4 Stock solutions 
1. Sodium chloride/sodium citrate (SSC) 
20x solution: 3 M NaCI, 0.3M trisodium citrate, pH7 
11. Trislborate electrophoresis buffer (TBE) 
IOx solution: 0.89mM Tris base, 0.89M Boric acid, 2mM EDTA (pHS) 
m. Ethidium bromide 
lOmg ml-1 in H20 
iv. Xylene cyanolloading buffer 
0.25% w/v Xylene cyanol, 10% v/v Glycerol in 10x TBE 
v. Tris-acetate (T AE) buffer 
SOx solution: 242g Tris base, 57.1ml Glacial acetic acid, O.SM EDTA (pHS) 
vi. Tris - EDT A (TE) buffer 
pH 7.4: 54g Tris base, 27.5g Boric acid, O.SM EDTA (pH8) 
pH 8.0: Tris-Cl10mM (pH7.4), EDTA 1mM (pHS) 
5.0.5 Autoclaving 
All solutions and all glassware and plasticware used in the techniques of DNA analysis were 
autoclaved at a temperature of 121°C and pressure of 15 p.s.i for 30 minutes in a steam 
autoclave (Rodwell Instruments UK.). 
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5.1 Extraction of High Molecular Weight DNA 
5-20ml of peripheral venous blood was taken from all subjects into 5% EDT A (Becton 
Dickenson UK)) and used to make high molecular weight DNA. During the course of this 
thesis two methods were employed to prepare DNA. 
A) Method 1 
5-l Oml sample of frozen blood was thawed at room temperature and transferred to a 50ml 
falcon tube (Philip Harris UK). 40mls of Nucleon A (10mM Tris-HCL, 320mM sucrose, 
5mM MgCI2, 1% Triton X-100, pH 8.0 using 40% NaOH) (Scotlab UK) was added and 
the sample shaken for 4 minutes at room temperature and then spun at 1300xg for a further 
4 minutes at room temperature in a MSE Mistral 1000 centrifuge (MSE UK). The 
supernatant containing the lysed red cells was discarded and 2ml of Nucleon B ( 400mM 
Tris-HCL pH 8.0 using 40% NaOH, 60mM EDTA, 150mM NaCl, 1% SDS) was added to 
the pellet to disrupt nuclear membranes. The pellet was resuspended by vortexing and then 
incubated at 37°C for 30 minutes to ensure that the nuclear membranes were disrupted and 
the protein denatured. The suspension was transferred to a 1 5ml falcon tube and 500~ of 
5M sodium perchlorate (Sigma UK) was added to precipitate the DNA and the mixture was 
gently shaken at room temperature for 1 5 minutes, followed by a second incubation in a 
65°C water bath for 25 minutes. 2ml of chloroform (Sigma UK) at -20°C was then added 
and the tubes shaken at room temperature for 1 0 minutes, and then centrifuged at 800xg for 
1 minute. 300J.1l of resuspended Nucleon silica (Scotlab UK) was added and then spun at 
1400xg for 3 minutes at room temperature and the aqueous phase containing the DNA 
removed. Care was taken not to disturb the Nucleon silica suspension layer (brown in 
colour), at the interphase and the organic phase. The aqueous solution was re-spun at 
1300xg to pellet any residual Nucleon silica and the supematant was carefully decanted to a 
fresh tube. The DNA was precipitated by placing the tubes at -20°C for 2-3 hours followed 
by the addition of 2 volumes of ice-cold 100% ethanol (Rathbums Ltd UK) and gentle 
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inversion. The DNA was extracted into an eppendorftube (Elkay Products) containing 70% 
ethanol using a hooking pasteur pipette, it was then air dried and finaaly resuspended in an 
eppendorf tube containing either I rnl of sterile water (Baxter) or TE buffer pH 8. DNA 
samples were then stored at -20°C 
B) Method 2 
5-l Ornl of frozen whole blood sample was thawed at room temperature and transferred to a 
50ml falcon tube. 15rnls of cold sucrose lysis buffer (0.32M sucrose, 10mM Tris-HCL at 
pH 7.5, 5mM MgCI2, 1% Triton X-100) at 4°C was added at a ratio 4:1, gently mixed and 
then chilled on ice for 10 minutes. The sample was then centrifuged at 12,000 rpm for 30 
minutes at 4°C. The supernatant containing the lysed red cells was discarded. The nuclear 
pellet was resuspended in 5rnl of Nuclei lysis buffer (10mM Tris-HCL pH 8, 400mM NaCl 
and 2mM NaCh!EDTA), 300J..1l 10% SDS and 100- 200J..1l Proteinase K (lOmg/rnl), mixed 
gently and incubated at 37°C in a water bath overnight with gentle agitation. 2rnls of 
saturated sodium chloride solution (5.5M) was added and the contents were vortexed 
before centrifugation at 2500 rpm for 15 minutes at room temperature. After centrifugation 
the upper aqueous layer, containing the DNA, was removed with a pasteur pipette and 
transferred to a fresh falcon tube and the interphase and organic layer containing proteins 
were discarded. 4mls of TE pH8 equilibrated phenol (Sigma) and 2rnls of chloroform 
(Sigma) were added, mixed and centrifuged at 2000 rpm for 10 minutes. The top aqueous 
layer was removed again (supernatant) and transferred into another clean falcon tube, and 
the above step repeated. The DNA was precipitated by adding 2 volumes of 100% ethanol 
to the sample, and subsequently 'hooked out' using a glass 'hooking pasteur pipette'. The 
DNA was rinsed in 70% ethanol and finally dissolved in an eppendorf tube with 1ml TE 
pH8 for 72 hours and then stored at -20°C. 
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5.2 Quantification of High Molecular Weight DNA 
The DNA sample was quantified by measuring the optical density using a Cecil 5500 
Spectrophotometer scanning 240nm to 280nm (CECIL UK). The DNA sample was diluted 
I in I 0, by adding I Oj.LI of sample to 90!11 of double distilled water, and compared to a blank 
containing double distilled water at 260nm. Readings were multiplied by 50 11I OD [optical 
density] reading being equivalent to 50!lg/ml DNA) then by IO {the dilution) and divided 
by I,OOO to convert to j.LI. The OD reading gives the DNA concentration in !lg/!ll. The 
amount of protein contamination was estimated by reading the OD at 280nm. The DNA 
samples were then stored at -20°C. 
5.3 Restriction fragment length polymorphism (RFLP) analysis 
This process was used to investigate the class I region and involved the use of several 
genomic probes P3A, 28L, 66R and P3B, and is described in the following sections. 
5.3.1 Restriction enzyme digestion 
5-IO!lg of DNA was digested using I0-20 units of the required enzyme (Boehringer 
Mannheim Germany) in 1.5ml eppindorftubes. This was carried out in a reaction mixture of 
30j.LI using 1/IOth volume restriction enzyme buffer, supplied with the enzyme by the 
manufacturers, and distilled water to make up the final volume. In some cases, spermidine 
(I mM) (Boerhinger Mannheim Germany) was added to a final concentration of 3mM to 
improve digestion. This was then incubated overnight in a 37°C or 65°C water bath (Grant 
UK) depending upon the enzyme used. Digestion was checked by running a 3j.LI aliquot with 
l.Sj.LI ofloading buffer (50% glycerol, ImM EDTA pH8, 0.25% bromophenol blue, 0.25% 
xylene cyanol) (Sigma UK) and 7!11 of distilled water on a I%, ethidium bromide stained 
horizontal mini agarose gel, for I hour at I50-200 volts. If digestion was incomplete a 
further 5-10 units of enzyme were added in 3!11 of IOX enzyme buffer and incubated for a 
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further 4 hours. The enzyme concentration in solution was always kept below 10% to 
minimise non-specific cleavage of DNA due to the presence of glycerol. 
5.3.3 Separation of DNA fragments by gel electrophoresis 
The DNA fragments were separated by electrophoresis in 0.8% agarose horizontal gels. 2.8 
grams of agarose (Boehringer Mannheim Germany) was added to 350ml of 0.5% Tris-
borate EDT A (TBE) buffer (BDH UK) in a 400ml glass bottle, and heated in a microwave 
for 2-3 minutes at 650 watts to dissolve. The agarose solution was cooled to 60°C-65°C 
and 0.01% v/v ethidium bromide (10mg/ml solution) was added and mixed by swirling. The 
agarose solution was poured into a 20x24cm ultraviolet light-transparent perspex tray 
(Gibco BRL, Flowgen), which was sealed at both ends with autoclave tape and contained 
moulds to generate the sample wells (28 tooth combs). After the gel was set it was placed 
at 4°C to harden the agarose, after removing the tape the gel was submerged in 0.5% TBE 
buffer in a Flowgen electrophoresis tank (Flowgen UK), and the comb moulds were 
removed. The digested DNA was concentrated using a microcentrifuge, 1110 volume of 
sample loading buffer was added to the DNA sample, vortexed and loaded into the gel. A 
lambda DNA Hind m digest/size marker (Boehringer Mannheim Germany) run in a 
separate lane was used to indicate when electrophoresis was complete and to allow 
appropriate sizing of bands. The gel was run for 16-20 hours at constant voltage of 80-90 
volts. The migration of the DNA was checked by visualising the separation of the lambda 
marker under UV illumination using a transilluminator (l.NP USA) linked to specialised 
computer software (Gelbase/Gelblot UVP USA) and a photograph was taken. 
5.3.4 Southern blotting (Southern, 1975) 
After completion of the electrophoresis of the DNA fragments, the agarose gel was 
denatured by treatment with an acid wash of 0.25M HCL (BDH UK) for 15 minutes and an 
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alkali wash with l.SM NaCI, O.SM NaOH (BDH UK) for 30 minutes. This lead to the 
formation of single stranded DNA. Neutralisation was then carried out by washing in 3M 
NaCI, O.SM Tris pH7.5 (BDH UK) solution for 30 minutes with constant gentle agitation. 
All washes were carried out at room temperature. A subsequent modification to this 
method, alkaline blotting, did not require denaturation or neutralisation of the agarose gel 
and blotting was carried out using 0.4M NaOH onto Hybond Nylon-N+ nucleic acid 
transfer membranes (Amersham Life Science UK) which also served to fix the DNA to the 
membranes. The blotting station was assembled, 2 sheets of 3MM Whatman 
chromatography paper (Whatman UK) were placed over a 30x20cm plastic support with 
the edges of the paper hanging down into the plastic trough containing 0.4M NaOH 
(denaturing buffer) to act as a wick. The 3MM paper was wetted with 0.4M NaOH and any 
air bubbles were smoothed out using a glass rod. The gel was trimmed to remove unused 
areas, the top right hand corner of the gel was cut this allowed the gel to be orientated 
during the procedure. The gel was then inverted and placed on the support, centred on the 
wet 3MM papers any air bubbles between the gel and the paper was removed as before. 
The blotting station was boarded with Saran Wrap™, leaving the area over the gel free, 
this served as a barrier to prevent liquid from flowing directly from the reservoir of 0.4M 
NaOH to the paper towels placed on top of the gel, causing a short circuit in the system. 
The dimensions of the gel were used as a template to cut the Hybond Nylon N+ membrane 
and the membrane was then placed on top of the gel and smoothed out. 2 sheets of pre-wet 
Whatman 3MM paper (moistened with 0.4M NaOH) were placed on top of the nylon 
membrane and smoothed out as before. Two parallel stacks of paper towels were placed on 
top of the sheets of 3MM Whatman paper, and a glass plate and 500g weight were placed 
on top of the paper towels. The gel was blotted overnight. The paper stack and 3MM 
Whatman paper were removed, the gel was discarded and the nylon membrane was 
washed for 10 minutes in 3xSSC (depth I cm) to remove NaOH and any adhering agarose. 
After 
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washing the nylon membrane was placed between 2 sheets of 3MM Whatman paper and 
blotted gently, the membrane was then wrapped in Saran Wrap and stored at 4°C until ready 
for probing. 
5.3.5 Preparation of DNA probes 
During the preparation of DNA probes two methods were employed. The use of the fresh 
bacteria strain JM109 (Promega) obtained from lab stock, prepared to competence for 
subsequent transformation and latterly the use of a commercial bacteria strain DH5ct cells 
(Gibco BRL-Life Technologies UK), which were already prepared to competence and ready 
for transformation. 
5.3.5.1 Preparation of competent JM109 
E. Coli JM109 cells were freshly streaked onto the surface of a LB agar plate (15g Bacto-
agar into 1L of LB medium [Difco USA]) using a sterile platinum wire from frozen stock. 
The plates were incubated overnight at 37°C. Well-isolated single colonies (l-2cm in 
diameter) were picked and transferred into a 50ml Falcon tube containing 10ml of LB 
medium and incubated overnight at 37°C with continuos agitation (Grant UK). 50-100~ of 
the overnight bacterial culture was added to l OOml of LB medium (1 Og bacto-tryptone, 
(Difco), 5g bacto-yeast extract, [Difco USA], lOg NaCI in l litre distilled water adjusted to 
pH 7.0) in a 1 litre flask for 2-5 hours at 37°C with shaking. The growth of the culture was 
monitored by frequent OD measurements at 600nm 
(1 OD6oo = 8 X 108 cellslml) until the OD600 had reached 0.5-0. 7 the early log phase of 
bacterial growth. The cells were then transferred to pre-chilled 50ml sterile Falcon tubes 
and cooled to 0°C by placing on ice for l 0 minutes. The cells were then centrifuged at 4000 
rpm for 10 minutes at 4°C in a Sorvall RC 3B plus rotor centrifuge (USA). The supernatant 
was discarded; the tubes were inverted for l minute to allow the last traces of media to 
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drain away. The cell pellet was then resuspended by gentle vortexing in 10-20ml ice cold 
SOmM CaCb (BDH UK) and 10mM Iris-Cl (BDH) and stored on ice for 10-20 minutes. 
The cells were recovered by further centrifugation at 4000 rpm for 10 minutes at 4°C; the 
supernatant was again discarded. The pellet was resuspended in 6ml of ice cold 0.1M CaCb 
for each SOml of original culture. The cells were immediately dispensed in 200ml aliquots 
into pre-chilled sterile l.Sml microcentrifuge, and snap-frozen in liquid nitrogen. For long 
term storage the cells were stored at -80°C until use. 
5.3.5.2 Transformation of competent cells 
Several sterile 1.5ml microcentrifuge tubes were chilled on ice and 200ml aliquot of the 
competent cells were transferred to the tubes. 1 0-20ng of plasmid DNA was dissolved in up 
to 1 OOml TE buffer pH8 and added to each of the tubes, after gentle mixing the tubes were 
placed on ice for 30 minutes. Controls that contained competent cells but no plasmid were 
also set up. The tubes were incubated at 42°C for 90 seconds (transformation) and then 
chilled on ice for 2 minutes. 800JJ.I S.O.C medium (20g bacto-tryptone, Sg bacto-yeast 
extract [Difco USA], O.Sg NaCI, 10ml250mM KCI, Smi2M MgCb, 20ml IM glucose in 1 
litre of double distilled water) was added to each tube and incubated for 60 minutes at 37°C. 
This allowed the bacteria to recover and to express the ampicillin resistance marker encoded 
by the plasmid. Agar plates (90mm Petri dishes) were prepared using YT medium (8g 
bacto-tryptone, Sg bacto-yeast extract and 2.Sg NaCI) to which bacto agar lSg/J..ll was 
added. Ampicillin (SOJ.!g/ml) was added to give 111000 volume. 4 dilutions of the 
transformed bacteria were made- SOJ.J.I, 100JJ.I, 150JJ.I and 200J..1.l all made up to 200JJ.I 
volume and each of the dilutions was added to an agar plate and spread using a bent end 
glass rod sterilised with 70% ethanol and flaming. A control plate containing no ampicillin 
was also used to detect un-transformed bacteria. The plates were then left at room 
temperature until the liquid had been absorbed; the dry plates were then inverted and 
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incubated at 3 "fc overnight. Bacterial cells without the plasmid was suppressed by the 
antibiotic ampicillin. The transfonnation efficiency can be approximated by counting the 
colonies up to 1 X 106 colonies per J,.Lg of plasmid DNA 
5.3.5.3 Amplification of plasmid DNA 
Single colonies were taken from the plates and transferred into I Oml LB medium to which 
10ml ampicillin (SOJ..Lg/ml) had been added and incubated overnight with vigorous shaking at 
3-fC. The plates were wrapped in parafilm'fM and stored in inverted position at 4°C. For 
longer-tenn storage, single bacterial colonies were picked and grown overnight in 1 Oml LB 
broth plus antibiotics, at 37°C and stored in 20% glycerol at -70°C. 
5.3.5.4 Transformation of DH5acompetent cells 
A dry ice bath was prepared and maintained at -70°C, using liquid nitrogen vapour. The 
competent cells were removed from the -70°C freezer, and thawed on wet ice. The required 
number of sterile 1. Sml microcentrifuge tubes was also placed on wet ice. The thawed cells 
were mixed gently and SOJ..Ll aliquots of the competent cells were placed into the chilled 
microcentrifuge tubes. Any unused cells were refrozen in a dry ice bath, as above, for 5 
minutes before returning them to the -70°C freezer. To determine transfonnation efficiency 
5~ (O.Sng) of control pUC19 was added to one of the tubes containing SOJ..Ll competent 
cells. The pipette was moved through the cells while dispensing. The tube was gently 
tapped to mix the contents. l-3J..Ll (1-lOng) of the DNA ligation reaction mix (plasmid 
pUC19 containing the DNA of interest in TE buffer pH8) was added directly to a tube 
containing SO~ of competent cells, the pipette was moved gently through the cells during 
dispensing. The tube was gently tapped to ensure that the contents had been mixed 
thoroughly. This procedure was repeated with different concentrations of the plasmid DNA 
A control batch of competent cells was also set up that received no plasmid DNA The cells 
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were incubated on ice for 30 minutes, followed by heat-shock for 30 seconds in a 40°C 
water bath without shaking. The tubes were then rapidly transferred onto ice for 2 minutes 
and 0.95ml of room temperature S.O.C medium was added to each of the tubes. The tubes 
were shaken at 225 rpm at 3 'fc for l hour, to allow the bacteria to recover and to express 
the antibiotic resistance marker encoded by the plasmid. After expression, O.lml of the 
reaction containing the control pUC19 was diluted into 0.9ml of S.O.C medium.lOO!J.l of 
the undiluted reaction and the 1: 1 0 dilution were spread on LB plates containing 501J.g/ml 
ampicillin using a bent-end glass rod sterilised with 70% ethanol and flaming. The reaction 
was vortexed before dilution in case the cells had settled out. After expression the 
experimental reactions were diluted as necessary- 501J.l, 1 OO!J.l, 1501J.l and 2001J.l made up to 
2001J.l and each of the dilutions was added to LB plates with 501J.g/ml ampicillin as above. 
The plates were left at room temperature until the liquid had been absorbed. The dry plates 
were then inverted and incubated at 37°C overnight. Bacterial cells without the plasmid was 
suppressed by the antibiotics. The plates were wrapped in parafilm and stored in an inverted 
position at 4°C. For longer-term storage, single bacterial colonies were picked and grown in 
1 Oml LB broth and antibiotic, at 3 7°C and stored in 20% glycerol at -70°C. 
5.3.5.5 Plasmid preparation 
Two methods were used for the preparation of plasmid DNA, the Lysis by boiling method 
and a commerical kit for plasmid extraction an Qiagen kit (Qiagen Ltd Germany). 
A) Lysis by boiling 
1.5ml of the bacterial culture was centrifuged in a microcentfifuge tube at 12,000xg for 2 
minutes at 4°C and the medium was removed to leave the pellet dry. It was then 
resuspended in 3501J.l of STET (0.1M NaCI, lOmM Tris.Cl pH 8.5, lmM EDTA pH8, 5% 
Triton X-100). 251J.l of a freshly prepared solution of lysozyme (Boehringer Mannhein 
Germany) (lOmg/ml in lOmM Tris.Cl pH8.5) was added, mixed by vortexing for 3 seconds 
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and placed in a boiling water bath for exactly 40 seconds. The bacterial lysate was 
centrifuged at 12,000xg for 10 minutes at room temperature in a microcentrifuge and the 
pellet of bacterial debris was removed from the microcentrifuge tube using a sterile 
toothpick. 401J.l of 2.5M sodium acetate (pH5.2) and 4201J.l of cold isopropanol was added 
to the supernatant and mixed by vortexing. The tube was stored for 15 minutes in dry-ice 
and the DNA pelleted by centrifugation at l3,000xg for 15 minutes at 4°C in a 
microcentrifuge. The supematant was removed by gentle aspiration and the tube was stood 
in an inverted position on a paper towel to allow all of the fluid to drain away. Any drops 
adhering to the walls of the tube were removed. l ml of 70% ethanol was added and 
recentrifuged at 13,000xg for minutes at 4°C in a microcentrifuge. All of the supematant 
was removed as before, the open tube was stored at room temperature until the ethanol had 
evaporated and no fluid was visible in the tube (2-5 minutes). The nucleic acids were 
redissolved in 501J.l of TE (pH8) containing DNAase free pancreatic RNAase (20!J.lfml) 
(Gibco Life Technologies UK) and vortexed. The DNA was stored at -20°C. 
B) Oiagen kit 
Designed for the preparation of up to 1 OO!J.g of plasmid DNA, plasmid midi protocol. 
The bacterial pellet was resuspended in 4 ml of buffer Pl/resuspension buffer (50mM Tris-
HCI pH8, 10mM EDTA, 1001J.g/ml RNase A, stored at 4°C) and added to a 20ml centrifuge 
tube before the addition of 4 ml of buffer P2/lysis buffer (200mM NaOH). The suspension 
was mixed gently, but thoroughly, by inverting the tube four to six times. The lysate should 
appear viscous. 4ml of chilled buffer P3/neutralisation buffer (3.0M potassium acetate 
pH5.5, stored at 4°C) was then added and mixed immediately, but gently, by inverting the 
tube five to six times. The tubes were stored on ice for 15 minutes (The solution appeared 
cloudy and very viscous after the addition of P3). The sample was mixed again and 
centrifuged at 4°C for 30 minutes at approx. 15,000 rpm. The supematant was removed 
promptly. If the supematant remained cloudy a second shorter centrifugation was carried 
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out at 4°C for 15 minutes at 15,000rpm. The supematant was removed promptly. A 
Qiagen-tip 100 was equilibrated with 4ml ofQBT buffer/equilibration buffer (750mM NaCl, 
SOmM MOPS pH 7.0, 15% ethanol, 0.15% Triton X-100), the column was allowed to 
empty by the flow of gravity. The flow of the buffer began automatically by the reduction in 
surface tension due to the presence of detergent in the equilibration buffer. If the flow 
stopped a syringe was placed in top of the Qiagen-tip 100 and gently pushed through. The 
supematant was applied onto the Qiagen-tip 100 and allowed to enter the resin by gravity 
flow. The supematant was loaded immediately onto the tip to prevent further precipitation 
of protein, which would cause clogging of the tip. If the flow stopped positive pressure was 
applied as before using a 10ml syringe. The Qiagen-tip 100 was washed with 2 X 10ml of 
QC buffer/wash buffer (l.OmM NaCl, 50mM MOPS pH7, 15% ethanol). The DNA was 
eluted with Sml of QF buffer/elution buffer (1.25M NaCI, SOmM Tris-HCl, pH8.5, 15% 
ethanol) and the sample was collected in a 30ml tube. The DNA was precipitated with 0.7 
volumes of isopropanol and centrifuged at 4°C for 30 minutes at 7,000rpm. The DNA was 
washed with Sml of cold 70% ethanol, air dryed for 5 minutes, and redissolved in 50J..Ll-
100J..L} ofTE or water. 
5.3.5.6 Recovery of probe DNA from plasmid 
The yield of plasmid DNA using the above procedures was approximately 100J..Lg. The 
samples of plasmid DNA were OD26orun to ascertain the exact concentration of the plasmid 
DNA 20-SOmg of plasmid DNA was digested with the appropriate restriction 
endonucleases in 1.5ml microcentrifuge tubes in a final volume of 65J..Ll. The reaction 
mixture varied depending on the probe to be extracted from the plasmid, in general it 
contained: 6.5J..L} lOX restriction enzyme buffer, 4-10J..Ll of restriction enzyme and double 
distilled water added to give the final volume. The samples were incubated for 50 minutes at 
37°C. A test digest was performed before the digest for probe preparation, 3J..Ll of the 
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plasmid DNA was used for this purpose. The samples were incubated for 50 minutes at 
3'fC, 9~ of the test digest was run out on a 1% mini agarose gel in 0.5% TBE buffer. 
5.3.5. 7 Preparation of probe in low melting point agarose (LMP) 
After the digestion for probe preparation was complete, the samples were run out on a 1% 
low melting-point agarose gel (Boehringer Mannheim UK), which was made up in IX Tris 
acetate EDT A (T AE) buffer with 31J.I of ethidium bromide. Samples were loaded with a 1 kb 
molecular weight marker (Boehringer Mannheim UK). The gel was run at SOV for 2-4 
hours depending upon the size of the fragments to be separated. The identified DNA insert 
was cut out of the gel using a sharp scalpel whilst visualized under an UV transilluminator, 
the amount of excess agarose excised was kept to a minimum. The cut gel was placed into a 
clean 0.2ml microcentrifuge tube with a hole in the bottom, made with a needle, and glass 
wool placed over the hole inside the tube. The 0.2ml tube was then placed in a clean l.Sml 
microcentrifuge tube, and centrifuged at 1 O,OOOxg for 10 minutes. The purified solution 
containing the DNA of interest was collected in the l.Sml tube below, 20% of the solution 
collected was run out on a 1% mini agarose gel to test for purity. An estimate of probe 
concentration was obtained by measuring the optical density (OD) at 260nm, assuming I 
OD unit to be equivalent to 50mg/ml. 
5.3.6 RadiolabeUing of DNA probes 
The DNA probes used were labelled with a 32P dCTP redivue (Amersham International 
3000Ci/mmol) radioactive isotope using the random primer method, for which the Klenow 
fragment ofDNA polymerase 1 was used. The Klenow enzyme, its reaction buffer, and the 
primers were part of a multi prime kit (Boehringer Mannhein Germany). The optical density 
of the extracted DNA was measured at 260nm spectrophotometrically (Cecil 5500 UK) to 
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determine the exact amount of DNA for optimum labelling. The reaction mixture was set up 
as follows: 
25ng of DNA probe plus a volume of double distilled water was added to a l.Sml 
microcentrifuge tube, the tube was then boiled for 10 minutes in a water bath, and 
subsequently cooled on ice. To this solution, in a total 301-ll reaction volume, was added 3J.L) 
ofmultiprimer solution (dATP, dGTP, dTTP prepared by making a 1+1+1 mixture of the 
individual solutions ofdNTPs) and 3!-ll of reaction buffer (Random Hexanucleotide mixture 
in 1 OX concentrated reaction buffer [MgCh]) were added, followed by 50!-LCi (Sill) of n32P 
dCTP and finally 1111 of Klenow enzyme (2 units/Ill). The labelling reaction was incubated 
at 37°C for 45 minutes. 
5.3. 7 Separation of unincorporated n 32P Particles from Labelled DNA 
Labelled DNA was separated from unincorparated nucleotides by column chromatography 
through a Sephadex G-50 column (Sambrook et al. 1989). The Sephadex G-50 (Sigma 
Chemicals UK) was prepared by slowly adding 30g Sephadex G-50 to 250ml TE buffer 
(pH7.6) in a SOOml bottle. The bottle was left to stand at room temperature overnight or 
heated to 65°C for 1-2 hours and then cooled to room temperature. The supematant was 
decanted and replaced with an equal volume of TE buffer (pH7.6) to equilibrate the resin. 
Filtration was as follows: 
The Sephadex G-50 column was prepared in a disposable glass pasteur pipette (Philip 
Harris UK) plugged with a small amount of sterile glass wool. A long sterile bio-loop was 
used to push the wool to the bottom of the glass pipette. Using a plastic pasteur pipette, the 
column was filled with a slurry of Sephadex G-50, care was taken to avoid producing air 
bubbles and to insure the Sephadex G-50 was well mixed and not separated into resin and 
TE buffer. The Sephadex G-50 was continually added until it packed to a level 1cm below 
the top of the column. At this point it was essential to irrigate the column continually to 
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avoid it drying out and then cracking. The labelled DNA sample was mixed with 180J.J.l of 
TE buffer (pH8) and loaded onto the top of the column. As soon as the DNA sample had 
entered the Sephadex G-50 a further 180J,.Ll of TE buffer was loaded onto the column, 
washing the DNA sample through the column. The sample was continually washed through 
the column with a series of 11 washes with 180J,.LI aliquots of TE buffer. The fractions 
washed through_ the column were immediately collected in 0.2ml microcentrifuge tubes, a 
total of 12 tubes were collected with a approx. 180!!1 in each. The specific activity was 
determined by liquid scintillation counting (Beckman Instruments USA), the whole of the 
collected sample was counted. Collecting the unincorparated nucleotides allows the 
labelling efficiency to be calculated Incorporation was routinely 70%, with specific 
activities of 109 /cpm/J..Lg DNA The nucleotides are smaller molecules than DNA molecules 
and therefore pass through the holes in the Sephadex G-50 beads and through the column at 
a much slower rate than the DNA molecules. This provides a profile of elution with the 
leading peak of radioactivity consisting of nucleotides incorporated into DNA and the 
trailing peak consisting of unincorporated 32P dNTP's. The radioactive fractions in the 
leading peak were pooled and stored at -20°C prior to use. 
5.3.8 Hybridisation of radiolabelled probes to immobilised nucleic acids 
Two methods were employed in the hybridisation of radiolabelled probes to immobilised 
nucleic acids. Genomic DNA immobilised onto Hybond Nylon N+ filters were hybridised 
with radiolabelled probes in a Techne hybridiser HB-ID oven (Techne UK) in revolving 
cylindrical siliconised borosilicate glass tubes, 21 cm in length and 7 cm in diameter with 
screw caps. 
A) Method I 
Before hybridisation to the radioactive probe, the filters were blocked with non-
homologous DNA to mask non-specific binding sites on the filter. This was achieved using 
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single strand salmon sperm DNA (lOmg/ml) which was denatured by boiling forS minutes 
and chilled on ice before adding to the hybridisation buffer at a final concentration of 
SOJ..1g/ml. The filters were pre-hybridised for l-4 hours (minimum of 1 hour) at 65°C in 10ml 
of hybridisation buffer; the buffer volume was kept to a minimum allowing probes that are 
highly concentrated to be employed. The hybridisation buffer contained 6X SSC (60ml), 
0.5% SDS (Sml), SX Denhardt's solution filtered through a disposable Nalgene filter (SOX 
= Sg Ficoll, Sg polyvinylpyrrolidone, 5g bovine serum albumin in SOOml double distilled 
water, stored at -20°C, Denhardt, 1996), 5% dextran sulphate (20ml) (Sigma UK) and 
'2P 10mglml denatured salmon sperm (5ml). The a' labelled probe (random primer method) 
was boiled for 5 minutes, to denature the DNA into single strand DNA and then placed 
straight on ice for 10 minutes. The probe was added a to the tube containing the filter and 
the hybridisation buffer, the amount of probe added was S-1 0 x 106 cpm per filter, 
hybridisation was carried out for 16-20 hours at 65°C, the length of time was kept to a 
minimum to reduce the amount of background. The temperature was chosen depending on 
the type ofprobe used i.e. the average content ofG + C pairs (40%) and the length ofthe 
probe in base pairs. The standard temperature for mammalian genomic probes with a 
specific activity of 109 /cpm/J..lg DNA for southern hybridisation was 65°C. 
B) Method II 
The hybridisation of radiolabelled probes using commerical Rapid-hyb buffer (Amersharn 
Life Science UK), the rapid-hyb buffer is optimised for use with radiolabelled DNA probes 
and contains chemical blocking agents. This removes the requirement for heterologus DNA 
to control non-specific binding of probes to the membrane. The buffer is optimised for use 
with Hybond Nylon N+ filters. The procedure was carried out as before in a Techne 
hybridiser HB-ID oven in revolving glass tubes. l Oml of the rapid hybridisation buffer was 
pre-warmed to 65°C, then added to the tube containing the filter and pre-hybridised with 
rotation for at least 1 S minutes. The 32P random primer labelled probe was boiled for S 
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minutes and then placed straight on ice for 10 minutes. The probe was added to the 
hybridisation tube at a concentration of 5 - 1 0 ( 106 cprn!per filter, hybridisation was carried 
out at 65°C for 2-4 hours with continuous rotation. 
5.3.9 Post hybridisation washes 
Post hybridisation washing was carried out to remove non-specifically bound probe, which 
would result in high detectable background levels. The washing conditions were chosen to 
be as stringent as possible, a combination of temperature, being approximately 12-20°C 
below the Tm of the probe and salt concentration were considered. The same washing 
procedure was employed for all the probes and for the two methods of hybridisation, which 
was as follows; 
The washing solutions of IX SSC, 0.1% SDS and 2X SSC, 0.3% SDS were pre-warmed to 
65°C, the hybridisation buffer was poured off the filters. The filters were first washed in 
approximately lOOml per tube of2X SSC, 0.3% SDS for 10 minutes at 65°C, followed by 
another 10 minute wash in 2X SSC, 0.3% SDS. The filters were then washed once in lOOml 
per tube of IX SSC, 0.1% SDS for 10 minutes at 65°C. 
5.3.10 Autoradiography 
Excess liquid was removed from the filters by blotting between two sheets of Whatman 
3MM paper, the damp filters were then wrapped in Saran WrapTM and placed in Cronex 
cassettes between Cronex lightening plus intensifying screens. In a dark room the filters 
were covered with a sheet ofX-ray film, Kodak XLSS (Scientific Imaging Systems UK) and 
the cassette firmly closed. The film was exposed at -80°C for 1-5 days. Usually after 24 
hours the film was developed using X-ray developer, indicator stop-bath solution and liquid 
fixer (Kodak Ltd UK). This confirmed the specific activity of the labelled probe, level of 
stringency of the last wash (if additional wash was required) and to predict the length of 
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total exposure to X-ray film required. If necessary a second sheet of X-ray film was placed 
in the cassette and left for up to 7 days. The polymorphic DNA bands were identified and 
sized according to the distance they travelled during electrophoresis. 
5.3.11 Stripping offdters 
To remove bound probe from the filters, the filters were soaked, with gentle agitation, in 
0.4M NaOH at 42°C for 30 minutes. Then in 0.1X SSC, 0.1% SOS, 0.2M Tris-HCL 
(pH7.5) at 42°C for 30 minutes The filters were then blotted between Whatmann 3MM 
paper and wrapped in Saran WrapTM and stored at 4°C or at room temperature until reused. 
This procedure allowed the filters to be re-used with different radiolabelled probes. 
Alternatively the filters were washed in 0.1% SDS, O.IX SSC at 65°C and allowed to cool 
to room temperature shaking gentle. The filters were then blotted between Whatmann 3MM 
paper and then washed for 10 minutes in 3X SSC with gentle agitation. Finally the filters 
were blotted and wrapped in Saran Wrapr.-.1 and stored at 4°C or room temperature until 
reuse. These procedures allowed the filters to be re-used with different radiolabelled probes. 
5.4 Microsatellite analysis 
Microsatellite analysis involves the use of specific oligonucleotide primers in the polymerase 
chain reaction (PCR) to investigate the polymorphism of the microsatellite marker. Two 
microsatellite markers were studied Pl and D6S306, both are located towards the telomeric 
end of the class I region. Alleles were detected by separation on denaturing polyacrylamide 
gels. 
5.4.1 Oligonucleotide Primer design and production 
Oligonucleotide primers were used in both sense and antisense positions. Sense primers 
were complementary to the 5'- 3' strand of DNA and antisense were complementary to the 
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3' - 5' strand of DNA. Primers were synthesised commercially using a Pharmacia Gene 
Assembler (Pharmacia Biotech UK) and latterly the primers were synthesised by MWG-
Biotech (Germany) at a scale of 0.21J.mol. All the primers were approximately 23 bases in 
length. Primers had a random base distribution and a guanosine and cytidine (G+C) ratio of 
approximately 50%. Sequences were often checked on DNAstar software (Lasergene USA) 
to avoid the possibility of forming 'primer dimers' or 'hairpin-loops', which may result in 
the formation of anomalies or artefacts. The primer sequences for the microsatellites studied 
are shown in Table 5.1. 
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Microsatellite Primer Sequence 
PI Forward 5'-TCAATCAAATCATCCCCAGAAG 
Reverse 5' -GGGTGCAACTTGTTCCTCCT 
D6S306 Forward 5'-AACAAGCCCCCAGAATTGACC 
Reverse 5' -GTTTGAGAGTTTCAGTGAGCC 
Table 5.1 Primer pairs used to amplify microsatellite polymorphisms 
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5.4.2 Amplification of DNA Fragments for MicrosateUite Analysis - Polymerase Chain 
Reaction (PCR) 
Thermostable DNA polymerase copies DNA, using a template and priming DNA molecules 
(oligonucleotide primers) complementary to sequences on either side of the sequence 
targeted for amplification i.e. the microsatellite marker sequence. The target amplification 
lengths ranged from 150-500 base pairs, and both microsatellite markers studied were (CA)n 
repeats. The primers for the P1 and D6S306 markers were used in a standard PCR reaction 
however, the specific concentrations and conditions varied for each microsatellite marker. 
All PCR reactions were performed on ice in either 0.2ml thin walled PCR tubes (Advanced 
Biotech UK) or 0.2ml thin walled strips (Anachem UK). 
The PCR reaction mixture and conditions for the PI microsatellite marker were as follows; 
the reaction mixture consisted of approximately 1 OOng of genomic DNA, I 0-20 pmoles of 
both sense and antisense primers (Pharrnacia Biotech), 4~-J.l10X PCR reaction buffer (SOmM 
Tris-HCL, pH9, l.SmM MgCb, 250mM KC!, I% Triton X-100, 0.1% [w/v] gelatin), 
2.0mM MgCh, 400mM of each dNTP (Pharmacia Biotech) and 2 units of Taq polymerase 
(HT Biotech). The final volume was made up to 40fl] with distilled water, and then 
vortexed. 30 cycles of amplification were carried out in either a Techne 40/96 well 
thermocycler (Techne UK) or a 48/48 well DNA engine (Genetic Research Instrumentation 
USA). Denaturation took place at 94°C for I minute IS seconds, annealing at 53°C for 1 
minute 15 seconds, and extension at 72°C for I minute 15 seconds. Samples were then held 
at 4°C. 
The PCR reaction mixture and conditions for the D6S306 microsatellite marker were as 
follows; the reaction mixture consisted of 1 OOng of genomic DNA, 15-20 pmoles of both 
sense and antisense primers, 2fl] !OX PCR reaction buffer, 4.0mM MgCh, 200mM of each 
dNTP and 1 unit of Taq polymerase. The final volume was made up to 20f..ll with distilled 
water, and then vortexed. 3 5 cycles of amplification were carried out in a Techne 40/96 well 
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thermocycler or the 48/48 well DNA Engine. Denaturation took place at 94°C for 1 minute 
30 seconds, annealing at 48°C for 2 minutes and extension at 72°C for 2 minutes. Samples 
were then held at 4°C. See Table 5.2 for conditions that were employed to optimise the 
PCR reactions. 
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Specific Conditions to Optimise DNA Amplification 
Use of Hot Start 
Use Touchdown PCR 
Optimise pH 
~ Taq DNA polymerase 
~ Cycle segment lengths 
~ Number of cycles 
. t Annealing temperature 
~ Inhibitors 
tRamp speed 
t Chance that the target temperature is achieved in each tube 
~ Primer concentration 
~ Primer degeneracy 
t Template denaturation efficiency 
Optimise primer design 
Table 5.2 Conditions Favouring Enhanced Specificity of PCR 
(adapted from 'PCR Primer' 1995) 
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The microsatellites studied were analysed by radiolabelling the 5' "flanking" primer with 
'(21' dATP in the PCR. The PCR reactions described previously were carried out to allow the 
optimisation of the reaction. In some cases the reaction was carried with both 'hot' and 
'cold' primers. For the microsatellites Pl and D6S306 the 'cold' 5' "flanking" primer was 
replaced by radiolabelled primer, there was no 'cold' primer used in the reaction. On 
average the amount of radiolabelled primer added was equal to 250,000cpm of radioactivity 
per reaction. In the PCR reaction for Pl lJ.Ll of labelled primer (5pmoles) was used, the 
amount of distilled water added was adjusted to give a final volume of 40J.Ll as the original 
reaction. The D6S306 PCR reaction 21J.l of labelled primer was added (15pmoles); the final 
reaction volume was adjusted with distilled water. 
5.4.3 5' End LabeUing of Oligonucleotide Primers 
Two methods were employed for the radiolabelling of oligonucleotides during this study, 
both were 5' end labelling systems, "Ready-To-Go" T4 Polyucleotide Kinase (Pharmacia 
Biotech Sweden) and DNA 5' End-Labelling System using ClAP (Promega USA). 
A) Method I 
In the "Ready-To-Go" T4 Polynucleotide Kinase reaction each individual reaction tube 
contained when reconstituted in a final volume of 50J.L] a solution containing 8-10 units of 
"FPLC pure" T4 polynucleotide Kinase, 50mM Tris-HCL (pH7.6), lOmM MgCh, 5mM 
DTT, O.lmM spermidine, O.lmM EDTA (pH8), 0.2J.LM ATP and stabilisers. 25J.Ll of 
distilled water was added to the tube that contained the "Ready-To-Go" T4 PNK 
(Polynucleotide Kinase), the tube was then incubated at room temperature for 2-5 minutes. 
The contents ofthe tube were then mixed by gently pipetting up and down. 5-10 pmoles of 
the desired oligonucleotide primer was added as well as a sufficient volume of distilled 
water to bring the total reaction volume to 48J.LI. 2J.LI of y 321' dATP (3,000Cilmmo~ 
(lO!J.Ci/J.L]) was added and mixed gently. The sample was centrifuged briefly at 13,000 rpm 
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for 30 seconds to collect the contents at the bottom of the tube, and then incubated for 30-
45 minutes in a water bath at 37°C. The reaction was terminated either by the addition of 
Sj.J.l of 250mM EDT A or by placing on ice. The sample was then precipitated to remove 
unincorporated nucleotides using 21-11 of Quick Precip ™ (Advanced Biotech Corps USA) a 
biologically inert product that is used as a carrier for the rapid precipitation of DNA and 
oligomers > 16 bases. To the sample 0.1 volumes of SM NaCl and 2-3 volumes of -20°C 
100% ethanol was added. The sample was briefly vortexed and then centrifuged for 2-3 
minutes at 13,000 rpm in a benchtop microfuge (Hereus Septech Germany) at room 
temperature. After centrifugation the sample was vortexed vigorously and centrifuged again 
for another 30 seconds. The supernatant was decanted and the tube was rinsed with 70% 
ethanol. The precipitated DNA was resuspended in SO!ll of distilled water (Baxter) and the 
side of the tube was rinsed with the water to ensure complete recovery, the tube was then 
vortexed. At this stage a l!ll aliquot of the sample was removed and dispensed into a O.Sml 
thin walled tube (Anachem) to determine percentage incorporation of the 12P molecules 
using liquid scintillation. The formula for calculation was: -
cpm x 2 x 50 = cpm in total SO!ll volume 
total cpm I 250,000cpm =number of samples with 250,000cpm 
SO!ll I number of samples with 250,000cpm = volume in Ill required to give concentration 
of250,000cpm per reaction 
B) Method II 
The second method was the 5' End-Labelling System, included in the kit was a 
dephosphorylation reaction to remove the 5' phosphate from the DNA oligonucleotide to 
be labelled, which can subsequently be end labelled with a radioactive phosphate. The kit 
contained: IOOunits T4 Polynucleotide Kinase (PNK), 0.5ml T4 PNK IOX buffer, 100u Calf 
Intestinal Alkaline Phosphatase (ClAP), 0. 5ml 1 OX ClAP Buffer, 500ng oligonucleotide 
(31mer) and 10f.lg "pGEM" DNA markers. 
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i) Dephosphorylation Reaction 
This reaction removed the phosphate groups from both 5' termini of the linear molecule. 
The reaction was carried out in a l.5ml microcentrifuge tube. 5~1 of IOX ClAP buffer were 
added to 1j.Ll of5'-ends ofthe oligonucleotide (label up to 10pmol of5' ends), 0.1u of 
ClAP (diluted in IX ClAP buffer) diluted lin 10 therefore 1~1 was added and finally 43j.Ll 
of distilled water to make the final reaction volume up to 50~1. The tube was incubated in a 
3'fC water bath for 30 minutes. After 30 minutes another 0.1 units (I~!) of ClAP was 
added and incubated for another 30 minutes at 37°C. The reaction was stopped using 1 
volume of rE-saturated phenol : chloroform : isoamly alcohol [25:24:1] (I part of TE 
saturated phenol (Sigma) with 1 part chloroform : amyl alcohol [24: 1]). The reaction was 
vortexed for I minute and then centrifuged at 12,000 rpm for 2 minutes. The aqueous phase 
was removed to a fresh I.5ml tube and the previous step was repeated. The upper aqueous 
phase was then transferred to a fresh 1.5ml tube and 1 volume of chloroform : isoamyl 
alcohol added [24:1] (24 parts of chloroform [Rathburns Scotland UK] were mixed with 1 
part of amyl alcohol[Sigma]). The reaction was vortexed for 1 minute and then 
microcentrifuged at 12,000 rpm for 2 minutes. The upper aqueous phase was transferred to 
a fresh 1. 5ml tube, and 5M NaCI was added to a final concentration of 0 .2M. 2 volumes of 
-20°C 100% ethanol were added and mixed by vortexing The tube was snap frozen in 
liquid nitrogen and stored at -70°C for 30 minutes. After incubation the sample was 
centrifuged at 13,000 rpm for 5 minutes, the supernatant discarded and the pellet dried 
under vacuum. The DNA was resuspended in 29~1 of distilled water and then vortexed. 
ii) Phosphorylation Reaction 
5j.Ll of T4 PNK 10X buffer were added to the 29~1 of DNA, prepared from the 
dephosphorylation reaction, 15 ~I of i 2P dATP (3, OOOCi/mmol, 1 OmCi/ml), and 1 !J.l of T 4 
Polynucleotide Kinase (8-1 Ou/~1), the final reaction volume being 50~-tl. The reaction was 
incubated in a 3'tC water bath for 10 minutes. The reaction was terminated after 10 
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minutes by adding 2J,LI of 0.5M EDT A, or by placing on ice. The sample was then purified 
to separate the end labelled DNA from the unincorporated nucleotides. This was achieved 
by running the sample down a Sephadex G-50 column, as described previously (section 
4.3. 7). The specific activity was determined by liquid scintillation counting (Beckman), the 
whole ofthe collected sample was counted (180J..Ll). The labelled DNA was precipitated out 
from the 180J..Ll of TE buffer (pH8) used in the Sephadex G-50 column, into a smaller 
volume of distilled water. This was achieved using l-2J..LI of Quick Precip™, 0.1 volume of 
5M NaCl and 2-3 volumes of -20°C 1 00% ethanol. The sample was briefly vortexed and 
then centrifuged for 2-3 minutes at 13,000 rpm in a bench top centrifuge at room 
temperature. After centrifugation the sample was vonexed vigorously and spun again for 
another 30 seconds. The supematant was decanted and the tube was rinsed with 70% 
ethanol. The precipitated DNA was resuspended in 50J..LI of distilled water, the side of the 
tube rinsed to ensure complete recovery, the tube was then vortexed. The specific activity 
of the sample was then determined as before, using liquid scintillation counting (Beckman) 
of a IJ,LI sample, and the amount of labelled primer to be added per reaction was 
determined. 
5.4.4 Polyacrylamide Gel Electrophoresis 
All PCR reactions were checked by running 10-15J..LI aliquot of the sample and l-1.5J,LI of 
loading buffer on a I% horizontal agarose gel for 1 hour at 150-200 volts. The gel was 
visualised under UV light, and a photograph was taken. If the PCR was successful the PCR 
products were electrophoresed on a venical denaturing polyacrylamide gel. A biorad 
Sequigen GT 30x50cm electrophoresis system was used with a 49 well vinyl sharkstooth 
comb with a 0.4mm spacer set. Before use, all aspects of the rig were washed in warm 
soapy water, glass plates, spacers and comb and clamp binders. After a thorough rinse in 
water, plates were dried and washed in 70% IMS solution (Rathbums). The inner surface of 
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the plates were siliconised with a thin layer of Repelcote (BDH UK) (2% solution of 
Dimethydichlorosilane in Octamethycyclotetra-siloxane), this was to allow the gel to be 
removed from the plates after running. The plates were allowed to dry and then a small 
amount of petroleum jelly ran down each edge of the base plate to grip the vinyl spacers. 
The top plate was then placed on top and sandwiched together using two arm clamps. The 
assembled plate unit was then stood in a casting gel tray and laid in a horizontal position. 
The denaturing polyacrylamide gel was prepared The gel was prepared using a series of 
solutions (National Diagnostics US), Ultra Pure Sequagel Sequencing ready made 
concentrate, diluent and buffer. 30-35mls of concentrate (237.5g acrylamide, 12.5g 
methylene bisacrylamide and SOOg urea), !Smls of buffer (50% 8.3M urea in IM Iris-
Borate, 20mM EDTA buffer pH 8.3), 99mls of diluent (SOOg 8.3M urea), and 12mls of 
10% formamide (Sigma Chemicals) were added into a 250ml conical flask. SO!J] TEMED 
(Sigma chemicals) and 1000J..LI of 10% Ammonium Persulphate (Sigma chemicals) were 
used to polymerise the gel. The plate assembly was filled with the gel solution using a 
ZOOm! syringe connected to a delivery tube (part of the gel system). When the 
polyacrylamide reached the top, the vinyl sharkstooth comb was inserted between the plates 
in an inverted position. The gel was allowed to polymerise for approximately 30-45 minutes 
at room temperature. When the gel was set, the casting tray was removed and the gel unit 
placed in the base or lower buffer chamber of the gel system. This contained 1X TBE 
buffer, the buffer chamber at the back of the base plate was also filled with 1 X TBE buffer 
to the top of the plate in the reservoir at the top of the system. Ideally the gel was made the 
day before running to allow the system to equilibrate. The system was connected to a power 
pack (Biorad PC3000) and pre-warmed at 1,800V for 30 minutes or until the temperature 
indicator read 40°C. The gel was then disconnected from the power supply and the comb 
reinserted to generate the 49 wells. 6!J.l of the amplified DNA was mixed with 3J..Ll of 10X 
Stop solution (Gibco BRL). The stop solution contained formamide and was based on a 
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standard sequencing gel-loading buffer (98% deionized formarnide, 10mM EDTA [pH8], 
0.025% xylene cyanol FF, 0.025% bromophenol blue) The samples were loaded into the 
wells using a 10111 Drummond sequencing pipette (Drummond Laboratories USA). 
Electrophoresis was carried out for 3-4 hours at 1,500-1,800V, or until the marker dye had 
migrated to the desired distance, which varied depending on the size of the microsatellite 
fragment being studied. The gel was removed from the plate and fixed using a solution of 
10% methanoVacetic acid, transferred onto 3l\1M filter paper (Heto Laboratory Equipment 
UK) and dried on a vacuum/heated gel drying system (Heto) at 80°C for approximately 1-2 
hours. 
The gel was then autoradiographed, in a Cronex cassette between Cronex lightening plus 
intensifying screens. In a dark room the gel was covered with a sheet of X-ray film, Kodak 
XLS5 (Scientific lmaging Systems lJK) and the cassette firmly closed. The film was 
exposed at -80°C for 8-24 hours. The film was developed using X-ray developer, Indicator 
stop-bath solution and liquid fixer (Kodak Ltd). 
5.5 PCR-Sequence-specific oligonucleotide probing (PCR-SSOP) 
This method was employed to type the polymorphisms of the class lb HLA-E gene by using 
exon 2 of the gene sequence. PCR-SSOP involves the hybridisation of sequence-specific 
oligonucleotide probes to an amplified fragment of the gene locus. Bound probe was 
detected by a non-radioactive system that detects 5 ' -digoxygenin labelled probe. 
5.5.1 Amplification of DNA (HLA-E exon 2) 
PCR to amplify the second exon of the HLA-E gene was carried out as described in section 
4.4.2 using the primers: 
Forward 
Reverse 
5 '-GAAACGGCCTCT ACCGGGAGT AG 
5 '-GTTCCGCAGCCTTGGGGTGAA TC 
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The reaction mixture consisted of 100ng of genomic DNA, 10-20 pmoles of both sense and 
antisense primers, 3 ~ 1 Ox PCR reaction buffer, 2 SmM MgCb, 400mM of each dNTP and 1 
unit of Taq polymerase made up to a final volume of 35111 with distilled water. 30 cycles of 
amplification were canied out with the following conditions: denaturation at 95°C for 1 
minute 30 seconds, annealing at 52/53°C for 1 minute 30 seconds and extension at 72°C for 
1 minute 30 seconds. 
5.5.2 Southern Blotting 
The PCR products were checked by running a S11l aliquot on a 1% horizontal mini agarose 
gel for 30-60 minutes at 150-200 volts. If the PCR had been successful the remaining PCR 
product was run out on a 1% agarose gel for approximately 30-40 minutes. Following 
electrophoresis the DNA was transferred from the gel to Hybond-N+ nucleic acid transfer 
membrane using the capillary transfer method. This was carried out as described in section 
5.3.4. The membranes were stored at 4°C. 
5.5.3 Oligonucleotide probes 
A series of six probes were employed that had been defined in a previous study (Arnaiz-
Villena et al. 1997). The combination of probes detected all four HLA-E exon 2 alleles. The 
sequences and specificity of the oligonucleotide probes are given in Table 5.3. The probes 
were purchased from the usual commercial supplier (MWG Biotech Germany) labelled at 
the 5'-end with digoxygenin (DIG) 
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Probe Probe Sequence Allele Specificities Wash 'f'l 
E2011 5'-GGCTCCCACTCCTTG *0101,0102,0103 54°C 
E2012 5'-GGCTCTCACTCCTTG *0104 52°C 
E202l 5'-CGAGTGAACCTGCGG *0101,0102,0104 54°C 
E2022 5'-CGAGTGAA TCTGCGG *0103 54°C 
E2031 5'-CTGCGCGGCT ACT AC *0101,0103,0104 54°C 
E2032 5'-CTGCGGCGCTACT AC *0102 54°C 
Table 5.3 Oligonucleotide probes used for PCR-SSOP typing of exon 2 of the 
HLA-E gene. 
Nucleotide differences in the probe for the four alleles at each polymorphism are 
shown in bold text. 
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5.5.4 Pre-hybridisation and hybridisation 
This was perfonned in a HB-ID oven in borosilicate glass roller tubes. The membranes 
were pre-hybridised at 42°C for I hour in 20mls of hybridisation solution per 100cm2 of 
membrane (Sx SSC, I% Blocking agent, I% N-Lauroylsarcosine, 0.02% SDS). The 20mls 
of hybridisation buffer was poured off and a further 6mls of the hybridisation buffer and 5-
1 Opmol m1"1 of the DIG-labelled probe per I 00cm2 of membrane were added for 1 hour at 
42°C. 
5.5.6 Post hybridisation washing 
The initial washing was perfonned in the hybridisation oven in the roller tubes. 3.2 M Tetra-
methyl-ammonium chloride (TMAC) solution *3.2M TMAC, 0.02M EDTA, 0.1% SDS and 
O.OSM Tris-HCl pH8) was used for the washing. TMAC is used as it is a reagent that binds 
AT-rich DNA polymers and abolishes the preferential melting of AT vs GC base pairs. The 
hybridisation of the probes was therefore a function of probe length. The washing protocol 
was as follows: 
Sx SSC at 42°C for 10 minutes, then 5x SSC at specific probe temperature (see Table 3) for 
10 minutes, then 3.2M TMAC solution at specific probe temperature for 20 minutes. The 
filters were then transferred to plastic boxes and washed twice at room temperature for 10 
minutes. 
5.5. 7 Detection of bound probe 
A commercial DIG luminescent detection system was used (Boehringer Mannheim GmbH 
Gennany). The manufacturers protocol was followed with slight modifications: 
Buffers: 
Buffer 1: O.ISM NaCI, O.IM Maleic acid ph7. 5 
Blocking reagent: 10% w/v Marvel TM skimmed milk in buffer 1 
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Buffer 2: Blocking reagent I : I 0 in buffer 1 
Buffer 3: O.IM Tris-HCI (pH9.5), O.IM NaCI 
Wash Buffer: 0.3% Tween 20@ in Buffer I 
The filters in the plastic boxes were washed briefly in Wash buffer and then blocked for 30 
minutes in Buffer 2. The filters were then transferred to the tubes in the hybridisation oven, 
the filters were incubated at room temperature in 1 Omls per 1 00cm2 of anti-DIG antibody 
solution (I: I 0, 000 in Buffer 2). Excess antibody was washed off with Wash buffer x2 for I5 
minutes. The filters were then equilibrated in Buffer 3 for 5 minutes and then 2ml per 
100cm2 of a l:IOO solution (in Buffer 3) of the chemoluminescence substrate, CSPD®. 
Filters were then briefly blotted on 3MM Whatman paper (DNA side up) and then wrapped 
in Saran Wrap™. The filters were incubated at 37°C for I5 minutes prior to exposure 
against Kodak: XLS5 X-ray film in a Cronex cassette between Cronex lightening plus 
intensifying screens for 2 hours. The films were then developed using X-ray developer, 
Indicator stop-bath and liquid fixer. 
5.5.8 Stripping of filters 
The filters were firstly rinsed briefly in distilled water, followed by tow I5 minute washes at 
37°C in 0.2M NaOH, SDS 0.1% to remove the DIG-labelled probe, and then a thorough 
wash in 2x SSC. This procedure allowed the filters to be re-used with different DIG-labelled 
probes. 
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5.6 Subjects 
5.6.1 Type 1 diabetic patients 
Three hundred and seventy eight unrelated British Caucasoid patients with type I diabetes 
as defined by the National Diabetes Group who had attended the diabetic clinic at King's 
College Hospital, London and Derriford Hospital, Plymouth (Dr B.A. Millward) were 
studied. Local ethical committee approval had been obtained. At presentation the ages 
ranged from 1 to 51 (mean value = 15.2 +/- 9.97). The duration of diabetes in the patients 
ranged from less than I to more than 71 years (mean= 20.9 +/- 16.1). Although age is a 
continuous variable, the patients studied were divided into three groups depending on the 
age at onset of type I diabetes. There are definite peaks of incidence of type I diabetes 
shown to exist at different ages, which are determined as follows: 
< I 0 years pre puberty at onset of the disease 
I 0-20 years time of puberty at onset of disease 
> 20 years post puberty at onset of the disease 
5.6.2 Multiplex families 
One hundred multiplex families were used in this study. The families were obtained from 
the BDA Warren Repository UK and the classification of the families was: there are at 
least two children with type I diabetes, at least one child was diagnosed as type I diabetic 
before the age of seventeen and both parents are alive. The HLA status and age at onset of 
the diabetic siblings was also known. 
5.6.3 Controls 
Two hundred and sixteen normal controls were unselected normal British Caucasoid 
residing in southern England. None of the control subjects had a personal or family history 
of type 1 diabetes or other autoimmune disease. 
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Patient 
Subgroup 
AD Patients 
< 10 years 
10-20 years 
> 20 years 
Controls 
Male : Female Age at onset of diabetes 
(years) 
177: 201 15.2 +/- 9.97 
(0- 51) 
57: 77 5.6 +/- 2.5 
(I - 9) 
71: 77 14.0 +/- 3.0 
(10- 20) 
49:47 29.0 +/- 6.7 
(21- 51) 
73: 93 
Duration of diabetes 
(years) 
20.9 +/- 16.1 
(1-71) 
20.3 +/- 15.9 
(2- 71) 
21.1+/-15.9 
(2- 71) 
24.4 +/- 16.5 
(1 - 66) 
Table 5.4 Clinical Characterisation of Patient Subgroups and Normal Controls 
The results are expressed as mean values +/- standard deviation together with the range in 
brackets. All patients had type I diabetes as defined by the National Diabetes Data Group. 
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5. 7 Analysis of data 
All the data collected was entered into a computerised spreadsheet (Microsoft® Excel 7.0). 
This allowed statistical analysis to be performed within the same application or from 
imported applications into the Excel® programme. 
5.7.1 Genotype and allele frequencies 
Genotype frequencies were determined as the percentage of subjects positive for each 
genotype. Allele frequencies were expressed as decimals and calculated from the number of 
copies of an allele divided by the total number of chromosomes tested in the population. 
Homozygotes were counted as two copies. The frequency of alleles and genotypes in the 
patient subgroups and the normal controls were compared using the x2 test and 2 X 2 
contingency tables. This was performed on the Statcalc program of the computer software 
package Epi Injo 6 (World Health Organisation, Geneva, Switzerland). The p values were 
corrected for the number of comparisons made (Pc) using the Bonferroni inequality method 
[Tiwari et al. 1985]. Pc values of< 0. 05 were considered to be significant. 
5. 7.2 Linkage analysis 
Linkage disequilibrium occurs when alleles at two loci combine more frequently than could 
be expected by random association. Expected frequency of an allelic association between 
two loci was calculated by multiplying the frequency of one of the alleles with the other. 
Expected and observed frequencies were compared using the x2 statistic [(0-E/ I E]. 
Linkage was considered to occur if the associated p value was< 0.05. 
5.7.3 Transmission Disequilibrium Test (TDT) 
The TDT [Spielman et al. 1993] was used in the analysis of the family data. The test 
evaluates the frequency with which a suspected susceptibility allele is transmitted from the 
parents to the affected offspring. TDT assesses deviation from 50% transmission. The 
association of an allele is determined by the use of the x 2 test and 2 X 2 contingency tables. 
A Pc value of< 0.05 was considered to be significant. 
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CHAPTER6: 
6.1 Introduction 
ASSOCIATIONS OF THE MHC CLASS I REGION WITH 
TYPE I DIABETES 
Presented in the following chapter is the data from each of the class I genetic markers used 
in this study; P3A, 28L, 66R, P3B, PI and D6S306. Initial analysis was of the allelic and 
genotype frequencies of the individual markers in both the patient and control subjects with 
respect to age at onset and gender. The data was then combined for haplotype analysis and 
linkage studies and also the study of combined genotype frequencies in both patient and 
control, subjects with respect to age at onset and gender. Finally the class I patient data was 
analysed with respect to class II diabetic patient data with respect to the age at onset of the 
disease. 
Not all the patients and control subjects (Table 5.4.) were analysed with all of the class I 
genetic markers and the different numbers of patient and control subjects in each of the 
analyses reflects this. The number of patient subjects also varied in the analysis with respect 
to age at onset and gender due to the fact that this information was not available for certain 
patient subjects used in the study. 
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CENTROMERIC TELOMERIC 
B c X E A F 
r r r r i i 
P3A 28L 66R P3B P1 D6S306 
H FIGURE 6.1 Map ofthe class I region ofthe human MHC 
100 kb This map shows the position and transcriptional orientation of the I-ll-A antigens and the positions of the probes used in this study. 
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6.2_Microsatellite marker P1 
The microsatellite marker P1 was among a number of new anonymous polymorphic 
markers identified in the class I region by the construction of a meiotic map localising 
cross-overs, by the use of families in which recombinant meiotic event(s) are known to have 
occurred. The marker was named P1 for the purpose of this study and is a (CAAA)n repeat 
developed by Drs Pontarotti and Crouau-Roy CNRS-CRPG Hospital, Purpan, Toulouse, 
France. P1 maps approximately 400kb telomeric ofP3B. 
6.2.1 Associations of the P1 microsatellite marker with type 1 diabetes. 
There were 7 alleles (numbered 1-7) at the P1 locus (Fig. 6.2) and 25 of the possible 28 
were detected. Out of the total patient population studied (Table 5.4.) 261 patients with type 
1 diabetes and 100 normal controls were analysed at the P 1 locus. All of the data obtained 
from the patient subgroups and control subjects analysed at the P 1 locus is presented in the 
following tables. Possible associations with P1 were investigated along with the effects of 
gender and age at onset on the association with type 1 diabetes. 
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Fig 6.2 Allelic polymorphism of the Pl microsatellite 
This is an example of an autoradiograph using the microsatellite marker Pl showing 
the 7 Pl alleles detected. 
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4 
2 
PI Patients Controls 
Genotype % % 
I 4.9 (13) 5 (5) 
I,2 5.3 (14) I (1) 
1,3 l.I (3) 6 (6) 
I,4 3.8 (10) 3 (3) 
I,5 3.4 (9) I (1) 
I,6 0.7 (2) 2 (2) 
I,7 0.3 (1) 0 (0) 
2 3.0 (8) 3 (3) 
2,3 2.3 (6) 3 (3) 
2,4 5.7 (15) 2 (2) 
2,5 1.9 (5) I (1) 
2,6 0.3 (1) I (1) 
3 3.8 (10) 7 (7) 
3,4 I2.0 (32) IO (10) 
3,5 6.9 (18) 4 (4) 
3,6 0.7 (2) 4 (4) 
4 7.6 (20) 2 (2) 
4,5 7.2 (19) 8 (8) 
4,6 2.6 (7) 6 (6) 
5 6.I (16) 4 (4) 
5,6 I0.7 (28) I7 (17) 
5,7 0. 7 (2) 0 (0) 
6 6.5 (17) 7 (7) 
6,7 o. 7 (2) I (1) 
7 0.3 (1) 2 (2) 
Total (n) 26I IOO 
Table 6.2.A Frequency of MHC Class I PI genotypes in patients and controls 
The table shows the actual number and frequency of patients and controls with 25 of the 
possible genotypes of the microsatellite marker Pl. Genotypes that were not present in either 
the patient or control subjects are not shown. n represents the number of patients and controls 
studied. The number in brackets represents the actual number of subjects with a particular 
genotype. Comparisons were made between the patient and control populations for each 
genotype using the x2 test and 2 X 2 contingency tables. No significant differences were found 
between the patient and control subjects. 
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The comparison of Pl genotype frequencies between patient and control subjects in table 
6.2.A. showed a significant decrease in the frequency of the 1,3 genotype in patients 
compared to controls 1.2% vs 6% (p = 0.008). However, when the p value was corrected for 
the number of comparisons made it was found to be non-significant. The 3,6 genotype was 
decreased in the patients compared to the controls 0.8% vs 4% (p = 0.03), this was non-
significant when corrected for the number of comparisons made. There were no other 
significant differences in the PI genotypes between the patients and controls. Due to the 
large number of possible genotypes for the marker PI the numbers analysed for each 
genotype was relatively small. 
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P1 
Genotype 
1 
1,2 
1,3 
1,4 
1,5 
1,6 
1,7 
2 
2,3 
2,4 
2,5 
2,6 
3 
3,4 
3,5 
3,6 
4 
4,5 
4,6 
5 
5,6 
5,7 
6 
6,7 
7 
Total (n) 
< 10 
0/o 
2.0 (2) 
6.1 (6) 
1.0 (1) 
6.1 (6) 
1.0 (1) 
1.0 (1) 
0 (0) 
4.0 (4) 
3.0 (3) 
5.1 (5) 
2.0 (2) 
1.0 (1) 
3.0 (3) 
10.2 (10) 
11.2 (11) 
0 (0) 
9.1 (9) 
7.1 (7) 
2.0 (2) 
7.1 (7) 
9.1 (9) 
0 (0) 
6.1 (6) 
1.0 (1) 
1.0 (1) 
98 
Age at onset of 
diabetes (years) 
10-20 
% 
7.4 (6) 
3.7 (3) 
0 (0) 
4.0 (4) 
3.0 (3) 
0 (0) 
0 (0) 
2.0 (2) 
2.0 (2) 
7.1 (7) 
2.0 (2) 
0 (0) 
4.0 (4) 
8.1 (8) 
4.0 (4) 
1.2 (1) 
7.4 (6) 
4.0 ( 4) 
3.0 (3) 
4.0 (4) 
12.2 (12) 
1.2 (1) 
4.0 ( 4) 
1.2 (1) 
0 (0) 
81 
>20 
% 
6.6 (5) 
6.6 (5) 
2.6 (2) 
0 (0) 
5.3 (4) 
1.3 (1) 
1.3 (1) 
2.6 (2) 
1.3 (1) 
2.6 (2) 
1.3 (1) 
0 (0) 
4 (3) 
16 (12) 
4 (3) 
0 (0) 
6.6 (5) 
9.3 (7) 
2.6 (2) 
6.6 (5) 
9.3 (7) 
1.3 (1) 
8 (6) 
0 (0) 
0 (0) 
75 
Controls 
% 
5 (5) 
1 (1) 
6 (6) 
3 (3) 
1 (1) 
2 (2) 
0 (0) 
3 (3) 
3 (3) 
2 (2) 
1 (1) 
1 (1) 
7 (7) 
10 (10) 
4 (4) 
4 (4) 
2 (2) 
8 (8) 
6 (6) 
4 (4) 
17 (17) 
0 (0) 
7 (7) 
1 (1) 
2 (2) 
100 
Table 6.2.B Frequency ofMHC Class I P1 genotypes with respect to age at onset of 
diabetes 
This table shows the distribution ofP1 genotypes in patients separated by age at onset into 
< 10, 10 - 20 and > 20 years of age. The actual number and frequency is shown for each 
genotype. n represents the number of subjects in each age at onset group. The number in 
brackets represents the actual number of subjects with a particular genotype. Comparisons 
were made between each age at onset group and the controls and also between the different 
age at onset groups for each genotype using the x? test and 2 X 2 contingency tables. No 
significant differences were found between the patient subgroups or the normal controls. 
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The effect of age at onset and the relationship with PI genotypes was examined by 
separating the patient population into 3 groups depending on the age at onset of type I 
diabetes, < lO years, IO - 20 years and > 20 years table 6.2.B. Comparisons were made 
between the patient subgroups and also the normal controls. There was a small but 
significant difference in the frequency of the I, 1 genotype between the > 20 years compared 
to the controls 6.6% vs I% (p = 0.04), but this became non-significant after correction for 
the p-value. The I ,3 genotype was absent in patients that were diagnosed between the age of 
I0-20 years of age but was present in 6% of normal controls (p = 0.02), but this became 
non-significant after correction of the p-value. The same trend was found with the 3/6 
genotype, which had previously been shown to have a reduced frequency in the patients 
compared to the controls (Table 6.2.A). The genotype frequency was either reduced or 
absent in each of the age at onset groups when compared to the controls, but the difference 
was only significant in the <IO years of age compared to the controls 0% vs 4% (p = 0.04). 
The corrected p value was non-significant. The reduced frequencies of the 1,3 and 3,6 
genotypes in the patient subgroups was accompanied by an increase of the 2, 4 genotype in 
patients with an age at onset between I0-20 years compared to controls 7.I% vs 2% (p = 
0.04). Again when the p-value was corrected, it became non-significant. The increase in the 
4,4 genotype frequency previously shown in the patients compared to controls occurred 
across the 3 age at onset subgroups, but a significant difference when uncorrected was only 
present in the <I 0 years group (p = 0.04). There were no other significant differences 
between any of the patient subgroups or the normal controls. 
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P1 
Genotype Patients Controls 
Males Females Males Females 
% % % % 
1 3.5 (4) 6.0 (9) 2.2 (I) 9.0 (4) 
1,2 5.3 (6) 5.4 (8) 0 (0) 2.2 (I) 
1,3 1.7 (2) 0.6 (1) 6.8 (3) 6.8 (3) 
1,4 1.7 (2) 5.4 (8) 2.2 (I) 4.5 (2) 
1,5 0.8 (I) 5.4 (8) 2.2 (I) 0 (0) 
1,6 0.8 (I) 0.6 (I) 2.2 (I) 2.2 (I) 
1,7 0.8 (I) 0 (0) 0 (0) 0 (0) 
2 1. 7 (2) 4.0 (6) 2.2 (I) 2.2 (I) 
2,3 1. 7 (2) 2.7 (4) 4.5 (2) 0 (0) 
2,4 3.5 (4) 7.4 (11) 2.2 (I) 0 (0) 
2,5 3.5 (4) 0.6 (I) 0 (0) 0 (0) 
2,6 0 (0) 0.6 (I) 0 (0) 2.2 (I) 
3 4.4 (5) 2.0 (3) 9.0 (4) 2.2 (I) 
3,4 12.3 (14) 12.1 (I8) 15.9 (7) 4.5 (2) 
3,5 7.0 (8) 6.7 (IO) 2.2 (I) 6.8 (3) 
3,6 0.8 (I) 0.6 (I) 2.2 (I) 4.5 (2) 
4 9.7 (I I) 6.0 (9) 0 (0) 2.2 (I) 
4,5 11.5 (13) 4.0 (6) 13.6 (6) 4.5 (2) 
4,6 2.6 (3) 2.7 (4) 4.5 (2) 6.8 (3) 
5 7.0 (8) 5.4 (8) 2.2 (I) 6.82 (3) 
5,6 11.5 (13) 10.1 (I5) 20.4 (9) 13.6 (6) 
5,7 0.8 (I) 0.6 (I) 0 (0) 0 (0) 
6 5.3 (6) 7.4 (II) 2.2 (I) 13.6 (6) 
6,7 0.8 (I) 0.6 (I) 0 (0) 2.2 (I) 
7 0 (0) 0.6 (I) 2.2 (I) 2.2 (I) 
Total (n) 113 148 44 44 
Table 6.2.C Frequency of MHC Class I P1 genotypes in patient and control subjects 
with respect to gender 
This table shows the distribution of PI genotypes in patient and control subjects separated by 
gender. The actual number and frequency is shown for each genotype in both gender groups in 
patients and controls. The number in brackets is the actual number of subjects for a particular 
genotype. n represents the number of subjects in each gender group. Comparisons were made 
between the male patients with the female patients for each genotype and also the male and 
female patients and male and female controls for each genotype, using x2 test and 
2 X 2 contingency tables. No significant differences were found between the gender groups in 
patients or normal controls. 
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Differences in gender were investigated in both patient and control populations with respect 
to PI genotypes table 6.2.C. When the control population was divided by gender there were 
an equal number of males to females and the range of PI genotype frequencies was similar 
for both genders. Comparisons between patient and controls showed a reduced frequency of 
the I,3 genotype in female patients compared to the female controls 0.6% vs 6.8% (p = 
O.OI, Pc = ns). The 4,4 PI genotype was increased in both male and female patients 
compared to controls, although this difference was not significant after correction (p = 0.03, 
Pc = ns). Comparisons between male and female patients showed a small but significant 
increase in the frequency of the 4,5 genotype in the male patients compared to the female 
patients I1.5% vs 4.0%, the increase was non-sigilificant after correction (p = 0.02, Pc = 
ns). This was accompanied by a subsequent but less significant decrease in the frequency of 
the I,5 genotype in male patients compared to female patients 0.8% vs 5.4I% (p = 0.04, Pc 
= ns). There were no other significant differences between any of the patient subgroups or 
the normal controls. 
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P1 Age at onset of diabetes Controls 
Genotype (years) 0/o 
< 10 10-20 > 20 
0/o o;o % 
Males Females Males Females Males Females Males Females 
1 2. 7 (I) 1.64(1) 5.2 (2) 9.3 (4) 2. 7 (I) 10.5 (4) 2.2 (I) 9.0 (4) 
1,2 5.4 (2) 6.5 (4) 5.2 (2) 2.3 (I) 5.4 (2) 7.8 (3) 0 (0) 2.2 (I) 
1,3 0 (0) 1.6 (I) 0 (0) 0 (0) 5.4 (2) 0 (0) 6.8 (3) 6.8 (3) 
1,4 2.7 (I) 8.2 (5) 2.6 (I) 6.9 (3) 0 (0) 0 (0) 2.2 (I) 4.5 (2) 
1,5 0 (0) 1.6 (I) 0 (0) 6.9 (3) 2. 7 (I) 7.8 (3) 2.2 (I) 0 (0) 
1,6 2.7 (1) 0 (0) 0 (0) 0 (0) 0 (0) 2.6 (1) 2.2 (I) 2.2 (I) 
1,7 0 (0) 0 (0) 0 (0) 0 (0) 2.7 (I) 0 (0) 0 (0) 0 (0) 
2 0 (0) 6.5 (4) 2.6 (I) 2.3 (I) 2. 7 (I) 2.6 (1) 2.2 (I) 2.2 (1) 
2,3 2.7 (1) 3.2 (2) 2.6 (I) 2.3 (1) 0 (0) 2.6 (I) 4.5 (2) 0 (0) 
2,4 5.4 (2) 4.9 (3) 5.2 (2) 11.6 (5) 0 (0) 5.2 (2) 2.2 (1) 0 (0) 
2,5 2.7 (I) 1.6 (1) 5.2 (2) 0 (0) 2. 7 (I) 0 (0) 0 (0) 0 (0) 
2,6 0 (0) 1.6 (I) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2.2 (I) 
3 0 (0) 4.9 (3) 7.8 (3) 2.3 (I) 5.4 (2) 2.6 (I) 9.0 (4) 2.2 (I) 
3,4 10.8 (4) 9.8 (6) 10.5 (4) 9.3 (4) 13.5 (5) 18.4 (7) 15.9 (7) 4.5 (2) 
3,5 8.1 (3) 13.1 (8) 7.8 (3) 2.3 (I) 5.4 (2) 2.6 (1) 2.2 (1) 6.8 (3) 
3,6 0 (0) 0 (0) 2.6 (I) 0 (0) 0 (0) 0 (0) 2.2 (1) 4.5 (2) 
4 10.8 ( 4) 8.2 (5) 10.5(4) 4.6 (2) 8.1 (3) 5.2 (2) 0 (0) 2.2 (I) 
4,5 13.5 (5) 3.2 (2) 5.2 (2) 4.6 (2) 16.2 (6) 2.6 (1) 13.6 (6) 4.5 (2) 
4,6 2.7 (I) 1.64 (1) 2.6 (I) 4.6 (4) 2. 7 (I) 2.6 (I) 4.5 (2) 6.8 (3) 
5 8.1 (3) 6.5 (4) 5.2 (2) 4.6 (2) 8.1 (3) 5.2 (2) 2.2 (I) 6.8 (3) 
5,6 10.8 (4) 8.2 (5) 13.1 (5) 16.2 (7) 10.8 (4) 7.8 (3) 20.4 (9) 13.6 (6) 
5,7 0 (0) 0 (0) 2.6 (1) 0 (0) 0 (0) 2.6 (1) 0 (0) 0 (0) 
6 10.1 (4) 3.2 (2) 0 (0) 9.3 (4) 5.4 (2) 10.5 (4) 2.2 (I) 13.6 (6) 
6,7 0 (0) 1.6 (I) 2.6 (1) 0 (0) 0 (0) 0 (0) 0 (0) 2.2 (I) 
7 0 (0) 1.6 (1) 0 (0) 0 (0) 0 (0) 0 (0) 2.2 (1) 2.2 (1) 
Total (n) 37 61 38 43 37 38 44 44 
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Table 6.2.D Frequency of MHC Class I Pl genotypes with respect to gender and age 
at onset of diabetes 
This table shows the distribution of PI genotypes in the patient subjects according to 
gender and age at onset and by gender in the control subjects. The actual number and 
frequency is shown for all genotypes, the actual number of subjects is shown in brackets. 
The n value represents the number of subjects in each subgroup. Comparisons were made 
using the x2 test and 2 X 2 contingency tables between; 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found from any of the comparisons between patients or 
normal controls 
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The effect of gender and the age at onset was analysed for Pl genotypes in relation to type 1 
diabetes table 6.2.D. Although there were minor differences in the frequency of the PI 
genotypes with age at onset and gender none of them were significant after correction ofthe 
p-value. 
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P1 Patients Controls 
Alleles 0/o 0/o 
1 12.4 11.5 
(65) (23) 
2 10.9 7.0 
(57) (14) 
3 15.5 20.5 
(81) (41) 
4 23.5 16.5 
(123) (33) 
5 21.6 19.5 
(113) (39) 
6 14.5 22.5 
(76) (45) 
7 1.3 2.5 
(7) (5) 
Total (n) 522 200 
Table 6.2.E. Frequency of MHC Class I P1 alleles in patients and controls 
This table shows the frequency of patients and controls with the 7 alleles of the microsatellite 
marker PI. n value represents the number of alleles for both patient and control subjects. The 
number in brackets is the actual number of alleles present (half of this number being the 
number of actual subjects with a particular allele). Comparisons were made between the 
patient and control subjects using the r! test and 2 x 2 contingency tables. No significant 
differences were found between the patient and control subjects. 
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When comparing the allelic frequencies between patients and normal controls table 6.2.E, 
the frequency of allele 4 was increased in the patients (23. 5%) compared to the controls 
(16.5%) (p = 0.03, Pc= ns), the difference was non-significant when corrected. There was 
a subsequent decrease in the frequency of allele 6 in the patients (14.5%) compared to the 
controls (22. 5%) (p = 0. 01, Pc = ns ), as well as a decrease in the frequency of allele 3 in the 
patients (15.5 %) compared to controls (20.5%) this difference was not significant. There 
were no other significant differences between the patients and normal controls. 
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PI Age at onset of Controls 
Alleles diabetes (years) % 
< IO I0-20 > 20 
% % % 
I 9.6 I3.5 I4.3 11.5 
(19) (22) (23) (23) 
2 I2.7 Il.I 8.6 7.0 
(25) (18) (13) (14) 
3 I5.8 I4.2 I6 20.5 
(31) (23) (24) (41) 
4 24.4 23.4 22 I6.5 
(48) (38) (33) (33) 
5 22.4 20.9 22 I9.5 
(44) (34) (33) (39) 
6 I3.2 I5.4 I4.6 22.5 
(26) (25) (22) (45) 
7 1.53 1.2 1.3 2.5 
(3) (2) (2) (5) 
Total (n) I96 I62 I 50 200 
Table 6.2.F Frequency of MHC Class I PI alleles with respect to age at onset of 
diabetes 
This table shows the frequency ofP1 alleles in patients separated by age at onset into 
< I 0, I 0 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of alleles present (half of this number 
being the number of subjects with a particular allele). Comparisons were made between each 
age at onset group and the controls and between the different age at onset groups for each 
allele using the ·l test and 2 X 2 contingency tables. No significant differences were found 
between any of the patient subgroups or the normal controls. 
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The effect of age at onset of diabetes and the association of P 1 alleles table 6. 2. F showed 
allele 4 was present at an increased frequency in all of the patient subgroups (24.4%, 23 .4%, 
22%) compared to the controls (16.5%). The frequency is shown to be significantly 
increased in the patients in the <10 years group compared to the controls (p = 0.04), 
however this was non-significant when corrected. The difference was non-significant for the 
other age at onset groups. This was accompanied by a significant decrease in the frequency 
of allele 6 in patients diagnosed <10 years (13.2%) compared to the controls (22.5%) (p = 
0.01), the difference was non-significant when corrected. The frequency was also decreased 
in the other age at onset groups compared to the controls but this was non-significant. Allele 
3 was detected at a higher frequency in the controls (20.5%) compared to the patients in 
each ofthe age at onset subgroups (15.8%, 14.2%, 16%), but the observed differences were 
not significant. There were no other significant differences or patterns of association 
between the patient subgroups or the controls. 
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P1 
Alleles 
1 
2 
3 
4 
5 
6 
7 
Total (n) 
Males 
o;o 
9.2 
(21) 
8.8 
(20) 
16.3 
(37) 
25.6 
(58) 
24.7 
(56) 
13.7 
(31) 
1.3 
(3) 
226 
Patients 
Females 
% 
14.8 
(44) 
13.1 
(39) 
13.5 
(40) 
21.9 
(65) 
19.2 
(57) 
15.2 
(45) 
2.0 
(6) 
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Controls 
Males Females 
o;o % 
9.0 17.0 
(8) (15) 
5.6 4.5 
(5) (4) 
25 13.6 
(22) (12) 
19.3 12.5 
(17) (11) 
21.5 19.3 
(19) (17) 
17.0 29.5 
(IS) (26) 
2.2 3.4 
(2) (3) 
88 88 
Table 6.2.G Frequency of MHC Class I P1 alleles in patients and controls with respect 
to gender 
This table shows the frequency of PI alleles in patient and control subjects separated by 
gender. n represents the number of alleles for each gender group. The number in brackets is 
the actual number of alleles present (half of this number being the number of subjects with a 
particular allele). Comparisons were made between the male patients with the female patients 
for each allele and also the male and female patients and male and female controls for each 
allele, using the x.2 test and 2 X 2 contingency tables. No significant differences were found 
between the patient subgroups or the normal controls. 
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When comparisons ofPl alleles were made in relation to gender table 6.2.G, the frequency 
of allele 6 was significantly increased in the female controls (29.5%) compared to the 
female patients (15.2%) (p = 0.002, Pc= 0.03). This is also seen in the male controls 
(17.0%) compared to the male patients (13. 7%) but this is not significant. Allele 2 was 
increased in the female patients (13.1%) compared to the female controls (4.5%) (p = 0.02, 
Pc = ns) the allele was also increased in the male patients (8.8%) compared to the male 
controls (5.6%) but this was not significant. There were no significant differences in allelic 
frequency between male and female patients or the normal controls. 
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P1 
Alleles 
1 
2 
3 
4 
5 
6 
7 
Total(n) 
Males 
8.1 
(6) 
8.1 
(6) 
10.8 
(8) 
28.3 
(2I) 
25.6 
(19) 
18.9 
(14) 
0 
(0) 
74 
< 10 
o/o 
Females 
10.6 
(13) 
15.5 
(19) 
18.8 
(23} 
22.1 
(27) 
20.4 
(2S) 
9.81 
(12} 
2.4 
(3} 
122 
Age at onset of diabetes 
(years) 
10-20 > 20 
0/o o/o 
Males Females Males Females 
9.2 17.4 10.8 19.7 
(7) (IS) (8) (IS) 
ll.8 10.4 6.7 10.5 
(9) (9) (S) (8) 
19.7 9.3 17.5 14.4 
(IS) (8) (13) (II) 
23.6 23.2 24.3 19.7 
(18) (20) (18) (IS) 
22.3 19.7 27.0 17.1 
(17) (I7) (20) (13) 
10.5 19.7 12.1 17.1 
(8) (I7) (9} (13) 
2.6 0 1.3 1.3 
(2) (0) (I) (I) 
76 86 74 76 
Table 6.2.H Frequency of MHC Class I PI alleles with respect to gender and age at onset of diabetes 
Males 
9.0 
(8) 
5.6 
(S} 
25 
(22) 
19.3 
(I7) 
21.5 
(I9) 
17.0 
(IS) 
2.2 
(2) 
88 
Controls 
o;o 
Females 
17.0 
(IS) 
4.5 
(4) 
13.6 
(I2) 
12.5 
(11) 
19.3 
(I7) 
29.5 
(26) 
3.4 
(3} 
88 
This table shows the frequency of PI alleles in the patient subjects according to gender and age at onset and by gender in the control subjects. The 
n value represents the number of alleles in each subgroup. The number in brackets is the actual number of alleles present (half of this number 
being the number of subjects with a particular allele). Comparisons were made using the x2 test and 2 X 2 contingency tables between; 
a) male patient and female age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
1 =Female< 10 years vs Female control x2 = 13.4, p = 0.0002 (ldf), Pc= 0.009 
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When the data was analysed for the effects of gender and age at onset of type 1 diabetes 
table 6.2.H, there was a highly significant decrease in the frequency of allele 6 in female 
patients with an age at onset of< 10 years (9.8%) compared to the female controls (29.5%) 
(p = 0.0002, Pc= 0.009). Although there were other minor differences in the frequency of 
the PI alleles with age at onset and gender none of them were significant after correction of 
the p-value. 
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6.3 Microsatellite marker D6S306 
The microsatellite marker D6S306 is a relatively new polymorphic marker localised 
to the class I region. The marker was the use families in which known meiotic events have 
occurred between the genes HLA-A and HLA-B, allowing the construction of a specific 
meiotic map [Bouissou et al. 1995]. D6S306 is a (CA)n repeat and maps approximately 
200-300kb telomeric ofHLA-A. 
6.3.1 Associations of the D6S306 microsatellite marker with type 1 diabetes 
There are 7 alleles at the D6S306 locus (Fig. 6.3), which give rise to a possible 28 
genotypes. Out of the total patient population studied (Table 5:4) 122 patients with type 1 
diabetes were analysed with the microsatellite D6S306 and 44 normal controls. A published 
control population was also used to provide a comparison for the controls in this study. All 
of the data obtained from the patient subgroups and control subjects analysed with D6S306 
is presented in the following tables. Possible associations with the D6S306 genotypes and 
alleles were investigated along with the effects of gender and age at onset on the association 
with type 1 diabetes. 
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Fig 6.3 Allelic polymorphism of the D6S306 microsatellite 
This is an example of an autoradiograph using the microsatellite marker D6S306 
showing the 7 D6S306 alleles detected. 
Note: Allele 7 appears only weakly on the autoradiograph 
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D6S306 Patients Controls 
Genoty(!e % % 
1 1.6(2) 0 (0) 
1,2 5. 7 (7) 0 (0) 
1,3 3.2 (4) 0 (0) 
1,6 0 (0) 2.2 (1) 
1,7 0.8 (1) 0 (0) 
2 9.8 (12) 0 (0) 
2,3 4.9 (6) 9.0 (4) 
2,4 8.2 (10) 2.2 (1) 
2,5 0.8 (1) 0 (0) 
3 10.6 (13) 20.4 (9) 
3,4 3.2 (4) 6.8 (3) 
3,5 27.8 (34) 18.1 (8) 
3,6 0.8 (1) 6.8 (3) 
3,7 0.8 (1) 0 (0) 
4 4.1 (5) 2.2 (1) 
4,5 0.8 (1) 0 (0) 
4,6 01 (0) 9.0 (4) 
4,7 0 (0) 4.5 (2) 
5 1.62 (2) 13.6 (6) 
5,6 6.5 (8) 0 (0) 
5,7 0 (0) 2.2 (1) 
6 2.4 (3) 0 (0) 
6,7 4.9 (6) 2.2 (1) 
7 0.8 (1) 0 (0) 
Total (n) 122 44 
Table 6.3.A Frequency ofMBC Class I D6S306 genotypes in patients and controls 
This table shows the frequency and actual number of patients and controls with 24 of the 
possible genotypes of the microsatellite marker D6S306. Genotypes that were not present 
in either the patient or control subjects are not shown. n represents the number of patients 
and controls studied. The number in parenthesis represents the actual number of subjects 
with a particular genotype. Comparisons were made between the patient and control 
subjects for each genotype using the·/ test and 2 X 2 contingency tables. 
1 =patient vs control x! = 11.5, p = 0.0007 (ldf), Pc= 0.01 
2 =patient vs control·/= 10.2, p = 0.001 (1df), Pc= 0.02 
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A comparison of genotype frequencies between the patient population and control subjects 
showed that 24 out of the total 28 genotypes were present in either or both populations table 
6.3.A. The 1,4, 1,5, 2,6 and 2,7 genotypes were not found in either patients or controls. The 
4,6 genotype was absent in the patients (0.0%) compared to the controls (9.0%) (p = 0.0007, 
Pc = 0.01). There was also a significant decrease in the frequency of the 5,5 genotype in 
patients (1.6%) compared to the controls (13.6%) (p = 0.001, Pc= 0.02). There were also 
minor differences in the 3,3 and 3,5 genotypes between the patient and controls but these 
were found to be non-significant when the p-value was corrected. 
291 
D6S306 Age at onset of Controls 
Genotype diabetes (years) % 
< 10 10-20 >20 
% 0/o 0/o 
1 0 (0) 2.5 (1) 3.3 (!) 0 (0) 
1,2 8 (4) 5.1 (2) 3.3 (1) 0 (0) 
1,3 4 (2) 5.1 (2) 0 (0) 0 (0) 
1,6 0 (0) 0 (0) 0 (0) 2.2 (1) 
1,7 0 (0) 0 (0) 3.3 (1) 0 (0) 
2 8 (4) 12.8 (5) 10 (3) 0 (0) 
2,3 8 (4) 5.1 (2) 0 (0) 9.0 (4) 
2,4 10 (5) 2.5 (1) 10 (3) 2.2 (1) 
2;5 2 (1) 0 (0) 0 (0) 0 (0) 
3 14 (7) 15.3 (6) 0 (0) 20.4 (9) 
3,4 2 (1) 2.5 (1) 6.6 (2) 6.8 (3) 
3,5 24 (12) 30.7 (12) 30 (9) 18.1 (8) 
3,6 2 (1) 0 (0) 0 (0) 6.8 (3) 
3,7 0 (0) 0 (0) 3.3 (!) 0(0) 
4 2 (1) 5.1 (2) 6.6 (2) 2.2 (1) 
4,5 2 (1) 0 (0) 0 (0) 0 (0) 
4,6 0 (0) 0 (0) 0 (0) 9.0 (4) 
4,7 0 (0) 0 (0) 0 (0) 4.5 (2) 
5 2 (1) 0 (0) 3.3 (1) 13.6 (6) 
5,6 4 (2) 7.6 (3) 10 (3) 0 (0) 
5,7 0 (0) 0 (0) 0 (0) 2.2 (1) 
6 2 (1) 2.5 (1) 3.3 (1) 0 (0) 
6,7 4 (2) 2.5 (1) 6.6 (2) 2.2 (I) 
7 2 (1) 0 (0) 0 (0) 0 (0) 
Total (n) 50 39 30 44 
Table 6.3.B Frequency of MHC Class I D6S306 genotypes with respect to age at 
onset of diabetes 
This table shows the distribution ofD6S306 genotypes in patients separated by age at onset 
into < I 0, 10 - 20 and > 20 years of age. For each genotype the actual number of subjects 
and frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using ·i test and 2 X 2 contingency tables. 
No significant differences were found between any of the patient subgroups or the normal 
controls. 
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The effect of age at onset and the relationship with D6S306 genotypes was examined by 
separating the patient population into 3 groups depending on the age at onset of type 1 
diabetes < 10years, 10-20 years and > 20 years (table 6.3.B). Comparisons were made 
between the patient subgroups as well as the normal controls. There was a significant 
increase in the frequency of the 2,2 genotype in patients diagnosed between the age of 
10-20 years (12.8%) compared to the controls (0.0%) (p = 0.01), the difference was found 
not to be significant when corrected. The 5,5 genotype is absent from patients diagnosed 
between the ages of 10-20 years (0.0%) compared to the controls (13.6%) (p = 0.01), the 
difference was non-significant when the p-value corrected. There were no other significant 
differences between any of the patient subgroups or the normal controls. 
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D6S306 
Genotype 
1 
1,2 
1,3 
1,6 
1,7 
2 
2,3 
2,4 
2,5 
3 
3,4 
3,5 
3,6 
3,7 
4 
4,5 
4,6 
4,7 
5 
5,6 
5,7 
6 
6,7 
7 
Total (n) 
Males 
1.7 (I) 
8.9 (5) 
3.5 (2) 
0 (0) 
0 (0) 
7.1 (4) 
8.9 (5) 
10.7 (6) 
0 (0) 
8.9 (5) 
1.7 (I) 
26.7 (I5) 
1.7 (I) 
0 (0) 
3.5 (2) 
0 (0) 
0 (0) 
0 (0) 
1.7(I) 
7.1 (4) 
0 (0) 
3.5 (2) 
3.5 (2) 
0 (0) 
56 
Patients 
% 
Females 
1.5 (I) 
3.0 (2) 
3.0 (2) 
0 (0) 
1.5 (I) 
10.6 (7) 
3.0 (2) 
6.0 (40 
1.5 (I) 
12.1 (8) 
4.5 (3) 
28.7 (I9) 
0 (0) 
1.5 (I) 
4.5 (3) 
1.5 (I) 
0 (0) 
0 (0) 
1.5 (I) 
6.0 (4) 
0 (0) 
1.5 (I) 
6.0 (4) 
1.5 (I) 
66 
Controls 
0/o 
Males Females 
0 (0) 0 (0) 
0 (0) 0 (0) 
0 (O) 0 (0) 
0 (0) 4. 7 (I) 
0 (0) 0 (0) 
0 (0) 0 (0) 
4.5 (I) 14.2 (3) 
0 (0) 4. 7 (I) 
0 (0) 0 (0) 
18.1 (4) 19.0 (4) 
9.0 (2) 4.7 (I) 
18.1 (4) 19.0 (4) 
13.6 (3) 0 (0) 
0 (0) 0 (0) 
4.5 (I) 0 (0) 
0 (0) 0 (0) 
9.0 (2) 9.5 (2) 
4.5 (I) 4. 7 (I) 
13.6 (3) 14.2 (3) 
0 (0) 0 (0) 
4.5 (I) 0 (0) 
0 (0) 0 (0) 
0 (0) 4.7 (I) 
0 (0) 0 (0) 
22 21 
Table 6.3.C Frequency of MHC Class I D6S306 genotypes in patients and controls 
with respect to gender 
This table shows the distribution of D6S306 genotypes in patient and control subjects 
separated by gender. For each genotype the actual number of subjects and the frequency is 
given. n represents the number of subjects in each gender group. Comparisons were made 
for each genotype between the male patients with the female patients and also the male and 
female patients and male and female controls using the x2 test and 2 X 2 contingency 
tables. No significant differences were found between any of the patient subgroups or the 
normal controls. 
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Differences in gender were investigated in both patient and control populations with respect 
to D6S306 genotypes table 6.3.C. When the control population was separated according to 
gender the frequency of the D6S306 genotypes were almost identical between the groups. 
There was an increase in the frequency of the 3,5 genotype in male and female patients 
(26.7%, 28.7%) compared to the respective controls (18.1%, 19.091'/o), when analysed the 
difference was shown not to be significant. There were no other significant differences 
found between any of the patient subgroups or the normal controls. 
295 
D6S306 Age at onset of diabetes Controls 
Genotype (years) 0/o 
< 10 10-20 >20 
% % % 
Males Females Males Females Males Females Males Females 
1 15.7 (3) 3.3 (I) 4.3 (I) 5.8 (I) 7.6 (I) 0 (0) 0 (0) 0 (0) 
1,2 0 (0) 6.6 (2) 8.7 (2) 5.8 (I) 7.6 (I) 0 (0) 0 (0) 0 (0) 
1,6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4.7 (I) 
1,7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5.8 (I) 0 (0) 0 (0) 
2 0 (0) 13.3 (4) 13.0 (3) 5.8 (I) 7.6 (I) 11.7 (2) 0(0) 0 (0) 
2,3 10.5 (2) 6.6 (2) 13.0 (3) 0 (0) 0 (0) 0 (0) 4.5 (I) 14.2 (3) 
2,4 15.7 (3) 6.6 (2) 0 (0) 5.8 (I) 15.3 (2) 5.8 (I) 0 (0) 4.7 (I) 
2,5 0 (0) 3.3 (I) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
3 15.7 (3) 13.3 (4) 8.7 (2) 23.5 (4) 0 (0) 0 (0) 18.1 (4) 19.0 (4) 
3,4 5.2 (I) 0 (0) 0 (0) 5.8 (I) 0 (0) 11.7 (2) 9.0 (2) 4.7 (I) 
3,5 21.0 (4) 26.6 (8) 34.7 (8) 23.5 (4) 23.0 (3) 35.2 (6) 18.1 (4) 19.0 (4) 
3,6 5.2 (I) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 13.6 (3) 0 (0) 
3,7 0 (0) 3.3 (I) 0 (0) 0 (0) 0 (0) 5.8 (1) 0 (0) 0 (0) 
4 0 (0) 3.3 (I) 4.3 (I) 5.8 (I) 7.6 (I) 5.8 (I) 4.5 (I) 0 (0) 
4,6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9.0 (2) 9.5 (2) 
4,7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4.5 (1) 4.7 (I) 
5 5.2 (I) 0 (0) 0 (0) 0 (0) 0 (0) 5.8 (I) 13.6 (3) 14.2 (3) 
5,6 5.2 (I) 3.3 (I) 4.3 (I) 11.7 (2) 15.3 (2) 5.8 (I) 0 (0) 0 (0) 
5,7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4.5 (I) 0 (0) 
6 0 (0) 3.3 (I) 4.3 (I) 0 (0) 7.6 (I) 0 (0) 0 (0) 0 (0) 
6,7 0 (0) 3.3 (I) 4.3 (I) 5.8 (1) 7.6 ( 1) 5.8 (1) 0 (0) 4. 7 (1) 
7 0 (0) 3.3 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total (n) 19 30 23 17 13 17 22 21 
Table 6.3.D Frequency of MHC Class I D6S306 genotypes with respect to gender and age at onset of diabetes 
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This table shows the distribution ofD6S306 genotypes in the patient subjects according to 
gender and age at onset and by gender in the control subjects. The actual number of 
subjects and the frequency is shown for all genotypes. Then value represents the number 
of subjects in each subgroup. Comparisons were made using the x} test and 2 X 2 
contingency tables between; 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found between any of the patient subgroups or the normal 
controls. 
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It was difficult to assess the effect of gender and age at onset at the D6S306 locus, due to 
the small numbers in each category table 6.3.D. After analysis between the patient 
subgroups and normal controls it was found that the 5,5 genotype was absent in female 
patients diagnosed before the age of 10 years (0.0%) compared to the female controls 
(14.2%) (p = 0.03) the difference was found not to be significant when corrected. There 
were no other significant differences found. 
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D6S306 
Alleles 
1 
2 
3 
4 
5 
6 
7 
Total (n) 
Patients 
0/o 
6.5 
(16) 
19.6 
(48) 
31.1 
(76) 
10.2 
(25) 
19.6 
(48) 
8.6 
(21) 
4.1 
(10) 
244 
Controls 
% 
1.1 
(I) 
5.6 
(5) 
40.9 
(36) 
13.6 
(12) 
23.8 
(21) 
10.2 
(9) 
4.5 
(4) 
88 
Table 6.3.E Frequency of MHC Class I D6S306 alleles in patients and controls 
This table shows the frequency of patients and controls with the 7 alleles of the 
microsatellite marker D6S306. n represents the number of alleles for both patient and 
control subjects. The number in brackets is the actual number of each allele present. 
Comparisons were made between the patient and control subjects using the -/ test and 2 X 
2 contingency tables. No significant differences were found between the patients and the 
controls. 
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When comparing the allelic frequencies between the patients and controls table 6.3.E there 
was a significant increase of allele 2 in the patients compared to the control frequency 
(p = 0.002, Pc = 0.02). Allele I is also increased in the patients compared to controls but 
was non-significant after correction of the p-value (p = 0.04, Pc= ns). In contrast, the other 
D6S306 alleles with the exception of allele 7 are all decreased in frequency compared to the 
controls. 
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068306 Age at onset Controls 
Alleles of diabetes 0/o 
(years) 
< 10 10-20 >20 
0/o 0/o 0/o 
1 6 7.6 6.6 1.1 
(6) (6) (4) (1) 
2 22 19.2 16.6 5.6 
(22) (15) {I 0) (5) 
3 34 37.1 20 40.9 
(34) (29) ( 12) (36) 
4 9 7.6 15 13.6 
(9) (6) (9) (12) 
5 18 19.2 23.3 23.8 
( 18) (15) (14) (21) 
6 7 7.6 11.6 10.2 
(7) (6) (7) (9) 
7 4 1.2 6.6 4.5 
(4) {I) (4) (4) 
Total (n) 100 78 60 88 
Table 6.3.F Frequency of MHC Class I 068306 alleles with respect to age at onset 
of diabetes 
This table shows the frequency of D6S306 alleles in patients separated by age at onset into 
< I 0, I 0 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the x} test and 2 X 2 contingency tables. No 
significant differences were found between the any of the patient subgroups or the controls. 
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When the D6S306 alleles were analysed with respect to age at onset of type 1 diabetes table 
6.3.F, there was a significant increase in the frequency of allele 2 in patients in the < 10 
years age at onset group (22%) compared to the controls (5.6%) (p = 0.001, Pc= 0.02). This 
was also seen in the 10-20 years age at onset group (19.2%) compared to the controls 
(5.6%) but the difference was non-significant when corrected. (p = 0.007, Pc= ns)., but less 
so in those diagnosed after the age of 20 (16.6%) compared to the controls (5.6%) (p = 
0.02), which was not significant when corrected. There were no other significant differences 
between the patient subgroups and the controls. There was also an increase in the frequency 
of allele 3 in patients in the I 0-20 years age at onset group (37.1 %) compared to patients 
diagnosed after 20 years (20%), but the increase was non-significant when corrected (p = 
0.02, Pc= ns). This was the only significant difference found between the patient subgroups 
for any of the D6S306 alleles. 
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D6S306 Patients Controls 
Alleles 0/o 0/o 
Males Females Males Females 
1 8.0 5.3 0 2.3 
(9) (7) (0) (I) 
2 21.41 17.4 2.2 9.5 
(24) (23) (I) (4) 
3 30.3 32.5 40.9 38.1 
(30) (43) (18) ( 16) 
4 9.8 10.6 15.9 11.9 
( 11) (14) (7) (5) 
5 18.7 20.4 25 23.8 
(21) (27) ( 11) (10) 
6 9.8 7.5 11.3 9.5 
( 11) (IO) (5) (4) 
7 1.7 6.0 4.5 4.7 
(2) (8) (2) (2) 
Total (n) 108 132 44 42 
Table 6.3.G Frequency of MHC Class I D6S306 alleles in patients and controls with 
respect to gender 
This table shows the frequency of D6S306 alleles in patient and control subjects separated 
by gender. o represents the number of alleles for each gender group. The number in 
brackets is the actual number of each allele present. Comparisons were made between the 
male patients with the female patients and also the male and female patients and male and 
female controls for each allele, using the ·l test 2 X 2 contingency tables. 
1 =male patient vs male control x2 = 9.05, p = 0.002 (Idt), Pc= 0.03 
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Comparisons ofD6S306 alleles were made in relation to gender table 6.3.0. The frequency 
of allele I was increased in the male patients (8.0%) compared to the male controls were 
the allele was absent (0.0%) (p = 0.004), the p value was non-significant when corrected. 
The frequency of allele 2 was significantly increased in the male patients (21.4%) when 
compared to the male controls (2.2%) (p = 0.002, Pc = 0.03). There were no other 
significant differences between any of the patient subgroups or the normal controls. 
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D6S306 Age at onset of diabetes Controls 
Alleles (years) o;o 
< 10 10-20 > 20 
% 0/o % 
Males Females Males Females Males Females Males Females 
1 7.8 5 6.5 8.8 11.5 2.9 0 2.3 
(3) (3) (3) (3) (3) (1) (0) (1) 
2 21.0 23.3 21.7 11.7 19.2 14.7 2.2 9.5 
(8) (14) (10) (4) (5) (5) (1) (4) 
3 36.8 33.3 36.9 38.2 11.5 26.4 40.9 38.1 
(14) (20) (17) (13) (3) (9) (18) (16) 
4 10.5 8.3 4.3 11.7 15.3 14.7 15.9 11.9 
(4) (5) (2) (4) (4) (5) (7) (5) 
5 18.4 18.3 19.5 17.6 19.2 26.4 25 23.8 
(7) (11) (9) (6) (5) (9) (11) (10) 
6 5.2 6.6 8.7 8.8 19.2 5.8 11.3 9.5 
(2) (4) (4) (3) (5) (2) (5) (4) 
7 0 5 2.1 2.9 3.8 8.8 4.5 4.7 
(0) (3) (1) (1) (1) (3) (2) (2) 
Total (n) 38 60 46 34 26 34 44 42 
Table 6.3.8 Frequency of MHC Class I D6S306 alleles with respect to gender and age at onset of diabetes 
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This table shows the distribution of D6S306 alleles in the patient subjects according to 
gender and age at onset and by gender in the control subjects. The n value represents the 
number of alleles in each subgroup. The number in brackets is the actual number of each 
allele present, the number in bold is the frequency. Comparisons were made using the x2 
test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found between any of the patient subgroups or the normal 
controls. 
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The effect of gender and the age at onset was analysed for D6S306 allelic frequencies in 
relation to type 1 diabetes table 6.3.H. Although there were minor differences in the 
frequency of the D6S306 alleles with age at onset and gender none of them were significant 
after correction of the p-value. 
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6.4 Genomic probe 28L 
The genomic probe 28L is a 1.3kb Pst-I/Eco-RI fragment derived from the yeast artificial 
chromosome Y AC28 (Geraghty et al unpublished). The approximate position of the 28L 
locus is between lll.,A-B and lll.,A-E 100kb centromeric to HLA-X. The 28L probe is 
derived from non-coding DNA, and produces a single pattern on Southern blots, which is 
consistent with a single copy gene status (Geraghty unpublished results). 
6.4.1 Associations of the genomic probe 28L with type 1 diabetes 
Using the restriction endonuclease Hind m 3 allelic fragments of 4.3, 3.8 and 3.6kb were 
detected (Fig. 6.4), with six possible genotypes. Out of the total patient population studied 
(Table 5:4) 271 were analysed at the probe 28L locus and 110 normal controls out of the 
total control population. The data from the patient subgroups and control subjects is 
presented in the following tables. Possible associations with alleles and genotypes of 28L 
were investigated along with the effects of gender and age at onset on the association with 
type 1 diabetes. 
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1 2 3 4 
Fig 6.4 Allelic polymorphism of the 28L locus 
5 
3.6 
3.8 
4.3 
Hind Ill digested genomic DNAs from five patient samples probed with 28L. The sizes of 
the polymorphic restriction fragments are indicated. 
Lane 1: 4.3 I 3.6 
Lane 2: 4.3 I 4.3 
Lane 3: 3.8 I 3.6 
Lane 4: 4.3 I 4.3 
Lane 5: 3.8 I 3.6 
310 
28L Patients Controls 
Genotypes % 0/o 
4.3,3.8 32.8 35.5 
(89) (39) 
4.3,3.6 14.0 10.0 
(38) (11) 
3.8,3.6 17.7 10.0 
(48) (11) 
4.3 18.0 27.3 
(49) (30) 
3.8 11.0 14.5 
(30) (16) 
3.6 6.2 2.7 
(17) (3) 
Total (n) 271 110 
Table 6.4.A Frequency of MHC Class I 28L Genotypes in patients and controls 
This table shows the frequency and the actual number of patients and controls with the 6 
possible genotypes of the genomic marker 28L. n represents the number of patients and 
controls studied. The number in brackets represents the actual number of subjects with a 
particular genotype. Comparisons were made between the patient and control subjects for 
each genotype using the x2 test and 2 X 2 contingency tables. No significant difference 
were found between the patient subjects and the control subjects. 
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Comparisons of genotype frequencies between patient and control subjects (table 6.4.A) 
showed that there was a small decrease in the frequency of the 4.3,4.3 genotype in the 
patients (18.0%) compared to the controls (27.3%) (p = 0.04), but when corrected was 
found not to be significant. This was accompanied by a weak and non-significant increase in 
the frequency of the 3.8,3.6 genotype in the patients (17.7%) compared to the normal 
controls (10.0%). There were no other significant differences between the patient and 
control populations. 
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28L Age at onset of Controls 
Genotype diabetes (years) 0/o 
< 10 10-20 >20 
% % % 
4.3,3.8 35.4 34.0 28.9 35.5 
(34) (33) (22) (39) 
4.3,3.6 12.5 18.5 10.5 10.0 
(12) (18) (8) (11) 
3.8,3.6 18.7 12.3 22.3 10.0 
(18) (12) (17) (11) 
4.3 17.7 18.5 17.1 27.3 
(17) (18) (13) (30) 
3.8 9.3 9.2 15.7 14.5 
(9) (9) (12) (16) 
3.6 6.2 7.2 5.2 2.7 
(6) (7) (4) (3) 
Total (n) 96 97 76 110 
Table 6.4.B Frequency of MBC Class I 28L Genotypes with respect to age at onset 
of diabetes 
This table shows the distribution of 28L genotypes in patients separated by age at onset 
into < 10, 10 - 20 and > 20 years of age. For each genotype the actual number of and 
frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using the x2 test and 2 X 2 contingency 
tables. No significant differences were found between any of the patient subgroups or the 
normal controls. 
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The relationship between age at onset of diabetes and the 28L genotype was examined by 
separating the patient population into 3 groups depending on the age at onset of type I 
diabetes, <10 years, 10-20 years and >20 years table 6.4.B. Comparisons were made 
between the patient subgroups and also the normal controls. There was a small increase in 
the 3.8,3.6 genotype in patients diagnosed after the age of 20 (22.3%) compared to the 
controls (10.0%), but this was non-significant when the p-value was corrected (p = 0.02, Pc 
= ns). The 3.8,3.6 genotype was also increased in the <10 years age at onset group 
compared to the controls 18.7% vs 10.0%, but the p value was found not to be significant 
but was close to 0.05. The frequency of the 3.8,3.6 genotype was also slightly increased in 
patients in the >20 years age at onset group compared to patients in the 10-20 years age at 
onset group 22.3% vs 12.3%, but the difference was found not to be significant. There were 
no other significant differences or patterns of association in the frequency of 28L genotypes 
between the patient subgroups or the normal controls. 
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28L Patient Control 
Genotype % 0/o 
Male Female Male Female 
4.3,3.8 31.7 33.7 29.7 38.9 
(39) (50) (11) (23) 
4.3,3.6 13.0 14.8 10.8 11.8 
(16) (22) (4) (7) 
3.8,3.6 18.7 16.8 13.5 6.7 
(23) (25) (S) (4) 
4.3 17.0 18.9 27.0 23.7 
(21) (28) (10) (14) 
3.8 13.0 9.4 18.9 13.5 
(16) (14) (7) (8) 
3.6 6.5 6.0 0 5.0 
(8) (9) (0) (3) 
Total (n) 123 148 37 59 
Table 6.4.C Frequency of MHC Class I 28L Genotypes in patients and controls with 
respect to gender 
This table shows the distribution of28L genotypes in patient and control subjects separated 
by gender. For each genotype the actual number of subjects and the frequency is shown for 
both genders in patients and controls. n represents the number of subjects in each gender 
group. Comparisons were made for each genotype between the male patients with the 
female patients and also the male and female patients and the male and female controls 
using the ·l test and 2 X 2 contingency tables. No significant differences were found 
between any of the patient subgroups or the normal controls. 
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Differences in gender were investigated in both patient and control populations with respect 
to 28L genotypes table 6.4.C. When the control population was divided by gender there 
were slightly more females to males however, the frequency of the 28L genotypes was 
similar in each group. Comparisons between the patients and controls showed a small 
increase of the 3.8,3.6 genotype in the female patients compared to the female controls 
16.8% vs 6.7% (p = 0.05), the p value was non-significant when corrected. There were no 
other differences between the patient subgroups or the normal controls. 
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28L Age at onset of diabetes Controls 
Genotype (years) % 
< 10 10-20 >20 
% 0/o 0/o 
Male Female Male Female Male Female Male Female 
4.3,3.8 39.4 32.7 29.1 40 27.7 28.2 29.7 38.9 
(15) (19) (14) (20) (10) (11) (11) (23) 
4.3,3.6 7.8 15.5 18.7 18 11.1 10.2 10.8 11.8 
(3) (9) (9) (9) (4) (4) (4) (7) 
3.8,3.6 21.0 17.2 16.6 8 16.6 28.2 13.5 6.7 
(8) (10) (8) (4) (6) (11) (5) (4) 
4.3 15.7 18.9 18.7 18 16.6 17.9 27.0 23.7 
(6) (11) (9) (9) (6) (7) (10) (14) 
3.8 13.1 6.1 8.3 10 19.4 12.8 18.9 13.5 
(5) (4) (4) (5) (7) (5) (7) (8) 
3.6 2.6 8.6 8.3 6 8.3 2.5 0 5.0 
(1) (5) (4) (3) (3) (1) (0) (3) 
Total (n) 38 58 48 50 36 39 37 59 
Table 6.4.D Frequency of MHC Class I 28L genotypes with respect to gender and age at onset 
This table shows the distribution of 28L genotypes in the patient subjects according to gender and age at onset and by gender in the control 
subjects. The actual number of subjects and the frequency is shown for all genotypes. The n value represents the number of subjects in each group. 
Comparisons were made using the x2 and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found between any of the patient subgroups or the normal controls. 
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The effect of gender and age at onset was analysed for 28L genotypes in relation to type I 
diabetes table 6.4.D. The 3.8,3.6 genotype was significantly increased in females in the >20 
years age at onset group compared to the female controls 28.1% vs 6. 7% but the increase 
was non-significant when the p=-value was corrected (p = 0.003, Pc= ns). A small increase 
in the 3.8,3.6 genotype was also found in the females diagnosed after the age of 20 
compared to females in the 10-20 years age at onset group 28.25 vs 8%, but the difference 
was non-significant when corrected (p = 0.01, Pc= ns). The 3.6,3.6 genotype was absent in 
the male controls but was found at a frequency of 8.3% in males diagnosed after the age of 
20 years, this difference was non-significant when corrected (p = 0.07, Pc= ns). There were 
no other significant differences in the frequency of 28L genotypes between any of the 
patient subgroups or the normal controls. 
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28L Patients Controls 
Alleles % % 
4.3 41.5 50.0 
(225) (110) 
3.8 36.3 37.2 
(197) (82) 
3.6 22.12 12.7 
(120) (28) 
Total (n) 542 220 
Table 6.4.E Frequency of MHC Class I 28L alleles in patients and controls 
This table shows the frequency of patients and controls with the 3 alleles of the genomic 
marker 28L. n represents the number of alleles for both patient and control subjects. The 
number in brackets is the actual number of each allele present. Comparisons were made 
between the patient and control subjects using the x2 test and 2 x 2 contingency tables. 
1 =patient vs controll = 4.58, p = 0.03 (1df), Pc= 0.06 
2 =patient vs control x2 = 8.86, p = 0.002 (1df), Pc= 0.004 
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When comparing the allelic frequencies between patients and normal controls table 6.4.£, 
the frequency ofthe 3.6 allele was significantly increased in patients compared to controls 
22.1% vs 12.7% (p = 0.002, Pc= 0.004). In contrast, the frequency of the 4.3 allele was 
slightly decreased in the patients compared to the controls 41.5% vs 50.0% (p = 0.03, Pc= 
0.06). There were no other significant differences between the patient and control subjects. 
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28L Age at onset of Controls 
Alleles diabetes (years) o/o 
< 10 10-20 >20 
% % % 
4.3 41.6 44.8 36.82 50.0 
{80) (87) (56) (110) 
3.8 36.4 32.4 41.4 37.2 
(70) (63) (63) (82) 
3.6 21.83 22.61 21.7 12.7 
{42) (44) (33) (28) 
Total (n) 192 194 152 220 
Table 6.4.F Frequency of MHC Class I 28L alleles with respect to age at onset of 
diabetes 
This table shows the frequency of 28L alleles in patients separated by age at onset into 
< 10, 10 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the x2 test and the 2 X 2 contingency tables. 
1 =patient 10-20 years vs control x2 = 3.1, p = 0.007 (ldf), Pc= 0.04 
2 =patient> 20 years vs control x2 = 6.3, p = 0.01 (ldf), Pc= 0.06 
3 =patient> 1 years vs control x2 6.0, p = 0.01 {ldf), Pc= 0.06 
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The association of 28L alleles and the effect of age at onset of type I diabetes table 6.4.F, 
showed a the frequency of the 3.6 allele was slightly increased in all the patient subgroups 
compared to the controls. The greatest difference in frequency was between patients with an 
age at onset of 10-20 years compared to the controls 22.6% vs 12.7% (p = 0.007, Pc= 0.04). 
The difference in frequency between the <1 Oyears and >20 years compared to the controls 
was smaller (Pc = 0.06, Pc = ns) respectively. There was a small decrease in the frequency 
of the 4.3 allele in patients diagnosed after the age of 20 compared to the control subjects 
36.85 vs 50.0% (p = 0.001, Pc= 0.06). This trend was also seen in the <10 and 10-20 years 
age at onset groups compared to the controls but the difference was found not to be 
significant. The difference in frequency between the <10years and >20 years compared to 
the controls was smaller (Pc= 0.02, Pc= 0.03) respectively. No other significant differences 
were found between the patient subgroups or the nonnal controls. 
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28L Patients Controls 
Alleles 0/o 0/o 
Males Females Males Females 
4.3 40.2 43.2 47.3 49.1 
(107) (128) (35) (58) 
3.8 35.3 34.8 40.5 36.4 
(94) (103) (30) (43) 
3.6 24.4 21.9 12.1 14.4 
(65) (65) (9) (17) 
Total (n) 266 296 74 118 
Table 6.4.G Frequency of MHC Class I 28L alleles in patients and controls with 
respect to gender 
This table shows the frequency of 28L alleles in patient and control subjects separated by 
gender. n represents the number of alleles for each gender group. The number in brackets 
is actual number of each allele present. Comparisons were made between the male patients 
with the female patients and also the male and female patients and male and female 
controls for each allele, using the x2 test and 2 X 2 contingency tables. No significant 
differences were found between any of the patient subgroups or the normal controls. 
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Comparisons of 28L alleles were made in relation to gender table 6.4.G; there was a small 
difference in the frequency of the 3.6 allele increased in male patients compared to male 
controls 24.4% vs 12.1%, the p-value was non-significant when corrected (p = 0.02, Pc= 
ns). A similar increase also occurred in the female patients compared to the female controls 
21.9% vs 14.4%, but the difference was not significant. There were no other differences 
found between the patient subgroups or the normal controls. 
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28L Age at onset of diabetes Controls 
Alleles (years) 0/o 
< 10 10-20 > 20 
0/o 0/o 0/o 
Males Females Males Females Males Females Males Females 
4.3 39.4 43.1 42.7 47 36.1 37.1 - 47.3 49.1 
(30) (SO) (41) (47) (26) (29) (35) (58) 
3.8 43.4 31.9 31.2 34 41.6 41.0 40.5 36.4 
(33) (37) (96) (34) (30) (32) (30) (43) 
3.6 17.1 25 26.0 19 22.2 21.7 12.1 14.4 
(13) (29) (25) (19) (16) (17) (9) (17) 
Total (n) 76 116 96 100 72 78 74 118 
Table 6.4.0 Frequency of MHC Class I 28L alleles with respect to gender and age at onset of diabetes 
This table shows the frequency of28L genotypes in the patient subjects according to gender and age at onset and by gender in the control subjects. 
The n value represents the number of alleles in each subgroup. The number in brackets is the actual number of each allele present. Comparisons 
were made using the x2 test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found between any of the patient subgroups or the normal controls. 
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When the 28L allelic frequency was analysed with respect to gender and age at onset of 
type 1 diabetes table 6.4.H, there was an increase in the 3.6 allele in males with an age at 
onset between 10-20 years compared to the male controls 26.0% vs 12.1%, but the this was 
non-significant when corrected (p = 0.02, Pc= ns). A similar but smaller increase was found 
in the female patients in the <10years age at onset group compared to the female controls 
25% vs 14.4% (p = 0.04, Pc= ns). The difference in frequencies found were only small and 
of weak significance when uncorrected, there were no other significant differences found 
between the patient subgroups or the controls. 
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6.5 Genomic probe 66R 
The genomic probe 66R is a 0.5kb Eco-RI/Bam-HI fragment derived from the yeast 
artificial chromosome YAC 66 (Geraghty, unpublished). However, current data has now 
renamed revealed that 66R is actually 67R derived from YAC 67 [Janer and Geraghty, 
1998]. For the purpose of this study the probe was known as 66R. 66R is located between 
HLA-8 and HLA-E and is located approximately 40kb centromeric to HLA-X. As with 28L 
it is not known whether the 66R sequence is derived from a single gene, but it has been 
shown on a Southern blot that it produces a single pattern, which is consistent with a single 
copy gene status (Geraghty, unpublished results). 
6.5.1 Association of the genomic probe 66R with type 1 diabetes 
With the restriction endonuclease Pvu-II two alleles of 4.5 and 3.9kb are detected at the 66R 
locus (Fig. 6.5). The resulting genotypes detected were 4.5/3.9, 4.5/4.5 and 3.9/3.9. (Table 
5:4) 307 patients with type 1 diabetes were analysed and 121 normal controls. All of the 
data obtained from the patient subgroups and control subjects analysed with 66R is 
presented in the following tables. Possible associations with alleles and genotypes of 66R 
were investigated along with the effects of gender and age at onset on the association with 
type 1 diabetes. 
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1 2 3 4 5 
Fig 6.5 Allelic polymorphism of the 66R locus 
3.9 
4.5 
Pvu II digested genomic DNAs from five patient samples probed with 66R. The sizes of 
the polymorphic restriction fragments are indicated. 
Lane 1: 4.5 I 4.5 
Lane 2: 4.5 I 3.9 
Lane 3: 4.5 I 4.5 
Lane 4: 4.5 I 4.5 
Lane 5: 3.9 I 3.9 
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66R Patients Controls 
Genotype % o;o 
4.5,3.9 56.3 50.4 
(173) (61) 
4.5 18.2 10.7 
(56) (13) 
3.9 25.41 38.8 
(78) (47) 
Total (n) 307 121 
Table 6.5.A Frequency of MHC Class I 66R genotypes in patients and controls 
This table shows the frequency and actual number of patients and controls with the 3 
possible genotypes of the genomic marker 66R. n represents the number of patients and 
controls studied. The number in brackets represents the actual number of subjects with a 
particular genotype. Comparisons were made between the patient and control subjects for 
each genotype using the x2 test and 2 X 2 contingency tables. 
1 =patient vs control x2 = 7.58, p = 0.005 (ldf), Pc= 0.01 
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Comparisons of genotype frequencies between patient and control subjects table 6.5.A 
showed a small but significant decrease in the frequency ofthe 3.9,3.9 66R genotype in 307 
patients compared to 121 normal controls (p = 0.005, Pc= 0.01). This was accompanied by 
a compensatory increase in the frequency of the other 66R genotypes in patients compared 
to the normal controls. There were no other significant differences found between the 
patient and control subjects. 
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66R Age at onset of Controls 
Genotypes diabetes (yean) % 
< 10 10-20 >20 
o;o % % 
4.5,3.9 47.7 59.8 62.9 50.4 
(53) (67) (51) (61) 
4.5 23.42 13.3 18.5 10.7 
(26) (IS) (IS) (13) 
3.9 28.8 26.7 18.51 38.8 
(32) (30) (IS) (47) 
Total (n) 111 112 81 121 
Table 6.5.B Frequency of MHC Class I 66R genotypes with respect to age at onset 
of diabetes 
This table shows the distribution of 28L genotypes in patients separated by age at onset 
into< 10, 10- 20 and> 20 years of age. For each genotype the actual number of subjects 
and frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using x? test and 2 X 2 contingency tables. 
1 =patient> 20 years vs control x2 = 9.4, p = 0.002 (I elf), Pc= 0.01 
2 =patient< 10 years vs control X2 = 6.6, p = 0.009 (Idf), Pc= 0.05 
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The effect of age at onset with 66R genotype was examined by separating the patient 
population into 3 groups depending on the age at onset of type I diabetes, <10 years, 10-20 
years and >20 years table 6.5.B. Comparisons were made between the patient subgroups 
and also the normal controls. There was a significant decrease in the frequency of the 
3.9,3.9 66R genotype in patients who were diagnosed after the age of 20 compared to the 
controls 18.5% vs 38.8% (p = 0.002, Pc= 0.01). There was also a significant increase in the 
4. 5/4.5 genotype in the patients with an age at onset of< 10 years compared to the controls 
23.4% vs 10.7% (p =0.009, Pc == 0.05). A small increase in the frequency of the 4 5/4.5 
genotype in the < 10 years age at onset group compared to patients with an age at onset 
between 10-20 years, while the p value was not significant it was near to 0.05. There was a 
small decrease in the frequency of the 4.5/3.9 genotype in patients in the <10 years age at 
onset group compared to patients diagnosed after the age of 20 47.7% vs 62.9% (p =0.03), 
the difference was found not to be significant when corrected. There were no other 
significant differences between the patient subgroups or the normal controls. 
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66R Patients Controls 
Genotype o/o o/o 
Males Females Males Females 
4.5,3.9 55.2 57.3 48.8 49.2 
(79) (94) (22) (32) 
4.5 22.32 14.6 4.4 13.8 
(32) (24) (2) (9) 
3.9 22.31 28.0 46.6 36.9 
(32) (46) (21} (24) 
Total (n) 143 164 45 65 
Table 6.5.C Frequency of MBC Class I 66R genotypes in patients and controls with 
respect to gender 
This table shows the distribution of28L genotypes in patient and control subjects separated 
by gender. For each genotype the actual number of subjects and the frequency is shown for 
both genders in patients and controls. n represents the number of subjects in each gender 
group. Comparisons were made for each genotype between the male patients with the 
female patients and also the male and female patients and the male and female controls 
using the x.2 test and 2 X 2 contingency tables. 
1 =male patient vs male control x.2 = 9.9, p = 0.001 (I cif), Pc= 0.006 
2 =male patient vs male control x.2 = 7.4, p = 0.006 (1df), Pc= 0.03 
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The effect of gender was investigated in both the patient and control population with respect 
to 66R genotypes, table 6.5.C. There were more female control subjects than male subjects 
in the control population, but the genotype frequencies were found to be similar in each 
group. There was a small but significant decrease in the 3.9,3.9 66R genotype in the male 
patients compared to the male controls 22.3% vs 46.6% (p = 0.001, Pc= 0.006). This was 
accompanied by a small compensatory increase in the frequency of the 4.5,4.5 genotype in 
the male patients compared to the male controls 55.2% vs 48.8% (p = 0.006, Pc= 0.03). No 
other significant differences were found between the patients or the nonnal controls. 
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66R Age at onset of diabetes Controls 
Genotype (years) o;o 
< 10 10-20 > 20 
o;o o;o o;o 
Males Females Males Females Males Females Males Females 
4.5,3.9 39.1 53.8 66.1 59.3 63.4 61.5 48.8 49.2 
(18) (35) (33) (35) (26) (24) (22) (32) 
4.5 30.42 18.4 12.9 13.5 26.83 10.2 4.4 13.8 
(14) (12) (7) (8) ( 11) (4) (2) (9) 
3.9 30.4 27.6 25.9 27.1 9.71 28.2 46.6 36.9 
(14) (18) (14) (16) (4) (11) (21) (24) 
Total (n) 46 65 54 59 41 39 45 65 
Table 6.5.D Frequency of MHC Class I 66R genotypes with respect to gender and age at onset of diabetes 
This table shows the distribution of 28L genotypes in patient subjects according to gender and age at onset and by gender in the control subjects .. 
The actual number of subjects and the frequency is shown for all genotypes. The n value represents the number of subjects in each group. 
Comparisons were made using the "K test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient at onset groups 
1 =male patient> 20 years vs male control ·l = 14.2, p = 0.0001 (1dt), Pc= 0.001 
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2 =male patient< 10 years vs male control x2 = 10.6, p = 0.001 (Idf), Pc= 0.01 
3 =male patient> 20 years vs male control x2 = 8.3, p = 0.003 (1df), Pc= 0.04 
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The effect of gender and age at onset was analysed for 66R genotypes in relation to type 1 
diabetes, table 6.5.D. There was a significant decrease in the frequency of the 3.9,3.9 
genotype in males diagnosed after the age of 20 compared to the controls 9. 75 vs 46.6% (p 
= 0.0001, Pc= 0.001). There was also a decrease in the frequency of the 3.9,3.9 genotype in 
males with an age at onset between 10-20 years and < 10 years compared to the normal 
controls however, these were non-significant when corrected. The 4.5,4.5 genotype was 
significantly increased in male patients with an age at onset of< 10 years compared to the 
control subjects 30.4% vs 4.4% (p = 0.001, Pc = 0.01). A similar but less dramatic 
difference was found between males diagnosed after the age of 20 compared to the normal 
controls 26.8% vs 4.4% (p = 0.003, Pc= 0.04). Although there were other minor differences 
in the frequency of the 66R genotypes with age at onset and gender none of them were 
significant after correction of the p-value. 
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66R Patients Controls 
Alleles 0/o % 
4.5 46.4 36.0 
(285) (87) 
3.9 53.52 64.0 
(329) (155) 
Total (n) 614 242 
Table 6.5.E Frequency ofMHC Class I 66R alleles in patients and controls 
This table shows the frequency of patients and controls with the 2 alleles of the genomic 
marker 66R. n represents the number of alleles for both patient and control subjects. The 
number in brackets is the actual number of each allele present. Comparisons were made 
between the patient and control subjects using the x2 test and 2 X 2 contingency tables. 
1 =patient vs control x2 = 7. 74, p = 0.005 (ldf), Pc= 0.05 
2 =patient vs control X2 = 7.74, p =0.005 (ldf), Pc= 0.05 
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When comparing the allelic frequencies between patient and control subjects table 6.5.E, the 
frequency of the 3.9 allele was significantly decreased in patients compared to normal 
controls 53.5% vs 64.0% (p = 0.005, Pc = 0.05). This was accompanied by a compensatory 
increase in the frequency of the 4.5 allele in patients compared to controls 46.4% vs 36.0% 
(p = 0.005, Pc= 0.05). 
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66R Age at onset of Controls 
Alleles diabetes (years) 0/o 
< 10 10-20 >20 
% % % 
4.5 47.3 43.3 50 36.0 
(105) (97) (81) (87) 
3.9 52.74 56.7 502 64.0 
(117) (127) (81) (155) 
Total (n) 222 224 162 242 
Table 6.5.F Frequency of MBC Class I 66R alleles with respect to age at onset of 
diabetes 
This table shows the frequency of 66R alleles in patients separated by age at onset into 
< 10, 10 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the x2 test and 2 X 2 contingency tables. 
1 =patient> 20 years vs control x2 = 7.8, p = 0.004 (ldf), Pc= 0.01 
2 =patient> 20 years vs control x2 = 7.8, p = 0.004 (1df), Pc= 0.01 
3 =patient< 10 years vs control x2 = 6.2, p = 0.01 (1df), Pc= 0.03 
4 =patient< 10 years vs control x2 = 6.2, p = 0.01 (1df), Pc= 0.03 
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The effect of age at onset of type I diabetes and the association of 66R a!leles table 6.5.F, 
showed there was a significant increase of the 4.5 allele in patients in the> 20 years age at 
onset group compared to the controls 50% vs 36.0% (p = 0.004, Pc= O.OI). A similar but 
less significant increase was found in patients diagnosed before the age of I 0 years 
compared to the controls 47.3% vs 36.0% (p = O.OI, Pc = 0.03). In contrast, the frequency 
of the 3.9 allele was significantly decreased in patients diagnosed after the age of 20 
compared to the controls 50% vs 64.0% (p = 0.004, Pc = O.OI). The 3.9 allele was also 
decreased in patients with an age at onset of< I 0 years compared to the controls 52.7% vs 
64.0% (p = 0.01, Pc= 0.03). There were no other significant differences found between the 
patient subgroups or the normal controls for either allele. 
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66R Patients Controls 
Alleles 0/o 0/o 
Male Female Male Female 
4.5 501 43.2 28.8 38.4 
(143) (142) (26) (50) 
3.9 502 56.7 71.1 61.5 
(143) (186) (64) (80) 
Total (n) 286 328 90 130 
Table 6.5.G Frequency of MBC Class I 66R alleles in patients and controls with 
respect to gender 
This table shows the frequency of 66R alleles in patient and control subjects separated by 
gender. n represents the number of alleles for each gender group. The number in brackets 
is the actual number of each allele present. Comparisons were made between the male 
patients with the female patients and also the male and female patients and male and 
female controls for each allele, using the x2 test and 2 X 2 contingency tables. 
1 =male patient vs male control x_2 = 12.3, p = 0.0004 (1df), Pc= 0.001 
2 =male patient vs male control x_2 = 12.3, p = 0.0004 (1df), Pc= 0.001 
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Comparisons made in relation to gender and alleles of the 66R locus, table 6.5.G, showed 
the 4.5 allele to be significantly increased in male patients compared to the male controls 50 
%vs 28.8% (p = 0.0004, Pc= 0.001). There was a significant decrease in the frequency of 
the 3.9 allele in male patients compared to the male controls 50% vs 71.1% (p = 0.0004, Pc 
= 0.001). There were no other differences between the patients and normal controls. 
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66R Age at onset of diabetes Controls 
Alleles (years) o/o 
< 10 10-20 >20 
o/o o/o o/o 
Males Females Males Females Males Females Males Females 
4.5 503 45.3 43.5 43.2 58.51 41.0 28.8 38.4 
(46) (59) (47) (51) (48) (32) (26) (50) 
3.9 504 54.6 56.4 56.7 41.42 58.9 71.1 61.5 
(46) (71) (61) (67) (34) (46) (64) (80) 
Total (n) 92 130 108 118 82 78 90 130 
Table 6.5.0 Frequency of MHC Class I 66R alleles with respect to gender and age at onset 
This table shows the frequency of 66R alleles in the patient subjects according to gender and age at onset and by gender in the control subjects. 
The n value represents the number of alleles in each subgroup. The number in brackets is the actual number of each allele present. Comparisons 
were made using the ..,; test and 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female age at onset groups 
d) male patient and female patient age at onset groups 
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1 =male patient> 20 years vs male control x2 = 15.3, p = 0.00001 (1df), Pc= 0.00007 
2 =male patient> 20 years vs male control x2 = 15.3, p = 0.00001 (1df), Pc= 0.00007 
3 =male patient <10 years vs male control x2 = 8.4, p = 0.003 (1df), Pc= 0.02 
4 =male patient< 10 years vs male control x2 = 8.4, p = 0.003 (ldf), Pc= 0.02 
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When the data was analysed for both the effects of gender and age at onset of type I 
diabetes table 6.5.H, the frequency of the 4.5 allele was significantly increased in the male 
patients with an age at onset of> 20 years compared to the male controls 58.4% vs 28.8% 
(p = 0.00001, Pc= 0.00007). The 4.5 allele was also increased in male patients diagnosed 
before the age of 10 years compared to male controls 50% vs 28.8% (p = 0.003, Pc= 0.02). 
Males in the 10-20 years age at onset group had an increased frequency of the 4.5 allele 
compared to the male controls, but the difference was found to be non-significant. In 
contrast, the 3.9 allele was significantly decreased in males with an age at onset of> 20 
years compared to the controls 41.6% vs 71.1% (p = 0.00001, Pc =0.00007). The 3.9 allele 
was also decreased in patients in the < 10 years age at onset group compared to the controls 
50% vs 71.1% (p = 0.003, Pc= 0.02). This decrease in the 3.9 allele was also find in male 
patients in the 10-20 years group compared to the controls but the difference was found not 
to be significant. The 3. 9 allele was increased in male patients in the 10-20 years age at 
onset group compared to males diagnosed after the age of 20 years 56.4% vs 41.4%, but the 
difference was non-significant. The 3.9 allele is increased in female patients in the > 20 
years age at onset group compared to males in the same group 41.6% vs 58.9%, but the 
difference was found to be non-significant. There were no other differences found between 
any of the patient subgroups or the normal controls. 
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6.6 Genomic probe PJA 
P3A is one of2loci recognised by the probe P3. The P3 probe is among one of the first to 
detect non-HLA polymorphic loci in the class I region [David et al. 1990]. P3 was isolated 
YAC 6F6, which has been mapped 550kb telomeric to HLA-C and at least 800kb 
centromeric of HLA-A. It is unclear whether P3 codes for an open reading frame (ORF). 
P3A maps approximately 40kb centromeric to HLA-B. 
6.6.1 Association of the genomic probe PJA with type 1 diabetes 
The P3 probe in conjunction with the restriction endonuclease Pst-I detects 2 aileles at the 
P3A locus, 4.0 and 3.8kb in size (Fig. 6.6). The resulting genotypes detected were 4.0,3.8, 
4.0,4.0 and 3.8,3.8. Out of the patient population studied (Table 5:4) 305 patients with type 
1 diabetes were analysed at the P3A locus and 216 normal controls out of the control 
population. All of the data obtained from the patient subgroups and control subjects 
analysed with P3A is presented in the following tables. Possible associations with alieles 
and genotypes ofP3A were investigated along with the effects of gender and age at onset 
with type 1 diabetes. 
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~ 3.8 
~ 4.0 
1 2 3 4 
Fig 6.6 Allelic polymorphism of the P3A locus 
Pst 1 digested genomic DNAs from four patient samples probed with P3A. The sizes of the 
polymorphic restriction fragments are indicated. 
Lane 1: 4.0 I 4.0 
Lane 2: 4.0 I 3.8 
Lane 3: 4.0 I 3.8 
Lane 4: 4.0 I 3.8 
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P3A Patients Controls 
Genotypes 0/o % 
4.0,3.8 40.9 46.7 
(125) (101) 
4.0 54.1 46.3 
(165) (100) 
3.8 4.9 6.9 
(15) (15) 
Total (n) 305 216 
Table 6.6.A Frequency of MBC Class I P3A genotypes in patients and controls 
This table shows the frequency and actual number of patients and controls with the 3 
possible genotypes of the genomic marker P3A. n represents the number of patients and 
controls studied. The number in brackets represents the actual number of subjects with a 
particular genotype. Comparisons were made between the patient and control subjects for 
each genotype using the x.2 test and 2 X 2 contingency tables. No significant differences 
were found between patient and control subjects. 
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Comparisons of genotype frequencies between patient and control populations (table 6.6.A} 
found there were no significant differences between patients and controls at the P3A locus. 
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P3A Age at onset of Controls 
Genotypes diabetes (years) % 
< 10 10-20 > 20 
% 0/o 0/o 
4.0,3.8 531,2 35.2 34.1 46.7 
(53) (43) (27) (101) 
4.0 44 59.83'4 58.2 46.3 
(44) (73) (46) (lOO) 
3.8 3 4.92 7.5 6.9 
(3) (6) (6) (15) 
Total (n) 100 122 79 216 
Table 6.6.B Frequency of MHC Class I P3A genotypes with respect to age at onset 
of diabetes 
This table shows the distribution of P3A genotypes in patients separated by age at onset 
into <10, 10- 20 and> 20 years of age. For each genotype the actual number of subjects 
and frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using the x2 test and 2 X 2 contingency 
tables. 
1 =patient< 10 years vs patient 10-20 years x2 = 7.0, p = 0.007 (ldf), Pc= 0.04 
2 =patient< 10 years vs patient> 20 years x2 = 6.3, p = 0.01 (1df), Pc= 0.06 
3 =patient 10-20 years vs control x2 = 5.7, p = 0.01 (ldf), Pc= 0.06 
4 =patient 10-20 years vs patient< 10 years x2 = 5.5, p = 0.01 (1df), Pc= 0.06 
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The relationship between P3A genotypes and age at onset was examined by separating the 
patient population into 3 groups depending on the age at onset of type I diabetes, < I 0 
years, i0-20 years and> 20 years age at onset of type 1 diabetes, table 6.6.B. Comparisons 
were made between the patient subgroups and also the normal controls. The 4.0,3.8 
genotype was increased in frequency in patients with an age at onset of < I 0 years 
compared to patients in the I0-20 and> 20 years age at onset groups (Pc= 0.04, Pc= 0.06). 
The 4.0,4.0 genotype was increased in patients with an age at onset between I0-20 years 
compared to controls 59.8% vs 46.3% (p = 0.01, Pc= 0.06). The frequency of the 4.0,4.0 
genotype was increased in patients in the 10-20 years group compared to patients in the < 
10 years group 59.8% vs 44% (p = 0.01, Pc= 0.06). No other significant differences were 
found between the patient subgroups or the normal controls. 
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P3A Patients Controls 
Genotypes % % 
Males Females Males Females 
4.0,3.8 34.0 46.6 47.1 45.6 
(48) (76) (42) (47) 
4.0 58.8 50.3 44.9 48.5 
(83) (82) (40) (50) 
3.8 7.0 3.0 7.8 5.8 
(10) (5) (7) (6) 
Total (n) 141 163 89 103 
Table 6.6.C Frequency of MHC Class I P3A genotypes in patients and controls with 
respect to gender 
This table shows the distribution of P3A genotypes in patient and control subjects 
separated by gender. For each genotype the actual number of subjects and the frequency is 
shown for both genders in patients and controls. n represents the number of subjects in 
each gender group. Comparisons were made for each genotype between the male patients 
with the female patients and also the male and female patients and the male and female 
controls using the r! test and 2 X 2 contingency tables. No significant differences were 
found between any ofthe patient subgroups or the normal controls. 
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Differences in gender were investigated in both patient and control populations with respect 
to P3A genotypes and type I diabetes, table 6.6.C. When the control population was divided 
by gender there were more females to males, but the genotype frequencies were similar in 
both. There was an increase in the frequency of the 4.0,3.8 genotype in female patients 
compared to male patients 46.6% vs 34.0%, but the difference was non-significant when 
corrected (p = 0.02, Pc = ns). The 4.0,3.8 genotype was slightly decreased in the male 
patients compared to the male controls 34.0% vs 47.1% (p = 0.04), but the difference was 
non-significant when corrected. The opposite effect was found with the 4.0,4.0 genotype, 
which was increased in the male patients compared to the male controls 58.8% vs 44.9% (p 
= 0.03), the difference was not significant when corrected. No other significant differences 
were found between the patient subgroups or the controls. 
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P3A Age at onset of diabetes Controls 
Genotypes (years) o;o 
< 10 10-20 >20 
o;o % % 
Males Females Males Females Males Females Males Females 
4.0,3.8 50 ss• 31.0 39.6 22.5 46.1 47.1 45.6 
(20) (33) (18) (25) (9) (18) (42) (47) 
4.0 45 43.3 62.0 57.1 67.5 48.7 44.9 48.5 
(18) (26) (36) (36) (27) (19) (40) (50) 
3.8 5 1.6 6.1 3.1 10 5.13 7.8 5.8 
(2) (1) (4) (2) (4) (2) (7) (6) 
Total(n) 40 60 58 63 40 39 89 103 
Table 6.6.D Frequency of MHC Class I P3A genotypes with respect to gender and age at onset of diabetes 
This table shows the distribution of P3A genotypes in the patient subjects according to gender and age at onset and by gender in the control 
subjects. The actual number of subjects and the frequency is shown for all genotypes. The n value represents the number of subjects in each group. 
Comparisons were made using the x2 test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female age at onset groups 
d) male patient and female patient age at onset groups 
1 =female patient< 10 years VS male patient> 20 years x2 = 10.4, p = 0.001 (ldf), Pc= 0.01 
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The effects of gender and age at onset were analysed for P3A genotype in relation to type 1 
diabetes, table 6.6.D. The frequency of the 4.0,3.8 genotype was significantly increased in 
female patients with an age at onset of< 10 years compared to male patients with an age at 
onset of> 20 years 55% vs 22.5% (p = 0.001, Pc = 0.01). Although there were minor 
differences in the P3A genotypes with an age at onset and gender none of them were 
significant after correction of the p-value. 
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P3A 
Alleles 
4.0 
3.8 
Total (n) 
Patients 
0/o 
74.5 
(455) 
25.4 
(155) 
610 
Controls 
D/o 
69.6 
(301) 
30.3 
(131) 
432 
Table 6.6.E Frequency of MHC Class I P3A alleles in patients and controls 
This table shows the frequency of patients and controls with the 2 alleles of the genomic 
marker P3A. n represents the number of alleles for both patient and control subjects. The 
number in brackets is the actual number of each allele present. Comparisons were made 
between the patient and control subjects using the x? test and 2 X 2 contingency tables. No 
significant differences were found between the patient and control subjects. 
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Comparisons of allelic frequencies between patient and control subjects (table 6.6.E) found 
there were no significant differences between patients and controls at the P3A locus. 
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P3A Age at onset of Controls 
Alleles diabetes (years) 0/o 
< 10 10-20 >20 
0/o 0/o % 
4.0 70.5 77.41 75.3 69.6 
(141) (189) (119) (301) 
3.8 29.5 22.52 24.6 30.3 
(59) (55) (39) (131) 
Total (n) 200 244 158 432 
Table 6.6.F Frequency of MHC Class I P3A alleles with respect to age at onset of 
diabetes 
This table shows the frequency ofP3A alleles in patients separated by age at onset into 
< 10, 10 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the ·l test and 2 X 2 contingency tables. 
1 =patient 10-20 years vs control x2 = 4.7, p = 0.02 (ldf), Pc= 0.06 
2 =patient 10-20 years vs control·l = 4.7, p = 0.02 (ldf), Pc= 0.06 
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The effect of age at onset of type 1 diabetes and the association of P3A alleles, table 6.6.F, 
showed there was a small increase in the frequency of the 4.0 allele in patients with an age 
at onset of 10-20 years compared to the controls 77.4% vs 69.6% (p = 0.02, Pc= 0.06). In 
contrast, the 3.8 allele was slightly decreased in the patients with an age at onset between 
10-20 years compared to the controls 22.5% vs 30.3% (p = 0.02, Pc= 0.03). There were no 
other significant differences found between the patient subgroups or the normal controls. 
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P3A Patients Controls 
Alleles % % 
Male Female Male Female 
4.0 75.8 73.6 68.5 71.3 
(214) (240) (122) (147) 
3.8 24.1 26.3 31.4 28.6 
(68) (86) (56) (59) 
Total (n) 282 326 178 206 
Table 6.6.G Frequency of MHC Class I P3A alleles in patients and controls witb 
respect to gender 
This table shows the frequency of P3A alleles in patient and control subjects separated by 
gender. n represents the number of alleles for each gender group. The number in brackets 
is the actual number of each allele present. Comparisons were made between the male 
patients with the female patients and also the male and female patients and male and 
female controls for each allele, using the x2 test and 2 X 2 contingency tables. No 
significant differences were found between any of the patient subgroups or the normal 
controls. 
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Comparisons were made with respect to gender and alleles of the P3A locus, table 6.6.G. 
These showed that there were no significant differences between the patient subgroups or 
the normal controls. 
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P3A Age at onset of diabetes Controls 
Alleles (years) o/o 
< 10 10-20 > 20 
o;o o;o % 
Males Females Males Females Males Females Males Females 
4.0 70 70.8 77.5 76.9 78.7 71.7 68.5 71.3 
(56) (85) (90) (97) (63) (56) (122) (147) 
3.8 30 29.1 22.4 23.0 21.2 28.2 31.4 28.6 
(24) (35) (26) (29) (17) (22) (56) (59) 
Total (n) 80 120 116 126 80 78 178 206 
Table 6.6.8 Frequency of MHC Class I P3A alleles with respect to gender and age at onset 
This table shows the frequency of P3A alleles in the patient subjects according to gender and age at onset and by gender in the controls. The n value 
represents the number of alleles in each subgroup. The number in brackets is the actual number of each allele present. Comparisons were made using the x2 
test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
No significant differences were found between any of the patient subgroups or the normal controls. 
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When the data was analysed for both the effects of gender and age at onset of type I 
diabetes with P3A alleles (table 6.6.H), there were no significant differences found between 
any of the patient subgroups or the nonnal controls. 
364 
6. 7 Genomic probe P3B 
P3B is one of the 2 loci recognised by the probe P3. P3B maps approximately 600kb from 
HLA-A and 700kb from HLA-B. 
6.7.1 Association of the genomic probe P3B 
The P3 probe in conjunction with the restriction endonuclease Pst-1 detects 2 alleles at the 
P3B locus of 1.8 and 1.5kb in size (Fig. 6.7). The resulting genotypes detected were 1.8, 1.5, 
1.8, 1.8 and 1.5, 1.5. Out of the patient population (Table 5:4) 300 patients with type 1 
diabetes were analysed at the P3B locus and 196 normal controls out of the control 
population. These patients and controls were studied independent of any previous analysis 
of the P3B locus. All of the data obtained from the patient subgroups and control subjects 
analysed with P3B is presented in the following tables. Possible associations with alleles 
and genotypes of P3B were investigated along with the effects of gender and age at onset 
with type I diabetes. 
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.. 1.5 
.. 1.8 
1 2 3 4 
Figure 6. 7 Allelic polymorphism of the PJB locus 
Pst 1 digested genomic DNAs from four patient samples probed with P3B. The sizes of the 
polymorphic restriction fragments are indicated. 
Lane 1: 1.8 I 1.5 
Lane 2: 1.5 I 1.5 
Lane 3: 1.8 I 1.8 
Lane4: 1.8 I 1.5 
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P3B Patients Controls 
Genotypes % % 
1.8,1.5 54.3 41.3 
(163) (81) 
1.8 26.61 51.5 
(80) (101) 
1.5 192 7.1 
(57) (14) 
Total (n) 300 196 
Table 6.7.A Frequency ofMHC Class I P3B genotypes in patients and normal 
controls 
This table shows the frequency and actual number of patients and controls with the 3 
possible genotypes of the genomic marker P3B. n represents the number of patients and 
controls studied. The number in brackets represents the actual number of subjects with a 
particular genotype. Comparisons were made between the patient and control subjects for 
each genotype using the x2 test and 2 X 2 contingency tables. 
1 =patient vs control x2 = 31.6, p = <0.000001 (1df), Pc= 0.000002 
2 =patient vs control x2 = 13.5, p = 0.0002 (1df), Pc= 0.0004 
3 =patient vs control x2 = 8.0, p = 0.004, Pc= 0.008 
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Comparisons of genotype frequencies between the patient and control populations, table 
6. 7.A, showed there was a highly significant decrease in the 1.8, 1.8 genotype in the patients 
compared to the normal controls 26.6% vs 51.5% (p = <0.000001, Pc = 0.000002). In 
contrast, the 1.5, 1.5 genotype was significantly increased in the patients compared to the 
controls 19% vs 7.1% (p = 0.0002, Pc = 0.0003). There was a significant increase in the 
1.8,1.5 genotype in the patients compared to the controls 53.3% vs 41.3% (p = 0.004, Pc= 
0.008). 
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P3B Age at onset of Controls 
Genotypes Diabetes (years) 0/o 
< 10 10-20 > 20 
% % % 
1.8,1.5 51.0 64.43'7 43.7 41.3 
(50) (76) (35) (81) 
1.8 34.68'6 16.91 304 51.5 
(34) (20) (24) (101) 
1.5 14.2 18.65 26.22 7.1 
(14) (22) (21) (14) 
Total (n) 98 118 80 196 
Table 6.7.B Frequency of MHC Class I P3B genotypes with respect to age at onset 
diabetes 
This table shows the distribution of P3B genotypes in patients separated by age at onset 
into 
< 10, 10 - 20 and > 20 years of age. For each genotype the actual number of subjects and 
frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using x2 test and 2 X 2 contingency tables. 
1 =patient 10-20 years vs control x2 = 37.2, p = <0.000001 (1df), Pc= 0.000006 
2 =patient> 20 years vs control x2 = 18.7, p = 0.00001 (I elf), Pc= 0.00006 
3 =patient 10-20 years vs control x2 = 15.6, p = 0.00007 (ldf), Pc= 0.0004 
4 =patient> 20 years vs control x2 = 10.6, p = 0.001 (1dt), Pc= 0.006 
5 =patient 10-20 years vs control x2 = 9.6, p = 0.001 (1dt), Pc= 0.006 
6 =patient< 10 years vs patient 10-20 years x2 = 8.9, p = 0.002 (1dt), Pc= 0.01 
7 =patient 10-20 years patient> 20 years x2 = 8.2, p = 0.004 (1dt), Pc= 0.02 
8 =patient< 10 years VS control x2 = 7.4, p = 0.006 (1dt), Pc= 0.03 
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The effect of age at onset of type 1 diabetes and the relationship with P3B genotypes was 
examined by separating the patient population into 3 groups depending on the age at onset 
of type 1 diabetes,< 10 years, 10-20 years and> 20 years, table 6.7.B. Comparisons were 
made between the patient subgroups as well as the normal controls. The 1.8, 1.8 genotype 
was significantly decreased in patients with an age at onset of 10-20 years compared to the 
controls 16.9% vs 51.3% (p = <0.000001, Pc= 0.000006). It was also decreased in patients 
with an age at onset of< 10 years and> 20 years compared to the controls (Pc= 0.03, Pc= 
0.006). The frequency of the 1.8, 1.8 genotype was increased in patients in the < lO years 
group compared to patients in the 10-20 years group 34.6% vs 16.9% (p = 0.002, Pc= 
0.006). A similar but smaller difference was seen in patients with an age at onset of> 20 
years compared to patients in the 10 -20 years age at onset group 30% vs 16.9% but the 
difference was non-significant when corrected (p = 0.03, Pc= ns). The 1.5, 1.5 genotype was 
significantly increased in patients diagnosed after the age of 20 compared to the normal 
controls 26.2% vs 7.1% (p = 0.00001, Pc= 0.00006). This was also found to a lesser extent 
in patients with an age at onset between 10-20 years compared to the controls 18.6% vs 
7.1% (p = 0.001, Pc= 0.006). There was a small increase in the frequency of the 1.5, 1.5 
genotype in patients with an age at onset of > 20 years compared to patients in the < 10 
years age at onset group 26.5% vs 14.2%, but the difference was not significant. The 
frequency of the l. 8, l. 5 genotype was significantly increased in the patients with an age at 
onset between 10-20 years compared to the controls 64.4% vs 41.3% (p = 0.00007, Pc= 
0.0004). A similar but less dramatic difference was also found in the frequency of the 
1.8,1.5 genotype in patients in the 10-20 years group compared to those in the> 20 years 
group 64.4% vs 43.7% (p = 0.004, Pc= 0.02). There were no other significant differences 
between the patient subgroups or the normal controls. 
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P3B 
Genotypes 
1.8,1.5 
1.8 
1.5 
Total (n) 
Males 
53.9 
(75) 
25.12 
(35) 
20.8 
(29) 
139 
Patients 
% 
Females 
54.3 
(87) 
28.1 1 
(45) 
17.sl 
(28) 
160 
Controls 
% 
Males Females 
44.8 42.1 
(35) (40) 
46.1 52.6 
(36) (50) 
8.9 5.2 
(7) (5) 
78 95 
Table 6.7.C Frequency ofMHC Class I P3B genotypes in patients and controls with 
respect to gender 
This table shows the distribution of P3B genotypes in patient and control subjects 
separated by gender. For each genotype the actual number of subjects and the frequency is 
shown for both genders in patients and controls. n represents the number of subjects in 
each gender group. Comparisons were made for each genotype between the male patients 
with the female patients and also the male and female patients and the male and female 
controls using the ·l test and 2 X 2 contingency tables. 
1 =female patient vs female control x} = 15.3, p = 0.00009 (ldf), Pc= 0.0005 
2 =male patient vs male control·l = 9.8, p = 0.001 (ldf), Pc= 0.006 
3 =female patient vs female control.,}= 7.9, p = 0.004 (Idf), Pc= 0.02 
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Differences in gender were investigated in both the patient and control populations with 
respect to P3B genotype and type I diabetes, table 6.7.C. When the control population was 
divided by gender there were more females to males, but the genotype frequencies were 
found to be in a similar range for both. There was a significant decrease in the I. 8, I. 8 
genotype in the female patients compared to the female controls 54.3% vs 42.1% (p = 
0.00009, Pc = 0.0005). A similar but less significant decrease was found in the male 
patients compared to the male controls 53.9% vs 44.8% (p = 0.001, Pc = 0.006). The 
opposite effect was seen with the 1.5, 1.5 genotype that was increased in the female patients 
compared to the female controls 17.5% vs 5,2% (p = 0.004, Pc= 0.02). The same increase 
in frequency was also found in the male patients compared to the male controls 20.8% vs 
8.9%, but the difference was non-significant when corrected (p = 0.02, Pc= ns). There were 
no other significant differences found between the patient subgroups or the normal controls. 
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P3B Age at onset of Diabetes Controls 
Genotypes (years) % 
< 10 10-20 >20 
0/o % % 
Males Females Males Females Males Females Males Females 
1.8,1.5 40 59.3 68.42'6 58.3 43.5 42.5 44.8 42.1 
(16) (35) (39 (35) (17) (17) (35) (40) 
1.8 35 33.9 19.34 16.61 25.6 32.5 46.1 52.6 
(14) (20) (11) (10) (10) (13) (36) (50) 
1.5 25 6.7 12.2 253 30.75 25 8.9 5.2 
(10) (4) (7) (15) (12) (10) (7) (5) 
Total (n) 40 59 57 60 39 40 78 95 
Table 6.7.D Frequency of MHC Class I P3B genotypes with respect to gender and age at onset 
This table shows the distribution of P3B genotypes in the patient subjects according to gender and age at onset and by gender in the control subjects. The 
actual number of subjects and the frequency is shown for all genotypes. The n value represents the number of subjects in each group. Comparisons were 
made using the x2 test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b )male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset group 
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1 =female patient 10-20 years vs female control·!!= 20.0, p = 0.000007 (1df), 
Pc= 0.00001 
2 =male patient 10-20 years vs male control·!!= 7.3, p = 0.00001 (1df), Pc= 0.0001 
3 =female patient 10-20 years vs female control x2 = 12.7, p = 0.0003 (ldf), Pc= 0.004 
4 =male patient 10-20 years vs male control x2 = 10.4, p = 0.001 (1df), Pc= O.ol 
5 =male patient> 20 years vs male control x2 = 9.0, p = 0.002 (1df), Pc= 0.02 
6 =male patient 10-20 years vs male patient< 10 years x2 = 7.7, p = 0.005 (1df), Pc= 0.07 
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The effect of gender and age at onset was analysed for P3B genotype in relation to type 1 
diabetes, table 6.7.D. There was a highly significant decrease in the frequency ofthe 1.8,1.8 
genotype in females with an age at onset between 10-20 years compared to the female 
controls 16.6% vs 52,3% (p = 0.000007, Pc = 0.00001). The frequency of the 1.8,1.5 
genotype in male patients with an age at onset between I 0-20 years was increased compared 
to the male controls 68.4% vs 44.8% (p = 0.00001, Pc= 0.0001). The 1.5,1.5 genotype was 
significantly increased in the female patients with an age at onset between 10-20 years 
compared to the female controls 25% vs 5.2% (p = 0.0003, Pc= 0.004). A similar but less 
significant increase was found in male patients with an age at onset of> 20 years compared 
to the male controls 30.7% vs 8.9% (p = 0.002, Pc= 0.02). There was a small difference in 
the frequency of the 1.8, 1.5 genotype in male patients in the 10-20 years group compared to 
male patients in the< 10 years group 68.4% vs 40% (p = 0.005, Pc= 0.07). Although there 
were other minor differences in the frequency of the P3B genotypes with age at onset and 
gender none of them were significant after correction of the p-value. 
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P3B Patients Controls 
Alleles 0/o % 
1.8 53.8 72.1 
(323) (283) 
1.5 46.12 27.8 
(277 (109) 
Total (n) 600 392 
Table 6.7.E Frequency ofMHC Class I P3B alleles in patients and controls 
This table shows the frequency of patients and controls with the 2 alleles of the genomic 
marker P3B. n represents the number of alleles for both patient and control subjects. The 
number in brackets is the actual number of each allele present. Comparisons were made 
between the patient and control subjects using the x2 test and 2 X 2 contingency tables. 
1 =patient vs control x2 = 33.62, p = <0.000001 (1df), Pc= <0.000001 
2 =patient vs control x2 = 33.62, p = <0.000001 (1df), Pc= <0.000001 
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A comparison of P3B allelic frequencies between patient and control subjects, table 6. 7.E, 
showed there was a highly significant increase in the frequency of the 1. 5 allele in the 
patients compared to the controls 46.1% vs 27.8% (p = <0.000001, Pc= <0.000001). There 
was a corresponding decrease in the frequency of the 1.8 allele in patients compared to the 
controls 53.8% vs 72.2% (p = <0.000001, Pc= <0.000001). 
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P3B Age at onset of Controls 
Alleles Diabetes (years) % 
< 10 10-20 > 20 
% % 0/o 
1.8 60.25'7 49.11 51.83 72.1 
(118) (116) (83) (283) 
1.5 39.86 50.82'8 48.14 27.8 
(78) (120) (77) (109) 
Total (n) 196 236 160 392 
Table 6. 7 .F Frequency of MHC Class I P3B alleles with respect to age at onset of 
diabetes 
This table shows the frequency ofP3B alleles in patients separated by age at onset into 
< 10, 10 - 20 and > 20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the x2 test and 2 X 2 contingency tables. 
1 =patient 10-20 years vs control x2 = 33.7, p = <0.000001 (1df), Pc= 0.000003 
2 =patient 10-20 years vs control x2 = 33.7, p = <0.000001 (1df), Pc= 0.000003 
3 =patient> 20 years vs control x2 = 21.1, p = 0.000004 (1df), Pc= 0.00001 
4 =patient> 20 years vs control x2 = 21.1, p = 0.000004 (ldf), Pc= 0.00001 
5 =patient< 10 years vs control x2 = 8.6, p = 0.003 (1df), Pc= 0.009 
6 =patient< 10 years vs control x2 = 8.6, p = 0.003 (1df), Pc= 0.009 
7 =patient< 10 years vs patient 10-20 years x2 = 5.2, p = 0.02 (1df), Pc= 0.06 
8 =patient 10-20 years vs patient< 10 years x2 = 5.2, p = 0.02 (1df), Pc= 0.06 
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The effect of age at onset and the relationship with P3B alleles,table 6.7.F, showed a highly 
significant decrease in the 1.8 allele in patients with an age at onset between 10-20 years 
compared to the controls 49.1% vs 72.1% (p = <0.000001, Pc= 0.000003). In contrast, the 
1.5 allele was significantly increased in the 10-20 years age at onset group compared to the 
controls 50.8% vs 27.8% (p = <0.000001, Pc = 0.000003). There was a similar but less 
significant decrease in the frequency of the 1.8 allele in patients diagnosed after the age of 
20 years compared to the controls 51.8% vs 72.1% (p = 0.000004, Pc= 0.00001). The 
opposite was found with the frequency of the 1.5 allele in patients diagnosed after the age of 
20 years compared to the controls 48.1% vs 27.8% (p = 0.000004, Pc= 0.00001). The same 
pattern was found with both the 1. 8 and 1.5 allele in patients in the < I 0 years group 
compared to the controls, the 1.8 allele decreased and the 1.5 allele showing an increased 
frequency, the resulting significance was the same for both alleles (p = 0.003, Pc= 0.009). 
The 1.8 allele was found more commonly in patients in the< 10 years group compared to 
the 10-20 years group 60.2% vs 49.1% (p = 0.02, Pc= 0.06). The reverse was found with 
the 1.5 allele that was increased in patients in the 10-20 years group compared to patients in 
the< 10 years group 50.8% vs 39.8% (p = 0.02, Pc= 0.06). There were no other significant 
differences found between any of the patient subgroups or the controls. 
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P3B Patients Controls 
Alleles 0/o % 
Males Females Males Females 
1.8 52.13 55.31 68.5 73.6 
(145) (177) (107) (140) 
1.5 47.84 44.62 31.4 26.3 
(133) (143) (49) (50) 
Total (n) 278 320 156 190 
Table 6.7.G Frequency of MHC Class I P3B alleles in patients and controls with 
respect to gender 
This table shows the frequency ofP3B alleles in patient and control subjects separated by 
gender. n represents the number of alleles for each gender group. The number in brackets 
is the actual number of allele present. Comparisons were made between the male patients 
with the female patients and also the male and female patients and male and female 
controls for each allele, using the x2 test and 2 X 2 contingency tables. 
1 =female patient vs female control x2 = 17.1, p = 0.00003 (I cif), Pc= 0.00009 
2 =female patient vs female control x2 = 17.1, p = 0.00003 (1df), Pc= 0.00009 
3 =male patient vs male control x2 = 11.0, p = 0.0008 (ldf), Pc= 0.002 
4 =male patient vs male control/= 11.0, p = 0.0008 (ldf), Pc= 0.002 
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When comparisons of P3B alleles were made in relation to gender, table 6.7.G, the 1.5 
allele was significantly increased in the female patients compared to the female controls 
44.6% vs 26.3% (p = 0.00003, Pc= 0.00009). A similarly significant decrease was found in 
the 1.8 allele in female patients compared to female controls 55.3% vs 73.6% (p = 0.00003, 
Pc= 0.00009). Less significant differences were observed in the male patients and controls, 
the 1.5 allele was increased in the patients compared to the control subjects 47.8% vs 31.4% 
(p = 0.0008, Pc = 0.002). In contrast, the 1.8 allele was decreased in the male patients 
compared to the male controls 52.1% vs 68.5% (p = 0.0008, Pc= 0.002). 
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P3B Age at onset of Diabetes Controls 
Alleles (years) o/o 
< 10 10-20 >20 
% % % 
-------
Males Females Males Females Males Females Males Females 
1.8 55 63.55 53.57 45.81 55.4 53.73 68.5 73.6 
(44) (75) (61) (SS) (SI) (43) (107) (140) 
1.5 45 36.4 46.48 54.12'6 44.5 46.24 31.4 26.3 
(36) (43) (53) (65) (41) (37) (49) (SO) 
Total (n) 80 118 114 120 92 80 156 190 
Table 6. 7 .H Frequency of MHC Class I P3B alleles with respect to gender and age at onset of diabetes 
This table shows the frequency of P3B alleles in the patient subjects according gender and age at onset and by gender in the control subjects. The n value 
represents the number of alleles in each subgroup. The number in brackets is the actual number of each allele present. Comparisons were made using the x2 
test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female age at onset groups 
d) male patient and female patient age at onset groups 
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1 = female patient 10-20 years vs female control ·/ = 24.4, p = <0.000008 ( 1 df), 
Pc= 0.00005 
2 =female patient 10-20 years vs female control--/= 24.4, p = <0.00001 (ldf), 
Pc= 0.00005 
3 = female patient > 20 years vs female control x2 = 1 0.2, p = 0.001 ( 1 df), Pc = 0.007 
4 = female patient> 20 years VS female control x2 = 1 0.2, p = 0.001 ( 1 df), Pc = 0.007 
5 = female patient> I 0 years vs female patient 10-20 years x2 = 7 .5, p = 0.006 ( 1 df), 
Pc= 0.04 
6 =female patient 10-20 years VS female patient< 10 years X2 = 7.5, p = 0.006 (ldf), 
Pc= 0.04 
7 = male patient 10-20 years vs male control x2 = 6.3, p = 0.01 ( 1 df), Pc = 0.07 
8 = male patient 10-20 years vs male control x2 = 6.3, p = 0.01 ( 1 df), Pc = 0.07 
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The data was analysed for both the effects of gender and age at onset of type I diabetes with 
P3B alleles, table 6.7.H. The frequency of the 1.5 allele was significantly increased in 
female patients with an age at onset between 10-20 years compared to the female controls 
54.1% vs 26.3% (p = <0.0000 1, Pc = 0.00005). In contrast, the 1.8 allele was decreased in 
female patients with an age at onset between 10-20 years compared to the female controls 
45.8% vs 73.6% (p = <0.000008, Pc= 0.00005). In female patients with an age at onset of> 
20 years compared to female controls a similar pattern of frequency was found with the 1.8 
and 1.5 alleles. The 1.5 allele increased in the > 20 years patients and the 1.8 allele 
decreased in the> 20 years patients both compared to normal female controls (p = 0.001, Pc 
= 0.007). The 1.8 allele was increased in female patients with an age at onset of< 10 years 
compared to female patients with an age at onset between 10-20 years 63.5% vs 45.8% (p = 
0.006, Pc = 0.04). The 1.5 allele was found at a higher frequency in female patients with an 
age at onset between 10-20 years compared to female patients with an age at onset of< 10 
years 54.1% vs 36.4% (p = 0.006, Pc = 0.04). Similar but less significant differences in 
allelic frequencies were found in the male patients and male controls. The 1.5 allele was 
increased in male patients with an age at onset between 10-20 years compared to compared 
to the male controls 46.4% vs 31.4% (p = 0.0 I, Pc = 0.07). In contrast, the 1.8 allele was 
decreased in males with an age at onset between I 0-20 years compared to the male controls 
53.5% vs 68.5% (p = 0.01, Pc = 0.07). There were no other significant differences found 
between any of the patient subgroups or the normal controls. 
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6.8 HLA-E 
HLA-E is one of the non-classical Class I (Class lb) genes. The gene coding for HLA-E is 
located approximately 650 kb telomeric ofHLA-B. As part of the Class lb group HLA-E is 
considered to demonstrate restricted polymorphism however, a number of allelic variants of 
HLA-E have been identified. 
6.8.1 Association of the HLA-E gene with type 1 diabetes 
4 alleles were detected at *exon 2 ofthe HLA-E gene designated, *OIOI, *OI02, *OI03 and 
*OI04 (Fig. 6.8). The resulting genotypes are OIOI,OIOI, OIOI,0102, OIOI,OI03, 
OIOI,OI04, 0102,0102, OI02,0I03, 0102,0I04, 0103,0103. 0103,0I04 and 0104,0104. Only 
nine out of the possible ten genotypes were detected. Out of the total patient population 
studied (Table 5:4) I99 patients with type I diabetes were analysed at the HLA-E locus and 
82 normal controls out of the control population. All of the data obtained from the patient 
subgroups and control subjects analysed with HLA-E exon 2 probes is presented in the 
following tables. Possible associations with alleles and genotypes of HLA-E were 
investigated along with the effects of gender and age at onset of type I diabetes. 
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11111 E2021 
11111 E2012 
11111 E2032 
11111 E2031 
~ E2022 
11111 E2011 
Fig 6.8 Allelic polymorphism of the HLA-E gene 
This an example of an autoradiograph using the 6 probes to detect the 4 
HLA-E alleles: - 0101, 0102, 0103, 0104. 
E2021: 0101,0102,0104 
E2012: 
E2032: 
E2031: 
E2022: 
0104 
0102 
0101,0103, 0104 
0103 
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HLA-E Patients Controls 
Genotypes % % 
0101 32.2 I 9.6 
(64) (8) 
0101,0102 7.5 15.9 
(15) (13) 
0101,0103 32.24 15.9 
(64) (13) 
0101,0104 4.0 6.1 
(8) (5) 
0102 2.0 6.1 
(4) (5) 
0102,0103 9.5 12.2 
(19) (10) 
0102,0104 3.52 15.9 
(7) (B) 
0103 5.1 2.4 
(10) (2) 
0103,0104 4.03 15.9 
(8) (13) 
Total (n) 199 82 
Table 6.8.A Frequency of MHC Class I HLA-E genotypes in patients and normal 
controls 
This table shows the frequency and actual number of patients and controls with the 9 
possible genotypes of HLA-E detected. The homozygous genotype 0104/0104 is not 
included in the table as it was absent in both the patient and control populations. n 
represents the number of patients and controls studied. The number in brackets represents 
the actual number of subjects with a particular genotype. Comparisons were made between 
the patient and control subjects for each genotype using the x2 test and 2 X 2 contingency 
tables. 
1 =patient vs control x2 = 15.3, p = 0.00009 (1df), Pc= 0.0007 
2 =patient vs control x2 = 13.3, p = 0.0002 (ldf), Pc= 0.001 
3 =patient vs control x2 = 11.7, p = 0.0006 (1df), Pc= 0.004 
4 =patient vs control x2 = 7.7, p = 0.005 (ldf), Pc= 0.025 
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When the genotypes of HLA-E were analysed in both patient and control populations, table 
6.8.A, it was found that the homozygous 0104,0104 genotype was not detected in either 
population. There was a significant increase in the frequency of the homozygous 0101,0101 
genotype in the patients compared to the controls 32.2% vs 9.6% (p = 0.00009, Pc = 
0.0007). This was accompanied by a significant decrease in both the 0102,0104 and 
0103,0104 genotypes in patients compared to controls (Pc= 0.001, Pc= 0.004) respectively. 
A less significant increase was found in the frequency of the 0101,0103 genotype in patients 
compared to controls 32.2% vs 15.9% (p = 0.005, Pc= 0.025). A small decrease was also 
detected in the 0101,0102 genotype in patient subjects compared to controls 7.5% vs 15.9% 
(p = 0.03), the p value was shown not to be significant when corrected. There were no other 
significant differences between the patients and normal controls. 
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HLA-E 
Genotypes 
0101 
0101,0102 
0101,0103 
0101,0104 
0102 
0102,0103 
0102,0104 
0103 
0103,0104 
Total (n) 
< 10 
% 
21.2 
(18) 
5.9 
(5) 
41.22 
(35) 
5.9 
(5) 
1.2 
(1) 
9.4 
(8) 
3.5 
(3) 
5.9 
(5) 
5.9 
(5) 
85 
Age at onset of 
Diabetes (years) 
10-20 
% 
47.0 1•3 
(31) 
7.6 
(5) 
19.7 
(13) 
4.5 
(3) 
3.0 
(2) 
9.1 
(6) 
3.0 
(2) 
3.0 
(2) 
3.0 
(2) 
66 
> 20 
% 
30.i 
(14) 
10.9 
(5) 
34.8 
(16) 
0 
(0) 
2.2 
(1) 
10.9 
(5) 
2.2 
(1) 
6.5 
(3) 
2.2 
(1) 
46 
Controls 
% 
9.6 
(8) 
15.9 
(13) 
15.9 
(13) 
6.1 
(5) 
6.1 
(5) 
12.2 
(10) 
15.9 
(13) 
2.4 
(2) 
15.9 
(13) 
82 
Table 6.8.B Frequency of MHC Class I HLA-E genotypes with respect to age at 
onset of diabetes 
This table shows the distribution ofHLA-E genotypes in patients separated by age at onset 
into <10, 10-20 and >20 years of age. For each genotype the actual number of and 
frequency is given. n represents the number of subjects in each age at onset group. 
Comparisons were made for each genotype between each age at onset group and the 
controls and the different age at onset groups using the x2 test and 2 X 2contingency tables. 
1 =patient 10-20 years vs control x2 = 26.0, p = <0.000003 (ldt), Pc= 0.00007 
2 =patient< 10 years vs control x2 = 13.0, p = 0.0003 (ldt), Pc= 0.0005 
3 =patient 10-20 years vs patient <10 years x2 = 11.2, p = 0.0007 (ldt), Pc= 0.001 
4 =patient> 20 years vs control x2 = 8.8, p = 0.002 (1dt), Pc= 0.006 
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The effect of age at onset of type I diabetes and the relationship with HLA-E genotype was 
examined by separating the patient population into 3 groups depending on the age at onset 
oftype I diabetes, <10 years, I0-20 years and >20 years, table 6.8.B. Comparisons were 
made between the patient subgroups and also the normal controls. The frequency of the 
010I,0101 genotype was significantly increased in patients with an age at onset between 10-
20 years compared to the controls 47.0% vs 9.6% (p = <0.000003, Pc = <0.00007). A 
similar but less dramatic difference was also found in the OI01,0101 frequency in patients 
with an age at onset of> 20 years compared to the controls 30.4% vs 9.6% (p = 0.002, Pc= 
0.006). The 010I,0103 genotype was significantly increased in patients in the < 10 years 
age at onset group compared to controls 41.2% vs I5.9% (p = 0.0003, Pc= 0.0005). The 
010I,OI03 genotype was also increased in the> 20 years group compared to controls 34.8% 
vs 15.9%, but the difference was non-significant after correction (p = 0.01, Pc= ns). The 
frequency ofthe 0101,0101 genotype was significantly increased in patients with an age at 
onset between I0-20 compared to patients diagnosed before the age of 10 years 47.0% vs 
21.2% (p = 0.0007, Pc= O.OOI). There was a significant increase in the 010I,0103 genotype 
in patients with an age at onset of< 10 years compared to patients in the 10-20 years group 
41.I% vs 19.7%, but the difference was non-significant after correction (p = 0.005, Pc= 
ns). There were no other significant differences between the patient subgroups or the normal 
controls. 
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HLA-E 
Genotypes 
0101 
0101,0102 
0101,0103 
0101,0104 
0102 
0102,0103 
0102,0104 
0103 
0103,0104 
Total (n) 
Male 
32.32 
(30) 
6.5 
(6) 
35.5 
(33) 
4.3 
(4) 
2.2 
(2) 
10.8 
(10) 
2.21 
(2) 
3.2 
(3) 
3.23 
(3) 
93 
Patients 
0/o 
Female 
32.1 
(34) 
8.5 
(9) 
29.2 
(31) 
3.7 
(4) 
1.9 
(2) 
8.5 
(9) 
4.7 
(5) 
6.6 
(6) 
4.7 
(5) 
106 
Controls 
% 
Male Female 
3.2 11.4 
(1) (5) 
9.7 20.5 
(3) (9) 
12.9 20.5 
(4) (9) 
9.7 4.5 
(3) (2) 
9.7 4.5 
(3) (2) 
6.5 15.9 
(2) (7) 
19.4 11.4 
(6) (5) 
9.7 0 
(3) (0) 
19.4 11.4 
(6) (5) 
31 44 
Table 6.8.C Frequency of MBC Class I HLA-E genotypes in patients and controls 
with respect to gender 
This table shows the distribution of HLA-E genotypes in patient and control subjects 
separated by gender. For each genotype the actual number of subjects and the frequency is 
shown for both genders in patients and controls. n represents the number of subjects in 
each gender group. Comparisons were made for each genotype between the male patients 
and the female patients and also the male and female patients and the male and female 
controls using the y} test and 2 X 2 contingency tables. 
1 =male patient vs male control x2 = 11.4, p = 0.0007 (1df), Pc= 0.01 
2 =male patient vs male control x2 = 10.4, p = 0.001 (1df), Pc= 0.02 
3 =male patient vs male control x2 = 8.9, p = 0.002 (1df), Pc= 0.04 
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Differences in gender were investigated in both the patient and control populations with 
respect to HLA-E genotype and type 1 diabetes, table 6.8.C. When the control population 
was divided by gender there were slightly more females than males. The genotype 
frequencies of the 0101,0101, 0101,0102 and 0101,0103 appeared to be increased in the . 
female controls compared to the male controls however, on analysis this was shown not to 
be significant. There was a significant decrease in the frequency of the 0102,0104 genotype 
in the male patients compared to the male controls 2.2% vs 19.4% (p = 0.0007, Pc= 0.01). 
Also a decrease in the 0103,0104 genotype in the male patients compared to the male 
controls 3.2% vs 19.4% (p = 0.002, Pc= 0.04). In contrast, there was a significant increase 
in the 0101,0101 genotype in the male patients compared to the male controls 32.3% vs 
3.2% (p = 0.001, Pc= 0.02). The 0101,0101 genotype was increased in female patients 
compared to female controls 32.1% vs 11.4%, but the increase was non-significant after 
correction (p = 0.008, Pc= ns). There were no other significant differences found between 
the patient subgroups or the normal controls. 
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HLA-E Age at onset of diabetes Controls 
Genotypes (years) 0/o 
< 10 10-20 >20 
0/o 0/o 0/o 
Male Female Male Female Male Female Male Female 
0101 19.4 20.8 46.91 47.1 2 29.2 34.8 3.2 11.4 
(7) (10) (IS) (16) (7) (8) (1) (5) 
0101,0102 2.8 8.3 6.3 8.8 12.5 8.7 9.7 20.5 
(1) (4) (2) (3) (3) (2) (3) (9) 
0101,0103 47.23 37.5 28.1 8.3 29.2 39.1 12.9 20.5 
(17) (I8) (9) (4) (7) (9) (4) (9) 
0101,0104 8.3 4.2 3.1 4.2 0 0 9.7 4.5 
(3) (2) (I) (2) (0) (0) (3) (2) 
0102 2.8 0 0 4.2 4.2 0 9.7 4.5 
(I) (0) (0) (2) (I) (0) (3) (2) 
0102,0103 8.3 10.4 12.5 4.2 12.5 8.7 6.5 15.9 
(3) (5) (4) (2) (3) (2) (2) (7) 
0102,0104 5.6 2.1 0 4.2 0 4.3 19.4 11.4 
(2) (1) (0) (2) (0) (I) (6) (5) 
0103 0 10.4 0 4.2 12.5 0 9.7 0 
(0) (5) (0) (2) (3) (0) (3) (0) 
0103,0104 5.6 6.3 3.1 2.1 0 4.3 19.4 11.4 
(2) (3) (1) (I) (0) (I) (6) (5) 
Total (n) 36 48 32 34 24 23 31 44 
Table 6.8.D Frequency of MHC Class I HLA-E genotypes with respect to gender and age at onset 
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This table shows the distribution of HLA-E genotypes in patient subjects according to 
gender and age at onset and by gender in the control subjects. The actual number of 
subjects and the frequency is shown for all genotypes. The n value represents the number 
of subjects in each group. Comparisons were made using the x2 test and 2 X 2 
contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
1 =male patient 10-20 years vs male control x2 = 15.8, p = 0.00006 (1df), Pc= 0.003 
2 =female patient 10-20 years vs female control x2 = 12.4, p = 0.0004 (1df), Pc= 0.02 
3 =female patient> 20 years vs female patient 10-20 years x2 = 10.4, p = 0.001 (1df), 
Pc= 0.05 
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The effect of gender and age at onset in relation to HLA-E genotype and type I diabetes, 
table 6.8.D. The frequency of the 0101,0101 genotype was significantly increased in the 
male patients with an age at onset between 10-20 years compared to the male controls 
46.9% vs 3.2% (p = 0.00006, Pc= 0.003). There was a similar increase in female patients 
with an age at onset between 10-20 years compared to the female controls 4 7.1% vs 11.4% 
(p = 0.0004, Pc = 0.02). The 0101,0103 genotype was significantly increased in male 
patients with an age at onset of< 10 years compared to female patients in the 10-20 years 
group 47.2% vs 8.3% (p = 0.001, Pc = 0.05). Although there were other minor differences 
in the frequency of HLA-E genotypes with age at onset and gender none of these were 
significant after correction of the p-value. 
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HLA-E Patients Controls 
Alleles % % 
0101 54.0 28.7 
(215) (47) 
0102 12.33 28.0 
(49) (46) 
0103 27.9 24.4 
(Ill) (40) 
0104 5.82 18.9 
(23) (31) 
Total (n) 398 164 
Table 6.8.E Frequency of MHC Class I HLA-E alleles in patients and normal controls 
This table shows the frequency of patients and controls with the 4 alleles of HLA-E. n 
represents the number of alleles for both patient and control subjects. The number in 
brackets is the actual number of each allele present. Comparisons were made between the 
patient and control subjects using the ·i test and 2 X 2 contingency tables. 
1 =patient vs control x2 = 30.0, p = <0.000001 (1dt), Pc= 0.000003 
2 =patient vs control x2 = 20.4, p = 0.000001 (1df), Pc= 0.000003 
3 =patient vs control x2 = 23.0, p = 0.000006 (1df), Pc= 0.00001 
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A comparison of allelic frequencies between patient and control subjects, table 6.8.E, found 
there was a highly significant increase in the frequency of the 0101 allele in patients 
compared to controls 54.0% vs 28.7% (p = <0.000001, Pc = <0.000003). This was 
accompanied by a significant decrease in the frequency of the 0102 allele in the patients 
compared to the controls 12.3% vs 28.0% (p = 0.000006, Pc = 0.00001). A similar 
significant decrease in the frequency of the 0104 allele was also detected in patients 
compared to the controls 4.8% vs 18.9% (p = 0.000001, Pc= 0.000003). The 0103 allele 
was slightly increased in the patients compared to the controls (27.9% vs 24.4%). 
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HLA-E Age at onset of Controls 
Alleles Diabetes (years) 0/o 
< 10 10-20 >20 
% % % 
0101 47.65 62.91,10 53.33 28.7 
(81) (83) (49) (47) 
0102 10.62 12.97 14.111 28.0 
(18) (17) (13) (46) 
0103 34.19 18.9 30.4 24.4 
(58) (25) (28) (40) 
0104 7.68 5.36 2.24 18.9 
(13) (7) (2) (31) 
Total (n) 170 132 92 164 
Table 6.8.F Frequency of MHC Class I HLA-E alleles with respect to age at onset 
of diabetes 
This table shows the frequency of HLA-E alleles in patients separated by age at onset into 
<10, 10-20 and >20 years of age. n represents the number of alleles in each age at onset 
group. The number in brackets is the actual number of each allele present. Comparisons 
were made between each age at onset group and the controls and between the different age 
at onset groups for each allele using the x2 test and 2 X 2 contingency tables. 
1 =patient 10-20 years vs control x2 = 42.7, p = <0.000001 (ldf), Pc= 0.000009 
2 =patient< 10 years vs control x2 = 16.4, p = 0.00005 (1df), Pc= 0.0004 
3 =patient> 20 years vs control x2 = 15.2, p = 0.00009 (1df), Pc= 0.0008 
4 =patient> 20 years vs control x2 = 14.6, p = 0.0001 (ldf), Pc= 0.0009 
5 =patient< 10 years vs control x2 = 12.7, p = 0.0003 (ldf), Pc= 0.002 
6 =patient 10-20 vs control x2 = 12.0, p = 0.0005 (1df), Pc= 0.004 
7 =patient 10-20 years vs control x2 = 10.0, p = 0.001(1df), Pc= 0.009 
8 =patient< 10 years vs control x2 = 9.2, p = 0.002 (1df), Pc= 0.01 
9 =patient< 10 years vs patient 10-20 years x2 = 8.5, p = 0.003 (ldf), Pc= 0.02 
10 =patient 10-20 years vs patient< 10 years x2 = 6.9, p = 0.008 (1df), Pc= 0.07 
11 =patient> 20 years vs control x2 = 6.4, p = 0.01 (1df), Pc= 0.09 
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The effect of age at onset and the associations of HLA-E alleles, table 6.8.F, showed there 
was a highly significant increase in the frequency of the 0101 allele in patients with an age 
at onset between I0-20 years compared to the controls 62.9% vs 28.7% (p = <0.000001, Pc 
= 0.000009). A similar pattern was observed in patients in the> 20 years group compared to 
the controls 53.3% vs 28.7% (p = 0.00009, Pc= 0.0008) and also in patients in the< IO 
years group compared to the controls 47.6% vs 28.7% (p = 0.0003, Pc= 0.002). In patients 
with an age at onset of < I 0 years there was a significant decrease in the frequency of the 
0102 allele compared to the normal controls I0.6% vs 28.0% (p = 0.00005, Pc= 0.0004). 
This decrease was also observed in patients with an age at onset between 10-20 years 
compared to the controls I2.9% vs 28.0% (p = O.OOI, Pc= 0.009) and to a lesser extent in 
patients in the> 20 years group I4.1% vs 28.0% (p = O.OI, Pc= 0.09). There was also a 
significant decrease in the 0 I 04 allele in patients with an age at onset of >20 years 
compared to the controls 2.2% vs 18.9% (p = O.OOOI, Pc= 0.0009). A similar decrease in 
the frequency of the 0 I 04 allele was detected in patients in the I 0-20 years group compared 
to-the controls 5.3% vs I8.9% (p = 0.0005, Pc= 0.004) and also in the <IO years group 
compared to the controls 7.6% vs I8.9% (p =0.002, Pc = O.OI). The OI03 allele was 
increased in patients with an age at onset of< I 0 years compared to patients in the I 0-20 
years group 34.I% vs I8.95 (p = 0.003, Pc= 0.02). The frequency of the 010I allele was 
increased in patients with an age at onset between I 0-20 years compared to patients 
diagnosed before the age of 10 years 62.9% vs 47.6% (p = 0.008, Pc= 0.07). There were no 
other significant differences found between the patient subgroups or the normal controls. 
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m...A-E Patients Controls 
Alleles % % 
Males Females Males Females 
0101 55.41 52.84 19.4 34.1 
(103) (112) (12) (30) 
0102 11.85 12.-f 27.4 28.4 
(22) (27) (17) (25) 
0103 28.0 27.8 29.0 23.9 
(52) (59) (18) (21) 
0104 4.82 6.6 24.2 13.6 
(9) (14) (15) (12) 
Total (n) 186 212 62 88 
Table 6.8.G Frequency of MHC Class I HLA-E alleles in patients and controls with 
respect to gender. 
This table shows the frequency of HLA-E alleles in patient and control subjects separated 
by gender. n represents the number of alleles for each gender group. The number in 
brackets is the actual number of each allele present. Comparisons were made between the 
male patients with the female patients and also the male and female patients and the male 
and female controls for each allele, using the ·l test and 2 X 2 contingency tables. 
1 =male patient vs male control x2 = 24.2, p = <0.000008 (ldf), Pc= 0.00007 
2 =male patient vs male control x2 = 19.9, p = 0.000008 (ldf), Pc= 0.00007 
3 =female patient vs female control x2 = 10.6, p = 0.001 (ldf), Pc= 0.009 
4 =female patient vs female control X2 = 8.7, p = 0.003 (ldf), Pc= 0.02 
5 =male patient vs male control x2 = 8.5, p = 0.003 (ldf), Pc= 0.02 
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When comparisons of HLA-E alleles were made with respect to gender, table 6.8.G, the 
0101 allele was significantly increased in male patients compared to the male controls 
(p = <0.000008, Pc = 0.00007). In contrast, there was a significant decrease in the 
frequency of the 0104 allele in male patients compared to the male controls 4.8% vs 24.2% 
(p = 0.000008, Pc = 0.00007). The 0102 allele was significantly decreased in the female 
patients compared to the female controls 12.7% vs 28.4% (p = 0.001, Pc= 0.009). A less 
significant decrease of the 0102 allele was found in the male patients compared to the male 
controls 11.8% vs 27.4% (p = 0.003, Pc = 0.02). There was a small increase in the 
frequency of the 0101 allele in the female patients compared to the female controls 52.8% 
vs 34.1% (p = 0.003, Pc= 0.02). There were no other significant differences between the 
patient subgroups or the normal controls. 
401 
HLA-E Age at onset of Diabetes Controls 
Alleles (years) % 
< 10 10-20 > 20 
o/o 0/o % 
Males Females Males Females Males Females Males Females 
0101 48.63 45.8 65.61 60.36 504 58.7 19.4 34.1 
(35) (44) (42) (41) (24) (27) (12) (30) 
0102 11.1 10.47 9.4 16.2 16.8 10.7 27.4 28.4 
(8) (10) (6) (11) (8) (S) (17) (25) 
0103 30.6 37.58 21.9 16.2 33.3 26.1 29.0 23.9 
(22) (36) (14) (11) (16) (12) (18) (21) 
0104 9.7 6.3 3.1s 7.4 02 4.3 24.2 13.6 
(7) (6) (2) (S) (0) (2) (IS) (12) 
Total (n) 72 96 64 68 48 46 62 88 
Table 6.8.H Frequency of MHC Class I RLA-E alleles with respect to gender and age at onset of diabetes 
This table shows the frequency of HLA-E alleles in the patient subjects according t gender and age at onset and by gender in the control subjects. 
The n value represents the number of alleles in each subgroup. The number in brackets is the actual number of each allele present. Comparisons 
were made using the ·/ test and 2 X 2 contingency tables between 
a) male patient and female patient age at onset groups and male and female controls 
b) male patient age at onset groups 
c) female patient age at onset groups 
d) male patient and female patient age at onset groups 
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1 =male patient 10-20 years vs male control·i = 27.5, p = <0.000002 (1df), Pc= 0.00004 
2 =male patient> 20 years vs male control x2 = 13.4, p = 0.0002 (1df), Pc= 0.004 
3 =male patient< 10 years vs male control x2 = 12.5, p = 0.0004 (1df), Pc= 0.008 
4 =male patient> 20 years vs male control x2 = 11.5, p = 0.0006 (1df), Pc= 0.01 
5 =male patient 10-20 years vs male control x2 = 10.2, p = 0.0005 (ldf), Pc= 0.001 
6 =female patient 10-20 years vs female control x2 = 10.6, p = 0.001 (ldf), Pc= 0.02 
7 =female patient< 10 years vs female control x2 = 9.6, p = 0.001 (1df), Pc= 0.02 
8 =female patient< 10 years vs female patient 10-20 years x2 = 8.8, p = 0.002 (ldf), 
Pc= 0.04 
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The effect of gender and age at onset was analysed for HLA-E alleles in relation to type I 
diabetes, table 6.8.H. The frequency of allele 0101 was significantly increased in male 
patients with an age at onset between 10-20 years compared to the male controls 65.6% vs 
19.4% (p = <0.000002, Pc = 0.00004). There was a similar significant increase in the 
frequency of the 0101 allele in male patients with an age at onset of< 10 years compared to 
male controls 48.6% vs 19.4% (p = 0.0004, Pc= 0.008). Also in male patients in the> 20 
years group compared to the controls 50% vs 19.4% (p = 0.0006, Pc= 0.01). In contrast, in 
male patients with an age at onset of> 20 years there was a significant decrease in the 
frequency of the 0104 allele compared to the male controls O%vs 24.2% (p = 0.0002, Pc= 
0.004). There was a similar but less significant decrease in the 0104 allele in male patients 
in the 10-20 years age group compared to the male controls (p = 0.0005, Pc= 0.01). The 
0101 allele was increased in female patients with an age at onset between 10-20 years 
compared to the female controls 60.3% vs 34.1% (p = 0.001, Pc = 0.02). There was a 
similar increase in the 0103 allele in female patients in the< 10 years age at onset group 
() 0..\.--Q. tl\lf. 
compared to the female controls 37.5% vs 23.9% (p = 0.002, Pc= 0.04). In female patients 
with an age at onset of< 10 years the frequency ofthe 0102 allele was decreased compared 
to the female controls 10.4% vs 28.4% (p = 0.001, Pc = 0.02). There were other minor 
differences in the frequency of the HLA-E alleles with age at onset and gender but none of 
these were significant after correction of the p-value. 
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6.9 Oass I haplotype analysis in patients with type 1 diabetes and normal controls 
6.9.1 Introduction 
Haplotypes of the five loci studied, P3A, 28L, 66R, P3B and HLA-E were determined in 
the patient subjects with type 1 diabetes and the nonnal control subjects. The two 
microsatellite markers P1 and D6S306 were not included in the haplotype analysis due to 
the large number of possible haplotypes arising from the two markers. This resulted in very 
small observed and expected haplotype frequencies, too small to be useful in the analysis 
for any significance. The frequency of 2, 3 and 4 loci haplotypes were detennined in 
subjects who were heterozygous at only one of the loci within a studied haplotype. The 
expected haplotype frequencies were obtained from the individual allelic frequencies. 
These were used to calculate linkage disequilibrium between the loci by comparing the 
observed and expected haplotypes using the x2 test. Using this method a bias may be 
introduced if there is a large number of double or triple heterozygotes. 
Haplotype frequencies were also investigated in the patient subjects with respect to age at 
onset of type 1 diabetes and also with respect to gender. 
In some of the haplotype analysis the numbers obtained for both the observed and expected 
haplotype frequencies were very small. If the observed or the expected haplotype 
frequency was < 5 these values were combined as an X haplotype, with an overall 
observed and expected frequency value. 
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6.9.2 Haplotype frequency in patient and normal controls: summary of results: 
Tables 6.9.1 - 6.9.48 
Overall there was little or no significant linkage in, 2, 3 or 4 loci haplotype analysis in both 
the patient population and the control population. Data that was found not to be significant 
after correction is not mentioned in the text. However, in the patient subjects 3 loci 
haplotype analysis showed some linkage in the P3B - 28L - HLA-E haplotype, table 
6.9.20. The observed frequency (5.6%) of the 1.8- 3.6-0103 haplotype was different to 
the expected frequency (1.8%) (p = 0.01, Pc = 0.08). There was also a difference in the 
observed and expected frequencies ofthe 1.5- 3.8-0101 haplotype 15.3% vs 7.1% (p = 
0.01, Pc= 0.08). 4loci haplotype analysis showed there was a significant difference in the 
observed and expected frequencies of the P3A- P3B- 28L- 66R haplotype 4- 1.5- 3.8-
4.5 in patients 12.1% vs 4% (p = 0.0007, Pc= 0.003), table 6.9.22. With the P3A- P3B-
28L - HLA-E haplotype 4 - 1.5 - 3.8 - 0101 (table 6.9.24) there was a significant 
difference in the observed and expected frequencies 15.9% vs 2.8% (p = 0.000001, Pc= 
0.000003). In some cases trends were found between certain loci in both the patient and 
control populations but after correction of the p-value these were non-significant. Data that 
was found to be non-significant after correction is not presented in the text. 
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P3A-P3B Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-1.8 110 44 117.2 47.0 0.4 
4-1.5 92 36.8 84.8 34.0 0.6 
3.8-1.8 36 14.4 27.6 11.1 2.7 
3.8-1.5 12 4.8 20.0 8.0 3.2 
Table 6.9.1 Frequency (%) of MHC Class 1 P3A- P3B haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous more than one locus). 
Comparisons were made between the observed and expected P3A- P3B haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A- P3B 
haplotypes. 
P3A-66R 
haplotype 
n 
Observed 
Freq 
Expected 
n Freq 
107 43.5 109 44.3 4-19 O.M 
94 38.2 92.8 37.7 4-4.5 0.02 
26 10.6 23.9 9.7 18-3.9 0.2 
19 7.7 20.4 8.3 3.8-4.5 0.1 
Table 6.9.2 Frequency (%) of MHC Class I P3A - 66R haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A - 66R 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- 66R haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A- 66R 
haplotypes 
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P3A-28L Observed 
haplotype 
Freq n 
4-4.3 85 39.7 
4-3.8 61 28.5 
4-3.6 34 15.9 
3.8-4.3 19 8.9 
3.8-3.8 9 4.2 
3.8-3.6 6 2.8 
n 
88.1 
59.3 
34.2 
16.8 
11.3 
6.5 
Expected 
Freq 
40.7 
27.4 
15.8 
7.8 
5.2 
3.0 
0.1 
0.05 
>0.01 
0.29 
0.47 
0.04 
Table 6.9.3 Frequency(%) ofMBC Class I P3A- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3 A - 28L 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- 28L haplotypes and r! 
values determined. The ·l test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A- 28L 
haplotypes. 
P3A-HLA-E Observed Expected '1.2 
haplotype 
n Freq n Freq 
4-0101 90 41.3 87.2 41.7 0.09 
4-0102 19 8.7 17.4 8.3 0.1 
4-0103 58 26.6 52.3 25.0 0.6 
4-0104 9 4.1 10.5 5.0 0.2 
3.8-0101 28 12.8 21.8 10.4 1.8 
3.8-0102 4 1.8 4.3 2.1 0.02 
3.8-0103 7 3.2 13.1 6.3 2.8 
3.8-0104 3 1.4 2.6 1.2 0.06 
Table 6.9.4 Frequency(%) ofMBC Class I P3A- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- HLA-
E haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- HLA-E haplotypes and 
l values determined. The x2 test was used to estimate linkage disequilibrium between the 
2 loci. There was no significant difference between the observed and expected P3A -
HLA-E haplotypes. 
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P3B-66R Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8- 4.5 62 28.2 59.4 26.7 0.1 
1.8- 3.9 71 32.3 73.9 33.3 0.1 
1.5- 4.5 38 17.3 39.6 17.8 0.01 
1.5- 3.9 49 22.3 49.3 22.2 >0.01 
Table 6.9.5 Frequency(%) ofMHC Class I P3B- 66R haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3B- 66R 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - 66R haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3B - 66R 
haplotypes. 
P3B-28L Observed 
haplotype 
Freq n 
1.8-4.3 64 33.3 
1.8-3.8 27 14.1 
1.8-3.6 25 13.0 
1.5-4.3 34 17.7 
1.5-3.8 32 16.7 
1.5-3.6 10 5.2 
n 
58.8 
35.7 
20.7 
39.2 
23.8 
13.8 
Expected 
Freq 
30.6 
18.6 
10.8 
20.4 
12.4 
7.2 
os 
2.1 
0.9 
0.7 
2.8 
1.0 
Table 6.9.6 Frequency(%) ofMHC Class I P3B- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3B - 28L 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - 28L haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3B - 28L 
haplotypes. 
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P3B-HLA-E Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8-0101 56 30.4 55.2 28.9 0.01 
1.8-0102 9 4.9 9.2 4.8 >0.01 
1.8-0103 28 15.2 27.6 14.5 >0.01 
1.8-0104 5 2.7 3.7 1.9 0.5 
1.5-0101 so 27.2 55.2 28.9 0.5 
1.5-0102 10 5.4 9.2 4.8 0.07 
1.5-0103 24 13.0 27.6 14.5 0.5 
1.5-0104 2 l.l 3.7 1.9 0.8 
Table 6.9.7 Frequency(%) ofMHC Class I P3B- HLA-E haplotype in patient 
This table shows the frequency and actual (observed) number of copies of the P3B - HLA-
E haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - HLA-E haplotypes and 
·l values determined. The x2 test was used to estimate linkage disequilibrium between the 
2 loci. There was no significant difference between the observed and expected P3B -
HLA-E haplotypes. 
66R-28L Observed 
haplotype 
Freq n 
4.5-4.3 38 19.6 
4.5-3.8 32 16.5 
4.5-3.6 18 9.2 
3.9-4.3 53 27.3 
3.9-3.8 30 15.5 
3.9-3.6 23 11.9 
n 
41.0 
27.9 
18.3 
50.1 
34.1 
22.4 
Expected 
Freq 
21.1 
14.4 
9.4 
25.9 
17.6 
11.6 
0.22 
0.6 
>0.01 
0.2 
0.5 
0.02 
Table 6.9.8 Frequency (%) of MHC Class I 66R- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the 66R - 28L 
haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected 66R - 28L haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected 66R - 28L 
haplotypes. 
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HLA-E-28L Observed Expected ·t 
haplotype 
n Freq n Freq 
0101-4.3 44 28.9 45.6 29.4 0.06 
0102-4.3 11 7.2 7.6 4.9 1.5 
0103-4.3 20 13.2 22.8 14.7 0.3 
0101-3.8 35 23.0 27.4 17.7 2.1 
0103- 3.8 8 5.3 13.7 8.8 2.4 
0101-3.6 16 10.5 18.2 11.7 0.3 
0103- 3.6 10 6.6 9.1 5.9 0.09 
X-X 8 5.3 10.6 6.8 0.6 
Table 6.9.9 Frequency(%) ofMHC Class I HLA-E- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the fll..A-E -
28L haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected fll..A-E - 28L haplotypes and 
x2 values determined. The x.2 test was used to estimate linkage disequilibrium between the 
2 loci. There was no significant difference between the observed and expected fll..A-E -
28L haplotypes. 
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HLA-E-66R Observed Expected '1.2 
haplotype 
n Freq n Freq 
0101-4.5 49 24.0 49.0 23.1 0 
0102-4.5 10 4.9 7.3 3.4 I 
0103-4.5 25 12.3 24.5 ll.6 0.01 
0104-4.5 7 3.4 4.1 1.9 2.1 
0101-3.9 75 36.8 73.4 34.6 0.03 
0102-3.9 9 4.4 11.0 5.2 0.4 
0103-3.9 26 12.7 36.7 17.3 3.1 
0104-3.9 3 1.5 6.1 2.9 1.6 
Table 6.9.10 Frequency(%) MHC Class I HLA-E- 66R haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the ID-A-E -
66R haplotypes detected within the patient population. Haplotypes were assigned in those 
. subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected ID-A-E- 66R haplotypes and 
x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 
2 loci. There was no significant difference between the observed and expected ID-A-E -
66R haplotypes. 
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P3A-P3B-66R Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-1.8-3.9 42 25.3 46.2 27.0 0.4 
4-1.5-3.9 31 18.7 30.8 18.0 >0.01 
4-1.8-4.5 34 20.5 35.9 21.0 0.1 
4-1.5-4.5 26 15.7 24 14.0 0.2 
3.8-1.8-3.9 12 7.2 11.6 6.8 0.01 
3.8 - 1.5 - 3.9 7 4.2 7.7 4.5 0.06 
3.8 - 1.8 - 4.5 12 7.2 9.0 5.3 1 
3.8-1.5-4.5 2 1.2 6 3.5 2.7 
Table 6.9.11 Frequency (%) of MHC Class I P3A- P3B- 66R haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
66R haplotypes detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at two or more loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- P3B - 66R haplotypes 
and r! values determined. The x2 test was used to estimate linkage disequilibrium between 
the 3 loci. Haplotypes that were not detected/observed in the patient population are not 
included in the above table. There was no significant difference between the observed and 
expected P3A- P3B- 66R haplotypes 
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P3A-P3B-28L Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-1.8-3.8 13 11.2 18.1 15.8 1.4 
4-1.5-3.8 18 15.5 10.2 8.9 6.0 1 
4-1.8-4.3 35 30.2 35.5 31.0 >0.01 
4-1.5-4.3 18 15.5 20.0 17.0 0.2 
4-1.8-3.6 12 10.3 10.3 9.0 0.3 
4-1.5-3.6 5 4.3 5.8 5.1 0.1 
3.8 - 1.8 - 4.3 10 8.6 5.3 4.6 4.2 
X-X-X 5 4.3 9.4 8.2 2.1 
Table 6.9.12 Frequency(%) MHC Oass I P3A- P3B- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
28L haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - P3B - 28L haplotypes and x2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. 
1 = 4- 1.5- 3.8 x2 = 6.0, p = 0.01 (1df), Pc= 0.07) 
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P3A-P3B-HLA-E Observed Expected '1.2 
haplotype 
n Freq n Freq 
4-1.8-0101 26 23.6 31.7 27.8 1 
4-1.5-0101 24 21.8 21.1 18.5 0.4 
4-1.8-0102 4 3.6 5.3 4.6 0.3 
4-1.5-0102 5 4.5 3.5 3.1 0.6 
4-1.8-0103 15 13.6 15.8 13.9 0.04 
4-1.5-0103 15 13.6 10.6 9.3 1.8 
3.8- 1.8- 0101 9 8.2 7.9 6.9 0.2 
3.8-1.5-0101 2 1.8 5.3 4.6 2.1 
X-X-X 10 9.1 13.2 11.5 9.5 
Table 6.9.13 Frequency(%) MHC Class I P3A- P3B- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
HLA-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- P3B - HLA-E haplotypes and x2 values determined. The x2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There were no significant 
differences between the observed and expected P3A- P3B- HLA-E haplotypes. 
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P3A-66R-28L Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-3.9-4.3 26 22.0 24.5 21.0 0.09 
3.8-3.9-4.3 5 4.2 5.0 4.3 0 
4-4.5-4.3 21 17.8 23.5 20.1 0.3 
3.8-4.5-4.3 6 5.1 4.8 4.1 0.3 
4-3.9-3.8 14 11.9 15.5 13.3 0.1 
4-4.5-3.8 18 15.3 14.9 12.8 0.6 
4-3.9-3.6 11 9.3 9.5 8.1 0.2 
4-4.5-3.6 8 6.8 9.1 7.8 0.1 
X-X-X 9 7.6 9.9 8.4 0.08 
Table 6.9.14 Frequency (%) MBC Class I P3A- 66R- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- 66R-
28L haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- 66R- 28L haplotypes and X2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There was no significant 
difference between the observed and expected P3A- 66R- 28L haplotypes. 
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P3B-66R-28L Observed Expected x2 
haplotype 
n Freq n Freq 
1.8 - 3.9 - 4.3 21 20.2 20.1 19.3 0.04 
1.5 - 3.9 - 4.3 12 11.5 10.8 10.4 0.1 
1.8 - 4.5 - 4.3 20 19.2 16.4 15.8 0.8 
1.5 - 4.5- 4.3 3 2.9 8.8 8.5 3.8 
1.8 - 3.9 - 3.8 5 4.8 10.8 10.4 3.1 
1.5 - 3.9 - 3.8 7 6.7 5.8 5.6 0.2 
1.8 - 4.5 - 3.8 8 7.7 8.8 8.5 0.07 
1.5 - 4.5 - 3.8 10 9.6 4.8 4.6 5.6 
1.8-3.9-3.6 9 8.7 6.3 6.1 1.2 
1.8 - 4.5 - 3.6 5 4.8 5.2 5 >0.01 
X-X-X 4 3.9 6.2 6 0.8 
Table 6.9.15 Frequency(%) MHC Class I P3B- 66R- 28L haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3B - 66R -
28L haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of> 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B- 66R- 28L haplotypes and r! values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There were no significant 
differences between the observed and expected P3B - 66R - 28L haplotypes. 
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P3A-66R-HLA-E Observed Expected .,: 
haplotype 
n Freq n Freq 
4-4.5-0101 21 18.4 21.9 18.1 0.04 
4-3.9-0101 32 28.1 32.8 27.1 0.02 
4-3.9-0102 6 5.3 5.5 4.5 0.05 
4-4.5-0103 14 12.3 10.9 9.0 0.9 
4-3.9-0103 10 8.8 16.4 13.6 2.5 
3.8- 4.5- 0101 4 3.5 5.5 4.5 0.4 
3.8- 3.9- 0101 10 8.8 8.2 6.8 0.4 
X-X-X 17 15.1 19.5 16.1 0.3 
Table 6.9.16 Frequency(%) MHC Class I P3A- 66R- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- 66R-
:En...A-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- 66R- :En...A-E haplotypes and r! values determined. The ·,} test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There was no significant 
difference between the observed and expected P3A- 66R- :En...A-E haplotypes. 
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P3A-28L-HLA-E Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-4.3-0101 24 26.7 25.9 29.1 0.1 
4-3.8-0101 15 16.7 13.0 14.6 0.3 
4-3.6-0101 6 6.7 4.3 4.8 0.7 
4-4.3-0103 11 12.2 13.0 14.6 0.3 
4-3.8-0103 5 5.6 6.5 7.3 0.3 
4-3.6-0103 5 5.6 2.2 2.5 3.6 
3.8- 4.3- 0101 6 6.7 6.5 7.3 0.04 
3.8-3.8- 0101 5 5.6 3.2 3.6 1.0 
X-X-X 13 14.3 14.4 16.1 0.1 
Table 6.9.17 Frequency (%) MHC Class I P3A- 28L- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3A- 28L-
HLA-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- 28L - HLA-E haplotypes and 7.2 values determined. The 7.2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There were no significant 
differences between the observed and expected P3A- 28L- HLA-E haplotypes. 
P3B-66R-HLA-E Observed Expected ·£ 
haplotype 
n Freq n Freq 
1.8- 4.5- 0101 12 12.5 20.7 19.3 3.7 
1.8- 3.9- 0101 21 21.9 17.3 16.2 0.8 
1.8- 4.5- 0103 9 9.4 10.3 9.6 0.2 
1.8- 3.9- 0103 6 6.3 8.6 8.0 0.8 
1.5- 4.5- 0101 11 11.5 13.8 12.9 0.6 
1.5- 3.9- 0101 16 16.7 11.5 10.7 1.8 
1.5- 4.5- 0103 5 5.2 6.9 6.4 0.5 
1.5- 3.9- 0103 5 5.2 5.8 5.4 0.1 
X-X-X 11 11.3 11.6 10.7 0.03 
Table 6.9.18 Frequency(%) MHC Class I P3B- 66R- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3B - 66R -
Ill..A-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B - 66R - Ill..A-E haplotypes and ·l values determined. The ·l test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There were no significant 
differences between the observed and expected P3B- 66R- Ill..A-E haplotypes. 
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P3B-28L-HLA-E Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8- 4.3- 0101 IS 20.8 15.6 21.4 0.02 
1.8- 3.8- 0101 6 8.3· 7.8 10.7 0.4 
1.8- 4.3- 0102 5 6.9 2.1 2.9 4.0 
1.8- 4.3- 0103 9 12.5 7.8 10.7 0.2 
1.8- 3.6- 0103 4 5.6 1.3 1.8 5.61 
1.5- 4.3- 0101 11 15.3 10.4 14.3 0.03 
1.5-3.8- 0101 11 15.3 5.2 7.1 6.52 
1.5-4.3- 0103 2 2.8 5.2 7.1 2.0 
X-X-X 9 12.6 17.49 23.9 4.1 
Table 6.9.20 Frequency(%) MHC Oass I P3B- 28L- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the P3B- 28L-
ID...A-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B - 28L - ID...A-E haplotypes and ·i values determined. The x2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. 
1 = 1.8-3.6-0103 x2 = 5.6, p = O.Ol(ldt), Pc= 0.08 
2 = 1.5- 3.8- 0101 x2 = 6.5, p = O.Ol(ldf), Pc= 0.08 
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28L- 66R-HLA-E Observed Expected ·l 
haplotype 
n Freq n Freq 
4.3-4.5-0101 10 10.6 14.1 18.1 1.2 
4.3- 3.9- 0101 20 21.3 14.1 18.1 2.5 
4.3-4.5- 0102 5 5.3 2.4 3.1 2.8 
4.3- 4.5- 0103 5 5.3 4.7 6.0 0.02 
4.3-3.9- 0103 7 7.4 4.7 6.0 1.1 
3.8- 4.5- 0101 11 11.7 5.6 7.2 5.2 
3.8-3.9-0101 9 9.6 5.6 7.2 2.1 
3.6-4.5- 0101 4 4.3 5.6 7.2 0.5 
3.6-3.9- 0101 7 7.4 5.6 7.2 0.4 
X-X-X 16 17.3 15.4 19.9 0.02 
Table 6.9.21 Frequency(%) MHC Class I 28L- 66R- HLA-E haplotype in patients 
This table shows the frequency and actual (observed) number of copies of the 28L - 66R -
lfl..A-E haplotypes detected within the patient population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected 28L - 66R - lfl..A-E haplotypes and X2 values determined. The X2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the patient population are not included in the above table. There were no significant 
differences between the observed and expected 28L- 66R -lfl..A-E haplotypes. 
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P3A- P3B-28~6R Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-1.8-4.3-3.9 9 15.5 8.2 15.6 0.08 
4 - 1.8 - 4.3 - 4.5 9 15.5 8.2 15.6 0.08 
4-1.5-3.8-4.5 7 12.1 2.1 4.0 11.41 
3.8-1.8-4.3-4.5 5 8.6 2.0 3.9 4.3 
X-X-X-X 28 48.1 35.5 64.5 1.6 
Table 6.9.22 Frequency (%) MHC Oass I P3A - P3B - 28L - 66R haplotype in 
patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
28L - 66R haplotypes detected within the patient population. The X - X - X - X 
haplotype represents haplotypes, which were detected at an observed or expected 
frequency of < 5. Haplotypes were assigned in those subjects who were homozygous at 
three or more loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made 
between the observed and expected P3A - P3B - 28L - 66R haplotypes and ·l values 
determined. The x2 test was used to estimate linkage disequilibrium between the 4 loci. 
Haplotypes that were not detected in the patient population are not included in the above 
table. 
1 = 4-1.5-3.8-4.5 x2 = 11.4, p = 0.0007 {1dt), Pc= 0.003 
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P3A- P3B-66R-HLA-E Observed Expected ·l 
haplotype 
n Freq n Freq 
4- 1.8- 4.5- 0101 6 12 8.4 14 0.7 
4- 1.8- 3.9- 0101 7 14 8.4 14 0.2 
4- 1.5- 4.5- 0101 7 14 5.6 9.3 0.4 
4- 1.5- 3.9- 0101 6 12 5.6 9.3 0.03 
X-X-X-X 24 48 32.1 53.2 2.0 
Table 6.9.23 Frequency (%) MHC Class I P3A - P3B- 66R- HLA-E haplotype in 
patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
66R - HLA-E haplotypes detected within the patient population. The X - X - X - X 
haplotype represents haplotypes, which were detected at an observed or expected 
frequency of < 5. Haplotypes were assigned in those subjects who were homozygous at 
three or more loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made 
between the observed and expected P3A - P3B - 66R - HLA-E haplotypes and x2 values 
determined. The x2 test was used to estimate linkage disequilibrium between the 4 loci. 
Haplotypes that were not detected in the patient population are not included in the above 
table. There was no significant difference between the observed and expected P3A- P3B-
66R- HLA-E haplotypes. 
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P3A- P3B-28L-HLA-E Observed Expected ·l 
haplotype 
n Freq n Freq 
. 4-1.8-4.3-0101 10 22.7 10.3 22.1 0.008 
4-1.8-3.8-0101 0 0 3.0 6.4 3.0 
4- 1.8- 4.3- 0103 5 11.4 5.2 11.2 0.008 
4- 1.5-3.8- 0101 7 15.9 1.3 2.8 25.01 
X-X-X-X 22 47.6 28.9 57.4 1.6 
Table 6.9.24 Frequency(%) MHC Class I P3A- P3B- 28L- HLA-E haplotype in 
patients 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
28L - lll..A-E haplotypes detected within the patient population. The X - X - X - X 
haplotype represents haplotypes, which were detected at an observed or expected 
frequency of< 5. Haplotypes were assigned in those subjects who were homozygous at 
three or more loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made 
between the observed and expected P3A- P3B- 28L -lll..A-E haplotypes and x2 values 
determined. The x2 test was used to estimate linkage disequilibrium between the 4 loci. 
Haplotypes that were not detected in the patient population are not included in the above 
table. There was no significant difference between the observed and expected P3A- P3B-
66R - lll..A-E haplotypes. 
1 = 4- 1.5- 3.8-0101 x2 = 25.0, p = O.OOOOOl(ldf), Pc= 0.000003 
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P3A-P3B Observed Expected "1: 
haplotype 
n Freq n Freq 
4-1.8 180 58.1 198.4 64 1.7 
4-1.5 56 18.1 49.6 16 0.8 
3.8-1.8 58 18.7 49.6 16 1.4 
3.8-1.5 16 5.2 12.4 4 1.0 
Table 6.9.25 Frequency(%) MHC Class I P3A- P3B.baplotype in normal controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual ·allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- P3B haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A - P3B 
haplotypes. 
P3A-66R Observed 
haplotype 
Freq n 
4-3.9 94 53.4 
4-4.5 50 28.4 
3.8-3.9 26 14.8 
3.8-4.5 6 3.4 
n 
98.6 
42.2 
24.6 
10.6 
Expected 
Freq 
56.0 
24.0 
14.0 
6.0 
0.2 
1.4 
0.08 
2.0 
Table 6.9.26 Frequency(%) MHC Class I P3A- 66R haplotype in normal controls 
This table shows the frequency and actual (observed) number of copies of the P3A- 66R 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- 66R haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A- 66R 
haplotypes. 
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P3A-28L Observed Expected 
·i 
haplotype 
n Freq n Freq 
4-4.3 67 44.1 60.8 40.0 0.6 
4-3.8 45 29.6 48.6 32.0 0.3 
4-3.6 13 8.6 12.2 8.0 0.05 
3.8-4.3 15 10.0 15.2 10 >0.01 
3.8-3.8 9 5.9 12.2 8.0 0.8 
3.8-3.6 3 2.0 3.0 2.0 0 
Table 6.9.27 Frequency(%) MHC Class I P3A- 28L haplotype in nonnal controls 
This table shows the frequency and actual (observed) number of copies of the P3A-28L 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A- 28L haplotypes and ·l 
values determined. The ·!} test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3A - 28L 
haplotypes. 
P3A- HLA-E Observed Expected ·i 
haplotype 
n Freq n Freq 
4-0101 23 26.1 21.l 24.0 0.2 
4-0102 19 21.6 21.l 24.0 0.2 
4-0103 19 21.6 14.1 16.0 1.7 
4-0104 13 14.8 14.1 16.0 0.09 
3.8-0101 6 6.8 5.3 6.0 0.09 
3.8-0102 5 5.7 5.3 6.0 0.02 
X-X 3 3.4 7 8.0 2.3 
Table 6.9.28 Frequency (%) MHC Class I P3A - HLA-E haplotype in nonnal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- HLA-
E haplotypes detected within the control population. The X - X haplotype represents 
haplotypes, which were detected at an observed or expected frequency of< 5. Haplotypes 
were assigned in those subjects who were homozygous one or both loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - HLA-E haplotypes and X2 values determined. The X2 test was used to 
estimate linkage disequilibrium between the 2 loci. There was no significant difference 
between the observed and expected P3A- HLA-E haplotypes. 
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P3B-66R Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8- 4.5 42 25.3 39.1 26.7 0.2 
1.8- 3.9 88 53.0 78.2 53.3 1.2 
1.5- 4.5 12 7.2 9.8 8.7 0.5 
1.5- 3.9 24 14.5 19.6 13.4 1.0 
Table 6.9.29 Frequency (%) MHC Class I P3B - 66R haplotype in normal controls 
This table shows the frequency and actual (observed) number of copies of the P3B - 66R 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B- 66R haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3B - 66R 
haplotypes. 
P3B-28L Observed 
haplotype 
Freq n 
1.8-4.3 65 43.3 
1.8-3.8 42 28 
1.8-3.6 14 9.3 
1.5-4.3 17 11.3 
1.5-3.8 11 7.3 
1.5-3.6 1 0.7 
n 
60 
48 
12 
15 
12 
3 
Expected 
Freq 
40.0 
32.0 
8.0 
10.0 
8.0 
2.0 
0.4 
0.8 
0.3 
0.3 
0.08 
1.3 
Table 6.9.30 Frequency(%) MHC Class I P3B- 28L haplotype in normal controls 
This table shows the frequency and actual (observed) number of copies of the P3B - 28L 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - 28L haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected P3B - 28L 
haplotypes. 
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P3B-HLA-E Observed Expected 
·i 
haplotype 
n Freq n Freq 
1.8-0101 28 33.3 55.2 28.9 0.01 
1.8--0102 18 21.4 9.2 4.8 >0.01 
1.8-- 0103 18 21.4 27.6 14.5 >0.01 
1.8-- 0104 8 9.5 3.7 1.9 0.5 
1.5-0101 6 7.1 55.2 28.9 0.5 
1.5-0102 10 6.0 9.2 4.8 0.07 
X-X I 1.2 2.8 3.4 1.2 
Table 6.9.31 Frequency (%) MHC Class I P3B - HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3B - HLA-
E haplotypes detected within the control population. The X - X haplotype represents 
haplotypes, which were detected an observed or expected frequency of < 5. Haplotypes 
were assigned in those subjects who were homozygous at one or both loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B - 28L haplotypes and y} values determined. The x2 test was used to estimate 
linkage disequilibrium between the 2 loci. Haplotypes that were not detected in the control 
population are not included in the above table. There was no significant difference between 
the observed and expected P3B - 28L haplotypes. 
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66R-28L Observed Expected 
·J! 
haplotype 
n Freq n Freq 
4.5-4.3 18 13.2 20.4 15.1 0.3 
4.5-3.8 16 11.8 16.3 12.1 >0.01 
4.5-3.6 8 5.9 3.7 2.7 5.0 
3.9-4.3 55 40.4 47.6 35.3 1.2 
3.9-3.8 35 25.7 38.1 28.3 0.3 
3.9-3.6 4 2.9 8.6 6.4 2.5 
Table 6.9.32 Frequency(%) MHC Class I 66R- 28L haplotype in normal controls 
This table shows the frequency and actual (observed) number of copies of the 66R- 28L 
haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected 66R - 28L haplotypes and ·l 
values determined. The ·i test was used to estimate linkage disequilibrium between the 2 
loci. There was no significant difference between the observed and expected 66R- 28L 
haplotypes. 
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HLA-E•28L Obsenred Expected "1.2 
haplotype 
n Freq n Freq 
0101-4.3 12 7.1 16.8 25.2 1.4 
0102-4.3 15 21.4 12.6 18.9 0.5 
0103-4.3 9 12.9 8.4 12.6 0.04 
0104-4.3 7 10 4.2 6.3 1.9 
0101-3.8 12 17.1 8.4 12.6 1.5 
0102-3.8 6 8.6 6.3 9.4 O.oi 
X-X 9 12.9 10 16.1 0.1 
Table 6.9.33 Frequency (%) MHC Class I HLA-E - 28L haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the HLA-E -
28L haplotypes detected within the control population. The X - X haplotype represents 
haplotypes, which were detected at an observed or expected frequency of< 5. Haplotypes 
were assigned in those subjects who were homozygous at one or both loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected HLA-E - 28L haplotypes and x2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 2 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected HLA-E- 28L haplotypes. 
431 
HLA-E-66R Observed Expected '1..2 
genotype 
n Freq n Freq 
0101-4.5 9 11.3 7.2 9.0 0.5 
0102-4.5 6 7.5 7.2 9.0 0.2 
0103-4.5 5 6.3 7.2 9.0 0.7 
0104-4.5 1.3 2.4 3.0 0.8 
0101-3.9 17 21.2 16.8 21.0 0.002 
0102-3.9 17 21.2 16.8 21.0 0.002 
0103-3.9 16 20.0 16.8 21.0 0.04 
0104-3.9 9 11.3 5.6 7.0 2.1 
Table 6.9.34 Frequency (%) MHC Class I HLA-E - 66R haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the HLA-E -
66R haplotypes detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected HLA-E - 66R haplotypes and 
x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 
2 loci. There was no significant difference between the observed and expected HLA-E -
66R haplotypes. 
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P3A- P3B- 66R Observed Expected 
·l 
genotype 
n Freq n Freq 
4- 1.8- 3.9 54 49.1 55.4 49.9 0.04 
4-1.5-3.9 13 11.8 13.9 12.5 0.06 
4-1.8-4.5 24 21.8 24.8 22.3 0.03 
4-1.5-4.5 5 4.5 5.9 5.3 0.1 
3.8 - 1.8 - 3.9 10 9.1 6.2 5.6 2.3 
X-X-X 4 3.6 4.8 4.3 0.4 
Table 6.9.35 Frequency (%) MHC Class I P3A- P3B- 66R haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
66R haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- P3B- 66R haplotypes and x2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. There was no significant difference 
between the observed and expected P3A- P3B - 66R haplotypes. 
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P3A-P3B-28L Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-1.8-3.8 25 22.7 21.1 20.0 0.7 
4-1.5-3.8 7 6.4 5.3 5.0 0.5 
4-1.8-4.3 43 39.1 42.2 40.0 0.02 
4-1.5-4.3 9 8.2 10.6 10.0 0.2 
4-1.8-3.6 9 8.2 6.3 6.0 1.2 
3.8 - 1.8 - 3.8 5 4.5 5.3 5.0 0.02 
3.8 - 1.8 - 4.3 8 7.3 10.6 10.0 0.6 
X-X-X 4 3.6 5.9 5.6 0.6 
Table 6.9.36 Frequency (%) MHC Class I P3A - P3B- 28L haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
28L haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - P3B - 28L haplotypes and ·l values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control . population are not included in the above table. There was no significant 
difference between the observed and expected P3A- P3B- 28L haplotypes. 
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P3A-P3B-HLA-E Observed Expected '1.2 
haplotype 
n Freq n Freq 
4-1.8-0101 16 28.6 18.1 36.2 0.2 
4-1.8-0102 9 16.1 9.1 18.2 0.001 
4-1.8-0103 12 21.4 9.1 18.2 0.9 
4-1.8-0104 7 12.5 4.5 9 1.4 
X-X-X 12 21.7 9.9 18.9 0.4 
Table 6.9.37 Frequency(%) MHC Class I P3A- P3B- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
Ill...A-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - P3B - Ill...A-E haplotypes and 1.2 values determined. The x? test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3A- P3B - Ill...A-E haplotypes. 
435 
P3A-66R-28L Observed Expected 
·l 
haplotype 
n Freq n Freq 
4-3.9-4.3 37 38.5 30.2 32.6 1.5 
4-4.5-4.3 10 10.4 13.0 14.0 0.7 
4-3.9-3.8 18 18.8 24.2 26.1 1.6 
3.8-3.9-3.8 6 6.3 2.7 2.9 4.0 
4-4.5-3.8 12 12.5 10.4 11.2 0.2 
X-X-X 13 13.5 12.2 15.0 0.05 
Table 6.9.38 Frequency (%) MHC Class I P3A- 66R- 28L haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- 66R-
28L haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - 66R- 28L haplotypes and X2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3A- 66R- 28L haplotypes. 
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P3B-66R-28L Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8 - 3.9- 4.3 36 39.1 30.9 34.4 0.8 
1.5 - 3.9 - 4.3 6 6.5 1.1 8.6 0.4 
1.8 - 4.5 - 4.3 8 8.7 13.2 14.7 2.0 
1.8 - 3.9 - 3.8 18 19.6 15.5 17.2 0.4 
1.8 - 4.5 - 3.8 9 9.8 6.6 7.3 0.9 
X-X-X 15 16.3 16.0 17.8 0.06 
Table 6.9.39 Frequency (%) MHC Class I P3B- 66R- 28L haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3B - 66R -
28L haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B - 66R- 28L haplotypes and X2 values determined. The x2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3B - 66R- 28L haplotypes. 
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P3A-66R-HLA-E Observed Expected 1..2 
haplotype 
n Freq n Freq 
4-4.5-0101 5 11.4 4.8 9.3 0.008 
4-3.9-0101 9 20.5 12.7 24.5 1.1 
4-3.9-0102 8 18.2 6.3 12.2 0.5 
4-3.9-0103 9 20.5 9.5 18.3 0.03 
4-3.9-0104 6 13.6 6.3 12.2 0.01 
X-X-X 7 15.9 12.2 24.2 2.2 
Table 6.9.40 Frequency (%) MBC Class I P3A- 66R- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- 66R-
HLA-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- 66R- HLA-E haplotypes and X2 values determined. The x2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3A- 66R- HLA-E haplotypes. 
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P3A-28L-HLA-E Observed 
haplotype 
Freq n 
4-4.3-0101 4 6.9 
4-3.8-0101 6 3.5 
4-4.3-0102 9 6.9 
4-4.3-0103 6 4.6 
X-X-X 21 48.2 
n 
6.9 
3.5 
6.9 
4.6 
24.5 
Expected 
Freq 
15 
7.6 
15 
10 
53.4 
1.2 
1.8 
0.6 
0.3 
0.5 
Table 6.9.41 Frequency(%) MHC Class I P3A- 28L- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3A- 28L-
HLA-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- 28L- HLA-E haplotypes and x2 values determined. The x_2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3A- 28L- HLA-E haplotypes. 
P3B-66R-HLA-E Observed 
haplotype 
n Freq 
1.8- 4.5- 0101 7 14.0 
1.8-3.9- 0101 12 24.0 
1.8-3.9- 0102 8 16.0 
1.8-3.9-0103 9 18.0 
X-X-X 14 28.0 
n 
5.4 
12.6 
9.5 
6.3 
15.4 
Expected 
Freq 
11.0 
25.7 
19.4 
12.9 
31.3 
0.5 
0.03 
0.3 
0.2 
0.1 
Table 6.9.42 Frequency (%) MHC Class I P3B- 66R- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3B - 66R-
HLA-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of< 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual ailelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B- 66R- HLA-E haplotypes and x2 values determined. The x_2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3B- 66R- HLA-E haplotypes. 
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P3B-28L-HLA-E Observed Expected 
·l 
haplotype 
n Freq n Freq 
1.8-4.3-0101 7 15.9 8.4 18.0 0.2 
1.8-3.8- 0101 7 15.9 4.2 9.0 1.9 
1.8- 4.3- 0102 6 13.6 6.3 13.5 0.01 
1.8-4.3- 0103 7 15.9 6.3 13.5 0.08 
X-X-X 17 38.6 21.5 45.8 0.9 
Table 6.9.44 Frequency (%) MHC Class I P3B- 28L- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the P3B - 28L -
HLA-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3B - 28L- HLA-E haplotypes and X2 values determined. The X2 test was used to 
estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected P3B- 28L- HLA-E haplotypes. 
28L- 66R-HLA-E Observed 
haplotype 
Freq n 
4.3 '- 3.9- 0101 5 11.4 
4.3-3.9- 0102 8 18.2 
3.8-3.9-0101 7 15.9 
X-X-X 24 54.0 
n 
6.2 
4.6 
6.2 
20.5 
Expected 
Freq 
16.6 
12.3 
16.6 
55.3 
0.2 
2.5 
0.1 
0.6 
Table 6.9.45 Frequency(%) MHC Class I 28L- 66R- HLA-E haplotype in normal 
controls 
This table shows the frequency and actual (observed) number of copies of the 28L - 66R -
HLA-E haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of > 5. 
Haplotypes were assigned in those subjects who were homozygous at two or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected 28L- 66R- HLA-E haplotypes and X2 values determined. The X2 test was used 
to estimate linkage disequilibrium between the 3 loci. Haplotypes that were not detected in 
the control population are not included in the above table. There was no significant 
difference between the observed and expected 28L- 66R- HLA-E haplotypes. 
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P3A- P3B-28L-66R Observed Expected 
·l 
haplotype 
n Freq n Freq 
4- 1.8 - 4.3 - 3.9 25 39.1 21.8 32.5 0.5 
4 - 1.8 - 3.8- 3.9 10 15.6 14.5 21.6 1.4 
4 - 1.8 - 3.8 - 4.5 7 10.9 6.2 9.3 0.1 
X-X-X-X 21 34.5 25.1 37.3 0.7 
Table 6.9.46 Frequency (%) MHC Class I P3A- P3B - 28L - 66R haplotype in 
normal controls 
This table shows the frequency and actual (observed) number of copies ofthe P3A- P3B-
28L - 66R haplotypes detected within the control population. The X - X - X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at three or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A - P3B - 28L - 66R haplotypes and ·i values determined. The x2 test was 
used to estimate linkage disequilibrium between the 4 loci. Haplotypes that were not 
detected in the control population are not included in the above table. There was no 
significant difference between the observed and expected P3A - P3B - 28L - 66R 
haplotypes. 
P3A- P3B-66R-HLA-E Observed 
haplotype 
Freq n 
4-1.8-3.9-0101 7 25.0 
4- 1.8-3.9- 0103 6 21.4 
X-X-X-X 15 49.7 
n 
9.1 
5.4 
14.6 
Expected 
Freq 
31.2 
18.5 
50.8 
0.5 
0.07 
0.01 
Table 6.9.47 Frequency(%) MHC Class I P3A- P3B- 66R- HLA-E haplotype in 
normal controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
66R - HLA-E haplotypes detected within the control population. The X - X - X 
haplotype represents haplotypes, which were detected at an observed or expected 
frequency of < 5. Haplotypes were assigned in those subjects who were homozygous at 
three or more loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made 
between the observed and expected P3A - P3B - 66R - HLA-E haplotypes and x2 values 
determined. The x2 test was used to estimate linkage disequilibrium between the 4 loci. 
Haplotypes that were not detected in the control population are not included in the above 
table. There was no significant difference between the observed and expected P3A- P3B -
66R- HLA-E haplotypes. 
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P3A- P3B-28L-HLA-E Observed Expected ·l 
haplotype 
n Freq n Freq 
4- 1.8- 4.3- 0101 6 20.0 6.1 16.4 0.002 
4-1.8-4.3-0103 5 16.7 4.5 12.1 0.06 
X-X-X-X 19 59.8 26.6 55.2 2.2 
Table 6.9.48 Frequency(%) MHC Class I P3A- P3B- 28L- HLA-E haplotype in 
normal controls 
This table shows the frequency and actual (observed) number of copies of the P3A- P3B-
28L- HLA-E haplotypes detected within the control population. The X- X- X haplotype 
represents haplotypes, which were detected at an observed or expected frequency of < 5. 
Haplotypes were assigned in those subjects who were homozygous at three or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected P3A- P3B - 28L- HLA-E haplotypes and ·l values determined. The ·l test was 
used to estimate linkage disequilibrium between the 4 loci. Haplotypes that were not 
detected in the control population are not included in the above table. There was no 
significant difference between the observed and expected P3A - P3B - 28L - HLA-E 
haplotypes. 
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6.9.3 Haplotype frequency in patients with respect to age at onset of type 1 diabetes: 
Summary of results: Tables 6.9.49 - 6.9.69 
Overall there was little or no significant linkage in, 2 or 3 loci haplotype analysis in 
patients separated into the age at onset groups <10, 10-20 and > 20 years. However, in 
some cases trends were found between certain loci within the age at onset groups, but after 
correction of the p-value these were found to be non-significant. The analysis of the 4 loci 
haplotypes with respect to age at onset has not been included due to the large number of 
possible haplotypes and the resulting small observed and expected frequencies in each of 
the age at onset groups. Data that was found to be non-significant after correction is not 
presented in the text. 
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P3B-28L xz xz xz 
haplotype <IO(n=83) 10- 20 (n =57) > 20 (n = 48) 
0 E 0 E 0 E 
1.8-4.3 28.0 28.8 0.02 38.6 34.2 0.3 29.2 24.0 0.5 
(23) (23.6) (22) (19.5) (14) (11.5) 
1.8-3.8 18.3 18.1 >0.01 10.5 18.2 1.9 12.5 18.2 0.8 
(15) (14.8) (6) (10.4) (6) (8.7) 
1.8-3.6 13.4 13.2 >0.01 12.3 8.6 0.9 10.4 9.8 0.02 
( 11) (10.8) (7) (4.9) (5) (4.7) 
1.5-4.3 19.5 19.2 >0.01 17.5 21.8 0.5 16.7 22.1 0.6 
(16) (15. 7) (10) (12.4) (8) (10.6) 
1.5-3.8 12.2 12.0 >0.01 19.3 11.8 2.6 22.9 16.9 1.0 
(10) (9.8) (11) (6.7) (11) (8) 
1.5-3.6 8.5 8.7 >0.01 1.8 5.4 1.4 8.3 9.2 0.04 
(7) (7.2) (1) (3.1) (4) (4.4) 
Table 6.9.49 Frequency(%) MHC Class I P3B- 28L haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P38 - 28L haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. n represents the total number of haplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the 
individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P38 - 28L haplotypes and x2 values determined. The x2 test was used to estimate linkage 
disequilibrium between the 2 loci within each age at onset group. There were no significant differences between the observed and expected P38 - 28L 
haplotypes in any of the age at onset groups. 
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P3B-66R r! ·l ·l 
haplotype < 10 (n = 108) 10-20 (n = 70) > 20 (n = 40) 
0 E 0 E 0 E 
1.8-4.5 25.9 25.4 0.01 30.0 27.2 0.1 32.5 33.3 0.02 
(28) (27.4) (21) (19.4) (13) (13.5) 
1.8-3.9 33.3 33.6 >0.01 32.9 35.9 0.3 25.0 24.7 0 
(36) (36.3) (23) (25.6) (10) (1 0.0) 
1.5-4.5 16.7 17.6 0.05 14.3 15.0 0.2 25.0 24.7 0 
(18) (19.0) (10) ( 11.4) (10) (10.0) 
1.5-3.9 24.1 23.4 0.03 22.9 21.0 0.07 17.5 18.3 0.02 
(26) (25.2) (16) (15.0) (7) (7.4) 
Table 6.9.50 Frequency(%) MHC Class I P3B- 66R haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - 66R haplotypes detected in the patients 
separated by age at onset into <1 0, 10-20 and > 20 years of age. n represents the total number of haplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the 
individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - 66R haplotypes and x2 values determined. The x2 test was used to estimate linkage 
disequilibrium between the 2 loci within in each age at onset group. There were no significant differences between the observed and expected P3B - 66R 
haplotypes in any of the age at onset groups. 
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PJB- PJA 
haplotype 
1.8-4 
1.8-3.8 
1.5-4 
1.5-3.8 
·l 
< 10 (n = 114) 
0 E 
44.7 47.5 0.2 
(51) (54.2) 
15.8 13.4 0.5 
(18) (15.3) 
33.3 30.4 0.3 
(38) (34.7) 
6.1 8.6 0.8 
(7) (9.8) 
·l 
10- 20 (n = 80) > 20 (n =54) 
0 E 0 E 
46.3 48.5 0.2 35.2 40.0 
(37) (39.8) (19) (21.6) 
13.8 11.7 0.2 14.8 10.0 
(11) (9.6) (8) (5.4) 
37.5 32.4 0.4 42.6 40.0 
(30) (26.6) (23) (21.6) 
2.5 7.8 3.0 7.4 10.0 
(2) (6.4) (4) (5.4) 
Table 6.9.51 Frequency(%) MHC Class I PJB- PJA haplotype with respect to age at onset of type 1 diabetes 
·l 
0.3 
0.1 
0 
0.4 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - P3A haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. n represents the total number of haplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the 
individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3B - P3A haplotypes and x2 values determined. The x2 test was used to estimate linkage 
disequilibrium between the 2 loci within in each age at onset group. There were no significant differences between the observed and expected P3B - P3A 
haplotypes in any of the age at onset groups. 
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P3B-HLA-E 
·t r! ·i 
haplotype < 10 (n = 74) 10-20 (n = 68) > 20 (n = 38) 
0 E 0 E 0 E 
1.8- 0101 29.7 28.9 0.002 39.7 40.9 0.09 18.4 22.4 0.05 
(22) (22.2) (27) (28.6) (7) (7.6) 
1.8-0103 20.2 23.1 0.4 10.3 11.7 0.2 15.8 13.5 0.4 
(15) (17.8) (7) (8.2) (6) (4.6) 
1.5-0101 18.9 19.2 0.04 30.9 27.2 0.2 31.6 27.9 0.7 
(14) (14.8) (21) (19.0) (12) (9.5) 
1.5-0103 16.2 15.3 0.003 5.9 7.7 0.4 18.4 16.8 0.3 
(12) (11.8) (4) (5.4) (7) (5.7) 
X-X 15.0 13.6 0.03 13.2 12.7 0.001 15.8 19.9 0.09 
(11) ( 1 0.4) (9) (8.9) (6) (6.8) 
Table 6.9.52 Frequency(%) MHC Class I P3B- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - HLA-E haplotypes detected in the patients 
separated by age at onset into <1 0, 10-20 and > 20 years of age. The X- X haplotype represents haplotypes, which were detected at an observed or expected 
frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3B - HLA-E haplotypes and ·/ values determined. The x? test was used to estimate linkage disequilibrium between the 2 loci within in each 
age at onset group. There were no significant differences between the observed and expected P3B- HLA-E haplotypes in any of the age at onset groups. 
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P3A-28L 7..2 7..2 7..2 
haplotype < 10 (n = 78) 10-20 (n = 86) > 20 (n = 48) 
0 E 0 E 0 E 
4-4.3 38.5 37.8 0.02 41.9 48.6 0.3 37.5 37.3 >0.01 
(30) (29.2) (36) (39.7) (I 8) (17.9) 
4-3.8 28.2 28.3 >0.01 25.6 20.3 1.8 33.3 32.5 0.01 
(22) (21.9) (22) (16.6) (16) (15.6) 
4-3.6 17.9 18.9 0.02 16.3 15.1 0.2 10.4 12.1 0.1 
(14) (14.6) (14) (12.3) (5) (5.8) 
3.8-4.3 6.4 6.6 >0.01 12.8 9.3 1.5 8.3 8.8 >0.01 
(5) (5.1) (11) (7.6) (4) (4.2) 
X-X 8.9 8.4 0.04 3.5 6.7 1.1 10.5 10.4 0 
(7) (6.5) (3) (5.5) (6) (5) 
Table 6.9.53 Frequency (%) MHC Class I P3A- 28L haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the obseiVed and expected P3A- 28L haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. The X- X haplotype represents haplotypes, which were detected at an obseiVed or expected 
frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the obseiVed 
and expected P3A- 28L haplotypes and 7..2 values determined. The 7..2 test was used to estimate linkage disequilibrium between the 2 loci within in each age 
at onset group. There was no significant difference between the obseiVed and expected P3A- 28L haplotypes in any of the age at onset groups. 
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P3A-66R xz xz xz 
haplotype < 10 (n = 102) 10-20(n=82) > 20 (n =50) 
0 E 0 E 0 E 
4-3.9 46.1 46.4 8.5xl0· 41.5 44.0 0.2 38.0 44.8 0.5 
(47) (46.8) (34) (36.8) (19) (22.4) 
4-4.5 36.3 35.6 0.03 40.2 37.4 0.09 42.0 35.2 0.7 
(37) (35.9) (33) (31.3) (21) (17.6) 
3.8-3.9 10.8 10.2 0.05 12.2 10.0 0.3 6.0 11.2 1.2 
(11) (10.3) (10) (8.4) (3) (5.6) 
3.8-4.5 6.9 7.8 0.1 6.1 8.6 0.7 14.0 8.8 l.5 
(7) (7.9) (5) (7.2) (7) (4.4) 
Table 6.9.54 Frequency(%) MHC Class I P3A- 66R haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- 66R haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. n represents the total number of haplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the 
individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P3A - 66R haplotypes and x2 values determined. The x2 test was used to estimate linkage 
disequilibrium between the 2 loci within in each age at onset group. There were no significant differences between the observed and expected P3A- 66R 
haplotypes in any of the age at onset groups. 
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P3A-HLA-E 
·l ·l xl 
haplotype < 10 (n = 88) 10-20 (n = 84) > 20 (n = 42) 
0 E 0 E 0 E 
4-0101 38.6 35.2 0.04 44.0 44.7 0.08 40.5 36.5 0.002 
(34) (38.3) (37) (35.3) (17) (16.8) 
4-0102 5.7 4.9 0.002 9.5 7.5 0.7 11.9 14.6 0.4 
(5) (5.3) (8) (5.9} (5) (6.7) 
4-0103 33.0 30.6 0.02 17.9 14.9 0.9 31.0 29.1 0.01 
(29) (28.2) (15) (11.8) (13) (13.4) 
4-0104 6.8 5.6 0.03 2.4 3.7 0.3 0 0 0 
(6) (6.1) (2) (2.9) (0) (0) 
3.8-0101 10.2 10.0 0.005 20.2 19.1 0.2 7.1 9.1 0.3 
(9) (8.8) (17) (15.1) (3) (4.2) 
3.8-0103 3.4 7.6 2.3 2.4 6.3 1.8 4.8 7.4 0.6 
(3) (7.0) (2) (5.0) (2) (3.4) 
X-X 2.2 2.8 0.1 3.6 4.8 0.2 4.8 3.7 0.05 
(2) (2.6) (3) (3.8) (2) (1.7) 
Table 6.9.55 Frequency(%) MHC Class I P3A- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- HLA-E haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. The X- X haplotype represents haplotypes, which were detected at an observed or expected 
frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3A- HLA-E haplotypes and x2 values determined. The r} test was used to estimate linkage disequilibrium between the 2 loci within in each 
age at onset group. There were no significant differences between the observed and expected P3A- HLA-E haplotypes in any of the age at onset groups. 
450 
28L-66R 
haplotype 
4.3-4.5 
3.8-4.5 
3.6-4.5 
4.3-3.9 
3.8-3.9 
3.6-3.9 
< 10 (n = 91) 
0 E 
17.6 19.8 
(16) (18.0) 
17.6 14.2 
(16) (12.9) 
7.7 9.0 
(7) (8.2) 
28.6 26.3 
(26) (23.9) 
15.4 18.8 
(14) (17.1) 
13.2 12.0 
(12) (10.9) 
·l 
10- 20 (n = 63) 
0 E 
0.2 22.6 20.9 
(14) (13.1) 
0.7 14.5 13.6 
(9) (8.5) 
0.2 6.5 9.1 
(5) (5.7) 
0.2 25.8 27.1 
(16) (17.0) 
0.6 16.1 17.5 
(10) (11.0) 
0.1 14.5 ll.8 
(9) (7.4) 
·l 
> 20 (n = 38) 
0 E 
0.06 23.7 26.0 
(9) (10.0) 
0.03 15.8 18.4 
(6) (7.1) 
0.5 18.4 13.8 
(7) (5.3) 
0.06 21.1 18.7 
(8) (7.2) 
0.1 15.8 13.2 
(6) (5.1) 
0.3 5.3 9.9 
(2) (3.8) 
Table 6.9.56 Frequency(%) MHC Class I 28L- 66R haplotype with respect to age at onset of type 1 diabetes 
0.1 
0.2 
0.5 
0.09 
0.2 
0.9 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 28L- 66R haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. n represents the total number ofhaplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the 
individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected 28L - 66R haplotypes and x2 values determined. The x? test was used to estimate linkage 
disequilibrium between the 2 loci within in each age at onset group. There were no significant differences between the observed and expected 28L - 66R 
haplotypes in any of the age at onset groups. 
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28L-BLA-E 
·l ·l ·l 
haplotype < 10 (n =54) 10-20 (n = 72) > 20 (n = 28) 
0 E 0 E 0 E 
4.3-0101 20.4 19.9 0.004 31.9 37.1 1.2 39.3 42.1 0.05 
(11) (10.8) (23) (28.8) (11) (11.8) 
4.3-0103 18.5 15.8 0.2 12.5 9.2 0.5 14.3 12.1 0.1 
(10) (8.6) (9) (7.2) (4) (3.4) 
3.8-0101 16.7 14.9 0.1 31.9 22.2 1.9 21.4 21.1 0.002 
(9) (8.1) (23) (17.3) (6) (5.9) 
3.8-0103 11.1 11.9 0.04 1.4 5.5 2.5 3.6 6.1 0.3 
(6) (6.5) (1) (4.3) (1) (1.7) 
3.6-0101 9.3 14.9 1.2 12.5 14.8 0.5 7.1 7.1 0 
(5) (8.1) (9) (11.5) (2) (2.0) 
3.6-0103 13.0 11.9 0.04 1.4 3.7 1.2 3.6 2.1 0.3 
(7) (6.5) (I) (2.9) (1) (0.6) 
X-X 11.3 10.7 0.007 8.4 7.3 0.02 10.7 10.1 0.01 
(6) (5.8) (6) (5.7) (3) (2.8) 
Table 6.9.57 Frequency(%) MHC Class I 28L- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 28L- lll-A-E haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and > 20 years of age. The X - X haplotype represents haplotypes, which were detected at an observed or 
expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned/determined in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons 
were made between the observed and expected 28L - lll-A-E haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium 
between the 2 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected 28L -lll-A-E haplotypes in any of the age at onset groups. 
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66R-HLA-E 
haplotype 
4.5-0101 
4.5-0102 
4.5-0103 
4.5-0104 
3.9-0101 
3.9-0103 
X-X 
·l 
< 10 (n = 92) 
0 E 
20.7 25.0 0.7 
(19) (23.0) 
5.4 5.0 0.03 
(5) (4.6) 
15.2 15.0 0.003 
(14) (13.8) 
5.4 5.0 0.03 
(5) (4.6) 
28.3 25.0 0.4 
(26) (23.0) 
16.3 15.0 0.1 
(IS) (13.8) 
8.6 10.07 0.2 
(8) (9.2) 
xz 
10-20 (n = 74) 
0 E 
27.0 29.7 0.6 
(20) (23. 7) 
4.1 2.6 0.4 
(3) (2.1) 
5.4 7.4 0.6 
(4) (5.9) 
1.4 0.4 1.6 
(1) (0.3) 
48.6 44.4 0.007 
(36) (35.5) 
10.8 11.1 0.09 
(8) (8.9) 
2.7 4.4 0.6 
(2) (3.5) 
Table 6.9.58 Frequency(%) MHC Class I 66R- HLA-E with respect to age at onset of type 1 diabetes 
xz 
> 20 (n = 36) 
0 E 
27.8 35.1 0.7 
(10) (13.0) 
8.3 5.9 0.3 
(3) (2.2) 
19.4 17.6 0.04 
(7) (6.5) 
2.8 1.6 0.3 
(I) (0.6) 
30.6 23.2 0.7 
(11) (8.6) 
5.6 11.6 1.2 
(2) (1.8) 
5.6 4.9 0.02 
(2) (1.8) 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 66R- HLA-E haplotypes detected in the patients 
separated by age at onset into <I 0, I 0-20 and > 20 years of age. The X - X haplotype represents haplotypes, which were detected at an observed or 
expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned/determined in those subjects who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons 
were made between the observed and expected 66R - HLA-E haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium 
between the 2 loci within in each age at onset group. There were no significant differences between the observed and expected 66R - HLA-E haplotypes in 
any of the age at onset groups. 
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P38- P3A- 66R 
·l ·l ·l 
haplotype < 10 (n = 96) 10-20 (n =56) > 20 (n = 42) 
0 E 0 E 0 E 
1.8-4-3.9 24.0 28.0 0.06 21.4 23.9 0.1 21.4 26.2 0.8 
(23) (24.2) (12) (13.4) (9) (12.1) 
1.5-4-3.9 22.9 18.6 2.2 16.1 16.1 0 14.3 17.5 0.5 
(22) (16.1) (9) (9.0) (6) (8.1) 
1.8-4-4.5 18.8 18.6 0.2 25.0 23.9 0.03 19.0 21.9 0.4 
(18) (16.1) (14) (13.4) (8) (10.1) 
1.5-4-4.5 11.5 12.5 >0.01 16.1 16.1 0 21.4 14.5 0.8 
(11) (10.8) (9) (9.0) (9) (6.7) 
1.8 - 3.8- 3.9 9.4 8.0 0.6 7.1 6.1 0.1 4.8 6.5 0.3 
(9) (6.9) (4) (3.4) (2) (3.0) 
1.5 - 3.8 - 3.9 7.3 5.3 1.3 7.1 3.9 1.5 4.8 4.3 0 
(7) (4.6) (4) (2.2) (2) (2.0) 
1.8-3.8-4.5 5.3 5.3 0.03 7.1 6.1 0.1 11.9 5.4 2.5 
(3) (4.6) (4) (3.4) (5) (2.5) 
1.5 - 3.8 - 4.5 1.0 3.6 1.4 0 3.9 2.2 2.4 3.7 0.3 
(I) (3.1) (0) (2.2) (I) (1.7) 
Table 6.9.59 Frequency (%) MBC Class I P38- P3A- 66R haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B- P3A- 66R haplotypes detected in the patients 
separated by age at onset into <I 0, I 0-20 and > 20 years of age. n represents the total number of haplotypes available to be assigned in each age at onset 
group. Haplotypes were assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from 
the individual allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected P38 - P3A- 66R haplotypes and ·i values determined. The ·i test was used to estimate 
linkage disequilibrium between the 3 loci within in each age at onset group. There were no significant differences between the observed and expected P3B -
P3A- 66R haplotypes in any of the age at onset groups. 
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P3B- P3A- 28L 1.2 lz 
haplotype < 10 (n = 42) 10-20 (n = 40) > 20 (n = 30) 
0 E 0 E 0 E 
1.8-4-3.8 14.3 17.2 0.3 12.5 17.5 0.9 10.0 17.6 1.4 
(6) (7.6) (5) (7.7) (3) (5.8) 
1.5-4-3.8 14.3 ll.3 0.2 15.0 6.6 3.3 20.0 ll.5 1.3 
(6) (5.0) (6) (2.9) (6) (3.8) 
1.8-4-4.3 26.2 28.5 0.2 35.0 35.0 0.1 26.7 21.8 0.09 
(11) (12.6} (14) (1 5.4) (8} (7.2) 
1.5-4-4.3 21.4 19.0 0.04 7.5 13.2 1.4 13.3 14.5 0.1 
(9) (8.4) (3) (5.8} (4) (4.8) 
1.8-4-3.6 14.3 ll.3 0.2 12.5 5.9 2.2 3.3 8.8 1.2 
(6) (5.0) (5) (2.6) (1) (2.9) 
1.8 - 3.8 - 4.3 4.8 1.4 3.3 15.0 8.6 1.3 6.7 5.5 0.02 
(2) (0.6} (6) (3.8) (2) (1.8) 
X-X-X 4.8 10.1 1.8 2.5 13.3 4.0 20.0 20.2 0.07 
(2) (9.2) (1) (5.8) (6) (6.7) 
Table 6.9.60 Frequency(%) MHC Class I P3B- P3A- 28L haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B- P3A- 28L haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. The X- X- X haplotype represents haplotypes, which were detected at an observed or 
expected frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were assigned in those 
subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the 
observed and expected P3B - P3A - 28L haplotypes and 1.2 values determined. The 1.2 test was used to estimate linkage disequilibrium between the 3 loci 
within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. There were no 
significant differences between the observed and expected P3B- P3A- 28L haplotypes in any of the age at onset groups. 
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P3B- 66R- 28L 
·l ·l '1.2 
haplotype < 10 (n = 44) 10-20 (n = 34) > 20 (n = 24) 
0 E 0 E 0 E 
1.8 - 3.9 - 4.3 15.9 17.9 0.1 23.5 24.4 0.01 16.7 12.1 0.4 
(7) (7.9) (8) (8.3) (4) (2.9) 
1.5 - 3.9 - 4.3 15.9 12.0 0.5 11.8 10.6 0.04 4.2 7.9 0.4 
(7) (5.3) (4) (3.6) (1) (1.9) 
1.8 - 4.5- 4.3 13.6 12.0 0.09 29.4 24.4 0.3 16.7 12.1 0.4 
(6) (5.3) (10) (8.3) (4) (2.9) 
1.8 - 4.5 - 3.8 13.6 7.3 0.5 2.9 7.1 0.8 4.2 12.1 1.2 
(6) (3.2) (1) (2.4) (1) (2.9) 
1.8 - 3.9 - 3.6 11.4 7.3 1.0 8.8 3.5 2.7 4.2 5.8 0.1 
(5) (3.2) (3) (1.2) (1) (1.4) 
X-X-X 29.5 43.7 2.0 23.5 28.1 0.5 54.2 50.0 0.08 
(13) (19.2) (8) (10.2) (13) (12.0) 
Table 6.9.61 Frequency (%) MHC Class I P3B - 66R- 28L haplotype with respect to age at onset of type l diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B- 66R - 28L haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. The X- X- X haplotype represents haplotypes, which were detected at an observed or 
expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned/determined in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons 
were made between the observed and expected P3B - 66R - 28L haplotypes and 7.2 values determined. The X2 test was used to estimate linkage 
disequilibrium between the 3 loci within in each age at onset group. There were no significant differences between the observed and expected P3B - 66R-
28L haplotypes in any of the age at onset groups. 
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P3A - 66R- 28L 
haplotype 
4-3.9-4.3 
3.8-3.9-4.3 
4-4.5-4.3 
4-3.9-3.8 
4-4.5-3.8 
4-3.9-3.6 
X-X-X 
< 10 (n =54) 
0 E 
22.2 18.1 0.5 
(12) (9.7) 
0 1.9 
(0) (1.0) 
18.5 18.1 >0.01 
(10) (9.7) 
14.8 18.1 0.3 
(8) (9.7) 
18.5 18.1 >0.01 
(10) (9.7) 
11.1 9.1 0.2 
(6) (4.9) 
15.0 16.6 0.09 
(8) (8.9) 
x2 
10- 20 (n = 36) > 20 (n = 22) 
0 E 0 E 
22.2 26.1 0.6 18.2 10.0 
(8) (10.4) (4) (3.1) 
13.9 9.8 0.3 0 4.2 
(5) (3.9) (0) (1.3) 
16.7 17.3 0.1 18.2 14.9 
(6) (6.9) (4) (4.6) 
5.6 8.8 0.6 13.6 8.1 
(2) (3.5) (3) (2.5) 
13.9 5.8 3.2 13.6 12.0 
(5) (2.3) (3) (3.7) 
11.1 8.8 0.07 0 10.0 
(4) (3.5) (0) (3.1) 
16.7 23.5 1.2 36.3 40.9 
(6) (9.3) (8) (12.6) 
Table 6.9.62 Frequency(%) MBC Class I P3A- 66R- 28L haplotype with respect to age at onset of type 1 diabetes 
0.3 
1.3 
0.08 
0.1 
0.1 
3.1 
1.7 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3 A- 66R - 28L haplotypes detected in the patients 
separated by age at onset into <10, 10-20 and> 20 years of age. The X- X- X haplotype represents haplotypes, which were detected at an observed or 
expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned/determined in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual 
allelic frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons 
were made between the observed and expected P3A - 66R - 28L haplotypes and x.2 values determined. The x.2 test was used to estimate linkage 
disequilibrium between the 3 loci within in each age at onset group. There were no significant differences between the observed and expected P3A- 66R-
28L haplotypes in any of the age at onset groups. 
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P3A- P3B- HLA-E 
·l x2 x2 
haplotype < 10 (n = 44) 10-20 (n = 36) > 20 (n = 28) 
0 E 0 E 0 E 
4-1.8-0101 22.7 24.7 003 25.0 27.4 0.2 14.3 27.1 1.7 
(10) (10.6) (9) (10.4) (4) (7.6) 
4-1.5-0101 20.6 16.3 0.6 19.4 18.2 0.001 35.7 27.1 0.8 
(9) (7.0) (7) (6.9) (10) (7.6) 
4-1.8-0103 15.9 19.5 0.2 11.1 9.2 0.07 17.9 13.6 0.7 
(7) (8.4) (4) (3.5) (5) (3.8) 
4-1.5-0103 18.2 13.0 1.0 8.3 6.1 0.2 10.7 13.6 1.4 
(8) (5.6) (3) (2.3) (3) (3.8) 
X-X-X 22.8 25.8 0.1 36.3 39.6 0.3 21.5 18.6 0.1 
(10) (11.1) (13) (15) (6) (5.2) 
Table 6.9.63 Frequency(%) MHC Class I P3A- P3B- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- P38 - HLA-E haplotypes detected in the 
patients separated by age at onset into <10, 10-20 and > 20 years of age. The X - X - X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected P3A- P3B- HLA-E haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected P3A- P3B- HLA-E haplotypes in any of the age at onset groups. 
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P3A- 28L- HLA-E 
·l xz xz 
haplotype < 10 (n = 30) 10-20 (n = 38) > 20 (n = 22) 
0 E 0 E 0 E 
4-4.3-0101 20.0 19.4 0.09 26.3 29.5 0.1 36.4 33.1 0.04 
(6) (6.8) (10) (11.2) (8) (8.6) 
4-3.8-0101 10.0 11.7 0.3 21.1 14.7 18.2 14.2 0.02 
(3) (4.1) (8) (5.6) (4) (3.7) 
4-4.3-0103 20.0 19.4 0.09 7.9 8.4 0.01 13.6 9.6 0.4 
{6) (6.8) (3) (3.2) (3) {2.5) 
X-X-X 49.8 50.5 0.6 44.7 49.2 0.1 31.7 45.5 2.0 
(15) (18.2) (17) (18.4) (7) ( 11.8) 
Table 6.9.64 Frequency (%) MHC Class I P3A- 28L- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- 28L - HLA-E haplotypes detected in the 
patients separated by age at onset into <10, I 0-20 and > 20 years of age. The X - X - X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected P3A- 28L- HLA-E haplotypes and x2 values determined. The X2 test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected P3A- 28L- HLA-E haplotypes in any of the age at onset groups. 
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P3A- 66R- HLA-E 
·l ·l xz 
haplotype < 10 (n = 46) 10-20 (n = 38) > 20 (n = 18) 
0 E 0 E 0 E 
4-4.5-0101 13.0 15.9 0.05 21.1 21.3 0.03 27.8 38.8 0.2 
(6) (6.6) (8) (8.5) (5) (6.2) 
4-3.9-0101 23.9 23.8 0.1 34.2 32.0 0.003 27.8 16.3 2.2 
(11) (9.9) (13) (12.8) (5) (2.6) 
4-4.5-0103 17.4 12.0 1.8 5.3 5.3 0.5 16.7 11.3 0.8 
(8) (5.0) (2) (2.1) (3) (1.8) 
4-3.9-0103 15.2 18.0 0.03 7.9 8.0 0.005 0 5.0 0.8 
(7) (7.5) (3) (3.2) (0) (0.8) 
3.8- 3.9- 0101 4.3 2.6 0.7 15.8 13.8 0.05 5.6 5.0 0.05 
(2) (1.1) (6) (5.5) (1) (0.8) 
X-X-X 26.2 27.6 0.02 15.7 34.4 0.001 22.4 43.2 0.01 
(12) (11.5) (8) (8.1) (4) (4.2) 
Table 6.9.65 Frequency(%) MHC Class I P3A- 66R- HLA-E haplotype with respect to age at onset of type I diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- 66R- HLA-E haplotypes detected in the 
patients separated by age at onset into <10, 10-20 and > 20 years of age. The X - X - X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected P3A- 66R- HLA-E haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. There were no significant differences between the observed and expected P3A - 66R - HLA-E 
haplotypes in any of the age at onset groups. 
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P3B- 28L- HLA-E 
·l ·l x2 
haplotype < 10 (n = 22) 10- 20 (n = 26) > 20 (n = 22) 
0 E 0 E 0 E 
1.8-4.3-0101 9.1 11.8 0.1 30.8 37.8 0.5 22.7 28.3 0.3 
(2} (2.6) (8) (10.2} (5) (6.5) 
1.5-3.8- 0101 9.1 5.9 0.4 19.2 7.0 5.1 18.1 7.8 2.7 
(2) (1.3) (5) (1.9} (4} (1.8} 
X-X-X 81.5 82.9 0.005 49.8 56.6 1.0 58.8 63.9 0.2 
(18) (18.3} (13) (17.2) (13) (14.7) 
Table 6.9.66 Frequency(%) MHC Class I P3B- 28L- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B- 28L- HLA-E haplotypes detected in the 
patients separated by age at onset into <10, 10-20 and > 20 years of age. The X- X- X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected P3B - 28L- HLA-E haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected P3B- 28L- HLA-E haplotypes in any of the age at onset groups. 
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P3B- 66R- HLA-E 
·l ·l 
haplotype < 10 (n = 41) 10- 20 (n = 36) > 20 (n = 17) 
0 E 0 E 0 E 
1.8- 4.5- 0101 12.2 12.2 0.002 16.7 20.8 0.5 11.8 26.9 1.2 
(5) (4.9) (6) (8.1) (2) (4.3) 
1.8-3.9- 0101 24.3 18.5 0.9 27.8 31.0 0.4 23.5 17.5 0.5 
(10) (7.4) (10) (12.1) (4) (2.8) 
1.5-3.9- 0101 12.2 12.2 0.002 22.2 13.0 1.5 11.8 7.5 0.5 
(5) (4.9) (8) (5.2) (2) (1.2) 
X-X-X 51.1 57.3 0.1 33.0 36.0 0.3 52.9 44.1 0.2 
(21) (22.8) (12) (14) (9) (7.8) 
Table 6.9.67 Frequency(%) MHC Class I P3B- 66R- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B- 66R- HLA-E haplotypes detected in the 
patients separated by age at onset into <10, 10-20 and > 20 years of age. The X - X - X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of < 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected P3B - 66R- HLA-E haplotypes and x2 values determined. The X2 test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected P3B- 66R- HLA-E haplotypes in any of the age at onset groups. 
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28L- 66R- HLA-E 
·l ·l ·l 
haplotype < 10 (n = 34) 10- 20 (n = 44) > 20 (n = 20) 
0 E 0 E 0 E 
4.3-- 4.5- 0101 2.9 11.6 2.5 9.1 12.0 0.3 15.0 20.0 0.8 
(1) (4.3) (4) (5.3) (3) (5.0) 
4.3-3.9- 0101 14.7 11.6 0.1 22.7 28.0 0.4 20.0 13.6 0.1 
(5) (4.3) (10) (12.3) (4) (3.4) 
4.3-3.9- 0103 17.6 9.2 2.0 4.5 3.4 0.2 0 4.0 1.0 
(6) (3.4) (2) (1.5) (0) (1.0) 
3.8-3.9- 0101 5.9 7.0 0.1 22.7 16.8 0.9 10.0 6.8 0.05 
(2) (2.6) (10) (7.4) (2) (1.7) 
X-X-X 58.8 61.9 0.9 40.9 40.9 0.0006 55.0 55.4 0.7 
(20) (24.8) (18) (17.9) (11) (14.1) 
Table 6.9.68 Frequency (%) MHC Class I 28L- 66R- HLA-E haplotype with respect to age at onset of type 1 diabetes 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 28L- 66R- HLA-E haplotypes detected in the 
patients separated by age at onset into <10, 10-20 and > 20 years of age. The X - X - X haplotype represents haplotypes, which were detected at an 
observed or expected frequency of< 5. n represents the total number of haplotypes available to be assigned in each age at onset group. Haplotypes were 
assigned in those subjects who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic 
frequencies. (The haplotype frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were 
made between the observed and expected 28L- 66R- HLA-E haplotypes and x2 values determined. The ·l test was used to estimate linkage disequilibrium 
between the 3 loci within in each age at onset group. Haplotypes that were not observed in any of the age at onset groups are not included in the above table. 
There were no significant differences between the observed and expected 28L- 66R- HLA-E haplotypes in any of the age at onset groups. 
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6.9.4 Haplotype freguency in patients with respect to gender: Summary of results: 
Tables 6.9.69 - 6.9.90 
Overall there was little or no significant linkage in, 2, 3 or 4 loci haplotype analysis in 
patients with type 1 diabetes separated by gender. However, there were some significant 
differences found between the observed and expected frequencies. Analysis of the P3A -
P3B haplotype 3.8- 1.8 (table 6.9.71) in female patients showed there was a difference in 
the 6.9.79 P3A- P3B - 28L haplotypes there was a significant difference found in the 
females with the 3.8- 1.8- 4.3 haplotype, observed frequency of 10.0% compared to the 
expected frequency of2.5% (p = 0.001, Pc= 0.006). There was a similar difference in the 
observed frequency (16.7%) and the expected frequency (7.2%) of the 4 - 1.5 - 3.8 
haplotype in males (p = 0.009, Pc = 0.05). There was a significant difference in the 
observed and expected frequencies of the P3A- P3B- HLA-E haplotype 4- 1.5- 0103 in 
the female patients 17.2% vs 7.7% (p = 0.001, Pc= 0.005), table 6.9.81. There was a small 
but significant difference in the observed frequency and expected frequency of the P3B -
28L - HLA-E haplotype 1.5 - 3.8 - 0101 in the males 5.2% vs 9.2% (p = 0.002, Pc = 
0.01), table 6.9.86. In addition, certain trends were found between loci in both male and 
female patients but these were non-significant after correction of the p-value. Data that was 
found to be non-significant after correction is not presented in the text. 
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P3A-28L Male (n = 96) 
·l Female (n = 118) ·l 
haplotype 
0 E 0 E 
4-4.3 38.5 40.0 0.05 40.7 40.0 2.4 
(37) (38.4) (48) (47.2) 
4-3.8 28.1 24.0 0.7 30.0 24.0 4.3 
(27) (23.0) (33) (28.3) 
4-3.6 17.7 16.0 0.2 14.4 15.9 0.2 
(17) (15.4) (17) (18.8) 
3.8-4.3 7.3 10.0 0.7 10.2 10.0 0.6 
(7) (9.6) (12) {11.8) 
3.8-3.8 3.1 6.0 1.4 5.9 6.0 0.2 
(3) (5.8) (7) (7.1) 
3.8-3.6 5.2 3.8 0.4 0.8 4.0 2.1 
(5) (4.0) (I) (4.7) 
Table 6.9.69 Frequency(%) MHC Class I P3A- 28L haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected haplotypes P3A - 28L detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3A- 28L haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. There were no significant differences in the observed and expected P3A- 28L haplotypes in either gender. 
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P3A-66R Male (n = 112) 
·l Female (n = 130) ·X: 
haplotype 
0 E 0 E 
4-3.9 39.3 40.0 0.01 47.7 48.0 >0.01 
(44) (44.8) (62) (62.4) 
4-4.5 43.8 40.0 0.4 33.8 32.0 0.1 
(49) (44.8) (44) (41.6) 
3.8-3.9 9.8 10.0 >0.01 10.8 12.0 0.2 
(11) (11.2) (14) (I 5.6) 
3.8-4.5 7.1 10.0 0.9 7.7 8.0 0.02 
(8) (11.2) (10) (10.4) 
Table 6.9.70 Frequency(%) MHC Class I P3A- 66R haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - 66R haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3A- 66R haplotypes and 7} values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. There were no significant differences in the observed and expected P3A- 66R haplotypes in either gender. 
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P3A-P3B Male (n = 114) 1.2 Female (n = 136) 1.2 
haplotype 
0 E 0 E 
4-1.8 45.6 48.0 0.1 43.4 48.0 0.3 
(52) (54.7) (59) (54.7) 
4-1.5 36.8 32.0 0.8 35.3 32.0 3.6 
(42) (36.5) (48) (36.5) 
3.8-1.8 10.5 12.0 0.2 17.6 12.0 7.71 
(12) (13.7) (24) (13.7) 
3.8- 1.5 7.0 8.0 0.1 3.7 8.0 1.8 
(8) (9.1) (5) (9.1) 
Table 6.9.71 Frequency(%) MHC Class I P3A- P3B haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - P3B haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3A- PJB haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. 
1 = 3.8- 1.8 (F) 7.2 = 7.7, p = 0.005 ( ldf), Pc= 0.01 
F = female patient 
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P3A-HLA-E Male (n = 104) x2 Female (n = 114) x2 
haplotype 
0 E 0 E 
4-0101 43.3 42.4 0.3 39.5 44.8 1.7 
(45) (41.6) (45) (54.7) 
4-0102 9.6 8.5 0.3 7.9 7.5 0.001 
(10) (8.3) (9) (9.1) 
4-0103 27.9 25.5 0.6 24.6 22.5 0.01 
(29) (25.0) (28) (27.4) 
4-0104 1.9 3.4 0.5 6.1 5.2 0.06 
(2) (3.3) (7) (6.4) 
3.8-0101 10.6 10.6 0.03 15.8 11.2 1.3 
(11) (10.4) (18) (13.7) 
3.8-0103 2.9 6.3 1.7 3.5 5.6 1.2 
(3) (6.2) (4) (6.8) 
X-X 3.8 2.9 0.4 2.7 3.2 0.2 
(4) (2.9) (3) (3.9) 
Table 6.9. 72 Frequency(%) MHC Class I P3A- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- HLA-E haplotypes detected in the patients 
separated by gender. The X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents the total 
number ofhaplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- HLA-E haplotypes and x2 
values determined. The ·i test was used to estimate linkage disequilibrium between the 2 loci within each gender group. There were no significant 
differences between the observed and expected P3A- HLA-E haplotypes in either gender. 
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P3B-28L Male (n = 86) 
·l Female (n = 104) r! 
haplotype 
0 E 0 E 
1.8-4.3 34.9 30.0 0.7 32.7 30.0 0.3 
(30) (25.8) (34) (31.2) 
1.8-3.8 12.8 18.0 1.3 15.4 18.0 0.4 
(11) (15.5) (16) (18.7) 
1.8-3.6 15.1 12.0 0.7 11.5 12.0 0.02 
(13) (10.3) (12) (12.5) 
1.5- 4.3 17.4 20.0 0.3 16.3 20.0 0.7 
(15) (17.2) (17) (20.8) 
1.5-3.8 15.1 12.0 0.07 18.3 12.0 3.4 
(13) (10.3) (19) (12.5) 
1.5-3.6 4.7 8.0 1.2 5.8 8.0 0.6 
(4) (6.9) (6) (8.3) 
Table 6.9.73 Frequency(%) MHC Class I P3B- 28L haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - 28L haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3B - 28L haplotypes and y} values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. There were no significant differences between the observed and expected P3B - 28L haplotypes in either gender. 
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P3B-66R Male (n = 98) 
·l Female (n = 122} '1.2 
haplotype 
0 E 0 E 
1.8-4.5 31.6 30.0 0.09 25.4 24.0 0.1 
(31) (29.4) (31) (29.3) 
1.8-3.9 25.5 30.0 0.7 37.7 36.0 0.1 
(25) (29.4) (46) (43.9) 
1.5-4.5 18.4 20.0 0.1 16.4 16.0 0.01 
(18) (19.6) (20) (19.5) 
1.5-3.9 24.5 20.0 1.0 20.5 24.0 0.6 
(24) (19.6) (25) (29.3) 
Table 6.9.74 Frequency(%) MHC Class I P3B- 66R haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - 66R haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3B - 66R haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. There were no significant differences between the observed and expected P3B - 66R haplotypes in either gender. 
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P3B-HLA-E Male (n = 98) 
·l Female (n = 122) x2 
haplotype 
0 E 0 E 
1.8-0101 28.2 28.5 0.08 32.1 29.4 0.2 
(22) (23.4) (34) (31.8) 
1.8-0102 3.8 4.8 0.2 5.7 4.4 0.3 
(3) (3.9) (6) (4.8) 
1.8-0103 15.4 14.3 0.008 15.1 14.7 0.0006 
(12) (11.7) (16) (1 5.9) 
1.5- 0101 28.2 28.5 0.08 26.4 29.4 0.5 
(22) (23.4) (28) (31.8) 
1.5-0102 7.7 4.8 1.1 3.8 4.4 0.1 
(6) (3.9) (4) (4.8) 
1.5-0103 11.5 14.3 0.6 14.2 14.7 0.05 
(9) (1.7) (IS) (15.9) 
X-X 5.1 4.8 0 2.8 3.0 0.01 
(4) (4.0) (3) (3.2) 
Table 6.9.75 Frequency(%) MHC Class I P38- HLA-E haplotype with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the obsetved and expected P3B - HLA-E haplotypes detected in the patients 
separated by gender. The X - X haplotype represents haplotypes, which were detected at an obsetved or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made between the obsetved and expected P3B- HLA-E haplotypes and x2 
values determined/the x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender group. There were no significant differences 
between the obsetved and expected P3B - HLA-E haplotypes in either gender. 
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66R-28L Male (n = 86) '1..2 Female (n = 106) '1..2 
haplotype 
0 E 0 E 
4.5-4.3 22.1 22.2 0.2 17.9 20.0 0.2 
(19) (17.2) (19) (21.2) 
4.5-3.8 15.1 16.7 >0.01 17.0 12.0 2.2 
(13) (12.9) (18) (12.7) 
4.5-3.6 11.6 11.1 0.2 7.5 8.0 O.Q3 
(10) (8.6) (8) (8.5) 
3.9-4.3 22.1 22.2 0.2 32.1 30.0 0.2 
(19) (17.2) (34) (31.8) 
3.9-3.8 17.4 16.7 0.3 14.2 18.0 0.9 
( 15) ( 12.9) (15) ( 19.1) 
3.9-3.6 11.6 11.1 0.2 11.3 12.0 0.04 
(10) (8.6) (12) (12.7) 
Table 6.9. 76 Frequency(%) MHC class 166R- 28L haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 66R - 28L haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at one or both loci. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected 66R- 28L haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender 
group. There were no significant differences between the observed and expected 66R- 28L haplotypes in either gender. 
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66R- HLA-E Male (n = 96) 
·i Female (n = 112) ·l 
haplotype 
0 E 0 E 
4.5-0101 31.3 33.9 0.4 17.9 20.8 0.3 
(30) (33.6) (20) (22.4) 
4.5-0102 4.2 3.8 0.01 6.3 4.2 1.4 
(4) (3.8) (7) (4.5) 
4.5-0103 12.5 9.7 3 11.6 12.5 0.01 
(12) (9.6) (13) (13.4) 
3.9-0101 34.4 33.9 0.01 36.6 31.3 1.6 
(33) (33.6) (41) (33.6) 
3.9-0102 4.2 3.8 0.01 5.4 6.2 0.07 
(4) (3.8) (6) (6.7) 
3.9-0103 8.3 9.7 0.3 16.1 18.8 0.2 
(8) (9.6) (18) (20.2) 
X-X 5.2 4.8 0.008 6.5 6.2 0.01 
(5) (4.8) (7) (6.7) 
Table 6.9. 77 Frequency(%) MHC Class I 66R- HLA-E haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 66R- HLA-E haplotypes detected in the patients 
separated by gender. The X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected 66R- HLA-E haplotypes and x2 
values determined. The x2 test was used to estimate linkage disequilibrium between the 2 loci within each gender group. There were no significant 
differences between the observed and expected 66R- HLA-E haplotypes in either gender. 
473 
28L-HLA-E Male (n = 78) 1.2 Female (n = 72) 1.2 
haplotype 
0 E 0 E 
4.3-0101 26.9 28.3 0.03 36.1 36.0 0.0004 
(21) (21.8) (26) (25.9) 
4.3-0102 1.3 2.1 0.2 8.3 5.0 0.7 
(I) (1.6) (6) (4.3) 
4.3-0103 14.1 8.1 3.7 11.1 18.1 1.9 
(I I) (6.2) (8) (13.0) 
3.8-0101 28.2 28.3 0.002 18.1 11.9 2.3 
(22) (21.8) (13) (8.6) 
3.8-0103 6.4 8.1 0.2 4.2 6.0 0.4 
(5) (6.2) (3) (4.3) 
3.6-0101 11.5 14.2 0.3 9.7 11.9 0.3 
(9) (10.9) (7) (8.6) 
3.6-0103 3.8 4.0 0.003 9.7 6.0 1.7 
(3) (3.1) (7) (4.3) 
X-X 7.7 7.1 0.03 2.7 3.8 0.2 
(6) (5.6) (2) (2.8) 
Table 6.9.78 Frequency(%) MHC Class I 28L- HLA-E haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 28L- HLA-E haplotypes detected in the patients 
separated by gender. The X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at one or both loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into account 
individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected 28L - HLA-E haplotypes and x2 
values determined. The 7.2 test was used to estimate linkage disequilibrium between the 2 loci within each gender group. There were no significant 
differences between the observed and expected 28L- HLA-E haplotypes in either gender. 
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P3A- P3B- 28L Male (n =54) 
·i Female (n = 60) .,; 
haplotype 
0 E 0 E 
4- 1.8-3.8 7.4 10.8 0.6 13.3 18.4 1.9 
(4) (5.8) (8) (13.0) 
4-1.5-3.8 16.7 7.2 6.72 21.7 12.2 2.3 
(9) (3.9) (13) (8.6) 
4- 1.8-4.3 33.3 32.5 0.01 23.3 22.9 0.3 
(18) ( 17. 5) (14) (16.2) 
4-1.5-4.3 16.7 21.7 0.6 13.3 15.3 0.7 
(9) (11. 7) (8) (10.8} 
4-1.8-3.6 11.1 10.8 >0.01 10.0 15.3 2.1 
(6) (5.8) (6) (10.8) 
3.8 - 1.8 - 4.3 7.4 3.5 2.3 10.0 2.5 9.81 
(4) (1.9) (6) (1.8) 
X-X-X 7.5 13.2 1.4 8.3 12.9 1.8 
(4) (7.2) (5) (9.1} 
Table 6.9.79 Frequency(%) MHC Class I P3A- P3B- 28L haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - P3B - 28L haplotypes detected in the patients 
separated by gender. The X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more than one 
locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into 
account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A - P3B - 28L 
haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not observed in either gender group are not included in the above table. 
1 = 3.8- 1.8- 4.3 (F) x2 = 9.8, p = 0.001 (ldt), Pc= 0.006 F =female 
2 = 4-1.5-3.8 (M) x2 = 6.7, p = 0.009 (ldt), Pc= 0.05 M= male 
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P3A- P3B- 66R Male (n = 74) "!! Female (n = 88) ·l 
haplotype 
0 E 0 E 
4-1.8-3.9 18.9 24.1 0.8 30.7 28.8 0.1 
(14) (17.8) (27) (25.3) 
4-1.5-3.9 17.6 15.9 0.1 22.7 19.2 0.6 
(13) ( 11.8) (20) (16.9) 
4-1.8-4.5 29.7 24.1 1.0 14.8 19.2 0.9 
(22) (17.8) (13) (16.9) 
4-1.5-4.5 13.5 15.9 0.3 13.6 12.9 0.04 
(10) ( 11.8) (12) (11.3) 
3.8 - 1.8 - 3.9 4.1 5.9 0.4 9.1 7.2 0.5 
(3) (4.4) (8) (6.3) 
3.8 - 1.5- 3.9 6.8 4.1 1.3 2.3 4.8 1.2 
(5) (3.0) (2) (4.2) 
3.8 - 1.8 - 4.5 8.1 5.9 0.6 5.7 4.8 0.2 
(6) (4.4) (5) (4.2) 
3.8 - 1.5 - 4.5 1.4 4.1 1.3 1.1 3.2 1.2 
(I) (3.0) (1) (2.8) 
Table 6.9.80 Frequency(%) MHC Class I P3A- P3B- 66R haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- P3B- 66R haplotypes detected in the patients 
separated by gender. n represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects 
who were homozygous at more than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed 
and expected P3A- P3B- 66R haplotypes and·£ values detennined. The·£ test was used to estimate linkage disequilibrium between the 3 loci within each 
gender group. There were no significant differences between the observed and expected P3A- P3B- 66R haplotypes in either gender. 
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P3A- P3B- HLA-E Male (n =50) xz Female (n = 58) xz 
haplotype 
0 E 0 E 
4-1.8-0101 26.0 26.5 0.02 19.0 29.0 0.6 
(13) (13.5) (11) (13.9) 
4-1.5-0101 26.0 26.5 0.02 20.7 19.4 0.8 
(13) (13.5) (12) (9.3) 
4- 1.8-0103 14.0 13.3 0.006 12.1 11.7 0.3 
(7) (6.8) (7) (5.6) 
4-1.5-0103 10.0 13.3 0.5 17.2 7.7 10.71 
(5) (6.8) (10) (3.7) 
3.8-1.8-0101 4.0 2.9 0.2 12.1 7.3 3.5 
(2) (1.5) (7) (3.5) 
X-X-X 20.0 18.2 0.05 18.8 24.5 0.1 
(10) (9.3) ( 11) (12.2) 
Table 6.9.81 Frequency(%) MHC Class I P3A- P3B- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- P3B - HLA-E haplotypes detected in the 
patients separated by gender. The X- X- X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. {The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- P3B - HLA-E 
haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not observed in either gender group are not included in the above table. 
1 = 4-1.5- 0103 (F) x2 = 10.7, p = 0.001 (1dt), Pc= o.oos 
F =female 
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P3A - 66R- 28L Male (n =58) '1.2 Female (n = 60) '1.2 
haplotype 
0 E 0 E 
4-3.9-4.3 13.8 16.0 0.2 30.0 24.5 0.2 
(8) (9.3) (18) (16.2) 
4-4.5-4.3 24.1 23.9 >0.01 11.7 16.4 1.3 
(14) (13.9) (7) (10.8) 
4-3.9-3.8 10.3 9.6 0.03 13.3 14.7 0.3 
(6) (5.6) (8) (9.7) 
4-4.5-3.8 15.5 14.5 0.04 15.0 9.8 1.0 
(9) (8.4) (9) (6.5) 
4-3.9-3.6 8.6 6.4 0.5 10.0 9.8 0.04 
(5) (3.7) (6) (6.5) 
4-4.5-3.6 8.6 9.6 0.06 5.0 6.5 0.4 
(5) (5.6) (3) (4.3) 
X-X-X 18.8 19.9 0.03 15.0 18.1 0.8 
(11) (11.6) (9) (12.0) 
Table 6.9.82 Frequency(%) MHC class I P3A- 66R- 28L haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- 66R- 28L haplotypes detected in the patients 
separated by gender. The X- X- X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more than one 
locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into 
account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A - 66R - 28L 
haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. There were no 
significant differences between the observed and expected P3A- 66R- 28L haplotypes in either gender. 
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P3B - 66R- 28L Male (n = 46) 7.2 Female (n = 58) 7.2 
haplotype 
0 E 0 E 
1.8 - 3.9 - 4.3 21.7 19.2 >0.01 22.4 17.9 0.7 
(10) (9.7) (13) (10.4) 
1.5 - 3.9 - 4.3 10.9 8.1 0.2 12.1 12.0 0 
(5) (4.1) (7) (7.0) 
1.8 - 4.5 - 4.3 21.7 19.2 >0.01 13.8 12.0 0.1 
(10) (9.7) (8) (7.0) 
1.8 - 3.9- 3.8 2.2 9.5 3.0 6.9 10.8 0.8 
(1) (4.8) (4) (6.3) 
1.5-4.5-3.8 8.7 4.2 1.7 10.3 4.8 3.7 
(4) (2.1) (6) (2.8) 
1.8 - 3.9 - 3.6 4.3 6.3 0.5 12.1 7.2 1.9 
(2) (3.2) (7) (4.2) 
X-X-X 30.4 33.7 0.5 22.3 35.2 2.7 
(14) (17.0) (13) (20.5) 
Table 6.9.83 Frequency(%) P3B- 66R- 28L haplotype in patients with respect to gender. 
This table shows the frequency and actual number of copies (in brackets) of the obsetved and expected PJB - 66R- 28L haplotypes detected in the patients 
separated by gender. The X - X - X haplotype represents haplotypes, which were detected at an obsetved or expected frequency of< 5. n represents the total 
number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more than one 
locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take into 
account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3B - 66R - 28L 
haplotypes and x.2 values determined. The 7.2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. There were no 
significant differences between the obsetved and expected PJB - 66R- 28L haplotypes in either gender. 
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P3A- 28L- HLA-E Male (n = 36) 1.2 Female (n = 54) 1.2 
haplotype 
0 E 0 E 
4-4.3-0101 22.2 28.9 0.6 31.5 29.7 0.07 
(8} ( 1 0.4) (17) (18.1) 
4-3.8-0101 22.2 14.4 l.5 13.0 14.9 0.5 
(8} (5.2) (7) (9.1) 
4-3.6-0101 5.6 2.8 l.O 7.4 9.8 0.7 
(2) (1.0) (4) (6.0) 
4-4.3-0103 16.7 14.4 0.1 9.3 12.8 l.O 
(6) (5.2) (5) (7.8) 
3.8-4.3- 0101 2.8 6.4 0.7 11.1 7.4 0.5 
(l) (2.3) (6) (4.5) 
X-X-X 25.2 32.4 0.04 28.0 26.0 0.04 
(ll) (11.7) (15) (15.8) 
Table 6.9.84 Frequency(%) MHC Class I P3A- 28L- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A- 28L - HLA-E hap1otypes detected in the 
patients separated by gender. The X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- 28L- HLA-E 
haplotypes and 1.,2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not observed in either gender group are not included in the above table. There were no significant differences between the observed and expected P3A 
- 28L- HLA-E haplotypes in either gender. 
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P3A- 66R- HLA-E Male (n =50) Female (n = 62) 
·l 
haplotype 
0 E 0 E 
4-4.5-0101 26.0 26.1 0.08 14.5 18.4 0.7 
{13) {12.0) (9) ( 11. 9) 
4-3.9-0101 26.0 26.1 0.08 30.6 27.7 0.07 
(13) (12.0) (19) (17.9) 
4-4.5-0103 14.0 8.7 2.3 11.3 9.3 0.2 
(7) (4.0) (7) (6.0) 
4-3.9-0103 4.0 8.7 1.0 12.9 13.8 0.09 
(2) (4.0) (8) (8.9) 
3.8-3.9- 0101 10.0 6.5 1.3 8.1 7.0 0.06 
(5) (3.0) (5) {4.5) 
X-X-X 20.0 26.3 0.3 22.4 23.8 0.1 
(10) ( 12.0) (14) ( 15.4) 
Table 6.9.85 Frequency(%) MHC Class I P3A- 66R- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - 66R - HLA-E haplotypes detected in the 
patients separated by gender. The X- X- X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- 66R- HLA-E 
haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. There were no 
significant differences between the observed and expected P3A- 66R- HLA-E haplotypes in either gender. 
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P3B - 28L- HLA-E Male (n =50) 
·l Female (n = 62) 
haplotype 
0 E 0 E 
1.8- 4.3- 0101 23.1 28.1 0.3 22.9 23.3 0.1 
(6) (7.6) (11) (12.1) 
1.8-3.8- 0101 7.7 12.2 0.5 8.3 11.5 0.7 
(2) (3.3) (4) (6.0) 
1.8-4.3- 0102 3.8 3.7 0 8.3 2.7 4.8 
(I) (1.0) (4) (1.4) 
1.8- 4.3- 0103 19.2 9.3 2.5 8.3 10.0 0.3 
(5) (2.5) (4) (5.2) 
1.8-3.6- 0103 3.8 1.1 1.6 6.3 1.7 4.9 
(1) (0.3) (3) (0.9) 
1.5- 4.3- 0101 7.7 12.2 0.5 16.7 15.6 0.001 
(2) (3.3) (8) (8.1) 
1.5- 3.8- 0101 9.2 5.2 9.3 1 12.5 7.7 
(5) (1.4) (6) (4.0) 
X-X-X 19.1 26.0 1.5 16.8 27.3 2.7 
(4) (7.3) (8) (14.2) 
Table 6.9.86 Frequency(%) MHC Class I P3B- 28L- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - 28L- HLA-E haplotypes detected in the 
patients separated by gender. The X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3B- 28L- HLA-E 
haplotypes and J} values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not observed in either gender group are not included in the above table. 
1 = 1.5-3.8-0101 (M) x2 = 9.3, p = 0.002 (ldf), Pc= 0.01 M= male 
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P3B- 66R- HLA-E Male (n = 44) 
·l Female (n = 48) .,; 
haplotype 
0 E 0 E 
1.8- 4.5- 0101 18.2 20.0 0.2 8.3 12.9 2.1 
(8) (9.2) (4) (8.1) 
1.8- 3.9- 0101 15.9 20.0 0.5 29.2 22.4 0.0007 
(7) (9.2) ( 14) (14.1) 
1.8-4.5- 0103 13.6 5.6 4.4 10.4 8.6 0.03 
(6) (2.6) (5) (5.4) 
1.8-3.9- 0103 2.3 5.6 1.0 10.4 14.9 2.1 
(1) (2.6) (5) (9.4) 
1.5-4.5- 0101 11.4 13.5 0.2 8.3 7.3 0.08 
(5) (6.2) (4) (4.6) 
1.5- 3.9- 0101 22.7 13.5 0.2 12.5 12.9 0.5 
(10) (6.2) (6) (8.1) 
1.5-3.9-0103 2.3 3.9 0.4 8.3 8.6 0.4 
(1) (1.8) (4) (5.4) 
X-X-X 13.7 18.3 0.7 12.6 13.1 0.6 
(6) (8.4) (6) (8.3) 
Table 6.9.87 Frequency(%) MHC Class I P3B- 66R- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3B - 66R - HLA-E haplotypes detected in the 
patients separated by gender. The X- X - X haplotype-represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3B- 66R- HLA-E 
haplotypes and x2 values determined. The x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not observed in either gender group are not included in the above table. There were no significant differences between the observed and expected P3B -
66R - HLA-E haplotypes in either gender. 
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28L- 66R- HLA-E Male (n = 42) xz Female (n = 56) xz 
haplotype 
0 E 0 E 
4.3-4.5- 0101 7.1 11.5 0.6 8.9 14.5 1.2 
(3) (4.7) (5) (8.1) 
4.3- 3.9 - 0101 14.3 17.3 0.2 25.0 21.6 0.3 
(6) (7.1) (14) (12.1) 
4.3-3.9- 0103 4.8 4.9 0 8.9 10.7 0.2 
(2) (2.0) (5) (6.0) 
3.8- 4.5- 0101 14.3 11.5 0.4 8.9 4.8 2.0 
(6) (4.7) (5) (2.7) 
3.8-3.9- 0101 23.81 17.3 1.2 7.1 7.1 0 
(10) (7.1) (4) (4.0) 
X-X-X 35.8 36.6 0.0006 41.1 40.7 0.002 
(IS) ( 15.1) (23) (22.8) 
Table 6.9.88 Frequency(%) MHC Class I 28L- 66R- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected 28L- 66R- HLA-E haplotypes detected in the 
patients separated by gender. The X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n represents 
the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous at more 
than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does not take 
into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected 28L- 66R- HLA-E 
haplotypes and x2 values determined/the x2 test was used to estimate linkage disequilibrium between the 3 loci within each gender group. Haplotypes that 
were not detected in either gender group are not included in the above table. Haplotypes that were not observed in either gender group are not included in 
the above table. 
1 = 3.8- 3.9- 0101 (M) vs (F) x2 = 5.4, p = 0.01 (I df), Pc= o.os 
M = male, F = female 
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P3A - 28L- 66R- P3B Male (n = 28) 7.2 Female (n = 28) 7.2 
haplotype 
0 E 0 E 
4 - 4.3 - 3.9 - 1.8 10.7 12.4 0.01 17.9 14.2 1.0 
(3) (3.2) (5) (3.2) 
4 - 4.3 - 4.5 - 1.8 28.61 29.1 0.03 3.6 9.7 0.7 
(8) (7.5) (I) (2.2) 
X-X-X-X 60.7 58.8 0.4 78.5 75.8 0.4 
(17) (14.6) (19) (16.4) 
Table 6.9.89 Frequency(%) MHC Class I P3A- 28L- 66R- P3B haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - 28L - 66R - P3B haplotypes detected in the 
patients separated by gender. The X - X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of < 5. n 
represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous 
at more than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does 
not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- 28L-
66R - P3B haplotypes and 7.2 values determined. The 7.2 test was used to estimate linkage disequilibrium between the 4 loci within each gender group. 
Haplotypes that were not observed in either gender group are not included in the above table. 
1 = 4-4.3-4.5- 1.8 {M) vs (F) 7.2 = p = 0.01 (Idf), Pc= 0.02 
485 
P3A- P3B- 66R- HLA-E Male (n = 30) 
·l Female (n = 32) 1.2 
haplotype 
0 E 0 E 
4- 1.8- 4.5 - 0101 16.7 20.0 0.2 3.1 13.0 2.5 
(5) (6.0) (1) (4.3) 
4- 1.8-3.9- 0101 10.0 13.3 0.3 21.9 19.7 0.04 
(3) (4.0) (7) (6.5) 
4- 1.5-4.5- 0101 16.7 13.3 0.3 9.4 5.5 0.8 
(5) (4.0) (3) (1.8) 
4- 1.5-3.9- 0101 16.7 9.0 2.0 12.5 8.5 0.5 
(5) (2.7) (4) (2.8) 
X-X-X-X 39.8 43.0 0.06 53.3 52.5 l.l 
(12) (12.9) (17) (22.0) 
Table 6.9.90 Frequency(%) MHC Class I P3A- PJB- 66R- HLA-E haplotype in patients with respect to gender 
This table shows the frequency and actual number of copies (in brackets) of the observed and expected P3A - P3B - 66R - HLA-E haplotypes detected in 
the patients separated by gender. The X -X - X - X haplotype represents haplotypes, which were detected at an observed or expected frequency of< 5. n 
represents the total number of haplotypes available to be assigned in each gender group. Haplotypes were assigned in those subjects who were homozygous 
at more than one locus. The expected haplotype frequencies were obtained from the individual allelic frequencies. (The haplotype frequency analysis does 
not take into account individuals who were heterozygous at more than one locus). Comparisons were made between the observed and expected P3A- P3B-
66R - HLA-E haplotypes and 7.2 values determined. The 7.2 test was used to estimate linkage disequilibrium between the 4 loci within each gender group. 
Observations were also made between the 2 gender groups. Haplotypes that were not observed in either gender group are not included in the above table. 
There were no significant differences between the observed and expected P3A- P3B- 66R- HLA-E haplotypes in either gender. 
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6.10 Class I combined genotype analysis in patients with type 1 diabetes and normal 
controls 
6.10.1 Introduction 
The frequency ofthe possible combined genotypes of the five loci studied, P3A, 28L, 66R, 
P3B and HLA-E were investigated in the patient subjects with type 1 diabetes and the 
normal control subjects. The two microsatellite markers PI and D6S306 were not included 
in the genotype analysis due to the large number of possible genotypes arising from 
combination with two markers. This resulted in small numbers of subjects with a particular 
genotype, which were too small to be useful in the analysis for any significance. 
Comparisons were made between particular genotype frequencies in patient and control 
subjects using the x2 test and 2 X 2 contingency tables. 
Genotype frequencies were also investigated in the patient subjects with respect to age at 
onset of type 1 diabetes and also with respect to gender. 
With some of the genotypes the number of subjects presenting with them were very small, 
which made it difficult to analyse for any significance. It was decided that with genotypes 
were there were two or less subjects presenting in both the patients and controls that the 
actual genotype numbers and % frequencies be combined as the X genotype with an 
overall actual number and % frequency. 
Data that was found to be non-significant after correction is not presented in the text. 
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66R-P3B 
genotype 
4.5 - 1.8/1.5 
4.5-1.8 
4.5-1.5 
3.9 - 1.8/1.5 
3.9-1.8 
3.9-1.5 
4.5/3.9-1.8/1.5 
4.5/3.9-1.8 
4.5/3.9-1.5 
Total (n) 
All1.5 subjects(%) 
All4.5 subjects(%) 
Patients 
% 
8.1 
(13) 
6.9 
(11) 
3.1 
(5) 
13.8 
(22) 
6.91 
(11) 
3.8 
(6) 
31.3 
(50) 
16.9 
(27) 
9.4 
(15) 
160 
69.48 
75.6 
Controls 
% 
5.4 
(6) 
4.5 
(5) 
0.9 
(1) 
16.2 
(18) 
19.8 
(22) 
0.9 
(1) 
25.2 
(28) 
23.4 
(26) 
3.6 
(4) 
111 
52.3 
63.1 
Table 6.10.1 Frequency (%) MHC Class I 66R - P3B genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the nine 
possible 66R - P3B genotypes. n represents the number of patients and controls studied. 
The number in brackets represents the actual number of subjects with a particular 
genotype. Comparisons were made between the 66R- P3B genotype frequencies in patient 
and control subjects using the x2 test and 2 X 2 contingency tables. 
1 = 3.9-1.8 genotype frequency x2 = 10.3, p = 0.001 (1d.f), Pc= 0.008 
a= presence of the 1.5kb aUele in patients vs controls x2 = 8.2, p = 0.004 (1df), 
Pc= 0.03 
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The frequency of 66R - P3B genotypes in 160 patients with type 1 diabetes and 111 
normal control subjects is shown in table 6.10.1. There was a small but significant decrease 
in the frequency of the 3.9- 1.8 genotype in the patients (6.9%) compared to the controls 
(19.8%) (p = 0.001, Pc= 0.01). This was accompanied by an increase in the frequency of 
the 4.5/3.9 - 1.8/1.5 genotype in the patients (31.3%) compared to the controls (25.2%), 
the difference was found not to be significant when the p value was corrected. The P3B 
1.5kb allele was present in 69.4% of the patients compared with 52.3% of control subjects 
(p = 0.004, Pc = 0.03). There were no other significant differences found between the 
patient subjects and the normal controls. 
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P3A-P3B 
genotype 
4-1.8/1.5 
4-1.8 
4-1.5 
3.8 - 1.8/1.5 
3.8-1.8 
3.8-1.5 
4/3.8 - 1.8/1.5 
4/3.8-1.8 
4/3.8-1.5 
Total (n) 
All 4.0 subjects(%) 
All1.5 subjects(%) 
Patients 
% 
25.1 
(43) 
14.01 
(24) 
·11.12 
(19) 
1.2 
(2) 
4.1 
(7) 
0 
(0) 
25.7 
(44) 
11.7 
(20) 
7.03 
(12) 
171 
94.7 
95.78 
Controls 
% 
20.7 
(25) 
25.6 
(31) 
3.3 
(4) 
2.5 
(3) 
0.8 
(I) 
0.8 
(I) 
24.8 
(30) 
20.7 
(25) 
0.8 
(I) 
121 
70.2 
52.9 
Table 6.10.2 Frequency (%) MHC Class I P3A - P3B genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the nine 
possible P3A - P3B genotypes. n represents the number of patients and controls studied. 
The number in brackets represents the actual number of subjects with a particular 
genotype. Comparisons were made between the P3A - P3B genotype frequencies in 
patient and control subjects using the x2 test and 2 X 2 contingency tables. 
1 = 4-1.8 genotype frequency x2 = 6.2, p = 0.01 (ldf), Pc= 0.08 
2 = 4-1.5 genotype frequency x! = 5.9, p = 0.01 (Idt), Pc= 0.08 
3 = 4/3.8-1.5 genotype frequency x2 = 6.4, p = 0.01 (ldf), Pc= 0.08 
a= presence of the 1.5kb allele in patients vs controls x2 = 9.1, p = 0.002 (ldt),Pc = 0.01 
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The frequency of P3A- P3B genotypes in 171 patients with type 1 diabetes and 121 
normal control subjects is shown in table 6.10.2. Four of the nine P3A- P3B genotypes 
(4.0- 1.8, 4.0- 1.8/1.5, 4.0/3.8- 1.8 and 4.0/3.8- 1.8/1.5) accounted for more than 83% 
of the total number of genotypes detected in both the patient and normal control 
populations. There was a small but significant increase in the frequency of the 4.0-1.5 
genotype in the patients (11.1%) compared to the controls (3.3%) (p = 0.01, Pc = 0.08). 
There was also a similar increase in the frequency of the 4.0/3.8 - 1.5 genotype in the 
patients (7.0%) compared to the control subjects (0.8%) (p = 0.01, Pc = 0.08). This was 
accompanied by a decrease in the frequency of the 4.0 - 1.8 genotype in the patients 
(14.0%) compared to the controls (25.6%) (p = 0.01, Pc= 0.08) and also a non-significant 
decrease in the 4.0/3.8- 1.8 genotype. The P3B 1.5kb allele was found in 95.7% of the 
patients compared with 52.9% of control subjects (p = 0.002, Pc = 0.01). There were no 
other significant difference found between the patient subjects and the normal control 
subjects. 
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28L-P3B Patients Controls 
genotype % % 
4.3 - 1.811.5 10.0 9.3 
(15) (10) 
4.3-1.8 8.7 15.9 
(13) (17) 
4.3-- 1.5 0.7 1.9 
(1) (2) 
3.8- 1.8/1.5 6.0 7.5 
(9) (8) 
3.8-1.8 1.3 7.5 
(2) (8) 
3.8-1.5 2.0 0 
(3) (0) 
3.6 - 1.8/1.5 3.3 0.9 
(5) (1) 
3.6-1.8 2.0 1.9 
(3) (2) 
4.3/3.8-1.8/1.5 8.0 18.9 
(12) (20) 
4.3/3.8-1.8 6.7 14.0 
(10) (15) 
4.3/3.8-1.5 9.3 2.8 
(14) (3) 
4.3/3.6-1.8/1.5 6.0 4.7 
(9) (5) 
4.3/3.6-1.8 6.7 5.6 
(10) (6) 
4.3/3.6-1.5 1.3 0 
(2) (0) 
3.8/3.6-1.8/1.5 12.0 6.5 
(18) (7) 
3.8/3.6-1.8 2.0 2.8 
(3) (3) 
3.8/3.6- 1.5 2.0 0 
(3) (0) 
Total (n) 150 107 
All 4.3 subjects(%) 57.3 72.9 
All1.8 subjects(%) 72.7 95.33 
Table 6.10.3 Frequency (%) MBC Class I 28L - P3B genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the 
seventeen possible 28L - P3B genotypes. Genotypes that were not observed in either the 
patient or control subjects are not included in the above table. n represents the number of 
patients and controls studied. The number in brackets represents the actual number of 
subjects with a particular genotype. Comparisons were made between the 28L - P3B 
genotype frequencies in patient and control subjects using the X2 test and 2 X 2 
contingency tables. 
a= presence of the 1.8kb allele in controls vs patients x2 = 21.8, p = 0.000003 (ldf), 
Pc= 0.00004 
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The frequency of 28L - P3B genotypes in I 50 patients with type I diabetes and I 07 
normal control subjects is shown in table 6.I0.3. The P3B 1.8kb allele was present in 95.3 
% of the controls subjects compared with 72.7% of the patients (p = 0.000003, Pc = 
0.00004). There were no other significant differences between the patients and normal 
control subjects. 
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HLA-E-P3B Patients Controls 
genotype % % 
0101 - 1.8/1.5 15.9 5.3 
(22) (4) 
0101-1.8 5.8 5.3 
(8) (4) 
0101-1.5 5.1 0 
(7) (0) 
010110102- 1.8/1.5 3.6 9.2 
(5) (7) 
010110102- 1.8 1.4 6.6 
(2) (5) 
0101/0103- 1.8/1.5 18.1 9.2 
(25) (7) 
010110103- 1.8 8.7 9.2 
(12) (7) 
010110103- 1.5 9.41 0 
(13) (0) 
010110104- 1.8 2.9 1.3 
(4) (1) 
0102/0103- 1.8/1.5 4.3 5.3 
(6) (4) 
0102/0103- 1.8 3.6 6.6 
(5) (5) 
0102/0103- 1.5 3.6 0 
(5) (0) 
0102/0104- 1.8/1.5 2.2 10.5 
(3) (8) 
0102/0104- 1.8 0 3.9 
(0) (3) 
0103- 1.8/1.5 3.6 0 
(5) (0) 
0103-1.8 2.2 2.6 
(3) (2) 
0103/0104- 1.8/1.5 4.3 10.5 
(6) (8) 
0103/0104- 1.8 0.7 3.9 
(1) (3) 
X-X 5.8 10.5 
(8) (8) 
Total (n) 138 76 
All 0101 subjects(%) 72.58 50.0 
All 1.5 subjects (%) 73.9 57.9 
Table 6.10.4 Frequency(%) MHC Class I HLA-E- P3B genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the 
eighteen possible HLA-E - P3B genotypes detected. The X - X genotype represents 
genotypes that were detected in 2 or less subjects in both patients and controls. Genotypes 
that were not observed in either the patient or control subjects are not included in the above 
table. n represents the number of patients and controls studied. The number in brackets 
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represents the actual number of subjects with a particular genotype. Comparisons were 
made between the HLA-E - P3B genotype frequencies in patient and control subjects 
using the ·l test and 2 X 2 contingency tables. 
1 = 0101/0103-1.5 genotype frequency·/= 7.6, p = 0.005 (ldf), Pc= 0.08 
a =presence of the 0101 allele in patients vs controls x2 = I 0.8, p = 0.00 I (I df), 
Pc= 0.01 
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The frequency of lll..A-E - P3B genotypes in 138 patients with type 1 diabetes and 76 
normal control subjects is shown in table 6.1 0.4. Out of the total of 30 possible lll..A-E -
P3B genotypes only eighteen are shown in the table. The others were either not observed in 
the patients or controls or were present in 2 or less patient or control subjects and are 
therefore included in the X - X genotype. There was an increase in the frequency of the 
0101/0103 - 1.5 genotype in the patients (9.4%) compared to the controls were the 
genotype was absent (p = 0.005, Pc= 0.08). There was also an increase in the frequency of 
the 0101- 1.8/1.5 and 0101- 1.5 genotypes in the patients (15.9%, 5.1%) compared to the 
controls (5.3%, 0%), the increase was found not to be significant when the p value was 
corrected. The lll..A-E 0101 allele was present in 72.5% of the patients compared with 
only 50.0% of the control population. There were no other significant differences between 
the patient and control subjects. 
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P3A-66R 
genotype 
4-4.5/3.9 
4-4.5 
4-3.9 
3.8-4.5/3.9 
3.8-4.5 
3.8-3.9 
4/3.8-4.5/3.9 
4/3.8-4.5 
413.8-3.9 
Total (n) 
All 4.0 subjects(%) 
All4.5 subjects(%) 
Patients 
% 
30.7 
(51) 
9.6 
(16) 
10.8 
(18) 
1.8 
(3) 
1.8 
(3) 
1.2 
(2) 
26.5 
(44) 
6.0 
(10) 
11.4 
(19) 
166 
95.2 
76.58 
Controls 
0/o 
23.3 
(27) 
7.8 
(9) 
19.8 
(23) 
2.6 
(3) 
0 
(0) 
0.9 
(I) 
24.1 
(28) 
3.4 
(4) 
18.1 
(21) 
116 
96.6 
61.2 
Table 6.10.5 Frequency (%) MHC Class I P3A - 66R genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the nine 
possible P3A- 66R genotypes detected. n represents the number of patients and controls 
studied. The number in brackets represents the actual number of subjects with a particular 
genotype. Comparisons were made between the P3A- 66R genotype frequencies in patient 
and control subjects using they} test and 2 X 2 contingency tables. 
a= presence of the 4.5kb allele in patients vs controls x2 = 7.6, p = 0.005 (ldt) 
Pc= 0.04 
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The frequency of the P3 A - 66R genotypes in 166 patients with type I diabetes and 116 
normal controls is shown in table 6.10.5. Four of the nine P3A- 66R genotypes (4.0 -
4.5/3.9, 4.0- 3.9, 4.0/3.8-4.5/3.9 and 4.0/3.8- 3.9) accounted for more than 82% of the 
total number of genotypes observed in both the patient and control populations. The 66R 
4.5kb allele was present in 76.5% of the patients compared to 61.2% of the normal 
controls. There were no other significant differences between the patient and control 
populations. 
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P3A-28L Patients Controls 
genotype % % 
4-4.3 8.9 15.9 
(14) (17) 
4-3.8 5.1 8.4 
(8) (9) 
4-3.6 2.5 0.9 
(4) (I) 
4-4.313.8 23.4 15.9 
(37) (17) 
4-4.3/3.6 8.2 5.6 
(13) (6) 
4-3.8/3.6 5.7 2.8 
(9) (3) 
3.8-4.3 1.9 1.9 
(3) (2) 
4/3.8-4.3 8.2 9.3 
(13) (10) 
4/3.8-3.8 3.8 6.5 
(6) (7) 
4/3.8-3.6 1.9 1.9 
(3) (2) 
4/3.8-4.3/3.8 14.6 18.7 
(23) (20) 
4/3.8-4.3/3.6 7.6 4.7 
(12) (5) 
413.8 - 3.813.6 6.3 5.6 
(10) (6) 
X-X 1.9 1.9 
(3) (2) 
Total (n) 158 107 
Table 6.10.6 Frequency (%) MHC Class I P3A - 28L genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the thirteen 
possible P3A - 28L genotypes detected. The X -X genotype represents genotypes that 
were detected in 2 or less subjects in both patients and controls. Genotypes that were not 
observed in either the patient or control subjects are not included in the above table. n 
represents the number of patients and controls studied. The number in brackets represents 
the actual number of subjects with a particular genotype. Comparisons were made between 
the P3A- 28L genotype frequencies in patient and control subjects using the ·i test and 
2 X 2 contingency tables. There were no significant differences in the P3A - 28L 
genotypes between the patient and control subjects. 
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P3A-HLA-E 
genotype 
4-0101 
4/3.8- 0101 
4- 010110102 
4/3.8- 010110102 
4- 01011 0103 
4/3.8- 010110103 
4- 010110104 
4/3.8-0102 
4- 0102/0103 
4/3.8- 0102/0103 
4- 0102/0104 
4/3.8- 0102/0104 
4-0103 
4/3.8-0103 
4- 0103/0104 
4/3.8- 0103/0104 
X-X 
Total (n) 
All4.0 subjects(%) 
All 0101 subjects(%) 
Patients 
% 
11.2 
(16) 
15.4 
(22) 
2.8 
(4) 
3.5 
(5) 
21.01 
(30) 
13.3 
(19) 
1.3 
(2) 
1.3 
(2) 
6.9 
(10) 
3.5 
(5) 
2.1 
(4) 
1.3 
(2) 
3.5 
(5) 
2.1 
(3) 
2.8 
(4) 
1.3 
(2) 
6.9 
(10) 
143 
95.8 
73.48 
Controls 
0/o 
5.1 
(4) 
5.1 
(4) 
3.8 
(3) 
10.1 
(8) 
7.6 
(6) 
12.7 
(10) 
3.8 
(4) 
3.8 
(3) 
3.8 
(3) 
7.6 
(6) 
6.3 
(5) 
6.3 
(5) 
1.3 
(1) 
1.3 
(1) 
7.6 
(6) 
8.9 
(7) 
6.3 
(5) 
79 
98.7 
51.9 
Table 6.10.7 Frequency(%) MHC Oass I P3A- HLA-E genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the sixteen 
possible P3A- ffi...A-E genotypes detected. The X - X genotype represents genotypes that 
were detected in 2 or less subjects in both patients and controls. Genotypes that were not 
observed in either the patient or control subjects are not included in the above table. n 
represents the number of patients and controls studied. The number in brackets represents 
the actual number of subjects with a particular genotype. Comparisons were made between 
the P3A- ffi...A-E genotype frequencies in patient and control subjects using the ·l test 
and 2 X 2 contingency tables. 
500 
1 = 4- 0101/0103 genotype frequency ·l = 6. 7, p = 0.009 (1df), Pc= 0.01 
a= presence of the 0101 allele in patients vs controls x2 = 10.5, p = 0.001 (1df), 
Pc= 0.01 (1df) 
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The frequency of P3A - lfi..A-E genotypes in 143 patients wit type 1 diabetes and 79 
normal control subjects is shown in table 6.10.7. Out of the total of 30 possible HLA-E-
P3A genotypes only sixteen are shown in the table. The others were either not observed in 
the patients or controls or were present in 2 or less patient or control subjects and are 
therefore included in the X- X genotype. There was an increase in the frequency of the 
4.0- 0101/0103 genotype in the patients (21.0%) compared to the control subjects (7.6%) 
(p = 0.009, Pc = 0.01). The lfi..A-E 0101 allele was found in 73.4% of the patients 
compared to 51.9% ofthe controls (p = 0.001, Pc= 0.01). There were no other significant 
difference found between the patients and controls. 
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28L-66R Patients Controls 
genotype % % 
4.3-4.5 3.6 0 
(6) (0) 
3.8-4.5 2.4 4 
(4) (4) 
3.6-4.5 0.6 2 
(I) (2) 
4.3/3.8-4.5 3.6 2 
(6) (2) 
4.3/3.6-4.5 2.4 l 
(4) (I) 
3.8/3.6-4.5 4.8 2 
(8) (2) 
4.3-3.9 5.4 12 
(9) (I2) 
3.8-3.9 1.2 81 
(2) (8) 
3.6-3.9 2.4 0 
(4) (0) 
4.3/3.8-3.9 7.1 14 
(I2) (14) 
4.3/3.6-3.9 4.2 2 
(7) (2) 
3.813.6 - 3.9 1.8 l 
(3) (I) 
4.3-4.5/3.9 9.5 15 
(I6) (IS) 
3.8-4.5/3.9 6.5 4 
(11) (4) 
3.6-4.5/3.9 2.9 l 
(5) (I) 
4.313.8-4.5/3.9 23.8 20 
(40) (20) 
4.3/3.6-4.5/3.9 10.7 8 
(I8) (8) 
3.8/3.6-4.5/3.9 7.1 4 
(I2) (4) 
Total (n) 168 lOO 
Table 6.10.8 Frequency (%) MHC Class I 28L - 66R genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the 
eighteen possible 28L - 66R genotypes detected. n represents the number of patients and 
controls studied. The number in brackets represents the actual number of subjects with a 
particular genotype. Comparisons were made between the 28L - 66R genotype frequencies 
in patient and control subjects using the ·l test and 2 X 2 contingency tables. 
l = 3.8- 3.9 genotype frequency x2 = 8.I, p = 0.004 (Id£), Pc= 0.06 
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The frequency of the 28L - 66R genotypes in 168 patients with type 1 diabetes and 1 00 
normal control subjects (Table 6.10.8). There was a small but significant decrease in the 
frequency of the 3.8- 3.9 genotype in the patients (1.2%) compared to the control subjects 
(8%) (p = 0.004, Pc = 0.06). There were no other significant differences between the 
patient and normal control subjects. 
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28L-HLA-E Patients Controls 
genotype % % 
4.3-0101 6.5 1.4 
(9) (1) 
3.8-0101 5.8 2.9 
(8) (2) 
3.6-0101 2.2 1.4 
(3) (1) 
4.3/3.8- 0101 7.9 2.9 
(11) (2) 
4.3/3.6- 0101 2.9 0 
(4) (0) 
4.3- 0101/0102 0.7 7.1 
(1) (5) 
4.3/3.8- 0101/0102 2.9 5.7 
(4) (4) 
4.3- 0101/0103 7.2 1.4 
(10) (1) 
3.8- 0101/0103 2.9 4.3 
(4) (3) 
4.313.8- 0101/0103 13.0 5.7 
(18) (4) 
4.3/3.6- 0101/0103 5.8 4.3 
(8) (3) 
3.8/3.6- 0101/0103 6.5 1.4 
(9) (1) 
4.3- 0102/0103 2.2 1.4 
(3) (1) 
4.3/3.8- 0102/0103 5.1 5.7 
(7) (4) 
4.3/3.8- 0102/0104 3.6 5.7 
(5) (4) 
3.8/3.6- 0102/0104 0.7 4.3 
(1) (3) 
4.3- 0103/0104 0.7 4.3 
(1) (3) 
4.3/3.8 - 0103/0104 1.4 5.7 
(2) (4) 
3.8/3.6- 0103/0104 0.7 4.3 
(1) (3) 
X-X 13.8 30.0 
(19) (21.0) 
Total (n) 138 70 
All4.3 subjects(%) 66.7 70.0 
All 0101 subjects(%) 70.38 50.0 
Table 6.10.9 Frequency (%) MHC Class I 28L- HLA-E genotype in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the 
nineteen possible 28L - HLA-E genotypes detected. The X - X genotype represents 
genotypes that were detected in 2 or less subjects in both patients and controls. Genotypes 
that were not observed in either the patient or control subjects are not included in the above 
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table. n represents the number of patients and controls studied. The number in brackets 
represents the actual number of subjects with a particular genotype. Comparisons were 
made between the 28L- HLA-E genotype frequencies in patient and control subjects using 
the ·/} test and 2 X 2 contingency tables. 
a= presence of the 0101 allele in patients vs controls·/}= 8.3, p = 0.004 (ldf), 
Pc= 0.07 
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The frequency of the 28L- HLA-E genotypes in 138 patients with type 1 diabetes and 70 
normal control subjects (Table 6.10.9). Out of the total of 60 possible 28L - HLA-E 
genotypes only eighteen are shown in the table. The others were either not observed in the 
patients or controls or were present in 2 or less patient or control subjects and are therefore 
included in the X - X genotype. The HLA-E 0101 allele was present in 70.3% of the 
patients compared with 50.0% of control subjects (p = 0.004, Pc= 0.07). There were no 
other significant differences between the patients and normal controls. 
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66R-HLA-E 
4.5-0101 
3.9-0101 
4.5/3.9- 0101 
3.9- 0101/0102 
4.5/3.9 ~ 0101/0102 
4.5-0101/0103 
3.9- 0101/0103 
4.5/3.9- 0101/0103 
4.5/3.9- 0101/0104 
4.5/3.9- 0102 
4.5-0102/0103 
4.5/3.9- 0102/0103 
3.9- 0102/0104 
4.5/3.9- 0102/0104 
3.9-0103 
4.5/3.9- 0103 
4.5- 0103/0104 
3.9-0103/0104 
4.5/3.9- 0103/0104 
X-X 
Total (n) 
All 4.5 subjects(%) 
All 0101 subjects(%) 
Patients 
% 
2.5 
(4) 
9.5 
(15) 
16.51 
(26) 
1.9 
(3) 
4.4 
(7) 
7.6 
(12) 
8.9 
(14) 
21.5 
(34) 
0.6 
(1) 
1.3 
(2) 
3.8 
(6) 
5.1 
(8) 
1.9 
(3) 
1.9 
(3) 
1.9 
(3) 
2.5 
(4) 
1.9 
(3) 
0.6 
(1) 
2.5 
(4) 
3.2 
(5) 
158 
73.4 
74.1a 
Controls 
% 
4.1 
(3) 
4.1 
(3) 
1.4 
(1) 
5.5 
(4) 
8.2 
(6) 
1.4 
(1) 
8.2 
(6) 
10.9 
(8) 
5.5 
(4) 
4.1 
(3) 
2.7 
(2) 
1.4 
(1) 
6.8 
(5) 
8.2 
(6) 
1.4 
(1) 
1.4 
(1) 
1.4 
(1) 
6.82 
(5) 
9.6 
(7) 
6.8 
(5) 
73 
61.6 
50.6 
Table 6.10.10 Frequency(%) MHC Class I 66R- HLA-E genotypes in patients and 
normal controls 
This table shows the frequency and actual number of patients and controls with the 
nineteen possible 66R - HLA-E genotypes detected. The X - X genotype represents 
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genotypes that were detected in 2 or less subjects in both patients and controls. Genotypes 
that were not observed in either the patient or control subjects are not included in the above 
table. n represents the number of patients and controls studied. The number in brackets 
represents the actual number of subjects with a particular genotype. Comparisons were 
made between the 66R- HLA-E genotype frequencies in patient and control subjects using 
the x2 test and 2 X 2 contingency tables. 
1 = 4.5/3.9- 0101 genotype frequency X2 = 11.0, p = 0.0009 (1df), Pc= 0.01 
2 = 3.9- 0103/0104 genotype frequency x2 = 7.6, p = 0.005 (1df), Pc= 0.09 
a= presence of the 0101 allele in patients vs controls x2 = 12.3, p = 0.0004 (1df), 
Pc= 0.007 
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The frequency of the 66R- HLA-E genotypes in 158 patients with type 1 diabetes and 73 
normal control subjects (Table 6.1 0.1 0). Out of the total of 30 possible 66R - HLA-E 
genotypes only nineteen are shown in the table. The others were either not observed in the 
patients or controls or were present in 2 or less patient or control subjects and are therefore 
included in the X - X genotype. There was a significant increase in the frequency of the 
4.5/3.9- 0101 genotype in the patients (16.5%) compared to the controls (1.4%) (p = 
0.0009, Pc = 0.01). This was accompanied by a decrease in the frequency of the 3.9 -
0103/0104 genotype in the patients (0.6%) compared to the controls (6.8%) (p = 0.005, Pc 
= 0.09). The HLA-E 0101 allele was found in 74.1 % ofthe patients compared with 50.6% 
of the normal control subjects (p = 0.0004, Pc= 0.008). There were no other significant 
differences between the patients and normal control subjects. 
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P3B-66R Age at onset of 
Genotype Diabetes (years) 
< 10 10-20 >20 
% % % 
1.8/1.5 - 4.5 10.7 6.1 5.6 
(8) (3) (2) 
1.8-4.5 6.7 6.1 8.3 
(5) (3) (3) 
1.5-4.5 4.0 0 5.6 
(3) (0) (2) 
1.8/1.5 - 3.9 14.7 18.3 5.6 
(11) (9) (2) 
1.8-3.9 10.7 4.1 5.6 
(8) (2) (2) 
1.5-3.9 5.3 4.1 2.8 
(4) (2) (I) 
1.8/1.5-4.5/3.9 26.7 30.6 36.1 
(20) (IS) (I3) 
1.8 - 4.5/3.9 14.7 22.4 13.9 
( II) (II) (5) 
1.5 - 4.5/3.9 6.7 8.2 16.7 
(5) (4) (6) 
Total (n) 75 49 36 
Table 6.10.11 Frequency(%) MBC Class I P3B- 66R genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the P3B- 66R genotypes in patients separated by age at 
onset into <IO, I0-20 and > 20 years. The number in brackets is the actual number of 
subjects with a particular genotype. n represents the number of subjects in each age at 
onset group. Comparisons were made between the P3B - 66R genotype frequencies in the 
three different ages at onset groups using the x.2 test and 2 x 2 contingency tables. There 
were no significant differences in the P3B- 66R genotypes between any of the age at onset 
groups. 
511 
P3B-P3A 
Genotype 
1.8/1.5- 4 
1.8-4 
1.5-4 
1.8-3.8 
1.8/1.5 - 4/3.8 
1.8-4/3.8 
1.5-4/3.8 
X-X 
Total (n) 
< 10 
0/o 
28.2 
(22) 
12.8 
(10) 
7.7 
(6) 
1.3 
(1) 
16.7 
(13) 
24.41 
(19) 
7.7 
(6) 
1.3 
(1) 
78 
Age at onset of 
Diabetes (years) 
10-20 > 20 
0/o 0/o 
22.4 21.6 
(13) (8) 
19.0 13.5 
(11) (5) 
12.1 16.2 
(7) (6) 
5.2 8.1 
(3) (3) 
29.3 24.3 
(17) (9) 
6.9 5.4 
(4) (2) 
3.4 10.8 
(2) (4) 
1.7 0 
(1) (0) 
58 37 
Table 6.10.12 Frequency(%) MHC Class I P3B- P3A genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the P3B- P3A genotypes in patients separated by age at 
onset into <10, 10-20 and> 20 years. The X- X genotype represents genotypes that were 
detected in 2 or less subjects in all of the age at onset groups. Genotypes that were not 
observed in any of the age at onset groups are not included in the above table. The number 
in brackets is the actual number of subjects with a particular genotype. n represents the 
number of subjects in each age at onset group. Comparisons were made between the P3B -
P3A genotype frequencies in the three different ages at onset groups using the x2 test and 
2 x 2 contingency tables. 
1 = 1.8- 4/3.8 genotype frequency< 10 years VS 10-20 years '"f! = 7.2, p = 0.007 (1df), 
Pc= 0.09 
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The frequency of the P3B- P3A genotypes in the 3 age at onset groups:< 10 years 
(n = 78), 10-20 years (n =58) and> 20 years (n = 37) is shown in table 6.10.12. Out of a 
total of nine P3B- P3A genotypes only seven are presented in the table. The others were 
either not observed in any of the patient subgroups or occurred in 2 or less subjects in all of 
the subgroups and were therefore included in the X - X genotype. The 1.8 - 4.0/3.8 
genotype was significantly increased in the patients with an age at onset of < 10 years 
(24.4%) compared to patients in the 10-20 years group (6.9%) (p = 0.007, Pc = 0.09). 
There were no other significant differences between the 3 patient subgroups. 
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P3B-28L Age at onset of 
Genotype Diabetes (years) 
< 10 10-20 >20 
% % % 
1.8/1.5 - 4.3 10.8 13.5 8.3 
(7) (7) (3) 
1.8/1.5- 3.8 6.2 7.7 5.6 
(4) (4) (2) 
1.8/1.5- 3.6 6.2 1.9 0 
(4) (1) (0) 
1.8/1.5-4.3/3.8 15.4 21.2 19.4 
(10) (11) (7) 
1.8/1.5-4.3/3.6 6.2 9.6 2.8 
(4) (5) (1) 
1.8/1.5-3.8/3.6 10.8 5.8 11.1 
(7) (3) (4) 
1.8-4.3 6.2 7.7 8.3 
(4) (4) (3) 
1.8 - 4.3/3.8 10.8 5.8 5.6 
(7) (3) (2) 
1.8 - 4.3/3.6 6.2 7.7 8.3 
(4) (4) (3) 
1.8 - 3.8/3.6 4.6 0 0 
(3) (0) (0) 
1.5 - 4.3/3.8 9.2 9.6 11.1 
(6) (5) (4) 
1.5 - 3.8/3.6 0 5.8 8.3 
(0) (3) (3) 
X-X 7.7 3.8 11.1 
(5) (2) (4) 
Total (n) 65 52 36 
Table 6.10.13 Frequency(%) MHC Class I P3B- 28L genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the P3B - 28L genotypes in patients separated by age at 
onset into <10, 10-20 and> 20 years. The X- X genotype represents genotypes that were 
detected in 2 or less subjects in all of the age at onset groups. Genotypes that were not 
observed in any of the age at onset groups are not included in the above table. The number 
in brackets is the actual number of subjects with a particular genotype. n represents the 
number of subjects in each age at onset group. Comparisons were made between the P3B -
28L genotype frequencies in the three different ages at onset groups using the x.2 test and 
2 x 2 contingency tables. There were no significant differences in the P3B - 28L genotypes 
between any of the age at onset groups. 
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P3B-HLA-E 
Genotype 
1.8/1.5- 0101 
1.8-0101 
1.5- 0101 
1.8/1.5- 010110102 
1.8/1.5- 010110103 
1.8- 010110103 
1.5-010110103 
1.8-010110104 
1.8/1.5- 0102/0103 
1.5- 0102/0103 
1.8/1.5- 0103 
1.8/1.5- 0103/0104 
X-X 
Total (n) 
All1.5 subjects(%) 
All 0103 subjects(%) 
< 10 
% 
9.5 
(6) 
4.8 
(3) 
1.6 
(1) 
4.8 
(3) 
22.2 
(14) 
9.5 
(6) 
11.1 
(7) 
4.8 
(3) 
1.6 
(1) 
4.8 
(3) 
4.8 
(3) 
6.3 
(4) 
14.3 
(9) 
63 
71.4 
73.08 
Age at onset of 
Diabetes (years) 
10-20 
% 
31.1 
(14) 
6.7 
(3) 
6.7 
(3) 
2.2 
(1) 
13.3 
(6) 
11.1 
(5) 
2.2 
(1) 
2.2 
(1) 
6.7 
(3) 
4.4 
(2) 
2.2 
(1) 
2.2 
(1) 
8.9 
(4) 
45 
75.6 
44.4 
>20 
% 
6.7 
(2) 
6.7 
(2) 
10.0 
(3) 
3.3 
(1) 
16.7 
(5) 
3.3 
(1) 
16.7 
(5) 
0 
(0) 
6.7 
(2) 
3.3 
(1) 
3.3 
(1) 
3.3 
(1) 
20.0 
(6) 
30 
80.0 
46.7 
Table 6.10.14 Frequency(%) MHC Class I P3B- HLA-E genotypes with respect to 
age at onset of type 1 diabetes 
This table shows the frequency of the P3B- ID...A-E genotypes in patients separated by age 
at onset into <1 0, 10-20 and > 20 years. The X - X genotype represents genotypes that 
were detected in 2 or less subjects in all of the age at onset groups. Genotypes that were 
not observed in any of the age at onset groups are not included in the above table. The 
number in brackets is the actual number of subjects with a particular genotype. n 
represents the number of subjects in each age at onset group. Comparisons were made 
between the P3B- ID...A-E genotype frequencies in the three different ages at onset groups 
using the X2 test and 2 X 2 contingency tables. 
a= presence of the 0103 allele in the< 10 years vs 10-20 years x2 = 9.0, p = 0.002 (1df), 
Pc= 0.05 
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The frequency ofP3B- HLA-E genotypes in the 3 age at onset groups:< 10 years 
(n = 63), 10-20 (n = 45) and > 20 years (n = 30) is shown in table 6.1 0.14. Out of a total of 
30 P3B- HLA-E genotypes only 12 are presented in the table. The others were either not 
observed in any of the patient subgroups or occurred in 2 or less subjects in all of the 
subgroups and were/are therefore included in the X- X genotype. The frequency of the 
1. 8/1.5 - 0 10 1 genotype was increased in patients in the 1 0-20 years group (31.1%) 
compared to patients in the< 10 years group (9.5%), the increase was non-significant when 
corrected (p = 0.004, Pc= ns). The frequency was also increased in the 10-20 years age at 
onset group when compared to all the other patients combined (<10 and> 20 years) 31.1% 
vs 8.6% (p = 0.05), the difference was non-significant after correction. The HLA-E 0103 
allele was found in 73.0% of patients who presented before the age of 10 years compared 
only 44.4% who presented between the age of 10-20 years (p = 0.002, Pc = 0.05). There 
were no other significant differences between any of the patient subgroups. 
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P3A-66R 
Genotype 
4/3.8-4.5 
4-4.5 
4/3.8-3.9 
4-3.9 
4/3.8-4.5/3.9 
4-4.5/3.9 
X-X 
Total (n) 
< 10 
% 
9.1 
(7) 
11.7 
(9) 
12.9 
(10) 
14.3 
(11) 
28.6 
(22) 
22.0 
(17) 
1.3 
(0) 
77 
Age at onset of 
Diabetes (years) 
10-20 >20 
0/o % 
1.9 5.4 
(1) (2) 
7.7 8.1 
(4) (3) 
13.5 5.4 
(7) (2) 
7.7 8.1 
(4) (3) 
23.1 27.0 
(12) (10) 
38.5 37.8 
(20) (14) 
7.7 8.1 
(4) (3) 
52 37 
Table 6.10.15 Frequency(%) MBC Class I P3A- 66R genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the P3A- 66R genotypes in patients separated by age at 
onset into <10, 10-20 and> 20 years. The X- X genotype represents genotypes that were 
detected in 2 or less subjects in all of the age at onset groups. The number in brackets is the 
actual number of subjects with a particular genotype. n represents the number of subjects 
in each age at onset group. Comparisons were made between the P3A - 66R genotype 
frequencies in the three different ages at onset groups using the x2 test and 2 x 2 
contingency tables. There were no significant differences in the P3A - 66R genotypes 
between any of the age at onset groups. 
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P3A-28L 
Genotype 
4/3.8-4.3 
4-4.3 
4-3.8 
4-3.6 
4/3.8-4.3/3.8 
4-4.3/3.8 
4/3.8-4.3/3.6 
4-4.3/3.6 
4/3.8-3.8/3.6 
4-3.8/3.6 
X-X 
Total (n) 
< 10 
% 
7.7 
(5) 
10.8 
(7) 
6.2 
(4) 
4.6 
(3) 
16.9 
(11) 
15.4 
(10) 
7.7 
(5) 
6.2 
(4) 
10.8 
(7) 
6.2 
(4) 
6.2 
(4) 
65 
Age at onset of 
Diabetes (years) 
10-20 >20 
0/o % 
12.0 5.6 
(6) (2) 
8.0 8.3 
(4) (3) 
2.0 8.3 
(1) (3) 
2.0 0 
(1) (0) 
16.0 13.9 
(8) (5) 
22.0 25.0 
(11) (9) 
6.0 8.3 
(3) (3) 
16.0 5.6 
(8) (2) 
0 8.3 
(0) (3) 
4.0 8.3 
(2) (3) 
12.0 8.3 
(6) (3) 
50 36 
Table 6.10.16 Frequency(%) MHC Class I P3A- 28L genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the P3A- 28L genotypes in patients separated by age at 
onset into <10, 10-20 and> 20 years. The X- X genotype represents genotypes that were 
detected in 2 or less subjects in all of the age at onset groups. Genotypes that were not 
observed in any of the age at onset groups are not included in the above table. The number 
in brackets is the actual number of subjects with a particular genotype. n represents the 
number of subjects in each age at onset group. Comparisons were made between the P3A-
28L genotype frequencies in the three different ages at onset groups using the x2 test and 
2 x 2 contingency tables. There were no significant differences in the P3A- 28L genotypes 
between any of the age at onset groups. 
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P3A-HLA-E Age at onset of 
Genotype Diabetes (years) 
< 10 10-20 >20 
0/o % 0/o 
4/3.8-0101 13.8 27.7 3.2 
(9) (13)1 (1) 
4-0101 4.6 14.9 19.4 
(3) (7) (6) 
4/3.8-0101/0102 4.6 0 6.5 
(3) (0) (2) 
4/3.8- 010110103 15.4 8.5 16.1 
(IO) (4) (5) 
4- 010110103 24.6 17.0 19.4 
(I6) (8) (6) 
4/3.8-0102/0103 6.2 2.1 12.9 
(4) (1) (4) 
4- 0102/0103 3.1 8.5 3.2 
(2) (4) (I) 
4-0103 4.6 2.1 3.2 
(3) (I) (I) 
4- 0103/0104 4.6 2.1 0 
(3) (I) (0) 
X-X 18.5 14.9 16.1 
(I2) (7) (5) 
Total (n) 65 47 31 
Table 6.10.17 Frequency(%) MHC Class I P3A- HLA-E genotype with respect to 
age at onset of type 1 diabetes 
This table shows the frequency of the P3A - HLA-E genotypes in patients separated by 
age at onset into <IO, I0-20 and> 20 years. The X- X genotype represents genotypes that 
were detected in 2 or less subjects in all of the age at onset groups. Genotypes that were 
not observed in any of the age at onset groups are not included in the above table. The 
number in brackets is the actual number of subjects with a particular genotype. n 
represents the number of subjects in each age at onset group. Comparisons were made 
between the P3A- HLA-E genotype frequencies in the three different ages at onset groups 
USing the X2 test and 2 X 2 contingency tables. 
1 = 413.8-0101 genotype frequency 10-20 years vs> 20 years x2 = 7.6, p = 0.005 (ldf), 
Pc= 0.09 
5I9 
The frequency of the P3A- HLA-E genotypes in the 3 age at onset groups:< 10 years 
(n = 65), 10-20 years (n = 47) and> 20 years (n = 31) is shown in table 6.10.17. Out of a 
total of 30 P3A- HLA-E genotypes only 9 are presented in the table. The others were 
either not observed in any of the patient subgroups or occurred in 2 or less subjects in all of 
the subgroups and were therefore included in the X - X genotype. There was a significant 
increase in the frequency of the 4.0/3.8- 0101 genotype in the 10-20 years group (27.7%) 
compared to patients in the> 20 years group (3.2%) (p = 0.005, Pc= 0.09). There were no 
other significant differences between any of the patient subgroups. 
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66R-28L 
Genotype 
4.5/3.9-4.3 
4.5/3.9-3.8 
4.5/3.9-3.6 
4.5/3.9-4.3/3.8 
4.5/3.9-4.3/3.6 
4.5/3.9-3.8/3.6 
4.5-4.3 
4.5-3.8 
4.5-4.3/3.8 
4.5 - 3.8/3.6 
3.9-4.3 
3.9 - 4.3/3.8 
3.9-4.3/3.6 
X-X 
Total (n) 
< 10 
% 
10.1 
(7) 
2.9 
(2) 
5.8 
(4) 
18.8 
(13) 
7.2 
(5) 
8.7 
(6) 
2.9 
(2) 
5.8 
(4) 
5.8 
(4) 
4.3 
(3) 
5.8 
(4) 
10.1 
(7) 
4.3 
(3) 
7.2 
(5) 
69 
Age at onset of 
Diabetes (years) 
10-20 >20 
% % 
8.8 9.8 
(5) (4) 
8.8 7.3 
(5) (3) 
1.8 2.4 
(I) (1) 
28.1 29.3 
(16) (12) 
14.0 9.8 
(8) (4) 
1.8 12.2 
(1) (5) 
5.3 2.4 
(3) (I) 
0 0 
(0) (0) 
1.8 2.4 
(1) (1) 
1.8 7.3 
(1) (3) 
7.0 2.4 
(4) (I) 
5.3 4.9 
(3) (2) 
5.3 2.4 
(3) (1) 
10.5 12.2 
(6) (5) 
57 41 
Table 6.10.18 Frequency (%) MBC Class I 28L- 66R genotypes with respect to age 
at onset of type 1 diabetes 
This table shows the frequency of the 28L - 66R genotypes in patients separated by age at 
onset into <10, 10-20 and> 20 years. The X- X genotype represents genotypes that were 
detected in 2 or less subjects in all of the age at onset groups. Genotypes that were not 
observed in any of the age at onset groups are not included in the above table. The number 
in brackets is the actual number of subjects with a particular genotype. n represents the 
number of subjects in each age at onset group. Comparisons were made between the 28L -
66R genotype frequencies in the three different ages at onset groups using the x2 test and 
2 x 2 contingency tables. There were no significant differences in the 28L - 66R genotypes 
between any of the age at onset groups. 
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HLA-E-28L Age at onset of 
Genotype Diabetes (years) 
< 10 10-20 . >20 
% % % 
0101-4.3 2.0 10.0 11.8 
(1) (4) (4) 
0101-3.8 2.0 12.5 5.9 
(1) (5) (2) 
0101- 4.3/3.8 6.1 15.0 5.9 
(3) (6) (2) 
0101- 4.3/3.6 2.0 10.0 2.9 
(1) (4) (1) 
010110103- 4.3 14.3 7.5 2.9 
(7) (3) (1) 
010110103-3.8 6.1 2.5 0 
(3) (1) (0) 
010110103- 4.3/3.8 18.4 7.5 17.6 
(9) (3) (6) 
010110103- 4.3/3.6 8.2 5.0 0 
(4) (2) (0) 
010110103- 3.8/3.6 4.1 2.5 14.7 
(2) (1) (5) 
010110104- 4.3/3.8 6.1 0 0 
(3) (0) (0) 
0102/0103- 4.3/3.8 6.1 5.0 5.9 
(3) (2) (2) 
X-X 44.9 37.5 32.4 
(22) (IS) (11) 
Total (n) 49 40 34 
Table 6.10.19 Frequency(%) MHC Class I HLA-E- 28L genotypes with respect to 
age at onset of type 1 diabetes 
This table shows the frequency of the HLA-E- 28L genotypes in patients separated by age 
at onset into <10, 10-20 and > 20 years. The X- X genotype represents genotypes that 
were detected in 2 or less subjects in all of the age at onset groups. Genotypes that were 
not observed in any of the age at onset groups are not included in the above table. The 
number in brackets is the actual number of subjects with a particular genotype. n 
represents the number of subjects in each age at onset group. Comparisons were made 
between the HLA-E- 28L genotype frequencies in the three different ages at onset groups 
using the r! test and 2 x 2 contingency tables. There were no significant differences in the 
HLA-E- 28L genotypes between any of the age at onset groups. 
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HLA-E-66R 
Genotype 
0101 - 4.5/3.9 
0101-3.9 
0101/0102- 4.5/3.9 
0101/0103- 4.5/3.9 
0101/0103- 4.5 
0101/0103- 3.9 
0101/0104- 4.5 
0102/0103- 4.5/3.9 
0102/0103- 4.5 
0103- 4.5/3.9 
0103/0104- 4.5/3.9 
X-X 
Total (n) 
All4.5 subjects (%) 
All 0103 subjects(%) 
<10 
0/o 
9.5 
(7) 
5.4 
(4) 
4.1 
(3) 
24.3 
(18) 
5.4 
(4) 
12.2 
(9) 
5.4 
(4) 
2.7 
(2) 
5.4 
(4) 
4.1 
(3) 
4.1 
(3) 
17.6 
(13) 
74 
71.6 
64.98 
Age at onset of 
Diabetes (years) 
10-20 
0/o 
26.0 
(13) 
18.0 
(9) 
6.0 
(3) 
10.0 
(5) 
6.0 
(3) 
6.0 
(3) 
0 
(0) 
6.0 
(3) 
0 
(0) 
0 
(0) 
4.0 
(2) 
18.0 
(9) 
50 
70.0 
38.8 
>20 
0/o 
18.1 
(6) 
3.0 
(1) 
3.0 
(1) 
33.3 
(11) 
3.0 
(I) 
3.0 
(1) 
0 
(0) 
6.0 
(2) 
9.0 
(3) 
3.0 
(1) 
0 
(0) 
18.2 
(6) 
33 
90.0 
63.6 
Table 6.10.20 Frequency(%) MHC Class I HLA-E- 66R genotypes with respect to 
age at onset of type 1 diabetes 
This table shows the frequency of the lll.A-E- 66R genotypes in patients separated by age 
at onset into <10, 10-20 and > 20 years. The X- X genotype represents genotypes that 
were detected in 2 or less subjects in all of the age at onset groups. Genotypes that were 
not observed in any of the age at onset groups are not included in the above table. The 
number in brackets is the actual number of subjects with a particular genotype. n 
represents the number of subjects in each age at onset group. Comparisons were made 
between the lll.A-E- 66R genotype frequencies in the three different ages at onset groups 
using the x.2 test and 2 x 2 contingency tables. 
a= presence of the 0103 allele in the< 10 years vs 10-20 years x.2 = 8.7, p = 0.003 (ldf), 
Pc=0.06 
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The frequency of the HLA-E- 66R genotypes in the 3 age at onset groups:< 10 years 
(n = 74), 10-20 years (n =50) and> 20 years (n = 33) is shown in table 6.10.20. Out of a 
total of 30 HLA-E - 66R genotypes only 11 are presented in the table. The others were 
either not observed in any of the patient subgroups or occurred in 2 or less subjects in all of 
the subgroups and were therefore included in the X- X genotype. The HLA-E 0103 allele 
was present in 64.9% of patients who presented before the age of 10 years compared to 
only 38.8% of those presenting between the age of 10-20 years (p = 0.003, Pc= 0.06). 
There were no other significant differences between any of the patient subgroups. 
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P3B-66R Male Female 
genotype 0/o % 
1.8/1.5 - 4.5 5.9 8.7 
(4) {8) 
1.8/1.5 - 3.9 14.7 13.0 
(10) (12) 
1.8/1.5-4.5/3.9 27.9 33.7 
(19) (31) 
1.8-4.5 11.8 5.4 
(8) (5) 
1.8-3.9 2.9 9.7 
(2) (9) 
1.8 - 4.5/3.9 16.2 16.3 
(11) (15) 
1.5-4.5 4.4 2.3 
(3) (2) 
1.5-3.9 4.4 3.3 
{3) {3) 
1.5 - 4.5/3.9 11.8 7.6 
(8) (7) 
Total (n) 68 92 
Table 6.10.21 Frequency (%) MHC Class I P3B - 66R genotypes in patients with 
respect to gender 
This table shows the frequency of the P3B - 66R genotypes in patients separated by 
gender. The number in brackets is the actual number of subjects with a particular genotype. 
n represents the number of subjects in each gender group. Comparisons were made 
between the P3B - 66R genotype frequencies in the male and females using the r! test and 
2 X 2 contingency tables. There were no significant differences in the P3B - 66R 
genotypes between the male and female patients. 
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P3B-P3A Male Female 
genotype 0/o % 
1.8/1.5-4 9.7 23 
(7) (23) 
1.8-4 18.1 11 
(13) (11) 
1.5-4 11.1 11 
(8) (11) 
1.8/1.5 - 3.8 2.8 0 
(2) (0) 
1.8-3.8 2.8 5 
(2) (5) 
1.8/1.5 - 4/3.8 19.4 30 
(14) (30) 
1.8-413.8 8.3 14 
(6) (14) 
1.5-4/3.8 9.7 6 
(7) (6) 
Total (n) 72 100 
All 1.8 subjects(%) 61.6 83.0 
AU4.0 subjects(%) 76.4 95.0b 
Table 6.10.22 Frequency (%) MBC Class I P3B - P3A genotypes in patients with 
respect to gender 
This table shows the frequency of the P3B - P3A genotypes in patients separated by 
gender. Genotypes that were not observed in either gender are not included in the above 
table. The number in brackets is the actual number of subjects with a particular genotype. n 
represents the number of subjects in each gender group. Comparisons were made between 
the P3B- P3A genotype frequencies in the male and females using the x2 test and 2 X 2 
contingency tables. 
a= presence oftbe 1.8kb allele in females vs males x2 = 10.4, p = 0.001 (ldf), 
Pc= 0.008 
b =presence of the 4.0kb allele in females VS males X2 = 13.0, p = 0.0003 (1df), 
Pc= 0.002 
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The frequency of the P3B- P3A genotypes in male patients (n = 72) and female patients 
(n = 100) is shown in table 6.10.22. The 1.8/1.5-4.0 genotype was increased in the 
female patients (23%) compared to the male subjects (9.7%) but the difference was found 
not to be significant when the p value was corrected. The PJB 1.8kb allele was found in 
83.0% of the females compared to 61.6% of the males (p = 0.001, Pc= 0.008). There was a 
similar difference with the presence of the P3A 4.0kb allele in 95.0% of the female 
subjects compared to 76.4% of the males (p = 0.0003, Pc= 0.002). There were no other 
significant differences between the male and female patients. 
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P3B-28L Male Female 
genotype 0/o % 
1.8/1.5 - 4.3 9.4 13.1 
(6) (11) 
1.8-4.3 9.4 8.3 
(6) (7) 
1.8/1.5 - 3.8 4.7 7.1 
(3) (6) 
1.8/1.5-4.3/3.8 14.1 22.6 
(9) (19) 
1.8 - 4.3/3.8 9.4 6.0 
(6) (5) 
1.5 - 4.3/3.6 12.5 7.1 
(8) (6) 
1.8/1.5-4.3/3.6 6.3 7.1 
(4) (6) 
1.8 - 4.3/3.6 7.8 7.1 
(5) (6) 
1.8/1.5-3.8/3.6 12.5 7.1 
(8) (6) 
1.5 - 3.8/3.6 0 3.6 
(0) (3) 
X-X 14.1 10.7 
(9) (9) 
Total (n) 64 84 
Table 6.10.23 Frequency (%) MBC Class I P3B - 28L genotypes in patients with 
respect to gender 
This table shows the frequency of the P3B - 28L genotypes in patients separated by 
gender. The X - X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either gender are not 
included in the above table. The number in brackets is the actual number of subjects with a 
particular genotype. n represents the number of subjects in each gender group. 
Comparisons were made between the P3B - 28L genotype frequencies in the male and 
females using the x2 test and 2 X 2 contingency tables. There were no significant 
differences in the P3B - 28L genotypes between the males and female patients. 
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P3B-HLA-E Male Female 
genotype % o/o 
1.8/1.5- 0101 12.7 18.7 
(8) (14) 
1.8-0101 3.2 8.0 
(2) (6) 
1.5-0101 7.9 2.7 
(5) (2) 
1.8/1.5- 0101/0102 3.2 4.0 
(2) (3) 
1.8/1.5- 0101/0103 25.4 12.0 
(16) (9) 
1.8- 0101/0103 11.1 6.7 
(7) (5) 
1.5- 010110103 6.3 12.0 
(4) (9) 
1.8/1.5- 0102/0103 4.8 4.0 
(3) (3) 
1.8- 0102/0103 1.6 4.0 
(I) (3) 
1.5- 0102/0103 6.3 2.7 
(4) (2) 
1.8/1.5- 0103 1.6 5.3 
(1) (4) 
1.8/1.5- 0103/0104 3.2 5.3 
(2) (4) 
X-X 12.7 14.7 
(8) (I 1) 
Total (n) 63 75 
Table 6.10.24 Frequency(%) MHC Class I P3B- HLA-E genotypes in patients with 
respect to gender 
This table shows the frequency of the P3B - HLA-E genotypes in patients separated by 
gender. The X - X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either gender are not 
included in the above table. The number in brackets is the actual number of subjects with a 
particular genotype. n represents the number of subjects in each gender group. 
Comparisons were made between the P3B - HLA-E genotype frequencies in the male and 
females using the x? test and 2 X 2 contingency tables. There were no significant 
differences in the P3B - HLA-E genotypes between the males and female patients. 
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P3A-66R Male Female 
genotype 0/o 0/o 
4/3.8-4.5 5.7 6.3 
(4) (6) 
4-4.5 12.9 7.3 
(9) (7) 
4/3.8-3.9 10.0 11.5 
(7) (II) 
4-3.9 7.1 13.5 
(5) (13) 
4/3.8-4.5/3.9 18.6 32.3 
(13) (3I) 
4-4.5/3.9 38.6 25.0 
(27) (24) 
3.8-4.5/3.9 1.4 3.1 
(I) (3) 
X-X 5.7 1.0 
(4) (I) 
Total (n) 70 96 
Table 6.10.25 Frequency (%) MHC Class I P3A - 66R genotypes in patients with 
respect to gender 
This table shows the frequency of the P3A - 66R genotypes in patients separated by 
gender. The X - X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. The number in brackets is the actual number of subjects with a 
particular genotype. n represents the number of subjects in each gender group. 
Comparisons were made between the P3A- 66R genotype frequencies in the male and 
females using the ·i test and 2 X 2 contingency tables. There were no significant 
differences in the P3A- 66R genotypes between the males and female patients. 
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P3A-28L Male Female 
genotype % % 
413.8-4.3 4.6 11.6 
(3) (10) 
4-4.3 10.8 8.1 
(7) (7) 
413.8-3.8 3.1 4.7 
(2) (4) 
4-3.8 4.0 5.8 
(3) (5) 
4-3.6 1.5 3.5 
(1) (3) 
4/3.8 - 4.3/3.8 13.8 16.3 
(9) (14) 
4-4.3/3.8 21.5 18.6 
(14) (16) 
4/3.8-4.3/3.6 6.2 8.1 
(4) (7) 
4-4.3/3.6 10.8 8.1 
(7) (7) 
4/3.8-3.8/3.6 4.6 8.1 
(3) (7) 
4-3.8/3.6 9.2 3.5 
(6) (3) 
X-X 9.2 3.5 
(6) (3) 
Total (n) 65 86 
Table 6.10.26 Frequency (%) MHC Class I P3A - 28L genotypes in patients with 
respect to gender 
This table shows the frequency of the P3A - 28L genotypes in patients separated by 
gender. The X- X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either the males or females 
are not included in the above table. The number in brackets is the actual number of 
subjects with a particular genotype. n represents the number of subjects in each gender 
group. Comparisons were made between the P3A - 28L genotype frequencies in the male 
and females using the ·l test and 2 X 2 contingency tables. There were no significant 
differences in the P3A- 28L genotypes between the males and female patients. 
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P3A-HLA-E Male Female 
genotype % % 
4/3.8-0101 15.4 15.2 
(10) (12) 
4-0101 10.8 11.4 
(7) (9) 
4/3.8- 010110102 1.5 5.1 
(1) (4) 
4/3.8- 0101/0103 12.3 13.9 
(8) ( 11) 
4- 0101/0103 27.7 15.2 
(I8) (12) 
4/3.8- 0102/0103 1.5 5.1 
(I) (4) 
4- 0102/0103 10.8 3.8 
(7) (3) 
4- 0102/0104 0 3.8 
(0) (3) 
4-0103 1.5 5.1 
(I) (4) 
4- 0103/0104 1.5 3.8 
(I) (3) 
X-X 16.9 16.5 
(11) (13) 
Total (n) 65 79 
Table 6.10.27 Frequency(%) MHC Class I P3A- HLA-E genotypes in patients with 
respect to gender 
This table shows the frequency of the P3A - HLA-E genotypes in patients separated by 
gender. The X- X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either the males or females 
are not included in the above table. The number in brackets is the actual number of 
subjects with a particular genotype. n represents the number of subjects in each gender 
group. Comparisons were made between the P3A- HLA-E genotype frequencies in the 
male and females using the r! test and 2 X 2 contingency tables. There were no significant 
differences in the P3A- HLA-E genotypes between the males and female patients. 
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28L-66R Male Female 
genotype 0/o % 
4.3-4.5/3.9 9.7 9.5 
(7) (9) 
4.3-4.5 4.2 3.2 
(3) (3) 
4.3-3.9 2.8 7.4 
(2) (7) 
3.8-4.5/3.9 6.9 6.3 
(5) (6) 
3.8-4.5 1.4 3.2 
(1) (3) 
3.6-4.5/3.9 4.2 2.1 
(3) (2) 
3.6-3.9 1.4 3.2 
(1) (3) 
4.3/3.8-4.5/3.9 20.8 27.4 
(15) (26) 
4.3/3.8-4.5 5.6 2.1 
(4) (2) 
4.3/3.8-3.9 6.9 7.4 
(5) (7) 
4.3/3.6-4.5/3.9 11.1 9.5 
(8) (9) 
4.3/3.6-3.9 4.2 4.2 
(3) (4) 
3.8/3.6-4.5/3.9 6.9 7.4 
(5) (7) 
3.8/3.6-4.5 4.2 4.2 
(3) (4) 
3.8/3.6-3.9 4.2 0 
(3) (0) 
X-X 5.6 3.2 
(4) (3) 
Total (n) 72 95 
Table 6.10.28 Frequency (%) MHC Class I 28L - 66R genotypes in patients with 
respect to gender 
This table shows the frequency of the 28L - 66R genotypes in patients separated by 
gender. The X- X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. The number in brackets is the actual number of subjects with a 
particular genotype. n represents the number of subjects in each gender group. 
Comparisons were made between the 28L - 66R genotype frequencies in the male and 
females using the x2 test and 2 X 2 contingency tables. There were no significant 
differences in the 28L - 66R genotypes between the males and female patients. 
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28L-HLA-E Male Female 
genotype % 0/o 
4.3-0101 1.5 10.7 
(1) (8) 
3.8- 0101 6.0 5.3 
(4) (4) 
4.3/3.8- 0101 11.9 5.3 
(8) (4) 
4.3/3.6 - 0101 4.5 1.3 
(3) (1) 
3.8/3.6 - 0101 4.5 0 
(3) (0) 
4.3- 0101/0103 10.4 4.0 
(7) (3) 
3.8-0101/0103 4.5 1.3 
(3) (1) 
4.3/3.8- 0101/0103 11.9 10.7 
(8) (8) 
4.3/3.6- 0101/0103 4.5 9.3 
(3) (7) 
3.8/3.6- 0101/0103 6.0 6.7 
(4) (5) 
4.3- 0102/0103 1.5 4.0 
(1) (3) 
4.3/3.8- 0102/0103 3.0 8.0 
(2) (6) 
4.3/3.8- 0102/0104 1.5 5.3 
(1) (4) 
X-X 28.4 28.0 
(19) (21) 
Total (n) 67 75 
Table 6.10.29 Frequency(%) MHC Oass I 28L- HLA-E genotypes in patients with 
respect to gender 
This table shows the frequency of the 28L - HLA-E genotypes in patients separated by 
gender. The X - X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either the males or females 
are not included in the above table. The number in brackets is the actual number of 
subjects with a particular genotype. n represents the number of subjects in each gender 
group. Comparisons were made between the 28L - HLA-E genotype frequencies in the 
male and females using the x.2 test and 2 X 2 contingency tables. There were no significant 
differences in the 28L - HLA-E genotypes between the males and female patients. 
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66R-HLA-E Male Female 
genotype 0/o % 
4.5/3.9- 0101 16.4 17.2 
(12) (15) 
4.5-0101 5.5 1.1 
(4) (I) 
3.9- 0101 9.6 9.2 
(7) (8) 
4.5/3.9- 0101/0102 4.1 4.6 
(3) (4) 
4.513.9- 0101/0103 23.3 19.5 
(17) (17) 
4.5- 010110103 8.2 2.3 
{6) (2) 
3.9- 0101/0103 8.2 8.0 
(6) (7) 
4.5-0101/0104 4.1 1.1 
(3) (I) 
4.5/3.9- 0102/0103 6.8 3.4 
(5) (3) 
4.5-0102/0103 2.7 4.6 
(2) (4) 
4.5/3.9- 0103 1.4 3.4 
(I) (3) 
3.9-0103 0 3.4 
{0) (3) 
4.5/3.9- 0103/0104 0 4.6 
{0) (4) 
X-X 9.6 17.2 
(7) (IS) 
Total (n) 73 87 
Table 6.10.30 Frequency(%) MHC Oass I 66R- HLA-E genotypes in patients with 
respect to gender 
This table shows the frequency of the 66R - HLA-E genotypes in patients separated by 
gender. The X- X genotype represents genotypes that were detected in 2 or less subjects 
in both males and females. Genotypes that were not observed in either the males or females 
are not included in the above table. The number in brackets is the actual number of 
subjects with a particular genotype. n represents the number of subjects in each gender 
group. Comparisons were made between the 66R- HLA-E genotype frequencies in the 
male and females using the x2 test and 2 X 2 contingency tables. There were no significant 
differences in the 66R- HLA-E genotypes between the males and female patients. 
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6.11 Class I and Class 11 genotype analysis 
6.11.1 Introduction 
The frequency of the class I genotypes of the five loci studied, P3A, 28L, 66R, P3B and 
HLA-E in combination with the class 11 genotypes of the DQB 1 locus were investigated in 
the patient subjects with type l diabetes. The two microsatellite markers PI and D6S306 
were not included in the class 1 - class ll genotype analysis due to the large number of 
possible genotypes arising from combination with the two markers. Comparisons were 
made between the DQB 1 genotypes associated with a particular class I genotype using the 
x_
2 test and 2 X 2 contingency tables. Not all of the class 11 alleles and therefore possible 
class 11 genotypes were included in the analysis, it was decided only to use alleles that are 
knowingly associated with susceptibility to type diabetes. Therefore X represents any 
alleles that were not DQBl *201, *302 or *501. 
Genotype frequencies were also investigated in the patient subjects with respect to age at 
onset of type I diabetes. 
With some of the genotypes the number of subjects presenting with them were small, 
which made it difficult to analyse. It was decided that if 2 or less subjects presented with a 
particular genotype in all of the patient subgroups then the genotypes would be combined 
as the Y-Y genotype, with an overall actual number and frequency. 
Haplotype analysis was not used to investigate the association between the MHC class I 
and class II regions as there were too many patients who were double heterozygotes for the 
class I loci to be used to determine haplotype frequencies. 
Data that was found to be non-significant after correction is not presented in the text. 
This study was not considered to be a complete analysis of the possible linkage/association 
between the class 11 and I regions, as only a selection of class ll alleles were used in the 
investigation. 
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DQB1 P3B genotype 
genotype 
1.5 1.8 1.811.5 
*201 I *302 44.8 22.0 38.3 
(13) (11) (33) 
*201 I *X 13.8 14.0 8.1 
(4) (7) (7) 
*302 I *X 6.9 16.0 8.1 
(2) (8) (7) 
*201 I *201 13.8 2.0 7.0 
(4) (1) (6) 
*302 I *302 0 4.0 7.0 
(0) (2) (6) 
*501 I *201 3.4 8.0 12.8 
(1) (4) (11) 
*501 I *302 10.3 2.0 3.5 
(3) (1) (3) 
*501 I *X 6.9 22.0 14.0 
(2) (11) (12) 
*XI*X 0 10.0 1.2 
(0) (5) (1) 
Total (n) 29 50 86 
Table 6.11.1 Frequency (%) MHC Class I P3B - Class ll DQBl genotypes in 
patients 
This table shows the frequency ofthe class I P3B- class II DQBI genotypes in patient 
with type 1 diabetes. X represents non-DQB 1 *20 1. 302, or 501. The number in brackets is 
the actual number of subjects with a particular genotype. n = represents the total number of 
subjects in a P3B genotype group. Comparisons were made between the DQB 1 genotypes 
associated with a particular P3B genotype using the x.2 test and 2X2 contingency tables. 
There were no significant differences found in the P3B - DQB 1 genotypes. 
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The frequency of the class I P3B - class 11 DQB 1 genotypes in 165 patients with type 1 
diabetes is shown in table 6.11.1. Out of the total number of subjects with a P3B - DQB 1 
genotype 52.1% had a genotype including the P3B 1.811.5 genotype, 30.3% had a genotype 
including the P3B 1.8/1.8 genotype and 17.6% had a genotype including the P3B 1.511.5 
genotype. There were no significant differences found between the DQB 1 genotypes 
associated with a particular P3B genotype. However, there was an increase in the 
frequency of the *201 I *302- 1811.5 genotype (38.3%) compared to the association with 
the P3B 1.8/1.8 genotype (22.0%) the difference was found not to be significant when 
corrected. The frequency ofthe *201 I *302- 1.511.5 genotype (44.8%) was also increased 
compared to the frequency of the *201 I *302 - 1.811.8 genotype (22.0%) but the 
difference was shown not to be significant when corrected. Six out of the 165 patients did 
not have one of the diabetic susceptibility class IT alleles. 
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DQBl 28L genotype 
genotype 
4.3 3.8 3.6 4.313.8 4.313.6 3.813.6 
"201 I "302 26.7 33.3 23.1 51.7 20.7 26.1 
(8) (6) (3) (31) (6) (6) 
"201 I *X 6.7 5.6 15.4 6.7 13.8 8.7 
(2) (I) (2) (4) (4) (2) 
"302 I *X 13.3 0 15.4 3.3 10.3 13.0 
(4) (0) (2) (2) (3) (3) 
"201 I "201 3.3 5.6 0 5.0 3.4 4.3 
(1) (1) (0) (3) (1) (1) 
"302 I "302 10.0 0 0 5.0 3.4 4.3 
(3) (0) (0) (3) (1) (1) 
"501 I "201 3.3 22.2 0 11.7 10.3 8.7 
(1) (4) (0) (7) (3) (2) 
"501 I "302 6.7 5.6 0 5.0 13.8 4.3 
(2) (1) (0) (3) (4) (I) 
"501 I "X 23.3 16.6 38.5 5.0 17.2 26.1 
(7) (3) (5) (3) (5) (6) 
"XI "X 6.7 11.1 7.7 3.3 6.9 4.3 
(2) (2) (1) (2) (2) (I) 
Total (n) 30 18 13 60 29 23 
Table 6.11.2 Frequency(%) MHC Class I 28L- Class 11 DQBl genotypes in patients 
This table shows the frequency of the class I 28L - class 11 DQB 1 genotypes in patients with type I diabetes. X is non-DQB I *20 I, 302 or SO 1. The number 
in brackets is the actual number of subjects with a particular genotype. n =represents the total number of subjects in a 28L genotype group. Comparisons 
were made between the DQB 1 genotypes associated with a particular 28L genotype using the x2 test and 2X2 contingency tables. There were no signficant 
differences found in the 28L - DQB 1 genotypes. 
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The frequency of the class I 28L - class II DQB 1 genotypes in 173 patients with type 1 
diabetes is shown in table 6.11.2. There were no significant differences/associations 
between any ofthe 28L- DQB1 genotypes in the patients. However, there was noticeable 
increase in the frequency of the *201 I *302- 4.3/3.8 genotype (51.7%) compared to the 
frequency of the *201 I *302- 4.3 genotype (26.7%), the difference was found to be non-
significant after correction. Ten out of the 173 patients did not have one of the diabetic 
susceptibility class II alleles. 
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DQB1 P3A genotype 
genotype 
4.0 3.8 4.0/4.3 
*201/ *302 36.7 18.2 29.7 
(33) (2) (22) 
*201/ *X 7.8 9.1 10.8 
(7) (1) (8) 
*302/ *X 6.7 18.2 10.8 
(6) (2) (8) 
*201/ *201 7.8 9.1 6.8 
(7) (1) (5) 
*302/ *302 1.1 9.1 9.5 
(1) (1) (7) 
*501/ *201 8.9 0 13.5 
(8) (0) (10) 
*501/ *302 8.9 0 1.4 
(8) (0) (1) 
*501/ *X 16.7 27.3 13.5 
(15) (3) (10) 
*X/*X 5.6 9.1 4.1 
(5) (1) (3) 
Total (n) 90 11 74 
Table 6.11.3 Frequency (%) MHC Class I P3A - Class 11 DQB1 genotypes in 
patients 
This table shows the frequency of the class I P3A- class 11 DQB 1 genotypes in patients 
with type 1 diabetes. X represents non-DQB 1 *0202. 302, or 501. The number in brackets 
is the actual number of subjects with a particular genotype. n =represents the total number 
of subjects in a P3A genotype group. Comparisons were made between the DQB 1 
genotypes associated with a particular P3A genotype using the ·l test and 2X2 
contingency tables. There were no significant differences found in the P3A - DQB I 
genotypes. 
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The frequency of the class I P3A - class IT DQB I genotypes in I75 patients with type I 
diabetes is shown in table 6.1I.3. There were no significant differences/associations 
between any of the P3A - DQB I genotypes. Out of the total number of subjects with a 
P3A- DQBI genotype 51.0% had a genotype including the P3A 4.0/4.0 genotype, 6.3% 
had a genotype including the P3A 3.8/3.8 genotype and 42.3% had a genotype including 
the P3 A 4. 0/3. 8 genotype. Nine of the I7 5 patients did not have one of the diabetic 
susceptibility class IT alleles. 
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DQB1 66R genotype 
genotype 
4.5 3.9 4.513.9 
*201 I *302 45.5 20.0 35.1 
(15) (9) (40) 
*201 I *X 3.0 8.9 10.5 
(1) (4) (12) 
*302 I *X 9.1 13.3 7.9 
(3) (6) (9) 
*201 I *201 3.0 2.2 7.0 
(1) (1) (8) 
*302 I *302 6.1 8.9 1.8 
(2) (4) (2) 
*501 I *201 9.1 11.1 9.6 
(3) (5) ( 11) 
*501 I *302 6.1 4.4 7.0 
(2) (2) (8) 
*501 I *X 9.1 22.2 15.8 
(3) (10) (18) 
*XI*X 9.1 8.9 5.3 
(3) (4) (6) 
Total (n) 33 45 114 
Table 6.11.4 Frequency (%) MHC Class I 66R - Class 11 DQB1 genotypes in 
patients 
This table shows the frequency of the class I 66R- class 11 DQB I genotypes in patients 
with type 1 diabetes. X represents non-DQBI *201, 302, or 501. The number in brackets is 
the actual number of subjects with a particular genotype. n = represents the total number of 
subjects in a 66R genotype group. Comparisons were made between the DQB I genotypes 
associated with a particular 66R genotype using the x2 test and 2X2 contingency tables. 
There were no significant differences found in the 66R- DQB I genotypes. 
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The frequency of the class I 66R - class IT DQB 1 genotypes in 192 patients with type 1 
diabetes is shown in table 6.11.4. There were no significant differences/associations 
between any of the 66R - DQB 1 genotypes. Out of the subjects with a 66R - DQB 1 
genotype 17.2% had a genotype including the 66R 4.5/4.5 genotype, 23.4% had a genotype 
including the 66R 3.9/3.9 genotype and 59.4% had a genotype including the 66R 4.5/3.9 
genotype. Thirteen of the 192 patients did not have one of the diabetic susceptibility class 
n alleles. 
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DQB1 HLA-E genotype 
genotype 
0101 0101/0102 0101/0103 0101/0104 0102 0102/0103 0102/0104 0103 0103/0104 
*201 I *302 31.3 50.0 36.5 66.7 0 33.3 57.1 10.0 55.6 
(20} (7) (23) (4) (0) (6) (4) (1} (5) 
*201 I *X 4.7 7.1 1l.l 0 33.3 5.6 14.3 20.0 0 
(3) (1) (7) (0) (1) (1) (1} (2} (0} 
*302 I *X 9.4 7.1 9.5 16.7 0 16.7 0 10.0 11.1 
(6) (1) (6) (1) (0) (3) (0) (1) (1) 
*201 I *201 6.3 14.3 6.3 0 0 5.6 0 10.0 0 
(4) (2) (4) (0) (0) (1) (0) (1) (0) 
*302 I *302 4.7 0 4.8 0 0 5.6 0 0 0 
(3) (0) (3) (0} (0) (1) (0} (0) (0) 
*501 I *201 9.4 0 7.9 16.7 0 11.1 0 10.0 0 
(6) (0) (5) (1) (0) (2) (0) (1) (0) 
*501 I *302 9.4 0 7.9 0 33.3 11.1 0 10.0 0 
(6) (0) (5) (0) (1) (2) (0) (I) (0) 
*501 I *X 14.1 21.4 12.7 0 33.3 5.6 28.6 30.0 22.2 
(9} (3) (8) (0) (1) (1) (2) (3) (2) 
*X/ *X 10.9 0 3.2 0 0 5.6 0 0 11.1 
(7) (0) (2) (0) (0) (I) (0) (0) (1) 
Total (n) 64 14 63 6 3 18 7 10 9 
Table 6.11.5 Frequency(%) MHC Class I HLA-E -Class 11 DQB1 genotypes in patients 
This table shows the frequency ofthe class I HLA-E- class 11 DQBI genotypes in patients with type 1 diabetes. X represents non-DQBI *201, 302, or 501. 
The number in brackets is the actual number of subjects with a particular genotype. n = represents the total number of subjects in a HLA-E genotype group. 
Comparisons were made between the DQB 1 genotypes associated with a particular HLA-E genotype using the x2 test and 2X2 contingency tables. There 
were no significant differences found in the HLA-E- DQB I genotypes. 
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The frequency of the class I HLA-E- class II DQB1 genotypes in 194 patients with type I 
diabetes is shown in table 6.11.5. There were no significant differences/associations 
between any of the HLA-E- DQB1 genotypes. HLA-E genotypes containing the 0101 
allele accounted for over 75% of the subjects with an HLA-E- DQB1 genotype. Eleven of 
the 194 patients did not have one of the diabetic susceptibility class II alleles. Nine of the 
eleven patients possessed at least one HLA-E 0101 allele. Only two patients did not have 
either an HLA-E 0101 allele or one of the diabetic susceptibility class II alleles. Of the 194 
patients there were only ten patients who possessed a class II diabetic susceptibility allele 
and an HLA-E genotype that did not contain a 0101 or 0103 allele. 
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DQB1-66R Age at onset of 
genotype Diabetes (years) 
< 10 10-20 >20 
*201 I *302- 3.9 7.8 3.3 0 
(7) (2) (0) 
*302 I *X- 3.9 1.1 8.3 0 
(1) (5) (0) 
*501 I *201 - 3.9 3.3 1.7 2.3 
(3) (1) (1) 
*501 I *X- 3.9 5.6 5.0 4.5 
(5) (3) (2) 
*201 I *302- 4.5 13.3 5.0 2.3 
(12) (3) (1) 
*302 I *X- 4.5 3.3 0 2.3 
(3) (0) (1) 
*201 I *302- 4.513.9 18.9 28.3 13.6 
(17) (17) (6) 
*201 I *X- 4.513.9 5.6 3.3 6.8 
(5) (2) (3) 
*302 I *X - 4.513.9 6.7 1.7 4.5 
(6) (1) (2) 
*201 I *201 - 4.513.9 2.3 3.3 11.4 
(2) (2) (5) 
*501 I *201 - 4.513.9 4.5 8.3 6.8 
(4) (5) (3) 
*5011 *302- 4.513.9 4.5 3.3 4.5 
(4) (2) (2) 
*501 I *X- 4.513.9 6.7 8.3 18.2 
(6) (5) (8) 
*X I *X - 4.513.9 1.1 5.0 4.5 
(1) (3) (2) 
Y:Y 15.6 15.0 18.2 
(14) (9) (8) 
Total (n) 90 60 44 
Table 6.11.6 Frequency (%) MHC Class I 66R - Class 0 DQB1 genotypes with 
respect to age at onset of type 1 diabetes 
This table shows the frequency of the class I 66R - class II DQB 1 genotype in patients 
separated by age at onset into< 10, 10-20 and> 20 years of age. X represents non-DQB1 
*201, *302 or *501. TheY- Y genotype represents genotypes that were detected in 2 or 
less subjects in all of the age at onset groups. The number in brackets is the actual number 
of subjects with a particular genotype. n represents the number of subjects in each age at 
onset group. Comparisons were made between the 66R - DQB 1 genotype frequencies in 
the 3 different age at onset groups using the .,; test and 2 X 2 contingency tables. There 
were no significant differences in the 66R - DQB 1 genotype frequencies in any of the age 
at onset groups. 
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The patient population was separated into 3 groups depending on the age at onset: < I 0 
years (n = 90), 10-20 years (n = 60) and> 20 years (n = 44). The frequency of the class I 
66R- class IT DQBI genotypes in these 3 groups is shown in table 6.Il.6. Out of the total 
of27 66R- DQBI genotypes only I4 are presented in the table. The others were either not 
observed in any of the patient subgroups or occurred in 2 or less subjects in all of the 
subgroups and were therefore included in the Y- Y genotype. The DQB I *302 allele was 
found to be present in 57.8% of patients who presented before the age of IO years 
compared to 31.8% in patients who presented after the age of 20 years, the difference was 
non-significant after correction (p = 0.004, Pc =ns). There were no other significant 
differences between the 3 patient subgroups. 
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DQB1-P3B 
genotype 
*201 I "302- 1.5 
*201 I *X- 1.5 
"501 I *302- 1.5 
"201 I "302- 1.8 
*201 I *X- 1.8 
*302 I *X - 1.8 
*501 I *201 - 1.8 
*501 I *X- 1.8 
*X I *X -1.8 
*201 I *302- 1.811.5 
"201 I *X- 1.811.5 
*302 I *X- 1.811.5 
*201 I *201 - 1.811.5 
*302 I *302- 1.811.5 
"501 I *201 - 1.811.5 
*501 I *X- 1.811.5 
Y:Y 
Total (n) 
All1.8 subjects(%) 
Al1302 subjects(%) 
< 10 
9.1 
(7) 
0 
(0) 
3.9 
(3) 
9.1 
(7) 
5.2 
(4) 
5.2 
(4) 
3.9 
(3) 
5.2 
(4) 
0 
(0) 
23.4 
(I8) 
3.9 
(3) 
6.5 
(5) 
2.6 
(2) 
3.9 
(3) 
5.2 
(4) 
6.5 
(5) 
6.5 
(5) 
77 
Age at onset of 
Diabetes (years) 
10-20 
7.7 
(4) 
1.9 
(I) 
0 
(0) 
0 
(0) 
9.6 
(5) 
5.8 
(3) 
1.9 
(1) 
7.7 
(4) 
3.8 
(2) 
26.91 
(14) 
3.8 
(2) 
7.7 
(4) 
0 
(0) 
5.8 
(3) 
5.8 
(3) 
5.8 
(3) 
5.8 
(3) 
52 
84.6 
53.8 
>20 
5.4 
(2) 
8.1 
(3) 
0 
(0) 
2.7 
(1) 
0 
(0) 
5.4 
(2) 
0 
(0) 
8.1 
(3) 
8.1 
(3) 
2.7 
(I) 
5.4 
(2) 
0 
(0) 
10.8 
(4) 
0 
(0) 
10.8 
(4) 
10.8 
(4) 
21.6 
(8) 
37 
56.8 
24.3 
Table 6.11.7 Frequency (%) MHC Class I P3B - Class 0 DQB1 genotypes with 
respect to age at onset of type 1 diabetes 
This table shows the frequency of the class I P3B - class II DQB I genotype in patients 
separated by age at onset into < I 0, I 0-20 and > 20 years of age. X represents non-DQB I 
*20I, *302 or *501. TheY- Y genotype represents genotypes that were detected in 2 or 
less subjects in all of the age at onset groups. Genotypes that were not observed in any of 
the age at onset groups are not included in the above table. The number in brackets is the 
actual number of subjects with a particular genotype. n represents the number of subjects 
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in each age at onset group. Comparisons were made between the P3B - DQB 1 genotype 
frequencies in the 3 different age at onset groups using the x2 test and 2 X 2 contingency 
tables. 
1 = *201 I "'302 -1.8/1.5 genotype frequency 10-20 vs> 20 years x2 = 9.1, p= 0.002 
(ldf), Pc= 0.06 
a= presence of the 1.8kb allele in the< 10 years vs> 20 years x2 = 10.3, p = 0.001 
(ldf), Pc =0.03 
b =presence of the "'0302 allele in the< 10 years vs> 20 years x2 = 15.5, p = 0.00008 
(ldf), Pc= 0.002 
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The frequency of the class I P3B- class II DQB 1 genotypes in the 3 age at onset groups: 
< 10 years (n = 77), 10-20 years (n =52) and> 20 years (n = 37) is shown in table 6.11.7. 
Out of the total of27 P3B- DQB1 genotypes only 15 are presented in the table. The others 
were either not observed in any of the patient subgroups or occurred in 2 or less subjects in 
all of the subgroups and were therefore included in the Y - Y genotype. There was a 
significant increase in the *201 I *302- 1.8/1.5 genotype in the 10-20 years group (26.9%) 
compared to the> 20 years group (2.7%) (p = 0.002, Pc= 0.06). The P3B 1.8kb allele was 
found in 84.4% of patients who presented before the age of 10 years compared to only 
56.8% of those presenting after the age of20 years (p = 0.001, Pc= 0.03). The DQB1 *302 
allele was present in 63.6% of patients with an age at onset of< 10 years compared to only 
24.3% of patients in the> 20 years group (p = 0.00008, Pc= 0.002). There were no other 
significant differences between any of the patient subgroups. 
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DQB1-P3A 
genotype 
*201 I *302- 413.8 
*201 I *X- 413.8 
*302 I *X- 413.8 
*201 I *201 - 413.8 
*302 I *302 - 413.8 
*501 I *201 - 413.8 
*501 I *302 - 4/3.8 
*501 I *X - 413.8 
*X I *X - 413.8 
*201 I *302 - 4 
*201 I *X- 4 
*302 I *X- 4 
*501 I *201 - 4 
*501 I *X- 4 
Y:Y 
Total (n) 
All4.0 subjects(%) 
All302 subjects(%) 
< 10 
16.3 
(13) 
2.5 
(2) 
5.0 
(4) 
2.5 
(2) 
3.8 
(3) 
10.0 
(8) 
3.8 
(3) 
6.3 
(5) 
0 
(0) 
22.5 
(18) 
6.3 
(5) 
3.8 
(3) 
0 
(0) 
6.3 
(5) 
11.3 
(9) 
80 
97.5 
61.38 
Age at onset of 
Diabetes (years) 
10-20 
15.1 
(8) 
5.7 
(3) 
5.7 
(3) 
0 
(0) 
5.7 
(3) 
0 
(0) 
0 
(0) 
5.7 
(3) 
0 
(0) 
22.6 
(12) 
3.8 
(2) 
5.7 
(3) 
9.4 
(5) 
5.7 
(3) 
15.1 
(8) 
52 
94.2 
55.8 
>20 
2.7 
(I) 
5.4 
(2) 
0 
(0) 
8.1 
(3) 
2.7 
(I) 
5.4 
(2) 
0 
(0) 
8.1 
(3) 
8.1 
(3) 
8.1 
(3) 
8.1 
(3) 
5.4 
(2) 
5.4 
(2) 
16.2 
(6) 
21.6 
(8) 
37 
89.2 
24.3 
Table 6.11.8 Frequency (%) MBC Class I P3A - Class 11 DQB1 genotypes with 
respect to age at onset of type 1 diabetes 
This table shows the frequency of the class I P3A - class 11 DQB 1 genotype in patients 
separated by age at onset into < 10, 10-20 and > 20 years of age. X represents non-DQB 1 
*201, *302 or *501. TheY- Y genotype represents genotypes that were detected in 2 or 
less subjects in all of the age at onset groups. Genotypes that were not observed in any of 
the age at onset groups are not included in the above table. The number in brackets is the 
actual number of subjects with a particular genotype. n represents the number of subjects 
in each age at onset group. Comparisons were made between the P3A- DQBl genotype 
frequencies in the 3 different age at onset groups using the ·£ test and 2 X 2 contingency 
tables. 
a= presence of the *0302 aUele in the< 10 years vs 1> 20 years y} = 13.8, p = 0.0002 
(Id£), Pc= 0.005 
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The frequency of the class I P3A- class II DQB 1 genotypes in the 3 age at onset groups: 
< 10 years (n = 80}, 10-20 years (n =52) and> 20 years (n = 37) is shown in table 6.11.8. 
Out of the total of27 P3B- DQB 1 genotypes only 14 are presented in the table. The others 
were either not observed in any of the patient subgroups or occurred in 2 or less subjects in 
all of the subgroups and were therefore included in the Y - Y genotype. The DQB 1 *302 
allele was found in 61.3% of patients who presented before the age of 10 years compared 
to only 24.3% of those presenting after the age of20 years (p = 0.0002, Pc= 0.005). There 
were no other significant differences between any of the patient subgroups. 
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DQB1-28L Age at onset of 
genotype Diabetes (years) 
< 10 10-20 >20 
*2011 *302- 4.3 5.4 7.3 2.4 
(4) (4) (1) 
*302 I *X - 4.3 4.1 5.5 4.8 
(3) (3) (2) 
*501 I *X- 4.3 2.7 3.6 7.1 
(2) (2) (3) 
*2011 *302- 3.8 5.4 5.5 0 
(4) (3) (0) 
*201 I "302- 3.6 4.1 0 0 
(3) (0) (0) 
*2011 *302- 4.313.8 17.6 21.8 9.5 
(13) (12) (4) 
*2011 *201 - 4.313.8 0 0 7.1 
(0) (0) (3) 
*5011 *201- 4.313.8 6.8 1.8 2.4 
(5) (1) (I) 
*501 I *X- 4.313.8 0 3.6 7.1 
(0) (2) (3) 
*2011 *302- 4.313.6 6.8 1.8 0 
(5) (I) (0) 
*201 I "X- 4.313.6 1.4 5.5 0 
(I) (3) (0) 
*5011 *302- 4.313.6 0 5.5 0 
(0) (3) (0) 
"201 I *302- 3.813.6 4.1 1.8 4.8 
(3) (1) (2) 
*501 I *X- 3.813.6 5.5 1.8 2.4 
(4) (1) (1) 
Y:Y 36.5 34.5 61.9 
(27) (19) (26) 
Total (n) 74 55 42 
Table 6.11.9 Frequency (%) MBC Class I 28L - Class II DQB1 genotypes with 
respect to age at onset of type 1 diabetes 
This table shows the frequency of the class I 28L - class IT DQB 1 genotype in patients 
separated by age at onset into < 10, 10-20 and > 20 years of age. X represents non-DQB 1 
*201, *302 or *501. TheY- Y genotype represents genotypes that were detected in 2 or 
less subjects in all of the age at onset groups. Genotypes that were not observed in any of 
the age at onset groups are not included in the above table. The number in brackets is the 
actual number of subjects with a particular genotype. n represents the number of subjects 
in each age at onset group. Comparisons were made between the 28L - DQB 1 genotype 
frequencies in the 3 different age at onset groups using the r} test and 2 X 2 contingency 
tables. There were no significant differences in the 28L - DQB 1 genotype frequencies in 
any of the age at onset groups. 
554 
The frequency ofthe class I 28L- class II DQBI genotypes in the 3 age at onset groups: 
< 10 years (n = 74), 10-20 years (n =55) and> 20 years (n = 42) is shown in table 6.11.9. 
Out of the total of 54 P3B- DQB I genotypes only 14 are presented in the table. The others 
were either not observed in any of the patient subgroups or occurred in 2 or less subjects in 
all of the subgroups and were therefore included in the Y - Y genotype. There were no 
significant differences between any of the patient subgroups. 
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DQB1-HLA-E Age at onset of 
genotype Diabetes (years) 
< 10 10-20 >20 
*201 I *302- 0101 9.4 13.8 6.8 
(8) (8) (3) 
*302 I *X- 0101 4.7 5.2 2.3 
(4) (3) (I) 
*501 I *201 - 0101 2.4 6.9 2.3 
(2) (4) (I) 
*501 I *X- 0101 1.2 3.4 13.6 
(I) (2) (6) 
*X I *X- 0101 0 6.9 2.3 
(0) (4) (I) 
*201 I *302- 0101/0102 3.5 3.4 2.3 
(3) (2) (I) 
*201 I *302- 0101/0103 15.31 0 9.1 
(13) (0) (4) 
*201 I *X- 0101/0103 3.5 12.1 4.5 
(3) (7) (2) 
*302 I *X- 0101/0103 5.9 1.7 0 
(5) (I) (0) 
*501 I *201- 0101/0103 5.9 0 2.3 
(5) (0) (I) 
*501 I *302- 0101/0103 4.7 1.7 0 
(4) (I) (0) 
*501 I *X- 0101/0103 2.4 0 9.1 
(2) (0) (4) 
*201 I *302- 0101/0104 4.7 0 2.3 
(4) (0) (I) 
*201 I *302- 010210103 3.5 3.4 4.8 
(3) (2) (2) 
*201 I *302- 010310104 3.5 1.7 0 
(3) (I) (0) 
Y:Y 29.4 36.2 45.5 
(25) (2I) (20) 
Total (n) 85 58 44 
Table 6.11.10 Frequency(%) MHC Class I HLA-E- Class 11 DQB1 genotypes with 
respect to age at onset of type 1 diabetes 
This table shows the frequency of the class I lfl..A-E- class II DQBI genotype in patients 
separated by age at onset into < I 0, I 0-20 and > 20 years of age. X represents non-DQB I 
•20I, *302 or *501. TheY- Y genotype represents genotypes that were detected in 2 or 
less subjects in all of the age at onset groups. Genotypes that were not observed in any of 
the age at onset groups are not included in the above table. The number in brackets is the 
actual number of subjects with a particular genotype. n represents the number of subjects 
in each age at onset group. Comparisons were made between the lfl..A-E - DQB I 
genotype frequencies in the 3 different age at onset groups using the x? test and 2 X 2 
contingency tables. 
1 = *201 I *302- 0101/0103 genotype frequency < 10 vs 10-20 x2 = 9.8, p = O.OOI (Idt), 
Pc= 0.03 
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The frequency ofthe class Ill.A-E- class ITDQBI genotypes in the 3 age at onset groups: 
< I 0 years (n = 85), I 0-20 years (n = 58) and > 20 years (n = 44) is shown in table 6.II.l 0 
Out of the total of 72 P3B - DQB I genotypes only IS are presented in the table. The others 
were either not observed in any of the patient subgroups or occurred in 2 or less subjects in 
all of the subgroups and were therefore included in the Y - Y genotype. There was a 
significant increase in the *20I I *302 - OI01/0I03 genotype in the < IO years group 
(I5.3%) compared to the I0-20 years group were the genotype was absent (p = O.OOI, Pc= 
0.03). Out ofthe 85 subjects in the< IO years group 3I had an Ill.A-E 010I allele and the 
DQBI genotype *20I I *302 and 20 subjects had the Ill.A-E 010I allele without the 
DQBI *201 I *302genotype. In contrast in the 10-20 years group only I2 subjects had the 
HLA-E 010I allele and the DQBI *201 I *302 genotype and 23 were found to have the 
HLA-E OIOI allele without the DQBI *20I I *302 genotype. There were no other 
significant differences between any of the patient subgroups. 
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6.12 Results of Multiplex family association studies 
6.12.llntroduction 
The possible associations of 4 of the loci studied; P3A, P3B, HLA-E and P1 with type 1 
diabetes were investigated in a collection of multiplex families obtained from the BOA-
Warren repository. The classification of a multiplex family in the repository was; there 
were/are at least two affected children, at least one child was diagnosed with type 1 
diabetes before the age of seventeen and that both parents are/were alive. For each family 
used in the study the HLA status was known however, only the HLA-B, HLA-DR and 
HLA-DQ information was provided. Also the age at onset of type 1 diabetes in most of the 
families was known in each of the diabetic siblings. 
The transmission disequilibrium test (TDT) [Spielman et al. 1993] was used to analyse the 
possible associations of the 4 loci with type 1 diabetes. The TDT test involves families 
with one or more affected offspring, where at least one of the parents is heterozygous for 
an allele thought to be associated with the disease of interest. The test evaluates the 
frequency with which that allele or its alternate is transmitted to the affected offspring. One 
of the two marker alleles of each heterozygous parent is transmitted to each affected 
offspring and one is not. The test compares the frequency of the marker allele among the 
transmitted and non-transmitted alleles. It is assumed there is a disease locus and an 
associated marker locus. TDT assesses the deviation from 50% of the transmission of 
alleles of a marker locus from parents to affected children. (Significant TDT results are not 
obtained unless the alleles being tested are in linkage disequilibrium with an allele of the 
etiological mutation). TDT determines the frequency of transmission of the "associated" 
allele to affected children from parents heterozygous for that allele is compared with the 
expected frequency of 50%. The significance of any association is tested/determined by 
the·/ test and 2X2 contingency tables. 
The association of the loci using the multiplex families was also investigated with respect 
to the age at onset of type 1 diabetes. 
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6.12.2 Association studies with type 1 diabetes in multiplex families: 
Summary of results 
When investigating the associations of the Pl, HLA-E, P3A and P3B loci with type 
diabetes in the multiplex families, it was only possible to study the associations of the 
1.8kb and 1.5kb alleles of the P3B locus. The study of the Pl, P3A, HLA-E loci was 
unfortunately difficult and alleles of the loci that were suspected of being associated with 
the disease could not be investigated. This was due to several reasons including both 
parents within a family were heterozygous for the marker allele (were both parents had an 
identical genotype), both parents were homozygous for the marker allele or the number of 
families that ·could be used was to small to determine if there was any significant 
associations. 
In table 6.12.1 the frequency of transmission of the P3B 1.5kb allele from 23 parents who 
were heterozygous for allele 1.5kb, the other parent was also included if homozygous for 
the allele of interest. It can be seen that 61 P3B 1.5kb alleles were transmitted from the 
parents to their diabetic offspring. Under the hypothesis of no linkage, the expected 
number of transmissions and non-transmissions of P3B 1.5kb is equal (i.e.35). The 
· difference from the observed and expected (i.e. a deviation from 50%) was found to be 
highly significant for the P3B 1.5kb allele (p = 0.000002, Pc = 0.000002). 
In table 6.12.2 the frequency of transmission of the P3B 1.8kb allele from 23 parents who 
were heterozygous for allele 1.5kb, the other parent was also included if homozygous for 
the allele of interest. It can be seen that 44 P3B 1.8kb alleles were transmitted from the 
parents to their diabetic offspring. Under the hypothesis of no linkage, the expected 
number of transmissions and non-transmissions of P3B 1.8kb is equal (i.e.35). The 
difference from the observed and expected (i.e. a deviation from 50%) was found not to be 
significant. 
In table 6.12.3 the frequency of transmission of the P3B 1.5Kb allele from 23 parents who 
were heterozygous for allele 1.5kb, the other parent was also included if homozygous for 
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the allele of interest. It can be seen that 7 P38 1.5kb alleles were transmitted from the 
parents to their diabetic offspring in the < I 0 years group compared to 20 1.5kb alleles in 
the > 10 years group. There was no significant difference between the two age at onset 
groups and no significant associations within the each age group. There was a small 
difference between the observed and expected values (i.e. a deviation from 50%) in the 
> I 0 years group but the difference was found not to be significant when corrected 
(p = 0.01 ). The transmission distortion of the 1.5Kb allele was only found in those patients 
after the age of I 0 years (p = <0.0 15). No distortion of the 1.5Kb allele was found in 
patients diagnosed before 10 years of age. 
In table 6.12.4 the frequency of transmission of the P3B 1.8Kb allele from 23 parents who 
were heterozygous for allele 1.8kb, the other parent was also included if homozygous for 
the allele of interest. It can be seen that 11 P38 1.8kb alleles were transmitted from the 
parents to their diabetic offspring in the< 10 years group compared to 4 1.8kb alleles in the 
> 10 years group. There was no significant difference between the two age at onset groups 
and no significant associations within the each age group. There was a small difference 
between the observed and expected values (i.e. a deviation from 50%) in the> 10 years 
group but the difference was found not to be significant when corrected (p = 0.01). 
There was a highly significant difference in the observed transmission of the P38 1.5kb 
allele in the> 10 years group (20) compared to the observed transmission of the P38 1.8kb 
allele in the > I 0 years group ( 4) ·/ = 22.2, p = 0.000002, Pc = 0.000002 (I df). 
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P3B l.Skb allele 
Transmitted Non-transmitted Total 
Observed 61 9 70 22.41 
Expected 35 35 
Table 6.12.1 Frequency of transmission of the P3B 1.5kb allele with respect to type 1 
diabetes in multiplex families 
This table shows the frequency of transmission of the P3B l.Skb allele within multiplex 
families with respect to type I diabetes. The frequency of transmission of the P3B 1.5 kb 
allele from parents who were heterozygous at the P3B locus for the l.Skb allele to the 
affected children was determined in a total of 23 families. The number in the transmitted 
column in the observed row (n= 6I) is the actual number of copies of the l.Skb allele 
transmitted from parent to child, the number below is the expected number of l.Skb alleles 
to be transmitted (n = 35). The number in the non-transmitted column in the observed row 
(n = 9) is the actual number of times that a l.Skb allele was not transmitted from a parent 
to a child, the number below is the expected number of times the l.Skb allele is not 
transmitted (n = 3 5). The deviation from 50% of the transmission of the 1. Skb allele from 
parents to affected children was determined using the x2 test and 2X2 contingency tables. 
1 =association of the P3B 1.5kb allele x2td = 22.4, p = 0.000002, Pc= 0.000002 (Idf) 
P3B 1.8kb allele 
Transmitted Non-transmitted Total 
Observed 44 26 70 2.3 
Expected 3 5 3 5 
Table 6.12.2 Frequency of transmission of the P3B 1.8kb allele with respect to type 1 
diabetes in multiplex families 
This table shows the frequency of transmission of the P3B 1.8kb allele within multiplex 
families with respect to type I diabetes. The frequency of transmission of the P3B I.S kb 
allele from parents who were heterozygous at the P3B locus for the I.Skb allele to the 
affected children was determined in a total of 23 families. The number in the transmitted 
column in the observed row (n= 44) is the actual number of copies of the I.Skb allele 
transmitted from parent to child, the number below is the expected number of 1.8kb alleles 
to be transmitted (n = 35). The number in the non-transmitted column in the observed row 
(n = 26) is the actual number of times that a l.Skb allele was not transmitted from a parent 
to a child, the number below is the expected number of times the l.Skb allele is not 
transmitted (n = 35). The deviation from 50% of the transmission of the 1.8kb allele from 
parents to affected children was determined using the x2 test and 2X2 contingency tables. 
There was no significant association of the P3B I. Skb allele with type 1 diabetes found in 
the multiplex families. 
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< 10 years 
Observed 
Expected 
> 10 years 
Observed 
Expected 
P3B 1.5kb allele 
Transmitted 
7 
8 
20 
12 
Non-transmitted 
9 
8 
4 
12 
Total 
16 
24 
Table 6.12.3 Frequency of transmission of the P3B 1.5kb allele with respect to age at 
onset of type 1 diabetes in multiplex families 
This table shows the frequency of transmission of the P3B l.Skb allele within multiplex 
families with respect to age at onset of type 1 diabetes. The frequency of transmission of 
the P3B 1.5 kb allele from parents who were heterozygous at the P3B locus for the l.Skb 
allele to the affected children was determined in a total of 23 families. The diabetic 
offspring were separated into 2 groups depending on the age at onset of the disease < 10 
years and > 10 years. The number in the transmitted column in the observed row for both 
age groups is the actual number of copies of the l.Skb allele transmitted from parent to 
child, the number below is the expected number of l.Skb alleles to be transmitted. The 
number in the non-transmitted column in the observed row for both age groups is the 
actual number of times that a l.Skb allele was not transmitted from a parent to a child, the 
number below is the expected number of times the l.Skb allele is not transmitted. There 
were no significant differences in either group or between the age at onset groups. 
< 10 years 
Observed 
Expected 
> 10 years 
Observed 
Expected 
P3B 1.8kb allele 
Transmitted 
11 
9 
4 
13 
Non-transmitted 
9 
9 
21 
13 
Total 
18 
26 
Table 6.12.4 Frequency of transmission of the P3B 1.5kb allele with respect to age at 
onset of type 1 diabetes in multiplex families 
This table shows the frequency of transmission of the P3B 1.8kb allele within multiplex 
families with respect to age at onset of type 1 diabetes. The frequency of transmission of 
the P3B 1.8 kb allele from parents who were heterozygous at the P3B locus for the 1.8kb 
allele to the affected children was determined in a total of 23 families. The diabetic 
offspring were separated into 2 groups depending on the age at onset of the disease < 10 
years and > 10 years. The number in the transmitted column in the observed row for both 
age groups is the actual number of copies of the 1. 8kb allele transmitted from parent to 
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child, the number below is the expected number of 1.8kb alleles to be transmitted. The 
number in the non-transmitted column in the observed row for both age groups is the 
actual number of times that a 1.8kb allele was not transmitted from a parent to a child, the 
number below is the expected number of times the 1.8kb allele is not transmitted. There 
were no significant differences in either group or between the age at onset groups. 
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Class I Loci Type 1 diabetes Alleles Age at onset 
Age at onset and Gender 
{All Patients) 
Male Female 
D6S306 p = ns p =ns p = ns p = ns 
P1 p = ns p= ns p = ns p = ns 
HLA-E p = <0.000001 0101 10-20 yrs vs <10 yr p = 0.008 p = ns p = ns 
0103 <10 yr vs 10-20 yrs p = 0.003 p = ns <10 yr vs 10-20 yrs p = 0.002 
PJB p = <0.000001 1.5 10-20 yrs vs <10 yr p = 0.02 p = ns <10 yr vs 10-20 yrs p = 0.006 
1.8 < 10yr vs 10-20 yrs p = 0.02 p = ns <10-20 yrs vs <10 yr p = 0.006 
67R p = 0.005 p =ns p = ns p = ns 
28L p = ns p = ns p = ns p = ns 
PJA p = ns p = ns p = ns p = ns 
Table 6.12.5 Summary of the major associations between the Class I region and type 1 diabetes 
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CHAPTER 7: GENERAL DISCUSSION 
7.1 Discussion 
The genetic component in the susceptibility to type 1 diabetes is well recognised, as 
is the involvement of the MHC as the main genetic susceptibility region identified so far 
With the employment of a large population study and also a number of BDA multiplex 
families this thesis attempted to interpret the associations of the MHC HLA antigens and in 
the process further characterise the immunogenetics of type 1 diabetes. This involved 
analysing the association of type 1 diabetes with a number of genetic markers and genes 
from the MHC class I region. 
This study included a comprehensive investigation of the class I region for 
associations with type 1 diabetes, such a large scale study of the class I region at the 
molecular level in relation to type I diabetes had not been done before. An area 
approximately 1800kb in size was covered by the use of a combination of genomic probes 
and microsatellite markers that detected a total of 7 loci. The genomic probes and the 
microsatellite markers were chosen based on the association found with the PJB locus 
[Demaine et al. 1995], the analysis was designed to confirm this association in a larger 
cohort of patients and controls and also to confirm the apparent lack of association 
centromeric ofPJB. The association at the PJB locus and evidence for the involvement of 
certain HLA-A alleles [Tienari et al. 1992, Fennessy et al. 1994] suggested that the 
susceptibility region may be located in the vicinity of, or telomeric of PJB, therefore other 
markers were chosen to investigate this. This study was possible in part due to the 
increasing information that has accumulated over the past few years on the organisation of 
the class I region [Amadou et al. 1995, Mizuki et al. 1997, Shiina et al. 1998, Janer and 
Geraghty, 1998]. Previously it has been difficult to investigate potential disease 
associations due to the lack of information at a molecular level. It is also exciting as these 
investigations have led to the discovery of a number of new genes and genetic markers 
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within this area, which may be important in filling in the missing links in the genetic 
susceptibility to type 1 diabetes and other diseases. 
Of the probes used in the study, the P3 probe had been used before in population and 
family studies as mentioned above and also in a number of other studies [Yaouanq et al. 
1992, Boretto et al. 1992, Janer et al. in press. 1999]. Two of the other probes 28L and 66R 
had also been used but to a lesser extent [Janer et al. in press, 1999], these two probes and 
the other microsatellite markers are considered to be novel genetic markers. Few 
conclusions could be drawn from the results obtained using the two microsatellite markers 
PI and D6S306. Both markers were located telomeric of the previously identified 
susceptibility region (P3B), so it could be suggested that any association did not extend 
towards the (extreme) telomeric region of the class I region. There has been some 
argument to the exact position of the D6S306 marker that in fact it is more centromerically 
located. However, recent studies into the location of the Haemochromatosis gene and 
organisation the MHC class I region appear to confirm the original telomeric position for 
the marker [Rahachowdhury et al. 1995 and Malfroy et al. 1997]. This is not consistent 
with other studies were associations have been found at the HLA-A locus located in the 
telomeric area of the class I region [Tienari et al. 1992, Fennessy et al. 1994]. However, 
the information provided by the two markers was not consistent through genotype and 
allelic analysis in both the normal control population and the patient population. In many 
cases due to the large number of possible alleles and genotypes for each marker the 
numbers that were being analysed in a particular group were very small making it difficult 
to analyse. The microsatellite marker data could not be used for haplotype analysis, 
combined genotype analysis or the analysis with the class II alleles due to the small 
numbers available to be studied. Therefore it was considered in this case that the use of 
microsatellite markers had not been successful. However, microsatellite markers are very 
important molecular tools due to them being highly polymorphic (highly informative) and 
have provided valuable information in many of the studies into the organisation of the class 
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I region and also many disease association studies [Davies et al. 1994, Hashimoto et al. 
1994, Todd et al. 1995, Todd. 1997, Merriman and Todd. 1996, Todd and Farrall. 1997, 
Janer and Geraghty. 1998]. The results from the P3A and 28L loci didn't show any 
associations with type 1 diabetes however, the 66R locus (situated nearer to the P3B 
region) showed some weak associations with the disease. A recent study has suggested that 
66R is renamed as 67R and that there is some sequence homology but not identical 
similarities to a vatyl tRNA synthetase protein [Janer and Geraghty. 1998]. It could be 
inferred from such an observation of negligible association towards the centromeric P3A 
locus that the susceptibility gene(s) may reside more towards the telomeric end of the class 
I region possibly in the vicinity of the P3B region, which as mentioned previously had a 
strong link with type 1 diabetes. The strongest associations found in the study were at the 
P3B and HLA-E loci. This confirmed the previous study showing P3B as an important 
genetic marker for type 1 diabetes and also extended the suggested area of susceptibility 
and possible location of susceptibility gene(s) 250kb telomeric ofP3B to the HLA-E locus. 
Analysis of the P3B locus in relation to age at onset of the disease revealed that the 
strongest association is in patients diagnosed between the age of 10-20 years of age and 
those patents diagnosed under 10 years had a weak or no association with P3B. Patients 
diagnosed between 10-20 years had a high frequency of the 1.5kb genotype and allele 
compared to those diagnosed before the age of 10 years and also the normal controls. In 
the previous study 96.2% of those diagnosed between 10-20 years of age had the l.SKb 
allele whilst in this study 83.0% had this allele. There was no link with the 1.8kb genotype 
and allele with respect to the age at onset of the disease. The strong association at this 
locus that has now been confirmed in this present study is probably due to linkage 
disequilibrium with a susceptibility gene. The P3B locus does not itself encode a protein, 
which further suggests linkage with a functional gene in the vicinity. It is also possible that 
the presence of a 1.5kb allele at the locus may be responsible for increased susceptibility 
during puberty. It has been previously shown that the l.Skb allele is present on the HLA-
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A1, B8-DR3 haplotype but not the B18-DR3 [Demaine et al. 1995]. Patients who are 
diagnosed before the age of 10 years are more likely to be HLA-DRJ/4 and have the HLA-
B18, DR3 haplotype rather than the HLA-A1, B8, DR3 haplotype [Tait et al. 1995, Sabbah 
et al. 1996]. The HLA-E locus is also linked to the age at onset of the disease. The HLA-E 
0101 genotype and allele is present at a high frequency in patients diagnosed between the 
age of 10-20 years compared to the those diagnosed before the age of 10 years, after the 
age of 20 years and also normal healthy controls. In contrast, when the HLA-E 0101 allele 
is combined with the HLA-E 0103 allele then the frequency of this genotype is present 
more frequently in patients diagnosed before the age of 10 years. This is found when 
compared to patients diagnosed between the age of 10-20 years, after the age of 20 years 
and also in the healthy normal controls. The association of the 0101 genotype and allele 
with an age at onset of between 10-20 years was greater than the effect seen with the 
0101/0103 genotype in the patients diagnosed before the age of 10 years. This suggests 
that depending on the particular combination of alleles (i.e. the genotype) present at the 
HLA-E locus that this may have an effect on the age at which the disease develops. 
However, it must also be considered that there may be other influences including genes 
that may be in linkage disequilibrium with the HLA-E gene effecting the link with age at 
onset of the disease. These findings suggest that the class I region has an important role in 
the genetic susceptibility to type 1 diabetes and that the area containing the P3B and HLA-
E loci has an influence on the age at onset of the disease. However, it is not as simple as to 
say that these 2 loci (either together or individually) are solely responsible for the genetic 
associations and the effects on the age at onset of the disease within the class I region. Due 
to the extensive linkage disequilibrium across the MHC and therefore the effects of 
extended haplotypes. Although P3B and HLA-E were strongly associated with age at 
onset of type 1 diabetes, this does not necessarily indicate that either locus itself affects 
that age at onset of type 1 diabetes, but the data does suggests that a gene(s) responsible for 
this effect map(s) to the class I region not the class ll. It may be possible that the P3B is in 
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linkage with HLA-E, which would explain the similar effects on the age at onset of the 
disease however, initial haplotype analysis/linkage analysis in patients revealed no linkage. 
Further extended haplotype analysis (involving the other class I loci studied in this project) 
did show that there was a possible association between the P3B l.Skb allele and the HLA-
E 0101 allele and the P3B 1.8kb allele and the HLA-E 0103 allele. The associations found 
may not be "real" results due to the lack of linkage found at analysis of the 2 loci however, 
it could be due to spurious effects of the allelic frequencies of the individual loci. The 
association was confirmed by further haplotype analysis. As the P3B l.Skb allele has been 
found to be present on the HLA-A1, B8-DR3 haplotype it is possible that the HLA-E 0101 
allele may also be linked to this susceptibility haplotype. It was felt that in this study 
further haplotype analysis including other class I and class 11 HLA-loci would have been 
useful. The suggested association of the P3B l.Skb allele and the HLA-E 010 I allele was 
not found in relation to the age at onset of the disease. Analysis of the larger haplotypes in 
which the association was found initially could not be carried out in relation the age at 
onset due to the small numbers that were available in each patient subgroup. It could be 
assumed that the presence of a l.Skb allele at the P3B locus in conjunction with a 0101 
allele at the HLA-E locus may be responsible for an age at onset between 10-20 years as 
both loci have been individually linked to this. Or that the effect on the age at onset is in 
fact an individual effect of one of the loci not a combination of both. Combined genotype 
analysis ofthe P3B- HLA-E loci showed there is a high frequency of the 1.8/1.5-0101 
genotype in patients that were diagnosed between the age of 10-20 years compared to 
patients diagnosed before the age of 10 years and also after the age of 20 years. Haplotype 
analysis has suggested that there is some linkage between the loci and the combined 
genotype data has confirmed this and suggested that the presence of both the P3B l.Skb 
allele and the HLA-E 0101 allele are linked to an age at onset of 10-20 years. As the class 
11 region is considered the major factor in the genetic susceptibility to type 1 diabetes it 
could be suggested that associations in the class I region are merely secondary to the 
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effects of the class II loci due to linkage disequilibrium. However, the P3B locus has been 
shown to be independent of class 11 loci that are known to be associated with susceptibility 
[Demaine et al. 1995], which has also been confirmed in this study, the HLA-E locus also 
appears to be an independently associated with type 1 diabetes. Linkage studies between 
the class I and class 11 loci could not be carried out in this investigation as to many 
heterozygotes were present at both loci, therefore combined genotypes were analysed. It 
was shown that there was an increase in the number of subjects who developed diabetes 
between the age of 10-20 years who had the HLA-E 0101 allele but did not have one of the 
class 11 susceptibility alleles DQB 1 *0201 or DQB 1 *0302. In patients who were diagnosed 
before the age of 10 years there were more patients with the class II DQB 1 *020 1 and 
DQB1 *0302 and also the HLA-E 0101 allele compared to patients with just the HLA-0101 
allele .. Similar results in the 10-20 age group have been found at the P3B locus, where there 
was an excess of the 1.5kb allele in those subjects who did not have the class 11 
susceptibility allele. These findings were reversed in patients diagnosed before the age of 
10 years where there was an excess of the class II susceptibility alleles [Demaine et al. 
1995]. In this present study the combined genotype data did not show the same findings, 
this might be due to the different methods of analysis that were used. However, this study 
was not designed to address the interaction between the class 11 and I regions, as only 
selected class 11 alleles were studied. This would require extensive studies of multiplex 
families. 
The findings of this present study emphasise the importance of class I loci in the 
age dependent genetic heterogeneity of type 1 diabetes. It has been suggested that whilst 
the class 11 region confers susceptibility to type 1 diabetes, the class I region determines the 
age at onset of the disease [Fujisawa et al. 1995]. There is evidence from other studies that 
support this role of the class I region [Nakanishi et al. 1993, Kobayashi et aL 1993 and 
Fennessy et aL 1994]. However, there is considerable evidence previous studies have 
shown the class 11 association to be linked with the age at onset of the disease [Knip et al. 
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1986, Ludvigsson et al. 1986, Karjalainen et al. 1989, Caillat-Zucman et al. 1992, 
Vandewalle et al. 1993 and Awata et al. 1995]. This suggests that the influence ofthe class 
I and class IT susceptibility loci varies according to age at onset of the disease. The class II 
region being important in early childhood and the class I region in older groups in 
particular during puberty. In younger children who are I:ll.A-DR3/DR4 type I diabetes is 
characterised by a reduced residual 13-cell function, a clinical remission of short duration 
and impaired metabolic control [Knip et al. 1986, Karjalainen et al. 1989]. Young children 
also have a higher titre insulin and islet cell antibodies compared to patients who develop 
the disease at a later age [Landin-Olsson et al. 1992, Vandewalle et al. 1993]. It is possible 
that these differences in age at onset are as a consequence of exposure to differing 
environmental triggers. The early exposure to cow's milk proteins has been implicated as a 
risk factor for type 1 diabetes [Virtanen et al. 1993, Gerstein. 1994, Akerblom and Vaarala, 
1997, Saukkonen et al. 1998] and it may be this that acts as a trigger in younger children 
Whilst those who develop the disease at a later age may have been exposed to additional 
environmental factors, which may include exposure to certain viruses [Pietropaolo and 
Trucco. 1996, Schranz and Lernmark. 1998]. It is possible that the response by the immune 
system varies depending on the age at onset of the disease. Subjects that develop diabetes 
at an early age have an autoimmune response, which is driven by the humoral arm of the 
immune system. In contrast, in those who develop the disease at a later age the cellular arm 
of the immune system may dominate the anti-islet-cell response. However, it is possible 
that the associations with the age at onset reflect different rates of disease progression, 
which is determined by genes in both the class I and class 11 regions [Ziegler et al. 1989]. 
Studies of immunological changes during the "pre-diabetic" period have shown variability 
in the rate of progression to type 1 diabetes. 
In type I diabetes it is generally assumed that the male:female (M:F) ratio is I. 
However, a recent study has revealed a high M:F ratio in countries with a high incidence of 
type 1 diabetes (mainly European) and a low M:F ratio in countries were there is a low 
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incidence (Asian and African) [Karvonen et al. 1997]. In our population the male to female 
ratio is approximately 1: 1 in all age groups [Zhao et al. 1998 unpublished]. In contrast, the 
non-obese diabetic (NOD) mouse model of type 1 diabetes has a marked excess of diabetes 
among females (70-80% at 30 weeks of age) compared with male mice (below 20%) 
[Makino et al. 1981, Beeson. 1994]. It should be noted that in this study the absolute 
number of girls slightly exceeded that of boys. A similar pattern has been found in a study 
in the north of England [Crow et al. 1991]. The results of this study showed that the 
association of the class I region was related to the gender of the patients. The gender effect 
has been observed in many other autoimmune diseases, which has led to an interest into the 
possible role of sex hormones in the pathogenesis of the diseases. In this study the 
strongest associations of P3B with type 1 diabetes were found in female patients. Female 
patients diagnosed before the age of 10 years have a distribution of P3B genotypes similar 
to normal healthy females. In contrast, females diagnosed between the ages of 1 0-20 years 
have an increased frequency of the 1.5kb genotype and allele when compared to those 
diagnosed before 10 years and the normal controls. It has been shown that HLA-
DR3+/DR4- patients diagnosed before the age of 13 years tend to be female while the 
DR3-/DR4+ patients tend to be male [Tait et al. 1995]. Further, patients who are diagnosed 
at an early age usually have increased levels of autoantibodies particularly against glutamic 
acid decarboxylase (GAD65A) with female patients tending to have the highest levels 
[Sabbah et al. 1996]. Male and female type 1 diabetic patients of Singaporean origin have 
been shown to have different associations with the HLA-DRB 1 locus, which also varies 
with age at onset. Female patients are mainly HLA-DRB1 *0301/*0901 whilst males are 
DRB 1 *030 11*04 [Chan et al. 1995]. The strong female bias at the P3B locus is similar to a 
number of other autoimmune disorders. At the HLA-E locus there isn't such an obvious 
strong link with gender, as with the P3B locus. However, males diagnosed between the 
ages of 10-20 years have an increased frequency of the 0101 genotype and allele when 
compared to those diagnosed before 10 years and the normal controls. The association at 
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the HLA-E locus exerts a weaker effect on males than that exerted on females by the P3B 
locus and may therefore be dismissed as a "true" result. However, if the result is a true 
reflection of the role of the HLA-E locus it is interesting. The assumption would be that as 
both loci are strongly associated with the same age at onset and there is some suggestion of 
association that there strongest effect would be in the same sex. From the haplotype 
analysis in relation to gender there was an association between the P3B 1. 5kb allele and the 
HLA-E 0103 allele found in female patients, opposite to the considered association of the 
1. 5 and 0101 alleles. This had also been detected in patients who were diagnosed before 
the age of 10 years and was thought to be a spurious result, which may be the case here. 
However, as the association has been found only in the female patients it may be that in 
relation to gender the P3B 1.5 determines the sex and with respect to age at onset of before 
the age of 10 years the HLA-E 0103 allele has the dominant effect. A recent study of the 
class 11 region in relation to gender and type 1 diabetes has shown there is an increase in 
the M:F ratio in patients who are HLA-DRJ compared to patients who are HLA-DR4 or 
DR3/DR4. There is also evidence for linkage between disease and chromosome X [Cucca 
et al. 1998]. It is possible that the HLA-E 0101 allele may be present on the HLA-DR3 
haplotype that has been demonstrated in the Cucca et al. study to have a strong effect in 
male patients and also a possible link to a gene on the X chromosome. Recent genetic data 
has shown that there is an increase risk of offspring developing type 1 diabetes to diabetic 
fathers compared to diabetic mothers [EI-Hashimy et al. 1993, The EURODIAB ACE 
study group. 1998, Rjasanowski et al. 1998]. The strong female bias found at the P3B 
locus is in keeping with a number of other autoimmune disorders including systemic lupus 
erythematosus, myasthenia gravis and rheumatoid arthritis [Beeson. 1994]. In this study 
the strongest associations of P3B and HLA-E with type 1 diabetes were found in the 
different sexes. There is evidence that sex hormones can influence the gender difference 
seen in certain diseases [Lahita. 1990, Ahmed and Talal. 1990, Beeson. 1994]. Hormones 
such as oestrogen have already been shown to enhance some autoimmune processes. 
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Hormones may regulate the expression and function of certain genes involved in the 
immune process. The associations seen in this study may be due to the interaction of 
hormonal and genetic factors. There is a suggestion for the role of hormones as the 
strongest associations were in the patients diagnosed between the ages of 10-20 years, 
which is the age of puberty and the highest levels of sex hormones. It may be that 
hormones have a direct effect on HLA-E as it codes for a functional protein or the target of 
hormonal action maybe the susceptibility gene in linkage with HLA-E or P3B. 
Due to the complexity of the MHC association with type 1 diabetes a large number 
of BDA HLA-typed multiplex families were employed in addition to the large sporadic 
patient and control populations. It was hoped that any associations detected within the 
sporadic populations could be further investigated in families were additional genetic 
information is available. Family studies are also valuable tool in the analysis of linkage 
disequilibrium between a suspected locus (loci) and the disease locus (loci). The 
transmission disequilibrium test (TDT) was employed to analyse the family data and is just 
one of several family based tests. TDT is a powerful test of association and application 
dose not require prior data implicating a polymorphism with the disease. It provides an 
alternative method for testing for linkage disequilibrium to the comparison of gene 
frequencies in patients and matched controls because it avoids the possibility that the 
patient and controls subjects have been inadvertently drawn from different gene pools. The 
associations of the P3B locus (1.5kb allele) with type 1 diabetes in patients with an age at 
onset between 10-20 years was confirmed in the multiplex families. The 1.5kb allele is 
transmitted from diabetic parents to affected offspring. Analysis by TDT of family data 
from the other class I loci in the study could not be carried out. This was due to the large 
number of both parents in a family being heterozygous or homozygous for the allele under 
investigation. The data from the multiplex families could not be used effectively in the 
investigations of genetic associations and linkage disequilibrium as the complete HLA 
class 11 and class I information was not available. New methods are being developed that 
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are more powerful and sensitive than linkage analysis in families, one of which is linkage 
disequilibrium mapping [Lucassen et al. 1993 and Vyse and Todd. 1996). This technique 
uses information obtained in genome scanning and may be the way forward in detecting 
precisely a disease locus. Although genome wide scanning has been carried out [Todd and 
Farrall. 1997] it is impractical to scan the whole human genome for linkage disequilibrium 
with 3000 markers, but in regions of linkage spanning smaller regions it is a feasible 
strategy. It is often considered that family studies give rise to more valuable data than 
population studies. Partly due to the reduced risk of genetically and ethnically mismatched 
patients and controls and population stratification that can give rise to spurious results 
sporadic population studies but not in family studies. However, the TDT in families cannot 
distinguish associations caused by linkage disequilibrium from those where the marker is 
itself a susceptibility factor. Therefore it is more useful in a genetic study such as this to 
use a combination of both population and family studies in the investigation for a disease 
susceptibility gene(s). 
This thesis provides further evidence that genes in the class I region confer 
susceptibility to type 1 diabetes. The susceptibility is related to gender and age at onset of 
the disease. The discovery of new loci associated with a particular age at onset, in patients 
of a particular gender provides additional evidence to the heterogeneous nature of type I 
diabetes. Different forms of the disease may present at different ages and in different sexes 
due not only to genetic factors but also the influence of external factors, acting to trigger or 
accelerate the disease process. Due to a particular set of genes interacting with different 
environmental factors or different genes interacting with the same environmental factor. 
The question of which gene(s) in the class I region are/is/ the susceptibility gene(s) has not 
been completely answered by this study. However, a susceptibility area in the region has 
been identified that contains the P3B locus, as the P3B locus does not itself encode a 
protein it suggests that P3B (is the marker for the susceptibility gene) is in linkage with the 
susceptibility gene. Recent investigations of the class I region have revealed a number of 
575 
new genes with very diverse functions and some of unknown function. PS-1 is a novel 
gene of unknown function that is located near to the P3B locus and is therefore a candidate 
for a susceptibility gene. The transcription of this gene is restricted to lymphoid tissues and 
natural killer like cell lines [Vernet et al. 1993], which may bear some relevance to 
immune functions and therefore may have some involvement in the autoimmune process in 
type 1 diabetes. The transcription factor OTF3 (octamer-binding transcription factor 3) is 
located 1 OOkb telomeric of HLA-C and is strong linkage disequilibrium with HLA-B, -C 
and -DR genes. OTF3 has been shown to be involved in early development and may be 
important regulator in tissue specific gene expression in lymphoid differentiation and early 
development [Takeda et al. 1992 and Crouau-Roy et al. 1994]. The expression of the gene 
in adult tissues has shown to be reduced. The presence of the gene in early development 
suggests that OTF3 expression/function may be influenced by sex hormones, the presence 
of increased levels of sex hormones during puberty may have a similar effect on OTF3. 
Due to the close proximity to P3B and its function OTF3 may be considered to have a role 
in type I diabetes. The susceptibility gene associated with type 1 diabetes may not have 
been described yet; it may be one of the many genes of unknown function. The gene is 
likely to have a function involved with the immune response, possibly cytokines, 
transcription factors or hormones. 
The association of the HLA-E locus identified in this study and the close proximity 
to the P3B locus suggest that HLA-E is a strong candidate for a susceptibility gene. HLA-E 
has not been previously associated with any disease although the expression of HLA-E on 
placental tissue may play a role in foetal-maternal tolerance [Sirvastava and Lambert.1991, 
Boucraut et al. 1993]. The expression of HLA-E in later life is little understood, but the 
observation that they are found on placental tissue suggests that the expression of HLA-E 
may be modulated by sex hormones. More excitingly the recent discovery that HLA-E is 
one of the cell surface receptors that are involved in natural killer cell lysis [Braud et al. 
1998]. HLA-E has also been shown to bind peptides derived from the signal sequences of 
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certain HLA class I molecules [Braud et al. 1997]. Previous studies have shown that the 
number and level of cytotoxic activity of natural killer cells is associated with the 
development of type 1 diabetes and this association may be genetically determined 
[Hussain et al. 1987 and Lorini et al. 1994]. It appears that HLA-E has an important role in 
the development of tolerance by preventing the autoreactivity of NK cells and also in the 
regulation ofNK cell mediated cytotoxicity both positively and negatively [Borrego et al. 
1998, Braud et al. 1998, Lanier et al. 1998]. A breakdown in this regulation of NK cell 
activity by HLA-E may result in the autoimmune destruction of normal cells or abnormal 
function ofNK cells, which may allow susceptibility to certain viral infections. The HLA-
E molecule may be altered or become altered or the expression of this class I molecule may 
be affected, which potentially could lead to or have a role in the autoimmune destruction of 
pancreatic p cells. Hypoexpression of MHC class I molecules has been found on the 
surface of lymphoid cells in patients with type I diabetes [Bottazzo et al. 1985, Faustman 
et al. 1991, Fu et al. 1993]. It has been suggested that the presentation ofself-peptides by 
MHC class I molecules is important in the positive selection of the CD8+ T -cell repertoire 
and therefore in development of tolerance to self. The lack of expression may result in an 
autoimmune process. Possible explanations for reduced expression are viral invasion of the 
cells and abnormalities in the genes responsible for the assembly of class I molecules, 
which include the HLA class II linked genes TAP I, TAP 2, Lmp2 and Lmp7 [Fu et al. 
1996]. However, it has been shown in studies of NOD mice that reduced levels of class I 
expression results in the prevention oftype I diabetes [Katz et al. 1993, Wicker et al. 1994, 
Serreze et al. 1994]. It has therefore been suggested that normal expression levels are 
required to select and target p cell autoreactive CD8+ T cells [Serreze et al. 1996]. In 
contrast, over-expression of class I molecules has also been found on the surface of 
pancreatic islet cells in type I diabetics, which may be triggered by a virus or toxin and 
later by cytokines [Foulis et al. 1987]. This over-expression of class I molecules may result 
in inappropriate T cell activation and destruction of the pancreatic islet cells. It is possible 
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that HLA-E is aberrantly expressed during puberty under the influence of excessive sex 
hormones. If this was the case it may explain the association with the age at onset shown in 
this study. 
The identification of an independent susceptibility area in the class I region 
provides further evidence to the importance of the MHC in the genetic susceptibility to 
type 1 diabetes. It is clear that genes outside of this region also have an important role to 
play and it is actually a combination of genes that are responsible for the susceptibility to 
the disease. The particular combination of genes may not be the same all countries and 
ethnic populations. Until other potential contributing genes are fully identified and their 
functions determined the genetic susceptibility of type I diabetes would not be fully 
can not be fully explained. Evidence suggests that type 1 diabetes may occur in the event 
that environmental influences interact in a susceptible individual to initiate a sequence of 
events that lead to the eventual destruction of pancreatic P cells. Further understanding of 
these interactions may explain the mechanisms involved in the pathogenesis of the disease 
and allow the development of possible preventive therapies. 
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7.2 Future work 
Future work that may arise from this thesis; 
+ Due to a number of recent studies the complete nucleotide sequence of the class I 
region is close to being realised. The availability of this information will aid the actual 
identification of the relevant susceptibility genes in the class I region concentrating on 
the area identified in this initial study. Sequence data will also facilitate the typing of 
high numbers of patients for the candidate genes identified. 
+ Continued investigation of the class I region and the association with type I diabetes 
with a panel of highly polymorphic microsatellite markers, covering the region not yet 
studied and also to further investigate the identified susceptibility region more closely. 
+ Analyse the effect of sex hormones on the expression of class I molecules by the 
culturing oflymphocytes of known class I genotypes. This may explain the age at onset 
and gender effects shown in this study. 
+ Investigate further the possible link between the class I molecule lll..A-E (identified as 
a candidate for a susceptibility gene) and NK cell activity in type I diabetic patients/in 
relation to type I diabetes. 
+ Using a large patient population investigate further the interaction of susceptibility loci 
in the class I, class 11 and class Ill regions this may lead to the identification of a high-
risk haplotypes in type I diabetic patients. The identification of such haplotypes may 
explain the heterogeneity that exists in the disease/different genetic combinations 
resulting in different age at onset and therefore involving different branches of the 
immune system. 
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7.3 Concluding points 
The main conclusions of this thesis are; 
+ shown a strong association with type 1 diabetes in the class I region of the MHC 
+ shown the association may be independent of the class 11 susceptibility loci 
+ shown the association is related to gender and age at onset 
+ identified a possible susceptibility gene non-classical HLA-E 
+ association ofHLA-E may be due to a link with the regulation ofNK cell activity. 
Figure 7 .I is a schematic representation of the associations found with the class I markers 
used in this study and type 1 diabetes. 
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P3A 28L 66R P3B HLA-E P1 D6S306 
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100 kb 
Figure 7.1 Association of studied MHC class I markers with type 1 diabetes. 
This is a schematic representation of the MHC class I region showing the positions of the markers used in this study. 
The markers shown in blue were found to have no significant/or weak association with type 1 diabetes, the markers shown in red were found to have a strong 
significant association with type 1 diabetes and the red oval indicates the suggested area of susceptibility within the class I region. 
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